Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors

ABSTRACT

Disclosed are novel multi-functional hematopoietic receptor agonist proteins, DNAs which encode the multi-functional hematopoietic receptor agonists proteins, methods of making the multi-functional hematopoietic receptor agonists proteins and methods of using the multi-functional hematopoietic receptor agonists proteins.

The present application is a Continuation-in-Part of PCT/US 96/15774 filed Oct. 4, 1996 which claims priority under 35 USC §119(e) of U.S. provisional application Serial No. 60/004,834 filed Oct. 5, 1995.

FIELD OF THE INVENTION

The present invention relates to multi-functional hematopoietic receptor agonists.

BACKGROUND OF THE INVENTION

Colony stimulating factors (CSFs) which stimulate the differentiation and/or proliferation of bone marrow cells have generated much interest because of their therapeutic potential for restoring depressed levels of hematopoietic stem cell-derived cells. CSFs in both human and murine systems have been identified and distinguished according to their activities. For example, granulocyte-CSF (G-CSF) and macrophage-CSF (M-CSF) stimulate the in vitro formation of neutrophilic granulocyte and macrophage colonies, respectively, while GM-CSF and interleukin-3 (IL-3) have broader activities and stimulate the formation of both macrophage, neutrophilic and eosinophilic granulocyte colonies. IL-3 also stimulates the formation of mast, megakaryocyte and pure and mixed erythroid colonies.

U.S. Pat. No. 4,877,729 and U.S. Pat. No. 4,959,455 disclose human IL-3 and gibbon IL-3 cDNAs and the protein sequences for which they code. The hIL-3 disclosed has serine rather than proline at position 8 in the protein sequence.

International Patent Application (PCT) WO 88/00598 discloses gibbon- and human-like IL-3. The hIL-3 contains a Ser⁸ ->Pro⁸ replacement. Suggestions are made to replace Cys by Ser, thereby breaking the disulfide bridge, and to replace one or more amino acids at the glycosylation sites.

U.S. Pat. No. 4,810,643 discloses the DNA sequence encoding human G-CSF.

WO 91/02754 discloses a fusion protein comprised of GM-CSF and IL-3 which has increased biological activity compared to GM-CSF or IL-3 alone. Also disclosed are nonglycosylated IL-3 and GM-CSF analog proteins as components of the multi-functional hematopoietic receptor agonist.

WO 92/04455 discloses fusion proteins composed of IL-3 fused to a lymphokine selected from the group consisting of IL-3, IL-6, IL-7, IL-9, IL-11, EPO and G-CSF.

WO 95/21197 and WO 95/21254 disclose fusion proteins capable of broad multi-functional hematopoietic properties.

GB 2,285,446 relates to the c-mpl ligand (thrombopoietin) and various forms of thrombopoietin which are shown to influence the replication, differentiation and maturation of megakaryocytes and megakaryocytes progenitors which may be used for the treatment of thrombocytopenia.

EP 675,201 A1 relates to the c-mpl ligand (Megakaryocyte growth and development factor (MGDF), allelic variations of c-mpl ligand and c-mpl ligand attached to water soluble polymers such as polyethylene glycol.

WO 95/21920 provides the murine and human c-mpl ligand and polypeptide fragments thereof. The proteins are useful for in vivo and ex vivo therapy for stimulating platelet production.

Rearrangement of Protein Sequences

In evolution, rearrangements of DNA sequences serve an important role in generating a diversity of protein structure and function. Gene duplication and exon shuffling provide an important mechanism to rapidly generate diversity and thereby provide organisms with a competitive advantage, especially since the basal mutation rate is low (Doolittle, Protein Science 1: 191-200, 1992).

The development of recombinant DNA methods has made it possible to study the effects of sequence transposition on protein folding, structure and function. The approach used in creating new sequences resembles that of naturally occurring pairs of proteins that are related by linear reorganization of their amino acid sequences (Cunningham, et al., Proc. Natl. Acad. Sci. U.S.A. 76: 3218-3222, 1979; Teather & Erfle, J. Bacteriol. 172: 3837-3841, 1990; Schimming et al., Eur. J. Biochem. 204: 13-19, 1992; Yamiuchi and Minamikawa, FEBS Lett. 260: 127-130, 1991; MacGregor et al., FEBS Lett. 378: 263-266). The first in vitro application of this type of rearrangement to proteins was described by Goldenberg and Creighton (J. Mol. Biol. 165: 407-413, 1983). A new N-terminus is selected at an internal site (breakpoint) of the original sequence, the new sequence having the same order of amino acids as the original from the breakpoint until it reaches an amino acid that is at or near the original C-terminus. At this point the new sequence is joined, either directly or through an additional portion of sequence (linker), to an amino acid that is at or near the original N-terminus, and the new sequence continues with the same sequence as the original until it reaches a point that is at or near the amino acid that was N-terminal to the breakpoint site of the original sequence, this residue forming the new C-terminus of the chain.

This approach has been applied to proteins which range in size from 58 to 462 amino acids (Goldenberg & Creighton, J. Mol. Biol. 165: 407-413, 1983; Li & Coffino, Mol. Cell. Biol. 13: 2377-2383, 1993). The proteins examined have represented a broad range of structural classes, including proteins that contain predominantly α-helix (interleukin-4; Kreitman et al., Cytokine 7: 311-318, 1995), β-sheet (interleukin-1; Horlick et al., Protein Eng. 5: 427-431, 1992), or mixtures of the two (yeast phosphoribosyl anthranilate isomerase; Luger et al., Science 243: 206-210, 1989). Broad categories of protein function are represented in these sequence reorganization studies:

Enzymes

T4 lysozyme Zhang et al., Biochemistry 32: 12311-12318, 1993; Zhang et al., Nature Struct. Biol. 1: 434-438 (1995)

dihydrofolate reductase Buchwalder et al., Biochemistry 31: 1621-1630, 1994; Protasova et al., Prot. Eng. 7: 1373-1377, 1995)

ribonuclease T1 Mullins et al., J. Am. Chem. Soc. 116: 5529-5533, 1994; Garrett et al., Protein Science 5: 204-211, 1996)

Bacillus β-glucanse Hahn et al., Proc. Natl. Acad. Sci. U.S.A. 91: 10417-10421, 1994)

aspartate transcarbamoylase Yang & Schachman, Proc. Natl. Acad. Sci. U.S.A. 90: 11980-11984, 1993)

phosphoribosyl anthranilate isomerase Luger et al., Science 243: 206-210 (1989; Luger et al., Prot. Eng. 3: 249-258, 1990)

pepsin/pepsinogen Lin et al., Protein Science 4: 159-166, 1995)

glyceraldehyde-3-phosphate dehydrogenase Vignais et al., Protein Science 4: 994-1000, 1995)

ornithine decarboxylase Li & Coffino, Mol. Cell. Biol. 13: 2377-2383, 1993)

yeast phosphoglycerate dehydrogenase Ritco-Vonsovici et al., Biochemistry 34: 16543-16551, 1995)

Enzyme Inhibitor

basic pancreatic trypsin inhibitor Goldenberg & Creighton, J. Mol. Biol. 165: 407-413, 1983)

Cytokines

interleukin-1β Horlick et al., Protein Eng. 5: 427-431, 1992)

interleukin-4 Kreitman et al., Cytokine 7: 311-318, 1995)

Tyrosine Kinase Recognition Domain

α-spectrin SH3 domain Viguera, et al., J. Mol. Biol. 247: 670-681, 1995)

Transmembrane Protein

omp A Koebnik & Kramer, J. Mol. Biol. 250: 617-626, 1995)

Chimeric Protein

interleukin-4-Pseudomonas exotoxin Kreitman et al., Proc. Natl. Acad. Sci. U.S.A. 91: 6889-6893, 1994).

The results of these studies have been highly variable. In many cases substantially lower activity, solubility or thermodynamic stability were observed (E. coli dihydrofolate reductase, aspartate transcarbamoylase, phosphoribosyl anthranilate isomerase, glyceraldehyde-3-phosphate dehydrogenase, ornithine decarboxylase, omp A, yeast phosphoglycerate dehydrogenase). In other cases, the sequence rearranged protein appeared to have many nearly identical properties as its natural counterpart (basic pancreatic trypsin inhibitor, T4 lysozyme, ribonuclease T1, Bacillus β-glucanase, interleukin-1β, α-spectrin SH3 domain, pepsinogen, interleukin-4). In exceptional cases, an unexpected improvement over some properties of the natural sequence was observed, e.g., the solubility and refolding rate for rearranged α-spectrin SH3 domain sequences, and the receptor affinity and anti-tumor activity of transposed interleukin-4-Pseudomonas exotoxin fusion molecule (Kreitman et al., Proc. Natl. Acad. Sci. U.S.A. 91: 6889-6893, 1994; Kreitman et al., Cancer Res. 55: 3357-3363, 1995).

The primary motivation for these types of studies has been to study the role of short-range and long-range interactions in protein folding and stability. Sequence rearrangements of this type convert a subset of interactions that are long-range in the original sequence into short-range interactions in the new sequence, and vice versa. The fact that many of these sequence rearrangements are able to attain a conformation with at least some activity is persuasive evidence that protein folding occurs by multiple folding pathways (Viguera, et al., J. Mol. Biol. 247: 670-681, 1995). In the case of the SH3 domain of a-spectrin, choosing new termini at locations that corresponded to β-hairpin turns resulted in proteins with slightly less stability, but which were nevertheless able to fold.

The positions of the internal breakpoints used in the studies cited here are found exclusively on the surface of proteins, and are distributed throughout the linear sequence without any obvious bias towards the ends or the middle (the variation in the relative distance from the original N-terminus to the breakpoint is ca. 10 to 80% of the total sequence length). The linkers connecting the original N- and C-termini in these studies have ranged from 0 to 9 residues. In one case (Yang & Schachman, Proc. Natl. Acad. Sci. U.S.A. 90: 11980-11984, 1993), a portion of sequence has been deleted from the original C-terminal segment, and the connection made from the truncated C-terminus to the original N-terminus. Flexible hydrophilic residues such as Gly and Ser are frequently used in the linkers. Viguera, et al. (J. Mol. Biol. 247: 670-681, 1995) compared joining the original N- and C-termini with 3- or 4-residue linkers; the 3-residue linker was less thermodynamically stable. Protasova et al. (Protein Eng. 7: 1373-1377, 1994) used 3- or 5-residue linkers in connecting the original N-termini of E. coli dihydrofolate reductase; only the 3-residue linker produced protein in good yield.

SUMMARY OF THE INVENTION

Novel hematopoietic proteins of this invention are represented by the formulas:

    R.sub.1 -L.sub.1 -R.sub.2, R.sub.2 -L.sub.1 -R.sub.1, R.sub.1 -R.sub.2, or R.sub.2 -R.sub.1

wherein R₁ and R₂ are independently selected from the group consisting of;

(I) A polypeptide comprising; a modified human G-CSF amino acid sequence of the formula:

    1                                   10                                         Xaa Xaa Xaa Gly Pro Ala Ser Ser Leu Pro Gln Ser Xaa                                                    20                                                     Leu Leu Xaa Xaa Xaa Glu Gln Val Xaa Lys Xaa Gln Gly Xaa Gly                        30                                      40                                 Ala Xaa Leu Gln Glu Xaa Leu Xaa Ala Thr Tyr Lys Leu Xaa Xaa                                            50                                                     Xaa Glu Xaa Xaa Val Xaa Xaa Gly His Ser Xaa Gly Ile Pro Trp                        60                                      70                                 Ala Pro Leu Ser Ser Xaa Pro Ser Xaa Ala Leu Xaa Leu Ala Gly                                            80                                                     Xaa Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu                        90                                      100                                Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu                                            110                                                    Xaa Thr Leu Gln Xaa Asp Val Ala Asp Phe Ala Xaa Thr Ile Trp                        120                                     130                                Gln Gln Met Glu Xaa Xaa Gly Met Ala Pro Ala Leu Gln Pro Thr                                            140                                                    Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Xaa Gln Xaa Xaa Ala                        150                                     160                                Gly Gly Val Leu Val Ala Ser Xaa Leu Gln Xaa Phe Leu Xaa Xaa                                            170                                                    Ser Tyr Arg Val Leu Xaa Xaa Leu Ala Gln Pro (SEQ ID NO:1)                 

wherein

Xaa at position 1 is Thr, Ser, Arg, Tyr or Gly;

Xaa at position 2 is Pro or Leu;

Xaa at position 3 is Leu, Arg, Tyr or Ser;

Xaa at position 13 is Phe, Ser, His, Thr or Pro;

Xaa at position 16 is Lys, Pro, Ser, Thr or His;

Xaa at position 17 is Cys, Ser, Gly, Ala, Ile, Tyr or Arg;

Xaa at position 18 is Leu, Thr, Pro, His, Ile or Cys;

Xaa at position 22 is Arg, Tyr, Ser, Thr or Ala;

Xaa at position 24 is Ile, Pro, Tyr or Leu;

Xaa at position 27 is Asp, or Gly;

Xaa at position 30 is Ala, Ile, Leu or Gly;

Xaa at position 34 is Lys or Ser;

Xaa at position 36 is Cys or Ser;

Xaa at position 42 is Cys or Ser;

Xaa at position 43 is His, Thr, Gly, Val, Lys, Trp, Ala, Arg, Cys, or Leu;

Xaa at position 44 is Pro, Gly, Arg, Asp, Val, Ala, His, Trp, Gln, or Thr;

Xaa at position 46 is Glu, Arg, Phe, Arg, Ile or Ala;

Xaa at position 47 is Leu or Thr;

Xaa at position 49 is Leu, Phe, Arg or Ser;

Xaa at position 50 is Leu, Ile, His, Pro or Tyr;

Xaa at position 54 is Leu or His;

Xaa at position 64 is Cys or Ser;

Xaa at position 67 is Gln, Lys, Leu or Cys;

Xaa at position 70 is Gln, Pro, Leu, Arg or Ser;

Xaa at position 74 is Cys or Ser;

Xaa at position 104 is Asp, Gly or Val;

Xaa at position 108 is Leu, Ala, Val, Arg, Trp, Gln or Gly;

Xaa at position 115 is Thr, His, Leu or Ala;

Xaa at position 120 is Gln, Gly, Arg, Lys or His

Xaa at position 123 is Glu, Arg, Phe or Thr

Xaa at position 144 is Phe, His, Arg, Pro, Leu, Gln or Glu;

Xaa at position 146 is Arg or Gln;

Xaa at position 147 is Arg or Gln;

Xaa at position 156 is His, Gly or Ser;

Xaa at position 159 is Ser, Arg, Thr, Tyr, Val or Gly;

Xaa at position 162 is Glu, Leu, Gly or Trp;

Xaa at position 163 is Val, Gly, Arg or Ala;

Xaa at position 169 is Arg, Ser, Leu, Arg or Cys;

Xaa at position 170 is His, Arg or Ser;

wherein optionally 1-11 amino acids from the N-terminus and 1-5 from the C-terminus can be deleted; and

wherein the N-terminus is joined to the C-terminus directly or through a linker capable of joining the N-terminus to the C-terminus and having new C- and N-termini at amino acids;

    ______________________________________                                         39-40          63-64       124-125                                             40-41                                     125-126                              41-42                                     126-127                              42-43                                     128-129                              43-44                                     128-129                              45-46                                     129-130                              48-49                                     130-131                              49-50                                     131-132                              52-53                                     132-133                              53-54                                     133-134                              54-55                                     134-135                              55-56                                     135-136                              56-57                                     136-137                              57-58                                     137-138                              58-59                                     138-139                              59-60                                     139-140                              60-61                                     140-141                              61-62                                    141-142                                                          or 142-143;                                         ______________________________________                                    

(II) A polypeptide comprising; a modified hIL-3 amino acid sequence of the formula:

    Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn                    1               5                   10                  15                     Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                                    20                  25                  30                     Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa                                    35                  40                  45                     Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                                    50                  55                  60                     Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                                    65                  70                  75                     Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                                    80                  85                  90                     Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                                    95                  100                 105                    Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                                    110                 115                 120                    Xaa Xaa Xaa Gln Gln Thr Thr Leu Ser Leu Ala Ile Phe                                            125                 130   (SEQ ID NO:2);                  

wherein

Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln, or Arg;

Xaa at position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln;

Xaa at position 19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys;

Xaa at position 20 is Ile, Cys, Gln, Glu, Arg, Pro, or Ala;

Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val;

Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly;

Xaa at position 23 is Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, or Arg;

Xaa at position 24 is Ile, Gly, Val, Arg, Ser, Phe, or Leu;

Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro, or Ala;

Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala, or Trp;

Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala;

Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp;

Xaa at position 29 is Gln, Asn, Leu, Pro, Arg, or Val;

Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys;

Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;

Xaa at position 32 is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu;

Xaa at position 33 is Pro, Leu, Gln, Ala, Thr, or Glu;

Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met;

Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gln, or Val;

Xaa at position 36 is Asp, Leu, or Val;

Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile;

Xaa at position 38 is Asn, or Ala;

Xaa at position 40 is Leu, Trp, or Arg;

Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, or Pro;

Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Met or Ala;

Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly or Ser;

Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro;

Xaa at position 45 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, Ile, Glu or His;

Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly;

Xaa at position 47 is Ile, Gly, Val, Ser, Arg, Pro, or His;

Xaa at position 48 is Leu, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn;

Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp;

Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His, Phe, Met or Gln;

Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His;

Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;

Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met;

Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His, Ala or Leu;

Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly;

Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys;

Xaa at position 57 is Asn or Gly;

Xaa at position 58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys;

Xaa at position 59 is Glu Tyr, His, Leu, Pro, or Arg;

Xaa at position 60 is Ala, Ser, Pro, Tyr, Asn, or Thr;

Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;

Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile;

Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val;

Xaa at position 64 is Ala, Asn, Pro, Ser, or Lys;

Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser;

Xaa at position 66 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;

Xaa at position 67 is Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro, or His;

Xaa at position 68 is Leu, Val, Trp, Ser, Ile, Phe, Thr, or His;

Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Leu;

Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;

Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, or Asn;

Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;

Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg;

Xaa at position 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala;

Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu;

Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp;

Xaa at position 77 is Ile, Ser, Arg, Thr, or Leu;

Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg;

Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile, Gly, or Asp;

Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg;

Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys;

Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, Ile, Met or Val;

Xaa at position 83 is Pro, Ala, Thr, Trp, Arg, or Met;

Xaa at position 84 is Cys, Glu, Gly, Arg, Met, or Val;

Xaa at position 85 is Leu, Asn, Val, or Gln;

Xaa at position 86 is Pro, Cys, Arg, Ala, or Lys;

Xaa at position 87 is Leu, Ser, Trp, or Gly;

Xaa at position 88 is Ala, Lys, Arg, Val, or Trp;

Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser;

Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, Ile, or Met;

Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His;

Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile or Leu;

Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg;

Xaa at position 94 is Arg, Ile, Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro;

Xaa at position 95 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, Ile, or Tyr;

Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr;

Xaa at position 97 is Ile, Val, Lys, Ala, or Asn;

Xaa at position 98 is His, Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro;

Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, Phe, or His;

Xaa at position 100 is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gln, or Pro;

Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu, or Gln;

Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro;

Xaa at position 103 is Asp, or Ser;

Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe, or Gly;

Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;

Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro;

Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala or Pro;

Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly;

Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser, or Trp;

Xaa at position 111 is Leu, Ile, Arg, Asp, or Met;

Xaa at position 112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe;

Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val or Asn;

Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu;

Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met;

Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gln, or Ile;

Xaa at position 117 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro;

Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr;

Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg;

Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gln;

Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly;

Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;

Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

wherein optionally from 1 to 14 amino acids can be deleted from the N-terminus and/or from 1 to 15 amino acids can be deleted from the C-terminus; and wherein from 0 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3; and

wherein the N-terminus is joined to the C-terminus directly or through a linker (L₂) capable of joining the N-terminus to the C-terminus and having new C- and N-termini at amino acids;

    ______________________________________                                         26-27          49-50       83-84                                               27-28                                       84-85                              28-29                                       85-86                              29-30                                       86-87                              30-31                                       87-88                              31-32                                       88-89                              32-33                                       89-90                              33-34                                       90-91                              34-35                                       91-92                              35-36                                       92-93                              36-37                                       97-98                              37-38                                       98-99                              38-39                                       99-100                             39-40                                       100-101                            40-41                                       101-102                            41-42                                       102-103                                                       or 103-104;                                         ______________________________________                                    

or

(III) A polypeptide comprising; a modified human c-mpl ligand amino acid sequence of the formula:

    SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer                      1           5              10             15                                   HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrPro                      20             25             30             35                                ValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGlu                         40             45             50             55                             ThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla                            60             65             70             75                          AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGly                               80             85             90             95                       GlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnXaaXaaXaa                                  100            105            110                                  XaaGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHis                      115            120            125            130                               LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysVal                         135            140            145            150                            ArgArgAlaProProThrThrAlaValProSerArgThrSerLeuValLeuThrLeu                            155            160            165            170                         AsnGluLeuProAsnArgThrSerGlyLeuLeuGluThrAsnPheThrAlaSerAla                               175            180            185            190                      ArgThrThrGlySerGlyLeuLeuLysTrpGlnGlnGlyPheArgAlaLysIlePro                                  195            200            205                                  GlyLeuLeuAsnGlnThrSerArgSerLeuAspGlnIleProGlyTyrLeuAsnArg                      210            215            220            225                               IleHisGluLeuLeuAsnGlyThrArgGlyLeuPheProGlyProSerArgArgThr                         230            235            240            245                            LeuGlyAlaProAspIleSerSerGlyThrSerAspThrGlySerLeuProProAsn                            250            255            260            265                         LeuGlnProGlyTyrSerProSerProThrHisProProThrGlyGlnTyrThrLeu                               270            275            280            285                      PheProLeuProProThrLeuProThrProValValGlnLeuHisProLeuLeuPro                                  290            295            300                                  AspProSerAlaProThrProThrProThrSerProLeuLeuAsnThrSerTyrThr                      305            310            315            320                               HisSerGlnAsnLeuSerGlnGluGly (SEQ ID NO:3)                                         325            330   332                                                    153                                                                       

wherein;

Xaa at position 112 is deleted or Leu, Ala, Val, Ile, Pro, Phe, Trp, or Met;

Xaa at position 113 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met;

Xaa at position 114 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met;

Xaa at position 115 is deleted or Gln, Gly, Ser, Thr, Tyr, or Asn; and

wherein the N-terminus is joined to the C-terminus directly or through a linker (L₂) capable of joining the N-terminus to the C-terminus and having new C- and N-termini at amino acids;

    ______________________________________                                         26-27          51-52       108-109                                             27-28                                       109-110                            28-29                                       110-111                            29-30                                       111-112                            30-31                                       112-113                            32-33                                       113-114                            33-34                                       114-115                            34-35                                       115-116                            36-37                                       116-117                            37-38                                       117-118                            38-39                                       118-119                            40-41                                       119-120                            41-42                                       120-121                            42-43                                       121-122                            43-44                                       122-123                            44-45                                       123-124                            46-47                                       124-125                            47-48                                       125-126                            48-49                                       126-127                            50-51                                       or 127-128;                        ______________________________________                                    

or

(IV) A polypeptide comprising; a modified hIL-3 amino acid sequence of the formula:

    Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn                    1               5                   10                  15                     Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                                    20                  25                  30                     Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa                                    35                  40                  45                     Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                                    50                  55                  60                     Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                                    65                  70                  75                     Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                                    80                  85                  90                     Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                                    95                  100                 105                    Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                                    110                 115                 120                    Xaa Xaa Xaa Gln Gln Thr Thr Leu Ser Leu Ala Ile Phe                                            125                 130 (SEQ ID NO:2)                     

wherein

Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln, or Arg;

Xaa at position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln;

Xaa at position 19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys;

Xaa at position 20 is Ile, Cys, Gln, Glu, Arg, Pro, or Ala;

Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val;

Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly;

Xaa at position 23 is Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, or Arg;

Xaa at position 24 is Ile, Gly, Val, Arg, Ser, Phe, or Leu;

Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro, or Ala;

Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala, or Trp;

Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala;

Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp;

Xaa at position 29 is Gln, Asn, Leu, Pro, Arg, or Val;

Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys;

Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;

Xaa at position 32 is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu;

Xaa at position 33 is Pro, Leu, Gln, Ala, Thr, or Glu;

Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met;

Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gln, or Val;

Xaa at position 36 is Asp, Leu, or Val;

Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile;

Xaa at position 38 is Asn, or Ala;

Xaa at position 40 is Leu, Trp, or Arg;

Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, or Pro;

Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Met or Ala;

Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly or Ser;

Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro;

Xaa at position 45 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, Ile, Glu or His;

Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly;

Xaa at position 47 is Ile, Gly, Val, Ser, Arg, Pro, or His;

Xaa at position 48 is Leu, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn;

Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp;

Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His, Phe, Met or Gln;

Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His;

Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;

Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or

Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His, Ala or Leu;

Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly;

Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys;

Xaa at position 57 is Asn or Gly;

Xaa at position 58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys;

Xaa at position 59 is Glu Tyr, His, Leu, Pro, or Arg;

Xaa at position 60 is Ala, Ser, Pro, Tyr, Asn, or Thr;

Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;

Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile;

Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val;

Xaa at position 64 is Ala, Asn, Pro, Ser, or Lys;

Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser;

Xaa at position 66 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;

Xaa at position 67 is Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro, or His;

Xaa at position 68 is Leu, Val, Trp, Ser, Ile, Phe, Thr, or His;

Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Leu;

Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;

Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, or Asn;

Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;

Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg;

Xaa at position 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala;

Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu;

Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp;

Xaa at position 77 is Ile, Ser, Arg, Thr, or Leu;

Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg;

Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile, Gly, or Asp;

Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg;

Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys;

Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, Ile, Met or Val;

Xaa at position 83 is Pro, Ala, Thr, Trp, Arg, or Met;

Xaa at position 84 is Cys, Glu, Gly, Arg, Met, or Val;

Xaa at position 85 is Leu, Asn, Val, or Gln;

Xaa at position 86 is Pro, Cys, Arg, Ala, or Lys;

Xaa at position 87 is Leu, Ser, Trp, or Gly;

Xaa at position 88 is Ala, Lys, Arg, Val, or Trp;

Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser;

Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, Ile, or Met;

Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His;

Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile or Leu;

Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg;

Xaa at position 94 is Arg, Ile, Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro;

Xaa at position 95 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, Ile, or Tyr;

Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr;

Xaa at position 97 is Ile, Val, Lys, Ala, or Asn;

Xaa at position 98 is His, Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro;

Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, Phe, or His;

Xaa at position 100 is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gln, or Pro;

Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu, or Gln;

Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro;

Xaa at position 103 is Asp, or Ser;

Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe, or Gly;

Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;

Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro;

Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala or Pro;

Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly;

Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser, or Trp;

Xaa at position 111 is Leu, Ile, Arg, Asp, or Met;

Xaa at position 112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe;

Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val or Asn;

Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu;

Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met;

Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gln, or Ile;

Xaa at position 117 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro;

Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr;

Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg;

Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gln;

Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly;

Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;

Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

wherein optionally from 1 to 14 amino acids can be deleted from the N-terminus and/or from 1 to 15 amino acids can be deleted from the C-terminus; and wherein from 1 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3; or

(V) a colony stimulating factor;

and wherein L₁ is a linker capable of linking R₁ to R₂ ;

with the proviso that at least R₁ or R₂ is selected from the polypeptide of formula (I) , (II), or (III); and

said hematopoietic protein can optionally be immediately preceded by (methionine⁻¹), (alanine⁻¹) or (methionine⁻², alanine⁻¹).

The more preferred breakpoints at which new C-terminus and N-terminus can be made in the polypeptide (I) above are; 38-39, 39-40, 40-41, 41-42, 48-49, 53-54, 54-55, 55-56, 56-57, 57-58, 58-59, 59-60, 60-61, 61-62, 62-63, 64-65, 65-66, 66-67, 67-68, 68-69, 69-70, 96-97, 125-126, 126-127, 127-128, 128-129, 129-130, 130-131, 131-132, 132-133, 133-134, 134-135, 135-136, 136-137, 137-138, 138-139, 139-140, 140-141 and 141-142.

The most preferred breakpoints at which new C-terminus and N-terminus can be made in the polypeptide (I) above are; 38-39, 48-49, 96-97, 125-126, 132-133 and 141-142.

The more preferred breakpoints at which new C-terminus and N-terminus can be made in the polypeptide (II) above are; 28-29, 29-30, 30-31, 31-32, 32-33, 33-34, 34-35, 35-36, 36-37, 37-38, 38-39, 39-40, 66-67, 67-68, 68-69, 69-70, 70-71, 84-85, 85-86, 86-87, 87-88, 88-89, 89-90, 90-91, 98-99, 99-100, 100-101 and 101-102.

The most preferred breakpoints at which new C-terminus and N-terminus can be made in the polypeptide (II) above are; 34-35, 69-70 and 90-91.

The more preferred breakpoints at which new C-terminus and N-terminus can be made in the polypeptide (III) above or the amino acid sequence of (SEQ ID NO:256) are; 80-81, 81-82, 82-83, 83-84, 84-85, 85-86, 86-87, 108-109, 109-110, 110-111, 111-112, 112-113, 113-114, 114-115, 115-116, 116-117, 117-118, 118-119, 119-120, 120-121, 121-122, 122-123, 123-124, 124-125, 125-126 and 126-127.

The most preferred breakpoints at which new C-terminus and N-terminus can be made in the polypeptide (III) above or the amino acid sequence of (SEQ ID NO:256) are; 81-82, 108-109, 115-116, 119-120, 122-123 and 125-126.

The invention is also intended to include multifunctional receptor agonists which comprises a sequence rearranged c-mpl receptor agonist in which the cysteine at position 7 and/or 151 are substituted with another amino acid. Preferably, the substitution at position 7 and 151 is Ser, Ala, Gly, His, Asn, Asp, Thr, Phe or Thr. More preferably, the substitution at position 7 and 151 is Ser, Ala, Gly, His or Asn.

The multifunctional receptor agonist of the present invention can also be represented by the following formula:

    (T.sup.1)a-(L.sup.1)b-X.sup.1 -(L)c-X.sup.2 -(L.sup.2)d-(T.sup.2)e

    X.sup.1 -(L)c-X.sup.2 -(L)-Y.sup.1 -(L)c-Y.sup.2

in which:

X¹ is a peptide comprising an amino acid sequence corresponding to the sequence of residues n+1 through J of the original protein having amino acids residues numbered sequentially 1 through J with an amino terminus at residue 1;

L is an optional linker;

X² is a peptide comprising an amino acid sequence of residues 1 through n of the original protein;

Y¹ is a peptide comprising an amino acid sequence corresponding to the sequence of residues n=1 through K of the original protein having amino acids residues numbered sequentially 1 through K with an amino terminus at residue 1;

Y² is a peptide comprising an amino acid sequence of residues 1 through n of the original protein;

L¹ and L² are optional peptide spacers:

n is an integer ranging from 1 to J-1;

b, c, and d are each independently 0 or 1;

a and e are either 0 or 1, provided that both a and e cannot both be 0; and

T¹ and T² are proteins.

Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the multi-functional hematopoietic receptor agonists, related microbial expression systems, and processes for making the multi-functional hematopoietic receptor agonists. The invention also relates to pharmaceutical compositions containing the multi-functional hematopoietic receptor agonists, and methods for using the multi-functional hematopoietic receptor agonists.

In addition to the use of the multi-functional hematopoietic receptor agonists of the present invention in vivo, it is envisioned that in vitro uses would include the ability to stimulate bone marrow and blood cell activation and growth before infusion into patients.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 schematically illustrates the sequence rearrangement of a protein. The N-terminus (N) and the C-terminus (C) of the native protein are joined through a linker, or joined directly. The protein is opened at a breakpoint creating a new N-terminus (new N) and a new C-terminus (new-C) resulting in a protein with a new linear amino acid sequence. A rearranged molecule may be synthesized de novo as linear molecule and not go through the steps of joining the original N-terminus and the C-terminus and opening of the protein at the breakpoint.

FIG. 2 shows a schematic of Method I, for creating new proteins in which the original N-terminus and C-terminus of the native protein are joined with a linker and different N-terminus and C-terminus of the protein are created. In the example shown the sequence rearrangement results in a new gene encoding a protein with a new N-terminus created at amino acid 97 of the original protein, the original C-terminus (a.a. 174) joined to the amino acid 11 (a.a. 1-10 are deleted) through a linker region and a new C-terminus created at amino acid 96 of the original sequence.

FIG. 3 shows a schematic of Method II, for creating new proteins in which the original N-terminus and C-terminus of the native protein are joined without a linker and different N-terminus and C-terminus of the protein are created. In the example shown the sequence rearrangement results in a new gene encoding a protein with a new N-terminus created at amino acid 97 of the original protein, the original C-terminus (a.a. 174) joined to the original N-terminus and a new C-terminus created at amino acid 96 of the original sequence.

FIG. 4 shows a schematic of Method III, for creating new proteins in which the original N-terminus and C-terminus of the native protein are joined with a linker and different N-terminus and C-terminus of the protein are created. In the example shown the sequence rearrangement results in a new gene encoding a protein with a new N-terminus created at amino acid 97 of the original protein, the original C-terminus (a.a. 174) joined to amino acid 1 through a linker region and a new C-terminus created at amino acid 96 of the original sequence.

DETAILED DESCRIPTION OF THE INVENTION

The present invention encompasses multi-functional hematopoietic receptor agonists formed from covalently linked polypeptides, each of which may act through a different and specific cell receptor to initiate complementary biological activities. Hematopoiesis requires a complex series of cellular events in which stem cells generate continuously into large populations of maturing cells in all major lineages. There are currently at least 20 known regulators with hematopoietic proliferative activity. Most of these proliferative regulators can only stimulate one or another type of colony formation in vitro, the precise pattern of colony formation stimulated by each regulator is quite distinctive. No two regulators stimulate exactly the same pattern of colony formation, as evaluated by colony numbers or, more importantly, by the lineage and maturation pattern of the cells making up the developing colonies. Proliferative responses can most readily be analyzed in simplified in vitro culture systems. Three quite different parameters can be distinguished: alteration in colony size, alteration in colony numbers and cell lineage. Two or more factors may act on the progenitor cell, inducing the formation of larger number of progeny thereby increasing the colony size. Two or more factors may allow increased number of progenitor cells to proliferate either because distinct subsets of progenitors cells exist that respond exclusively to one factor or because some progenitors require stimulation by two or more factors before being able to respond. Activation of additional receptors on a cell by the use of two or more factors is likely to enhance the mitotic signal because of coalescence of initially differing signal pathways into a common final pathway reaching the nucleus (Metcalf, Nature 339: 27, 1989). Other mechanisms could explain synergy. For example, if one signaling pathway is limited by an intermediate activation of an additional signaling pathway which is caused by a second factor, then this may result in a super additive response. In some cases, activation of one receptor type can induce an enhanced expression of other receptors (Metcalf, Blood 82: 3515-3523, 1993). Two or more factors may result in a different pattern of cell lineages than from a single factor. The use of multi-functional hematopoietic receptor agonists may have a potential clinical advantage resulting from a proliferative response that is not possible by any single factor.

The receptors of hematopoietic and other growth factors can be grouped into two distinct families of related proteins: (1) tyrosine kinase receptors, including those for epidermal growth factor, M-CSF (Sherr, Blood 75: 1, 1990) and SCF (Yarden et al., EMBO J. 6: 3341, 1987): and (2) hematopoietic receptors, not containing a tyrosine kinase domain, but exhibiting obvious homology in their extracellular domain (Bazan, PNAS USA 87: 6934-6938, 1990). Included in this latter group are erythropoietin (EPO) (D'Andrea et al., Cell 57: 277, 1989), GM-CSF (Gearing et al., EMBO J. 8: 3667, 1989), IL-3 (Kitamura et al., Cell 66: 1165, 1991), G-CSF (Fukunaga et al., J. Bio. Chem. 265: 14008-15, 1990), IL-4 (Harada et al., PNAS USA 87: 857, 1990), IL-5 (Takaki et al., EMBO J. 9: 4367, 1990), IL-6 (Yamasaki et al., Science 241: 825, 1988), IL-7 (Goodwin et al., Cell 60: 941-51, 1990), LIF (Gearing et al., EMBO J. 10: 2839, 1991) and IL-2 (Cosman et al., Mol-Immunol. 23: 935-94, 1986). Most of the latter group of receptors exists in a high-affinity form as heterodimers. After ligand binding, the specific α-chains become associated with at least one other receptor chain (β-chain, γ-chain). Many of these factors share a common receptor subunit. The α-chains for GM-CSF, IL-3 and IL-5 share the same β-chain (Kitamura et al., Cell 66: 1165, 1991), Takaki et al., EMBO J. 10: 2833-8, 1991) and receptor complexes for IL-6, LIF and IL-11 share a common β-chain (gp130) (Taga et al., Cell 58: 573-81, 1989; Gearing et al., Science 255: 1434-7, 1992). The receptor complexes of IL-2, IL-4, IL-7, IL-9 and IL-15 share a common γ-chain (Kondo et al., Science 262: 1874, 1993; Russell et al., Science 266: 1042-1045, 1993; Noguchi et al., Science 262: 1877, 1993; Giri et al., EMBO J. 13: 2822-2830, 1994).

The use of a multiply acting hematopoietic factor may also have a potential advantage by reducing the demands placed on factor-producing cells and their induction systems. If there are limitations in the ability of a cell to produce a factor, then by lowering the required concentrations of each of the factors, and using them in combination may usefully reduce demands on the factor-producing cells. The use of a multiply acting hematopoietic factor may lower the amount of the factors that would be needed, probably reducing the likelihood of adverse side-effects.

Novel compounds of this invention are represented by a formula selected from the group consisting of:

    R.sub.1 -L.sub.1 -R.sub.2, R.sub.2 -L.sub.1 -R.sub.1, R.sub.1 -R.sub.2, and R.sub.2 -R.sub.1

Where R₁ and R2 are as defined above. R₂ is preferably a colony stimulating factor with a different but complementary activity than R₁. By complementary activity is meant activity which enhances or changes the response to another cell modulator. The R₁ polypeptide is joined either directly or through a linker segment to the R₂ polypeptide. The term "directly" defines multi-functional hematopoietic receptor agonists in which the polypeptides are joined without a peptide linker. Thus L₁ represents a chemical bond or polypeptide segment to which both R₁ and R₂ are joined in frame, most commonly L₁ is a linear peptide to which R₁ and R₂ are joined by amide bonds linking the carboxy terminus of R₁ to the amino terminus of L₁ and carboxy terminus of L₁ to the amino terminus of R₂. By "joined in frame" is meant that there is no translation termination or disruption between the reading frames of the DNA encoding R₁ and R₂.

A non-exclusive list of other growth factors, i.e. colony stimulating factors (CSFs), are cytokines, lymphokines, interleukins, hematopoietic growth factors which can be joined to (I), (II) or (III) include GM-CSF, G-CSF, c-mpl ligand (also known as TPO or MGDF), M-CSF, erythropoietin (EPO), IL-1, IL-4, IL-2, IL-3, IL-5, IL 6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, LIF, flt3 ligand, human growth hormone, and stem cell factor (SCF) also known as steel factor or c-kit ligand. Additionally, this invention encompasses the use of modified R₁ or R₂ molecules or mutated or modified DNA sequences encoding these R₁ or R₂ molecules. The present invention also includes multi-functional hematopoietic receptor agonists in which R₁ or R₂ is an hIL-3 variant, c-mpl ligand variant, or G-CSF variant. A "hIL-3 variant" is defined as a hIL-3 molecule which has amino acid substitutions and/or portions of hIL-3 deleted as disclosed in WO 94/12638, WO 94/12639 and WO 95/00646, as well as other variants known in the art. A "c-mpl ligand variant" is defined an c-mpl ligand molecule which has amino acid substitutions and/or portions of c-mpl ligand deleted, disclosed in U.S. application Ser. No. 08/383,035 as well as other variants known in the art. A "G-CSF variant" is defined an G-CSF molecule which has amino acid substitutions and/or portions of G-CSF deleted, as disclosed herein, as well as other variants known in the art.

The linking group (Li) is generally a polypeptide of between 1 and 500 amino acids in length. The linkers joining the two molecules are preferably designed to (1) allow the two molecules to fold and act independently of each other, (2) not have a propensity for developing an ordered secondary structure which could interfere with the functional domains of the two proteins, (3) have minimal hydrophobic characteristics which could interact with the functional protein domains and (4) provide steric separation of R₁ and R₂ such that R₁ and R₂ could interact simultaneously with their corresponding receptors on a single cell. Typically surface amino acids in flexible protein regions include Gly, Asn and Ser. Virtually any permutation of amino acid sequences containing Gly, Asn and Ser would be expected to satisfy the above criteria for a linker sequence. Other neutral amino acids, such as Thr and Ala, may also be used in the linker sequence. Additional amino acids may also be included in the linkers due to the addition of unique restriction sites in the linker sequence to facilitate construction of the multi-functional hematopoietic receptor agonists.

Preferred L₁ linkers of the present invention include sequences selected from the group of formulas: (Gly³ Ser)^(n) (SEQ ID NO:4), (Gly⁴ Ser)^(n) (SEQ ID NO:5), (Gly⁵ Ser)^(n) (SEQ ID NO:6), (Gly^(n) Ser)^(n) (SEQ ID NO:7) or (AlaGlySer)^(n) (SEQ ID NO:8).

One example of a highly-flexible linker is the glycine and serine-rich spacer region present within the pIII protein of the filamentous bacteriophages, e.g. bacteriophages M13 or fd (Schaller et al., PNAS USA 72: 737-741, 1975). This region provides a long, flexible spacer region between two domains of the pIII surface protein. The spacer region consists of the amino acid sequence:

    GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGluGlyGlyGlySerGluGlyGlyGlySerGluGlyGlyGlySerGluGlyGlyGlySerGlyGlyGlySer                          (SEQ ID NO:9).

The present invention also includes linkers in which an endopeptidase recognition sequence is included. Such a cleavage site may be valuable to separate the individual components of the multi-functional hematopoietic receptor agonist to determine if they are properly folded and active in vitro. Examples of various endopeptidases include, but are not limited to, plasmin, enterokinase, kallikrein, urokinase, tissue plasminogen activator, clostripain, chymosin, collagenase, Russell's viper venom protease, postproline cleavage enzyme, V8 protease, Thrombin and factor Xa.

Peptide linker segments from the hinge region of heavy chain immunoglobulins IgG, IgA, IgM, IgD or IgE provide an angular relationship between the attached polypeptides. Especially useful are those hinge regions where the cysteines are replaced with serines. Preferred linkers of the present invention include sequences derived from murine IgG gamma 2b hinge region in which the cysteines have been changed to serines. These linkers may also include an endopeptidase cleavage site. Examples of such linkers include the following sequences:

    IleSerGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerPro (SEQ ID NO:10)

and

    IleGluGlyArgIleSerGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerPro                                                  (SEQ ID NO:11).

The present invention is, however, not limited by the form, size or number of linker sequences employed and the only requirement of the linker is that functionally it does not interfere with the folding and function of the individual molecules of the multi-functional hematopoietic receptor agonist.

One aspect of the invention includes multi-functional hematopoietic receptor agonists which comprise a sequence rearranged c-mpl receptor agonist in which the cysteine(s) at position 7 and 151 of c-mpl ligand, have been substituted with another amino acid. Kaushansky et al. (Blood 86: 255a Abstract 1008, 1995) teaches that all four of the cysteines at positions 7, 29, 85, and 151 are required for bioactivity. The presence of cysteines in a protein can cause problems in processing when the protein is being produced recombinantly in a bacterial host. Microbially produced cysteine-containing proteins may tend to form multimers which greatly complicate purification of the protein product. Several additional purification steps, such as reduction and reoxidation of the recombinant protein may be required to obtain the protein in the proper confirmation. Removal of one of the cysteine residues, with concurrent replacement by a chemically equivalent neutral amino acid, would be desirable, in order to simplify the isolation and purification of the molecule. However, the successful removal of cysteines from biologically active molecules is unpredictable, in that the tertiary structure in the absence of the normally formed disulfide bridges, can be substantially altered. A molecule in which a pair of cysteines at positions 7 and 151 are substituted with another amino acid may have one or more advantages including, but not limited to: 1) increased folding efficiency of the heterologously expressed protein; 2) elimination of mispaired disulfides, 3) use of milder refold conditions (ie. Guanidine vs. Urea); 4) increased purification yields, 5) increased protein solubility; and 6) increased protein stability.

Determination of the Linker L₂

The length of the amino acid sequence of the linker L₂ to be used in R₁ and/or R₂ can be selected empirically or with guidance from structural information, or by using a combination of the two approaches.

When no structural information is available, a small series of linkers can be prepared for testing using a design whose length is varied in order to span a range from 0 to 50 Å and whose sequence is chosen in order to be consistent with surface exposure (hydrophilicity, Hopp & Woods, Mol. Immunol. 20: 483-489, 1983), Kyte & Doolittle, J. Mol. Biol. 157: 105-132; solvent exposed surface area, Lee & Richards, J. Mol. Biol. 55: 379-400, 1971) and the ability to adopt the necessary conformation with out deranging the conformation of R¹ or R² (conformationally flexible; Karplus & Schulz, Naturwissenschaften 72: 212-213, 1985). Assuming an average of translation of 2.0 to 3.8 Å per residue, this would mean the length to test would be between 0 to 30 residues, with 0 to 15 residues being the preferred range. Exemplary of such an empirical series would be to construct linkers using a cassette sequence such as Gly-Gly-Gly-Ser (SEQ ID NO:12) repeated n times, where n is 1, 2, 3 or 4. Those skilled in the art will recognize that there are many such sequences that vary in length or composition that can serve as linkers with the primary consideration being that they be neither excessively long nor short (cf., Sandhu, Critical Rev. Biotech. 12: 437-462, 1992); if they are too long, entropy effects will likely destabilize the three-dimensional fold, and may also make folding kinetically impractical, and if they are too short, they will likely destabilize the molecule because of torsional or steric strain.

Those skilled in the analysis of protein structural information will recognize that using the distance between the chain ends, defined as the distance between the c-alpha carbons, can be used to define the length of the sequence to be used, or at least to limit the number of possibilities that must be tested in an empirical selection of linkers. They will also recognize that it is sometimes the case that the positions of the ends of the polypeptide chain are ill-defined in structural models derived from x-ray diffraction or nuclear magnetic resonance spectroscopy data, and that when true, this situation will therefore need to be taken into account in order to properly estimate the length of the linker required. From those residues whose positions are well defined are selected two residues that are close in sequence to the chain ends, and the distance between their c-alpha carbons is used to calculate an approximate length for a linker between them. Using the calculated length as a guide, linkers with a range of number of residues (calculated using 2 to 3.8 Å per residue) are then selected. These linkers may be composed of the original sequence, shortened or lengthened as necessary, and when lengthened the additional residues may be chosen to be flexible and hydrophilic as described above; or optionally the original sequence may be substituted for using a series of linkers, one example being the Gly-Gly-Gly-Ser (SEQ ID NO:12) cassette approach mentioned above; or optionally a combination of the original sequence and new sequence having the appropriate total length may be used.

Determination of the Amino and Carboxyl Termini of R₁ and R₂

Sequences of R₁ and R₂ capable of folding to biologically active states can be prepared by appropriate selection of the beginning (amino terminus) and ending (carboxyl terminus) positions from within the original polypeptide chain while using the linker sequence L₂ as described above. Amino and carboxyl termini are selected from within a common stretch of sequence, referred to as a breakpoint region, using the guidelines described below. A novel amino acid sequence is thus generated by selecting amino and carboxyl termini from within the same breakpoint region. In many cases the selection of the new termini will be such that the original position of the carboxyl terminus immediately preceded that of the amino terminus. However, those skilled in the art will recognize that selections of termini anywhere within the region may function, and that these will effectively lead to either deletions or additions to the amino or carboxyl portions of the new sequence.

It is a central tenet of molecular biology that the primary amino acid sequence of a protein dictates folding to the three-dimensional structure necessary for expression of its biological function. Methods are known to those skilled in the art to obtain and interpret three-dimensional structural information using x-ray diffraction of single protein crystals or nuclear magnetic resonance spectroscopy of protein solutions. Examples of structural information that are relevant to the identification of breakpoint regions include the location and type of protein secondary structure (alpha and 3-10 helices, parallel and anti-parallel beta sheets, chain reversals and turns, and loops; Kabsch & Sander, Biopolymers 22: 2577-2637, 1983), the degree of solvent exposure of amino acid residues, the extent and type of interactions of residues with one another (Chothia, Ann. Rev. Biochem. 53: 537-572, 1984) and the static and dynamic distribution of conformations along the polypeptide chain (Alber & Mathews, Methods Enzymol. 154: 511-533, 1987). In some cases additional information is known about solvent exposure of residues; one example is a site of post-translational attachment of carbohydrate which is necessarily on the surface of the protein. When experimental structural information is not available, or is not feasible to obtain, methods are also available to analyze the primary amino acid sequence in order to make predictions of protein tertiary and secondary structure, solvent accessibility and the occurrence of turns and loops. Biochemical methods are also sometimes applicable for empirically determining surface exposure when direct structural methods are not feasible; for example, using the identification of sites of chain scission following limited proteolysis in order to infer surface exposure (Gentile & Salvatore, Eur. J. Biochem. 218: 603-621, 1993) Thus using either the experimentally derived structural information or predictive methods (e.g., Srinivisan & Rose Proteins: Struct., Funct. & Genetics, 22: 81-99, 1995) the parental amino acid sequence is inspected to classify regions according to whether or not they are integral to the maintenance of secondary and tertiary structure. The occurrence of sequences within regions that are known to be involved in periodic secondary structure (alpha and 3-10 helices, parallel and anti-parallel beta sheets) are regions that should be avoided. Similarly, regions of amino acid sequence that are observed or predicted to have a low degree of solvent exposure are more likely to be part of the so-called hydrophobic core of the protein and should also be avoided for selection of amino and carboxyl termini. In contrast, those regions that are known or predicted to be in surface turns or loops, and especially those regions that are known not to be required for biological activity, are the preferred sites for location of the extremes of the polypeptide chain. Continuous stretches of amino acid sequence that are preferred based on the above criteria are referred to as a breakpoint region.

Non-covalent Multifunctional hematopoietic growth factors

An alternative method for connecting two hematopoietic growth factors is by means of a non-covalent interaction. Such complexed proteins can be described by one of the formulae:

    R.sub.1 -C.sub.1 +R.sub.2 -C.sub.2 ; or C.sub.1 -R.sub.1 +C.sub.2 -R.sub.2 ; C.sub.1 -R.sub.1 +R.sub.2 -C.sub.2 ; or C.sub.1 -R.sub.1 +R.sub.2 -C.sub.2.

R₁ and R₂ are as is defined above. Domains C₁ and C₂ are either identical or non-identical chemical structures, typically proteinaceous, which can form a non-covalent, specific association. Complexes between C₁ and C₂ result in a one-to-one stoichiometric relationship between R₁ and R₂ for each complex. Examples of domains which associate are "leucine zipper" domains of transcription factors, dimerization domains of bacterial transcription repressors and immunoglobulin constant domains. Covalent bonds link R₁ and C₁, and R₂ and C₂, respectively. As indicated in the formulae, the domains C₁ and C₂ can be present either at the N-terminus or C-terminus of their corresponding hematopoietic growth factor (R). These multimerization domains (C₁ and C₂) include those derived from the bZIP family of proteins (Abel et al., Nature 341: 24-25, 1989; Landshulz et al., Science 240: 1759-1764, 1988; Pu et al., Nuc. Acid Res. 21: 4348-4355, 1993; Kozarides et al., Nature 336: 646-651, 1988), as well as multimerization domains of the helix-loop-helix family of proteins (Abel et al., Nature 341: 24-25, 1989; Murre et al., Cell 56: 777-783, 1989; Tapscott et al., Science 242: 405-411, 1988; Fisher et al., Genes & Dev. 5: 2342-2352, 1991). Preferred multi-functional hematopoietic receptor agonists of the present invention include colony stimulating factors dimerized by virtue of their incorporation as translational multi-functional hematopoietic receptor agonists with the leucine zipper dimerization domains of the bZIP family proteins Fos and Jun. The leucine zipper domain of Jun is capable of interacting with identical domains. On the other hand, the leucine zipper domain of Fos interacts with the Jun leucine zipper domain, but does not interact with other Fos leucine zipper domains. Mixtures of Fos and Jun predominantly result in formation of Fos-Jun heterodimers. Consequently, when joined to colony stimulating factors, the Jun domain can be used to direct the formation of either homo- or heterodimers. Preferential formation of heterodimers can be achieved if one of the colony stimulating factor partners is engineered to possess the Jun leucine zipper domain while the other is engineered to possess the Fos zipper.

Additional peptide sequences may also be added to facilitate purification or identification of multi-functional hematopoietic receptor agonist proteins (e.g., poly-His). A highly antigenic peptide may also be added that would enable rapid assay and facile purification of the multi-functional hematopoietic receptor agonist protein by a specific monoclonal antibody.

"Mutant amino acid sequence," "mutant protein", "variant protein", "mutein", or "mutant polypeptide" refers to a polypeptide having an amino acid sequence which varies from a native sequence due to amino acid deletions, substitutions, or both, or is encoded by a nucleotide sequence intentionally made variant from a native sequence. "Native sequence" refers to an amino acid or nucleic acid sequence which is identical to a wild-type or native form of a gene or protein.

Hematopoietic growth factors can be characterized by their ability to stimulate colony formation by human hematopoietic progenitor cells. The colonies formed include erythroid, granulocyte, megakaryocyte, granulocytic macrophages and mixtures thereof. Many of the hematopoietic growth factors have demonstrated the ability to restore bone marrow function and peripheral blood cell populations to therapeutically beneficial levels in studies performed initially in primates and subsequently in humans. Many or all of these biological activities of hematopoietic growth factors involve signal transduction and high affinity receptor binding. Multi-functional hematopoietic receptor agonists of the present invention may exhibit useful properties such as having similar or greater biological activity when compared to a single factor or by having improved half-life or decreased adverse side effects, or a combination of these properties.

Multi-functional hematopoietic receptor agonists which have little or no agonist activity maybe useful as antagonists, as antigens for the production of antibodies for use in immunology or immunotherapy, as genetic probes or as intermediates used to construct other useful hIL-3 muteins.

Biological activity of the multi-functional hematopoietic receptor agonist proteins of the present invention can be determined by DNA synthesis in factor-dependent cell lines or by counting the colony forming units in an in vitro bone marrow assay.

The multi-functional hematopoietic receptor agonists of the present invention may have an improved therapeutic profile as compared to single acting hematopoietic agonists. For example, some multi-functional hematopoietic receptor agonists of the present invention may have a similar or more potent growth factor activity relative to other hematopoietic agonists without having a similar or corresponding increase in side-effects.

The present invention also includes the DNA sequences which code for the multi-functional hematopoietic receptor agonist proteins, DNA sequences which are substantially similar and perform substantially the same function, and DNA sequences which differ from the DNAs encoding the multi-functional hematopoietic receptor agonists of the invention only due to the degeneracy of the genetic code. Also included in the present invention are the oligonucleotide intermediates used to construct the mutant DNAs and the polypeptides coded for by these oligonucleotides.

Genetic engineering techniques now standard in the art (U.S. Pat. No. 4,935,233 and Sambrook et al., "Molecular Cloning A Laboratory Manual", Cold Spring Harbor Laboratory, 1989) may be used in the construction of the DNA sequences of the present invention. One such method is cassette mutagenesis (Wells et al., Gene 34: 315-323, 1985) in which a portion of the coding sequence in a plasmid is replaced with synthetic oligonucleotides that encode the desired amino acid substitutions in a portion of the gene between two restriction sites.

Pairs of complementary synthetic oligonucleotides encoding the desired gene can be made and annealed to each other. The DNA sequence of the oligonucleotide would encode sequence for amino acids of desired gene with the exception of those substituted and/or deleted from the sequence.

Plasmid DNA can be treated with the chosen restriction endonucleases then ligated to the annealed oligonucleotides. The ligated mixtures can be used to transform competent JM101 cells to resistance to an appropriate antibiotic. Single colonies can be picked and the plasmid DNA examined by restriction analysis and/or DNA sequencing to identify plasmids with the desired genes.

Cloning of the DNA sequences of the novel multifunctional hematopoietic agonists wherein at least one of the with the DNA sequence of the other colony stimulating factor may be accomplished by the use of intermediate vectors. Alternatively one gene can be cloned directly into a vector containing the other gene. Linkers and adapters can be used for joining the DNA sequences, as well as replacing lost sequences, where a restriction site was internal to the region of interest. Thus genetic material (DNA) encoding one polypeptide, peptide linker, and the other polypeptide is inserted into a suitable expression vector which is used to transform bacteria, yeast, insect cells or mammalian cells. The transformed organism is grown and the protein isolated by standard techniques. The resulting product is therefore a new protein which has a colony stimulating factor joined by a linker region to a second colony stimulating factor.

Another aspect of the present invention provides plasmid DNA vectors for use in the expression of these novel multi-functional hematopoietic receptor agonists. These vectors contain the novel DNA sequences described above which code for the novel polypeptides of the invention. Appropriate vectors which can transform microorganisms capable of expressing the multi-functional hematopoietic receptor agonists include expression vectors comprising nucleotide sequences coding for the multi-functional hematopoietic receptor agonists joined to transcriptional and translational regulatory sequences which are selected according to the host cells used.

Vectors incorporating modified sequences as described above are included in the present invention and are useful in the production of the multi-functional hematopoietic receptor agonist polypeptides. The vector employed in the method also contains selected regulatory sequences in operative association with the DNA coding sequences of the invention and which are capable of directing the replication and expression thereof in selected host cells.

As another aspect of the present invention, there is provided a method for producing the novel multi-functional hematopoietic receptor agonists. The method of the present invention involves culturing suitable cells or cell line, which has been transformed with a vector containing a DNA sequence coding for expression of a novel multi-functional hematopoietic receptor agonist. Suitable cells or cell lines may be bacterial cells. For example, the various strains of E. coli are well-known as host cells in the field of biotechnology. Examples of such strains include E. coli strains JM101 (Yanish-Perron et al. Gene 33: 103-119, 1985) and MON105 (Obukowicz et al., Applied Environmental Microbiology 58: 1511-1523, 1992). Also included in the present invention is the expression of the multi-functional hematopoietic receptor agonist protein utilizing a chromosomal expression vector for E. coli based on the bacteriophage Mu (Weinberg et al., Gene 126: 25-33, 1993). Various strains of B. subtilis may also be employed in this method. Many strains of yeast cells known to those skilled in the art are also available as host cells for expression of the polypeptides of the present invention. When expressed in the E. coli cytoplasm, the gene encoding the multi-functional hematopoietic receptor agonists of the present invention may also be constructed such that at the 5' end of the gene codons are added to encode Met⁻² -Ala⁻¹ - or Met⁻¹ at the N-terminus of the protein. The N termini of proteins made in the cytoplasm of E. coli are affected by post-translational processing by methionine aminopeptidase (Ben Bassat et al., J. Bac. 169: 751-757, 1987) and possibly by other peptidases so that upon expression the methionine is cleaved off the N-terminus. The multi-functional hematopoietic receptor agonists of the present invention may include multi-functional hematopoietic receptor agonist polypeptides having Met⁻¹, Ala⁻¹ or Met⁻² -Ala⁻¹ at the N-terminus. These mutant multi-functional hematopoietic receptor agonists may also be expressed in E. coli by fusing a secretion signal peptide to the N-terminus. This signal peptide is cleaved from the polypeptide as part of the secretion process.

Also suitable for use in the present invention are mammalian cells, such as Chinese hamster ovary cells (CHO). General methods for expression of foreign genes in mammalian cells are reviewed in Kaufman, R. J., 1987) Genetic Engineering, Principles and Methods, Vol. 9, J. K. Setlow, editor, Plenum Press, New York. An expression vector is constructed in which a strong promoter capable of functioning in mammalian cells drives transcription of a eukaryotic secretion signal peptide coding region, which is translationally joined to the coding region for the multi-functional hematopoietic receptor agonist. For example, plasmids such as pcDNA I/Neo, pRc/RSV, and pRc/CMV (obtained from Invitrogen Corp., San Diego, Calif.) can be used. The eukaryotic secretion signal peptide coding region can be from the gene itself or it can be from another secreted mammalian protein (Bayne, M. L. et al., Proc. Natl. Acad. Sci. USA 84: 2638-2642, 1987). After construction of the vector containing the gene, the vector DNA is transfected into mammalian cells. Such cells can be, for example, the COS7, HeLa, BHK, CHO, or mouse L lines. The cells can be cultured, for example, in DMEM media (JRH Scientific). The polypeptide secreted into the media can be recovered by standard biochemical approaches following transient expression for 24-72 hours after transfection of the cells or after establishment of stable cell lines following selection for antibiotic resistance. The selection of suitable mammalian host cells and methods for transformation, culture, amplification, screening and product production and purification are known in the art. See, e.g., Gething and Sambrook, Nature, 293: 620-625, 1981), or alternatively, Kaufman et al, Mol. Cell. Biol., 5 (7): 1750-1759, 1985) or Howley et al., U.S. Pat. No. 4,419,446. Another suitable mammalian cell line is the monkey COS-1 cell line. A similarly useful mammalian cell line is the CV-1 cell line.

Where desired, insect cells may be utilized as host cells in the method of the present invention. See, e.g., Miller et al., Genetic Engineering, 8: 277-298 (Plenum Press 1986) and references cited therein. In addition, general methods for expression of foreign genes in insect cells using Baculovirus vectors are described in: Summers, M. D. and Smith, G. E., 1987)--A manual of methods for Baculovirus vectors and insect cell culture procedures, Texas Agricultural Experiment Station Bulletin No. 1555. An expression vector is constructed comprising a Baculovirus transfer vector, in which a strong Baculovirus promoter (such as the polyhedron promoter) drives transcription of a eukaryotic secretion signal peptide coding region, which is translationally joined to the coding region for the multi-functional hematopoietic receptor agonist polypeptide. For example, the plasmid pVL1392 (obtained from Invitrogen Corp., San Diego, Calif.) can be used. After construction of the vector carrying the gene encoding the multi-functional hematopoietic receptor agonist polypeptide, two micrograms of this DNA is co-transfected with one microgram of Baculovirus DNA (see Summers & Smith, 1987) into insect cells, strain SF9. Pure recombinant Baculovirus carrying the multi-functional hematopoietic receptor agonist is used to infect cells cultured, for example, in Excell 401 serum-free medium (JRH Biosciences, Lenexa, Kans.). The multi-functional hematopoietic receptor agonist secreted into the medium can be recovered by standard biochemical approaches. Supernatants from mammalian or insect cells expressing the multi-functional hematopoietic receptor agonist protein can be first concentrated using any of a number of commercial concentration units.

The multi-functional hematopoietic receptor agonists of the present invention may be useful in the treatment of diseases characterized by decreased levels of either myeloid, erythroid, lymphoid, or megakaryocyte cells of the hematopoietic system or combinations thereof. In addition, they may be used to activate mature myeloid and/or lymphoid cells. Among conditions susceptible to treatment with the polypeptides of the present invention is leukopenia, a reduction in the number of circulating leukocytes (white cells) in the peripheral blood. Leukopenia may be induced by exposure to certain viruses or to radiation. It is often a side effect of various forms of cancer therapy, e.g., exposure to chemotherapeutic drugs, radiation and of infection or hemorrhage. Therapeutic treatment of leukopenia with these multi-functional hematopoietic receptor agonists of the present invention may avoid undesirable side effects caused by treatment with presently available drugs.

The multi-functional hematopoietic receptor agonists of the present invention may be useful in the treatment of neutropenia and, for example, in the treatment of such conditions as aplastic anemia, cyclic neutropenia, idiopathic neutropenia, Chediak-Higashi syndrome, systemic lupus erythematosus (SLE), leukemia, myelodysplastic syndrome and myelofibrosis.

The multi-functional hematopoietic receptor agonist of the present invention may be useful in the treatment or prevention of thrombocytopenia. Currently the only therapy for thrombocytopenia is platelet transfusion which are costly and carry the significant risks of infection (HIV, HBV) and alloimmunization. The multi-functional hematopoietic receptor agonist may alleviate or diminish the need for platelet transfusion. Severe thrombocytopenia may result from genetic defects such as Fanconi's Anemia, Wiscott-Aldrich, or May Hegglin syndromes. Acquired. thrombocytopenia may result from auto- or allo-antibodies as in Immune Thrombocytopenia Purpura, Systemic Lupus Erythromatosis, hemolytic anemia, or fetal maternal incompatibility. In addition, splenomegaly, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, infection or prosthetic heart valves may result in thrombocytopenia. Severe thrombocytopenia may also result from chemotherapy and/or radiation therapy or cancer. Thrombocytopenia may also result from marrow invasion by carcinoma, lymphoma, leukemia or fibrosis.

The multi-functional hematopoietic receptor agonists of the present invention may be useful in the mobilization of hematopoietic progenitors and stem cells in peripheral blood. Peripheral blood derived progenitors have been shown to be effective in reconstituting patients in the setting of autologous marrow transplantation. Hematopoietic growth factors including G-CSF and GM-CSF have been shown to enhance the number of circulating progenitors and stem cells in the peripheral blood. This has simplified the procedure for peripheral stem cell collection and dramatically decreased the cost of the procedure by decreasing the number of pheresis required. The multi-functional hematopoietic receptor agonist may be useful in mobilization of stem cells and further enhance the efficacy of peripheral stem cell transplantation.

The multi-functional hematopoietic receptor agonists of the present invention may also be useful in the ex vivo expansion of hematopoietic progenitors and stem cells. Colony stimulating factors (CSFs), such as hIL-3, have been administered alone, co-administered with other CSFs, or in combination with bone marrow transplants subsequent to high dose chemotherapy to treat the neutropenia and thrombocytopenia which are often the result of such treatment. However the period of severe neutropenia and thrombocytopenia may not be totally eliminated. The myeloid lineage, which is comprised of monocytes (macrophages), granulocytes (including neutrophils) and megakaryocytes, is critical in preventing infections and bleeding which can be life-threatening. Neutropenia and thrombocytopenia may also be the result of disease, genetic disorders, drugs, toxins, radiation and many therapeutic treatments such as conventional oncology therapy.

Bone marrow transplants have been used to treat this patient population. However, several problems are associated with the use of bone marrow to reconstitute a compromised hematopoietic system including: 1) the number of stem cells in bone marrow, spleen, or peripheral blood is limited, 2) Graft Versus Host Disease, 3) graft rejection and 4) possible contamination with tumor cells. Stem cells make up a very small percentage of the nucleated cells in the bone marrow, spleen and peripheral blood. It is clear that a dose response exists such that a greater number of stem cells will enhance hematopoietic recovery. Therefore, the in vitro expansion of stem cells should enhance hematopoietic recovery and patient survival. Bone marrow from an allogeneic donor has been used to provide bone marrow for transplant. However, Graft Versus Host Disease and graft rejection limit bone marrow transplantation even in recipients with HLA-matched sibling donors. An alternative to allogeneic bone marrow transplants is autologous bone marrow transplants. In autologous bone marrow transplants, some of the patient's own marrow is harvested prior to myeloablative therapy, e.g. high dose chemotherapy, and is transplanted back into the patient afterwards. Autologous transplants eliminate the risk of Graft Versus Host Disease and graft rejection. However, autologous bone marrow transplants still present problems in terms of the limited number of stems cells in the marrow and possible contamination with tumor cells. The limited number of stem cells may be overcome by ex-vivo expansion of the stem cells. In addition, stem cells can be specifically isolated, based on the presence of specific surface antigens such as CD34+ in order to decrease tumor cell contamination of the marrow graft.

The following patents contain further details on separating stem cells, CD34+ cells, culturing the cells with hematopoietic factors, the use of the cells for the treatment of patients with hematopoietic disorders and the use of hematopoietic factors for cell expansion and gene therapy.

U.S. Pat. No. 5,061,620 relates to compositions comprising human hematopoietic stem cells provided by separating the stem cells from dedicated cells.

U.S. Pat. No. 5,199,942 describes a method for autologous hematopoietic cell transplantation comprising: (1) obtaining hematopoietic progenitor cells from a patient; (2) ex-vivo expansion of cells with a growth factor selected from the group consisting of IL-3, flt3 ligand, c-kit ligand, GM-CSF, IL-1, GM-CSF/IL-3 fusion protein and combinations thereof; (3) administering cellular preparation to a patient.

U.S. Pat. No. 5,240,856 relates to a cell separator that includes an apparatus for automatically controlling the cell separation process.

WO 91/16116 describes devices and methods for selectively isolating and separating target cells from a mixture of cells.

WO 91/18972 describes methods for in vitro culturing of bone marrow, by incubating suspension of bone marrow cells, using a hollow fiber bioreactor.

WO 92/18615 relates to a process for maintaining and expanding bone marrow cells, in a culture medium containing specific mixtures of cytokines, for use in transplants.

WO 93/08268 describes a method for selectively expanding stem cells, comprising the steps of (a) separating CD34+ stem cells from other cells and (b) incubating the separated cells in a selective medium, such that the stem cells are selectively expanded.

WO 93/18136 describes a process for in vitro support of mammalian cells derived from peripheral blood.

WO 93/18648 relates to a composition comprising human neutrophil precursor cells with a high content of myeloblasts and promyelocytes for treating genetic or acquired neutropenia.

WO 94/08039 describes a method of enrichment for human hematopoietic stem cells by selection for cells which express c-kit protein.

WO 94/11493 describes a stem cell population that are CD34+ and small in size, which are isolated using a counterflow elutriation method.

WO 94/27698 relates to a method combining immunoaffinity separation and continuous flow centrifugal separation for the selective separation of a nucleated heterogeneous cell population from a heterogeneous cell mixture.

WO 94/25848 describes a cell separation apparatus for collection and manipulation of target cells.

The long term culturing of highly enriched CD34+ precursors of hematopoietic progenitor cells from human bone marrow in cultures containing IL-1a, IL-3, IL-6 or GM-CSF is discussed in Brandt et al J. Clin. Invest. 86: 932-941, 1990).

One aspect of the present invention provides a method for selective ex-vivo expansion of stem cells. The term "stem cell" refers to the totipotent hematopoietic stem cells as well as early precursors and progenitor cells which can be isolated from bone marrow, spleen or peripheral blood. The term "expansion" refers to the differentiation and proliferation of the cells. The present invention provides a method for selective ex-vivo expansion of stem cells, comprising the steps of: (a) separating stem cells from other cells, (b) culturing said separated stem cells with a selective media which contains multi-functional hematopoietic receptor agonist protein(s) and (c) harvesting said stems cells. Stem cells, as well as committed progenitor cells destined to become neutrophils, erythrocytes, platelets, etc. may be distinguished from most other cells by the presence or absence of particular progenitor marker antigens, such as D34, that are present on the surface of these cells nd/or by morphological characteristics. The phenotype for a highly enriched human stem cell fraction is reported as CD34+, Thy-1+ and lin-, but it is to be understood that the present invention is not limited to the expansion of this stem cell population. The CD34+ enriched human stem cell fraction can be separated by a number of reported methods, including affinity columns or beads, magnetic beads or flow cytometry using antibodies directed to surface antigens such as the CD34+. Further, physical separation methods such as counterflow elutriation may be used to enrich hematopoietic progenitors. The CD34+ progenitors are heterogeneous, and may be divided into several sub-populations characterized by the presence or absence of co-expression of different lineage associated cell surface associated molecules. The most immature progenitor cells do not express any known lineage associated markers, such as HLA-DR or CD38, but they may express CD90(thy-1). Other surface antigens such as CD33, CD38, CD41, CD71, HLA-DR or c-kit can also be used to selectively isolate hematopoietic progenitors. The separated cells can be incubated in selected medium in a culture flask, sterile bag or in hollow fibers. Various colony stimulating factors may be utilized in order to selectively expand cells. Representative factors that have been utilized for ex-vivo expansion of bone marrow include, c-kit ligand, IL-3, G-CSF, GM-CSF, IL-1, IL-6, IL-11, flt-3 ligand or combinations thereof. The proliferation of the stem cells can be monitored by enumerating the number of stem cells and other cells, by standard techniques (e.g. hemacytometer, CFU, LTCIC) or by flow cytometry prior and subsequent to incubation.

Several methods for ex-vivo expansion of stem cells have been reported utilizing a number of selection methods and expansion using various colony stimulating factors including c-kit ligand (Brandt et al., Blood 83: 1507-1514 [1994], McKenna et al., Blood 86: 3413-3420 [1995]), IL-3 (Brandt et al., Blood 83: 1507-1514 [1994], Sato et al., Blood 82: 3600-3609 [1993]), G-CSF (Sato et al., Blood 82: 3600-3609 [1993]), GM-CSF (Sato et al., Blood 82: 3600-3609 [1993]), IL-1 (Muench et al., Blood 81: 3463-3473 [1993]), IL-6 (Sato et al., Blood 82: 3600-3609 [1993]), IL-11 (Lemoli et al., Exp. Hem. 21: 1668-1672 [1993], Sato et al., Blood 82: 3600-3609 [1993]), flt-3 ligand (McKenna et al., Blood 86: 3413 3420 [1995]) and/or combinations thereof (Brandt et al., Blood 83: 1507 1514 [1994], Haylock et al., Blood 80: 1405-1412 [1992], Koller et al., Biotechnology 11: 358-363 [1993], (Lemoli et al., Exp. Hem. 21: 1668-1672 [1993]), McKenna et al., Blood 86: 3413-3420 [1995], Muench et al., Blood 81: 3463-3473 [1993], Patchen et al., Biotherapy 7: 13-26 [1994], Sato et al., Blood 82: 3600-3609 [1993], Smith et al., Exp. Hem. 21: 870-877 [1993], Steen et al., Stem Cells 12: 214-224 [1994], Tsujino et al., Exp. Hem. 21: 1379-1386 [1993]). Among the individual colony stimulating factors, hIL-3 has been shown to be one of the most potent in expanding peripheral blood CD34+ cells (Sato et al., Blood 82: 3600-3609 [1993], Kobayashi et al., Blood 73: 1836-1841 [1989]). However, no single factor has been shown to be as effective as the combination of multiple factors. The present invention provides methods for ex vivo expansion that utilize multi-functional hematopoietic receptor agonists that are more effective than a single factor alone.

Another aspect of the invention provides methods of sustaining and/or expanding hematopoietic precursor cells which includes inoculating the cells into a culture vessel which contains a culture medium that has been conditioned by exposure to a stromal cell line such as HS-5 (WO 96/02662, Roecklein and Torok-Strob, Blood 85: 997-1105, 1995) that has been supplemented with a multi-functional hematopoietic receptor agonist of the present invention.

Another projected clinical use of growth factors has been in the in vitro activation of hematopoietic progenitors and stem cells for gene therapy. Due to the long life-span of hematopoietic progenitor cells and the distribution of their daughter cells throughout the entire body, hematopoietic progenitor cells are good candidates for ex vivo gene transfection. In order to have the gene of interest incorporated into the genome of the hematopoietic progenitor or stem cell one needs to stimulate cell division and DNA replication. Hematopoietic stem cells cycle at a very low frequency which means that growth factors may be useful to promote gene transduction and thereby enhance the clinical prospects for gene therapy. Potential applications of gene therapy (review Crystal, Science 270: 404-410 [1995]) include; 1) the treatment of many congenital metabolic disorders and immunodeficiencies (Kay and Woo, Trends Genet. 10: 253-257 [1994]), 2) neurological disorders (Friedmann, Trends Genet. 10: 210-214 [1994]), 3) cancer (Culver and Blaese, Trends Genet. 10: 174-178 [1994]) and 4) infectious diseases (Gilboa and Smith, Trends Genet. 10: 139-144 [1994]).

There are a variety of methods, known to those with skill in the art, for introducing genetic material into a host cell. A number of vectors, both viral and non-viral have been developed for transferring therapeutic genes into primary cells. Viral based vectors include; 1) replication deficient recombinant retrovirus (Boris-Lawrie and Temin, Curr. Opin. Genet. Dev. 3: 102-109 [1993], Boris-Lawrie and Temin, Annal. New York Acad. Sci. 716: 59-71 [1994], Miller, Current Top. Microbiol. Immunol. 158: 1-24 [1992]) and replication-deficient recombinant adenovirus (Berkner, BioTechniques 6: 616-629 [1988], Berkner, Current Top. Microbiol. Immunol. 158: 39-66 [1992], Brody and Crystal, Annal. New York Acad. Sci. 716: 90-103 [1994]). Non-viral based vectors include protein/DNA complexes (Cristiano et al., PNAS USA. 90: 2122-2126 [1993], Curiel et al., PNAS USA 88: 8850-8854 [1991], Curiel, Annal. New York Acad. Sci. 716: 36-58 [1994]), electroporation and liposome mediated delivery such as cationic liposomes (Farhood et al., Annal. New York Acad. Sci. 716: 23-35 [1994]).

The present invention provides an improvement to the existing methods of expanding hematopoietic cells, which new genetic material has been introduced, in that it provides methods utilizing multi-functional hematopoietic receptor agonist proteins that have improved biological activity, including an activity not seen by any single colony stimulation factor.

Many drugs may cause bone marrow suppression or hematopoietic deficiencies. Examples of such drugs are AZT, DDI, alkylating agents and anti-metabolites used in chemotherapy, antibiotics such as chloramphenicol, penicillin, gancyclovir, daunomycin and sulfa drugs, phenothiazones, tranquilizers such as meprobamate, analgesics such as aminopyrine and dipyrone, anti-convulsants such as phenytoin or carbamazepine, antithyroids such as propylthiouracil and methimazole and diuretics. The multi-functional hematopoietic receptor agonists of the present invention may be useful in preventing or treating the bone marrow suppression or hematopoietic deficiencies which often occur in patients treated with these drugs.

Hematopoietic deficiencies may also occur as a result of viral, microbial or parasitic infections and as a result of treatment for renal disease or renal failure, e.g., dialysis. The multi-functional hematopoietic receptor agonists of the present invention may be useful in treating such hematopoietic deficiencies.

The treatment of hematopoietic deficiency may include administration of a pharmaceutical composition containing the multi-functional hematopoietic receptor agonists to a patient. The multi-functional hematopoietic receptor agonists of the present invention may also be useful for the activation and amplification of hematopoietic precursor cells by treating these cells in vitro with the multi-functional hematopoietic receptor agonist proteins of the present invention prior to injecting the cells into a patient.

Various immunodeficiencies, e.g., in T and/or B lymphocytes, or immune disorders, e.g., rheumatoid arthritis, may also be beneficially affected by treatment with the multi-functional hematopoietic receptor agonists of the present invention. Immunodeficiencies may be the result of viral infections, e.g., HTLVI, HTLVII, HTLVIII, severe exposure to radiation, cancer therapy or the result of other medical treatment. The multi-functional hematopoietic receptor agonists of the present invention may also be employed, alone or in combination with other colony stimulating factors, in the treatment of other blood cell deficiencies, including thrombocytopenia (platelet deficiency), or anemia. Other uses for these novel polypeptides are the in vivo and ex vivo treatment of patients recovering from bone marrow transplants, and in the development of monoclonal and polyclonal antibodies generated by standard methods for diagnostic or therapeutic use.

Other aspects of the present invention are methods and therapeutic compositions for treating the conditions referred to above. Such compositions comprise a therapeutically effective amount of one or more of the multi-functional hematopoietic receptor agonists of the present invention in a mixture with a pharmaceutically acceptable carrier. This composition can be administered either parenterally, intravenously or subcutaneously. When administered, the therapeutic composition for use in this invention is preferably in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such a parenterally acceptable protein solution, having due regard to pH, isotonicity, stability and the like, is within the skill of the art.

The dosage regimen involved in a method for treating the above-described conditions will be determined by the attending physician considering various factors which modify the action of drugs, e.g., the condition, body weight, sex and diet of the patient, the severity of any infection, time of administration and other clinical factors. Generally, a daily regimen may be in the range of 0.2-150 μg/kg of multi-functional hematopoietic receptor agonist protein per kilogram of body weight. Dosages would be adjusted relative to the activity of a given multi-functional hematopoietic receptor agonist protein and it would not be unreasonable to note that dosage regimens may include doses as low as 0.1 microgram and as high as 1 milligram per kilogram of body weight per day. In addition, there may exist specific circumstances where dosages of multi-functional hematopoietic receptor agonist would be adjusted higher or lower than the range of 0.2-150 micrograms per kilogram of body weight. These include co-administration with other colony stimulating factors or IL-3 variants or growth factors; co-administration with chemotherapeutic drugs and/or radiation; the use of glycosylated multi-functional hematopoietic receptor agonist protein; and various patient-related issues mentioned earlier in this section. As indicated above, the therapeutic method and compositions may also include co-administration with other human factors. A non-exclusive list of other appropriate colony stimulating factors (CSFs), cytokines, lymphokines, hematopoietic growth factors and interleukins for simultaneous or serial co-administration with the polypeptides of the present invention includes GM-CSF, G-CSF, c-mpl ligand (also known as TPO or MGDF), M-CSF, erythropoietin (EPO), IL-1, IL-4, IL-2, IL-3, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-16, LIF, flt3 ligand, and eosinophil differentiation factor, stem cell factor (SCF) also known as steel factor or c-kit ligand, or combinations thereof. The dosage recited above would be adjusted to compensate for such additional components in the therapeutic composition. Progress of the treated patient can be monitored by periodic assessment of the hematological profile, e.g., differential cell count and the like.

Materials and Methods

Unless noted otherwise, all specialty chemicals were obtained from Sigma, Co. (St. Louis, Mo.). Restriction endonucleases and T4 DNA ligase were obtained from New England Biolabs (Beverly, Mass.) or Boehringer Mannheim (Indianapolis, Ind.).

Transformation of E. coli strains

E. coli strains, such as DH5α™ (Life Technologies, Gaithersburg, Md.) and TG1 (Amersham Corp., Arlington Heights, Ill.) are used for transformation of ligation reactions and are the source of plasmid DNA for transfecting mammalian cells. E. coli strains, such as JM101 (Yanisch-Perron, et al., Gene, 33: 103-119, 1985) and MON105 (Obukowicz, et al., Appl. and Envir. Micr., 58: 1511-1523, 1992) can be used for expressing the multi-functional hematopoietic receptor agonist of the present invention in the cytoplasm or periplasmic space.

MON105 ATCC#55204: F-, lambda-,IN(rrnD, rrE)1, rpoD+, rpoH358

DH5α™: F-, phi80dlacZdeltaM15, delta(lacZYA-argF)U169, deoR, recA1, endA1, hsdR17(rk-,mk+), phoA, supE44lamda-, thi-1, gyrA96, relA1

TG1: delta(lac-pro), supE, thi-1, hsdD5/F'(traD36, proA+B+,

lacIq, lacZdeltaM15)

JM101 ATCC#33876: delta (pro lac), supE, thi, F'(traD36, proA+B+, lacIq, lacZdeltaM15)

DH5α™ Subcloning efficiency cells are purchased as competent cells and are ready for transformation using the manufacturer's protocol, while both E. coli strains TG1 and MON105 are rendered competent to take up DNA using a CaCl₂ method. Typically, 20 to 50 mL of cells are grown in LB medium (1% bacto-tryptone, 0.5% bacto-yeast extract, 150 mM NaCl) to a density of approximately 1.0 optical density unit at 600 nanometers (OD600) as measured by a Baush & Lomb Spectronic spectrophotometer (Rochester, N.Y.). The cells are collected by centrifugation and resuspended in one-fifth culture volume of CaCl₂ solution (50 mM CaCl₂, 10 mM Tris-Cl, pH7.4) and are held at 4° C. for 30 minutes. The cells are again collected by centrifugation and resuspended in one-tenth culture volume of CaCl₂ solution. Ligated DNA is added to 0.2 mL of these cells, and the samples are held at 4° C. for 30-60 minutes. The samples are shifted to 42° C. for two minutes and 1.0 mL of LB is added prior to shaking the samples at 37° C. for one hour. Cells from these samples are spread on plates (LB medium plus 1.5% bacto-agar) containing either ampicillin (100 micrograms/mL, ug/mL) when selecting for ampicillin-resistant transformants, or spectinomycin (75 ug/mL) when selecting for spectinomycin-resistant transformants. The plates are incubated overnight at 37° C. Colonies are picked and inoculated into LB plus appropriate antibiotic (100 ug/mL ampicillin or 75 ug/mL spectinomycin) and are grown at 37° C. while shaking.

Methods for creation of genes with new N-terminus/C-terminus

Method I. Creation of genes with new N-terminus/C-terminus which contain a linker region (L₂).

Genes with new N-terminus/C-terminus which contain a linker region (L₂) separating the original C-terminus and N-terminus can be made essentially following the method described in L. S. Mullins, et al J. Am. Chem. Soc. 116, 5529-5533, 1994). Multiple steps of polymerase chain reaction (PCR) amplifications are used to rearrange the DNA sequence encoding the primary amino acid sequence of the protein. The steps are illustrated in FIG. 2.

In the first step, the first primer set ("new start" and "linker start") is used to create and amplify, from the original gene sequence, the DNA fragment ("Fragment Start") that contains the sequence encoding the new N-terminal portion of the new protein followed by the linker (L₂) that connects the C-terminal and N-terminal ends of the original protein. In the second step, the second primer set ("new stop" and "linker stop") is used to create and amplify, from the original gene sequence, the DNA fragment ("Fragment Stop") that encodes the same linker as used above, followed by the new C-terminal portion of the new protein. The "new start" and "new stop" primers are designed to include the appropriate restriction sites which allow cloning of the new gene into expression plasmids. Typical PCR conditions are one cycle 95° C. melting for two minutes; 25 cycles 94° C. denaturation for one minute, 50° C. annealing for one minute and 72° C. extension for one minute; plus one cycle 72° C. extension for seven minutes. A Perkin Elmer GeneAmp PCR Core Reagents kit is used. A 100 ul reaction contains 100 pmole of each primer and one ug of template DNA; and 1× PCR buffer, 200 uM dGTP, 200 uM DATP, 200 uM dTTP, 200 uM dCTP, 2.5 units AmpliTaq DNA polymerase and 2 mM MgCl2. PCR reactions are performed in a Model 480 DNA thermal cycler (Perkin Elmer Corporation, Norwalk, Conn.).

"Fragment Start" and "Fragment Stop", which have complementary sequence in the linker region and the coding sequence for the two amino acids on both sides of the linker, are joined together in a third PCR step to make the full-length gene encoding the new protein. The DNA fragments "Fragment Start" and "Fragment Stop" are resolved on a 1% TAE gel, stained with ethidium bromide and isolated using a Qiaex Gel Extraction kit (Qiagen). These fragments are combined in equimolar quantities, heated at 70° C. for ten minutes and slow cooled to allow annealing through their shared sequence in "linker start" and "linker stop". In the third PCR step, primers "new start" and "new stop" are added to the annealed fragments to create and amplify the full-length new N-terminus/C-terminus gene. Typical PCR conditions are one cycle 95° C. melting for two minutes; 25 cycles 94° C. denaturation for one minute, 60° C. annealing for one minute and 72° C. extension for one minute; plus one cycle 72° C. extension for seven minutes. A Perkin Elmer GeneAmp PCR Core Reagents kit is used. A 100 ul reaction contains 100 pmole of each primer and approximately 0.5 ug of DNA; and 1× PCR buffer, 200 uM dGTP, 200 uM dATP, 200 uM dTTP, 200 uM dCTP, 2.5 units AmpliTaq DNA polymerase and 2 mM MgCl2. PCR reactions are purified using a Wizard PCR Preps kit (Promega).

Method II. Creation of genes with new N-terminus/C-terminus without a linker region.

New N-terminus/C-terminus genes without a linker joining the original N-terminus and C-terminus can be made using two steps of PCR amplification and a blunt end ligation. The steps are illustrated in FIG. 3. In the first step, the primer set ("new start" and "P-bl start") is used to create and amplify, from the original gene sequence, the DNA fragment ("Fragment Start") that contains the sequence encoding the new N-terminal portion of the new protein. In the second step, the primer set ("new stop" and "P-bl stop") is used to create and amplify, from gene sequence, the DNA fragment ("Fragment Stop") that contains the sequence encoding the new C-terminal portion of the new protein. The "new start" and "new stop" primers are designed to include appropriate restriction sites which allow cloning of the new gene into expression vectors. Typical PCR conditions are one cycle 95° C. melting for two minutes; 25 cycles 94° C. denaturation for one minute, 50° C. annealing for 45 seconds and 72° C. extension for 45 seconds. Deep Vent polymerase (New England Biolabs) is used to reduce the occurrence of overhangs in conditions recommended by the manufacturer. The "P-bl start" and "P-bl stop" primers are phosphorylated at the 5' end to aid in the subsequent blunt end ligation of "Fragment Start" and "Fragment Stop" to each other. A 100 ul reaction contained 150 pmole of each primer and one ug of template DNA; and 1× Vent buffer (New England Biolabs), 300 uM dGTP, 300 uM DATP, 300 uM dTTP, 300 uM dCTP, and 1 unit Deep Vent polymerase. PCR reactions are performed in a Model 480 DNA thermal cycler (Perkin Elmer Corporation, Norwalk, Conn.). PCR reaction products are purified using a Wizard PCR Preps kit (Promega).

The primers are designed to include appropriate restriction sites which allow for the cloning of the new gene into expression vectors. Typically "Fragment Start" is designed to create NcoI restriction site, and "Fragment Stop" is designed to create a HindIII restriction site. Restriction digest reactions are purified using a Magic DNA Clean-up System kit (Promega). Fragments Start and Stop are resolved on a 1% TAE gel, stained with ethidium bromide and isolated using a Qiaex Gel Extraction kit (Qiagen). These fragments are combined with and annealed to the ends of the ˜3800 base pair NcoI/HindIII vector fragment of pMON3934 by heating at 50° C. for ten minutes and allowed to slow cool. The three fragments are ligated together using T4 DNA ligase (Boehringer Mannheim). The result is a plasmid containing the full-length new N-terminus/C-terminus gene. A portion of the ligation reaction is used to transform E. coli strain DH5a cells (Life Technologies, Gaithersburg, Md.). Plasmid DNA is purified and sequence confirmed as below.

Method III. Creation of new N-terminus/C-terminus genes by tandem-duplication method

New N-terminus/C-terminus genes can be made based on the method described in R. A. Horlick, et al Protein Eng. 5: 427-431, 1992). Polymerase chain reaction (PCR) amplification of the new N-terminus/C-terminus genes is performed using a tandemly duplicated template DNA. The steps are illustrated in FIG. 3.

The tandemly-duplicated template DNA is created by cloning and contains two copies of the gene separated by DNA sequence encoding a linker connecting the original C- and N-terminal ends of the two copies of the gene. Specific primer sets are used to create and amplify a full-length new N terminus/C-terminus gene from the tandemly-duplicated template DNA. These primers are designed to include appropriate restriction sites which allow for the cloning of the new gene into expression vectors. Typical PCR conditions are one cycle 95° C. melting for two minutes; 25 cycles 94° C. denaturation for one minute, 50° C. annealing for one minute and 72° C. extension for one minute; plus one cycle 72° C. extension for seven minutes. A Perkin Elmer GeneAmp PCR Core Reagents kit (Perkin Elmer Corporation, Norwalk, Conn.) is used. A 100 ul reaction contains 100 pmole of each primer and one ug of template DNA; and 1× PCR buffer, 200 uM dGTP, 200 uM DATP, 200 uM dTTP, 200 uM dCTP, 2.5 units AmpliTaq DNA polymerase and 2 mM MgCl₂. PCR reactions are performed in a Model 480 DNA thermal cycler (Perkin Elmer Corporation, Norwalk, Conn.). PCR reactions are purified using a Wizard PCR Preps kit (Promega).

Cloning of new N-terminus/C-terminus genes into multi-functional receptor agonist expression vectors

The new N-terminus/C-terminus gene is digested with restriction endonucleases to create ends that are compatible to insertion into an expression vector containing another colony stimulating factor gene. This expression vector is likewise digested with restriction endonucleases to form compatible ends. After purification, the gene and the vector DNAs are combined and ligated using T4 DNA ligase. A portion of the ligation reaction is used to transform E. coli. Plasmid DNA is purified and sequenced to confirm the correct insert. The correct clones are grown for protein expression.

DNA isolation and characterization

Plasmid DNA can be isolated by a number of different methods and using commercially available kits known to those skilled in the art. A few such methods are shown herein. Plasmid DNA is isolated using the Promega Wizard™ Miniprep kit (Madison, Wis.), the Qiagen QIAwell Plasmid isolation kits (Chatsworth, Calif.) or Qiagen Plasmid Midi kit. These kits follow the same general procedure for plasmid DNA isolation. Briefly, cells are pelleted by centrifugation (5000×g), plasmid DNA released with sequential NaOH/acid treatment, and cellular debris is removed by centrifugation (10000×g). The supernatant (containing the plasmid DNA) is loaded onto a column containing a DNA-binding resin, the column is washed, and plasmid DNA eluted with TE. After screening for the colonies with the plasmid of interest, the E. coli cells are inoculated into 50-100 mls of LB plus appropriate antibiotic for overnight growth at 37° C. in an air incubator while shaking. The purified plasmid DNA is used for DNA sequencing, further restriction enzyme digestion, additional subcloning of DNA fragments and transfection into mammalian, E. coli or other cells.

Sequence confirmation

Purified plasmid DNA is resuspended in dH₂ O and quantitated by measuring the absorbance at 260/280 nm in a Bausch and Lomb Spectronic 601 UV spectrometer. DNA samples are sequenced using ABI PRISM™ DyeDeoxy™ terminator sequencing chemistry (Applied Biosystems Division of Perkin Elmer Corporation, Lincoln City, Calif.) kits (Part Number 401388 or 402078) according to the manufacturers suggested protocol usually modified by the addition of 5% DMSO to the sequencing mixture. Sequencing reactions are performed in a Model 480 DNA thermal cycler (Perkin Elmer Corporation, Norwalk, Conn.) following the recommended amplification conditions. Samples are purified to remove excess dye terminators with Centri-Sep™ spin columns (Princeton Separations, Adelphia, N.J.) and lyophilized. Fluorescent dye labeled sequencing reactions are resuspended in deionized formamide, and sequenced on denaturing 4.75% polyacrylamide-8M urea gels using an ABI Model 373A automated DNA sequencer. Overlapping DNA sequence fragments are analyzed and assembled into master DNA contigs using Sequencher v2.1 DNA analysis software (Gene Codes Corporation, Ann Arbor, Mich.).

Expression of multi-functional receptor agonists in mammalian cells

Mammalian Cell Transfection/Production of Conditioned Media

The BHK-21 cell line can be obtained from the ATCC (Rockville, Md.). The cells are cultured in Dulbecco's modified Eagle media (DMEM/high-glucose), supplemented to 2 mM (mM) L-glutamine and 10% fetal bovine serum (FBS). This formulation is designated BHK growth media. Selective media is BHK growth media supplemented with 453 units/mL hygromycin B (Calbiochem, San Diego, Calif.). The BHK-21 cell line was previously stably transfected with the HSV transactivating protein VP16, which transactivates the IE110 promoter found on the plasmid pMON3359 (See Hippenmeyer et al., Bio/Technology, pp.1037-1041, 1993). The VP16 protein drives expression of genes inserted behind the IE110 promoter. BHK-21 cells expressing the transactivating protein VP16 are designated BHK-VP16. The plasmid pMON1118 (See Highkin et al., Poultry Sci., 70: 970-981, 1991) expresses the hygromycin resistance gene from the SV40 promoter. A similar plasmid is available from ATCC, pSV2-hph.

BHK-VP16 cells are seeded into a 60 millimeter (mm) tissue culture dish at 3×10⁵ cells per dish 24 hours prior to transfection. Cells are transfected for 16 hours in 3 mL of "OPTIMEM"™ (Gibco-BRL, Gaithersburg, Md.) containing 10 ug of plasmid DNA containing the gene of interest, 3 ug hygromycin resistance plasmid, pMON1118, and 80 ug of Gibco-BRL "LIPOFECTAMINE"™ per dish. The media is subsequently aspirated and replaced with 3 mL of growth media. At 48 hours post-transfection, media from each dish is collected and assayed for activity (transient conditioned media). The cells are removed from the dish by trypsin-EDTA, diluted 1:10 and transferred to 100 mm tissue culture dishes containing 10 mL of selective media. After approximately 7 days in selective media, resistant cells grow into colonies several millimeters in diameter. The colonies are removed from the dish with filter paper (cut to approximately the same size as the colonies and soaked in trypsin/EDTA) and transferred to individual wells of a 24 well plate containing 1 mL of selective media. After the clones are grown to confluence, the conditioned media is re-assayed, and positive clones are expanded into growth media.

Expression of multi-functional receptor agonists in E. coli

E. coli strain MON105 or JM101 harboring the plasmid of interest are grown at 37° C. in M9 plus casamino acids medium with shaking in a air incubator Model G25 from New Brunswick Scientific (Edison, N.J.). Growth is monitored at OD600 until it reaches a value of 1.0 at which time Nalidixic acid (10 milligrams/mL) in 0.1 N NaOH is added to a final concentration of 50 μg/mL. The cultures are then shaken at 37° C. for three to four additional hours. A high degree of aeration is maintained throughout culture period in order to achieve maximal production of the desired gene product. The cells are examined under a light microscope for the presence of inclusion bodies (IB). One mL aliquots of the culture are removed for analysis of protein content by boiling the pelleted cells, treating them with reducing buffer and electrophoresis via SDS-PAGE (see Maniatis et al. Molecular Cloning: A Laboratory Manual, 1982). The culture is centrifuged (5000×g) to pellet the cells.

Inclusion Body preparation, Extraction, Refolding, Dialysis, DEAE Chromatography, and Characterization of the multi-functional hematopoietic receptor agonists which accumulate as inclusion bodies in E. coli

Isolation of Inclusion Bodies

The cell pellet from a 330 mL E. coli culture is resuspended in 15 mL of sonication buffer (10 mM 2-amino-2-(hydroxymethyl) 1,3-propanediol hydrochloride (Tris-HCl), pH 8.0+1 mM ethylenediaminetetraacetic acid (EDTA). These resuspended cells are sonicated using the microtip probe of a Sonicator Cell Disruptor (Model W-375, Heat Systems-Ultrasonics, Inc., Farmingdale, N.Y.). Three rounds of sonication in sonication buffer followed by centrifugation are employed to disrupt the cells and wash the inclusion bodies (IB). The first round of sonication is a 3 minute burst followed by a 1 minute burst, and the final two rounds of sonication are for 1 minute each.

Extraction and refolding of proteins from inclusion body pellets

Following the final centrifugation step, the IB pellet is resuspended in 10 mL of 50 mM Tris-HCl, pH 9.5, 8 M urea and 5 mM dithiothreitol (DTT) and stirred at room temperature for approximately 45 minutes to allow for denaturation of the expressed protein.

The extraction solution is transferred to a beaker containing 70 mL of 5 mM Tris-HCl, pH 9.5 and 2.3 M urea and gently stirred while exposed to air at 4° C. for 18 to 48 hours to allow the proteins to refold. Refolding is monitored by analysis on a Vydac (Hesperia, Calif.) C18 reversed phase high pressure liquid chromatography (RP-HPLC) column (0.46×25 cm). A linear gradient of 40% to 65% acetonitrile, containing 0.1% trifluoroacetic acid (TFA), is employed to monitor the refold. This gradient is developed over 30 minutes at a flow rate of 1.5 mL per minute. Denatured proteins generally elute later in the gradient than the refolded proteins.

Purification

Following the refold, contaminating E. coli proteins are removed by acid precipitation. The pH of the refold solution is titrated to between pH 5.0 and pH 5.2 using 15% (v/v) acetic acid (HOAc). This solution is stirred at 4° C. for 2 hours and then centrifuged for 20 minutes at 12,000×g to pellet any insoluble protein.

The supernatant from the acid precipitation step is dialyzed using a Spectra/Por 3 membrane with a molecular weight cut off (MWCO) of 3,500 daltons. The dialysis is against 2 changes of 4 liters (a 50-fold excess) of 10 mM Tris-HCl, pH 8.0 for a total of 18 hours. Dialysis lowers the sample conductivity and removes urea prior to DEAE chromatography. The sample is then centrifuged (20 minutes at 12,000×g) to pellet any insoluble protein following dialysis.

A Bio-Rad Bio-Scale DEAE2 column (7×52 mm) is used for ion exchange chromatography. The column is equilibrated in a buffer containing 10 mM Tris-HCl, pH 8.0, and a 0-to-500 mM sodium chloride (NaCl) gradient, in equilibration buffer, over 45 column volumes is used to elute the protein. A flow rate of 1.0 mL per minute is used throughout the run. Column fractions (2.0 mL per fraction) are collected across the gradient and analyzed by RP HPLC on a Vydac (Hesperia, Calif.) C18 column (0.46×25 cm). A linear gradient of 40% to 65% acetonitrile, containing 0.1% trifluoroacetic acid (TFA), is employed. This gradient is developed over 30 minutes at a flow rate of 1.5 mL per minute. Pooled fractions are then dialyzed against 2 changes of 4 liters (50-to-500-fold excess) of 10 mM ammonium acetate (NH4Ac), pH 4.0 for a total of 18 hours. Dialysis is performed using a Spectra/Por 3 membrane with a MWCO of 3,500 daltons. Finally, the sample is sterile filtered using a 0.22 μm syringe filter (μStar LB syringe filter, Costar, Cambridge, Mass.), and stored at 4° C.

In some cases the folded proteins can be affinity purified using affinity reagents such as mAbs or receptor subunits attached to a suitable matrix. Alternatively, (or in addition) purification can be accomplished using any of a variety of chromatographic methods such as: ion exchange, gel filtration or hydrophobic chromatography or reversed phase HPLC.

These and other protein purification methods are described in detail in Methods in Enzymology, Volume 182 `Guide to Protein Purification` edited by Murray Deutscher, Academic Press, San Diego, Calif. (1990).

Protein Characterization

The purified protein is analyzed by RP-HPLC, electrospray mass spectrometry, and SDS-PAGE. The protein quantitation is done by amino acid composition, RP-HPLC, and Bradford protein determination. In some cases tryptic peptide mapping is performed in conjunction with electrospray mass spectrometry to confirm the identity of the protein.

AML Proliferation Assay for Bioactive Human Interleukin-3

The factor-dependent cell line AML 193 was obtained from the American Type Culture Collection (ATCC, Rockville, Md.). This cell line, established from a patient with acute myelogenous leukemia, is a growth factor dependent cell line which displayed enhanced growth in GM-CSF supplemented medium (Lange, B., et al., Blood 70: 192, 1987; Valtieri, M., et al., J. Immunol. 138: 4042, 1987). The ability of AML 193 cells to proliferate in the presence of human IL-3 has also been documented. (Santoli, D., et al., J. Immunol. 139: 348, 1987). A cell line variant was used, AML 193 1.3, which was adapted for long term growth in IL-3 by washing out the growth factors and starving the cytokine dependent AML 193 cells for growth factors for 24 hours. The cells are then replated at 1×10⁵ cells/well in a 24 well plate in media containing 100 U/mL IL-3. It took approximately 2 months for the cells to grow rapidly in IL-3. These cells are maintained as AML 193 1.3 thereafter by supplementing tissue culture medium (see below) with human IL-3.

AML 193 1.3 cells are washed 6 times in cold Hanks balanced salt solution (HBSS, Gibco, Grand Island, N.Y.) by centrifuging cell suspensions at 250×g for 10 minutes followed by decantation of the supernatant. Pelleted cells are resuspended in HBSS and the procedure is repeated until six wash cycles are completed. Cells washed six times by this procedure are resuspended in tissue culture medium at a density ranging from 2×10⁵ to 5×10⁵ viable cells/mL. This medium is prepared by supplementing Iscove's modified Dulbecco's Medium (IMDM, Hazelton, Lenexa, Kans.) with albumin, transferrin, lipids and 2-mercaptoethanol. Bovine albumin (Boehringer-Mannheim, Indianapolis, Ind.) is added at 500 μg/mL; human transferrin (Boehringer-Mannheim, Indianapolis, Ind.) is added at 100 μg/mL; soybean lipid (Boehringer-Mannheim, Indianapolis, Ind.) is added at 50 μg/mL; and 2-mercaptoethanol (Sigma, St. Louis, Mo.) is added at 5×10⁻⁵ M.

Serial dilutions of human interleukin-3 or multi-functional hematopoietic receptor agonist proteins are made in triplicate series in tissue culture medium supplemented as stated above in 96 well Costar 3596 tissue culture plates. Each well contained 50 μl of medium containing interleukin-3 or multi-functional hematopoietic receptor agonist proteins once serial dilutions are completed. Control wells contained tissue culture medium alone (negative control). AML 193 1.3 cell suspensions prepared as above are added to each well by pipetting 50 μl (2.5×10⁴ cells) into each well. Tissue culture plates are incubated at 37° C. with 5% CO₂ in humidified air for 3 days. On day 3, 0.5 μCi ³ H-thymidine (2 Ci/mM, New England Nuclear, Boston, Mass.) is added in 50 μl of tissue culture medium. Cultures are incubated at 37° C. with 5% CO₂ in humidified air for 18-24 hours. Cellular DNA is harvested onto glass filter mats (Pharmacia LKB, Gaithersburg, Md.) using a TOMTEC cell harvester (TOMTEC, Orange, Conn.) which utilized a water wash cycle followed by a 70% ethanol wash cycle. Filter mats are allowed to air dry and then placed into sample bags to which scintillation fluid (Scintiverse II, Fisher Scientific, St. Louis, Mo. or BetaPlate Scintillation Fluid, Pharmacia LKB, Gaithersburg, Md.) is added. Beta emissions of samples from individual tissue culture wells are counted in a LKB BetaPlate model 1205 scintillation counter (Pharmacia LKB, Gaithersburg, Md.) and data is expressed as counts per minute of ³ H-thymidine incorporated into cells from each tissue culture well. Activity of each human interleukin-3 preparation or multi-functional hematopoietic receptor agonist protein preparation is quantitated by measuring cell proliferation (³ H-thymidine incorporation) induced by graded concentrations of interleukin-3 or multi-functional hematopoietic receptor agonist. Typically, concentration ranges from 0.05 pM-10⁵ pM are quantitated in these assays. Activity is determined by measuring the dose of interleukin-3 or multi-functional hematopoietic receptor agonist protein which provides 50% of maximal proliferation (EC₅₀ =0.5×(maximum average counts per minute of ³ H-thymidine incorporated per well among triplicate cultures of all concentrations of interleukin-3 tested--background proliferation measured by ³ H-thymidine incorporation observed in triplicate cultures lacking interleukin-3). This EC₅₀ value is also equivalent to 1 unit of bioactivity. Every assay is performed with native interleukin-3 as a reference standard so that relative activity levels could be assigned.

Typically, the multi-functional hematopoietic receptor agonist proteins were tested in a concentration range of 2000 pM to 0.06 pM titrated in serial 2 fold dilutions.

Activity for each sample was determined by the concentration which gave 50% of the maximal response by fitting a four-parameter logistic model to the data. It was observed that the upper plateau (maximal response) for the sample and the standard with which it was compared did not differ. Therefore relative potency calculation for each sample was determined from EC₅₀ estimations for the sample and the standard as indicated above. AML 193.1.3 cells proliferate in response to hIL-3, hGM-CSF and hG-CSF. Therefore the following additional assays were performed for some samples to demonstrate that the G-CSF receptor agonist portion of the multi-functional hematopoietic receptor agonist proteins was active. The proliferation assay was performed with the multi-functional hematopoietic receptor agonist plus and minus neutralizing monoclonal antibodies to the hIL-3 receptor agonist portion. In addition, a fusion molecule with the factor Xa cleavage site was cleaved then purified and the halves of the molecule were assayed for proliferative activity. These experiments showed that both components of the multi-functional hematopoietic receptor agonist proteins were active.

TF1 c-mpl ligand dependent proliferation assay

The c-mpl ligand proliferative activity can be assayed using a subclone of the pluripotential human cell line TF1 (Kitamura et al., J. Cell Physiol 140: 323-334. [1989]). TF1 cells are maintained in h-IL3 (100 U/mL). To establish a sub-clone responsive to c-mpl ligand, cells are maintained in passage media containing 10% supernatant from BHK cells transfected with the gene expressing the 1-153 form of c-mpl ligand (pMON26448). Most of the cells die, but a subset of cells survive. After dilution cloning, a c-mpl ligand responsive clone is selected, and these cells are split into passage media to a density of 0.3×10⁶ cells/mL the day prior to assay set-up. Passage media for these cells is the following: RPMI 1640 (Gibco), 10% FBS (Harlan, Lot #91206), 10% c-mpl ligand supernatant from transfected BHK cells, 1 mM sodium pyruvate (Gibco), 2 mM glutamine (Gibco), and 100 ug/mL penicillin-streptomycin (Gibco). The next day, cells are harvested and washed twice in RPMI or IMDM media with a final wash in the ATL, or assay media. ATL medium consists of the following: IMDM (Gibco), 500 ug/mL of bovine serum albumin, 100 ug/mL of human transferrin, 50 ug/mL soybean lipids, 4×10-8M beta-mercaptoethanol and 2 mL of A9909 (Sigma, antibiotic solution) per 1000 mL of ATL. Cells are diluted in assay media to a final density of 0.25×10⁶ cells/mL in a 96-well low evaporation plate (Costar) to a final volume of 50 ul. Transient supernatants (conditioned media) from transfected clones are added at a volume of 50 ul as duplicate samples at a final concentration of 50% and diluted three-fold to a final dilution of 1.8%. Triplicate samples of a dose curve of IL-3 variant pMON13288 starting at 1 ng/mL and diluted using three-fold dilutions to 0.0014 ng/mL is included as a positive control. Plates are incubated at 5% CO₂ and 37° C. At day six of culture, the plate is pulsed with 0.5 Ci of 3H/well (NEN) in a volume of 20 ul/well and allowed to incubate at 5% CO₂ and 37° C. for four hours. The plate is harvested and counted on a Betaplate counter.

Other in vitro cell based proliferation assays

Other in vitro cell based assays, known to those skilled in the art, may also be useful to determine the activity of the multi-functional hematopoietic receptor agonists depending on the factors that comprise the molecule in a similar manner as described in the AML 193.1.3 cell proliferation assay. The following are examples of other useful assays.

TF1 proliferation assay: TF1 is a pluripotential human cell line (Kitamura et al., J. Cell Physiol 140: 323-334. [1989]) that responds to hIL-3.

32D proliferation assay: 32D is a murine IL-3 dependent cell line which does not respond to human IL-3 but does respond to human G-CSF which is not species restricted.

Baf/3 proliferation assay: Baf/3 is a murine IL-3 dependent cell line which does not respond to human IL-3 or human c-mpl ligand but does respond to human G-CSF which is not species restricted.

T1165 proliferation assay: T1165 cells are a IL-6 dependent murine cell line (Nordan et al., 1986) which respond to IL-6 and IL-11.

Human Plasma Clot meg-CSF Assay: Used to assay megakaryocyte colony formation activity (Mazur et al., 1981).

Transfected cell lines

Cell lines such as the murine Baf/3 cell line can be transfected with a colony stimulating factor receptor, such as the human G-CSF receptor or human c-mpl receptor, which the cell line does not have. These transfected cell lines can be used to determine the activity of the ligand for which the receptor has been transfected into the cell line.

One such transfected Baf/3 cell line was made by cloning the cDNA encoding c-mpl from a library made from a c-mpl responsive cell line and cloned into the multiple cloning site of the plasmid pcDNA3 (Invitrogen, San Diego Calif.). Baf/3 cells were transfected with the plasmid via electroporation. The cells were grown under G418 selection in the presence of mouse IL-3 in Wehi conditioned media. Clones were established through limited dilution.

In a similar manner the human G-CSF receptor can be transfected into the Baf/3 cell line and used to determine the bioactivity of the multi-functional hematopoietic receptor agoinsts.

Analysis of c-mpl ligand proliferative activity

Methods

1. Bone marrow proliferation assay

a. CD34+ Cell Purification

Bone marrow aspirates (15-20 mL) were obtained from normal allogeneic marrow donors after informed consent. Cells were diluted 1:3 in phosphate buffered saline (PBS, Gibco-BRL), 30 mL were layered over 15 mL Histopaque-1077 (Sigma) and centrifuged for 30 minutes at 300 RCF. The mononuclear interface layer was collected and washed in PBS. CD34+ cells were enriched from the mononuclear cell preparation using an affinity column per manufacturers instructions (CellPro, Inc, Bothell Wash.). After enrichment, the purity of CD34+ cells was 70% on average as determined by using flow cytometric analysis using anti-CD34 monoclonal antibody conjugated to fluorescein and anti-CD38 conjugated to phycoerythrin (Becton Dickinson, San Jose Calif.).

Cells were resuspended at 40,000 cells/mL in X-Vivo 10 media (Bio-Whittaker, Walkersville, Md.) and 1 mL was plated in 12-well tissue culture plates (Costar). The growth factor rhIL-3 was added at 100 ng/mL (pMON5873) was added to some wells. hIL3 variants were used at 10 ng/mL to 100 ng/mL. Conditioned media from BHK cells transfected with plasmid encoding c-mpl ligand or multi-functional hematopoietic receptor agonists were tested by addition of 100 μl of supernatant added to 1 mL cultures (approximately a 10% dilution). Cells were incubated at 37° C. for 8-14 days at 5% CO₂ in a 37° C. humidified incubator.

b. Cell Harvest and Analysis

At the end of the culture period a total cell count was obtained for each condition. For fluorescence analysis and ploidy determination cells were washed in megakaryocyte buffer (MK buffer, 13.6 mM sodium citrate, 1 mM theophylline, 2.2 μm PGE1, 11 mM glucose, 3% w/v BSA, in PBS, pH 7.4,) (Tomer et al., Blood 70: 1735-1742, 1987) resuspended in 500 μl of MK buffer containing anti-CD41a FITC antibody (1:200, AMAC, Westbrook, Me.) and washed in MK buffer. For DNA analysis cells were permeablized in MK buffer containing 0.5% Tween 20 (Fisher, Fair Lawn N.J.) for 20 min. on ice followed by fixation in 0.5% Tween-20 and 1% paraformaldehyde (Fisher Chemical) for 30 minutes followed by incubation in propidium iodide (Calbiochem , La Jolla Calif.) (50 μg/mL) with RNA-ase (400 U/mL) in 55% v/v MK buffer (200 mOsm) for 1-2 hours on ice. Cells were analyzed on a FACScan or Vantage flow cytometer (Becton Dickinson, San Jose, Calif.). Green fluorescence (CD41a-FITC) was collected along with linear and log signals for red fluorescence (PI) to determine DNA ploidy. All cells were collected to determine the percent of cells that were CD41+. Data analysis was performed using software by LYSIS (Becton Dickinson, San Jose, Calif.). Percent of cells expressing the CD41 antigen was obtained from flow cytometry analysis (Percent). Absolute (Abs) number of CD41+ cells/mL was calculated by: (Abs)=(Cell Count)*(Percent)/100.

2. Megakaryocyte fibrin clot assay

CD34+ enriched population were isolated as described above. Cells were suspended at 25,000 cells/mL with or without cytokine(s) in a media consisting of a base Iscoves IMDM media supplemented with 0.3% BSA, 0.4 mg/mL apo-transferrin, 6.67 μM FeCl₂, 25 μg/mL CaCl₂, 25 μg/mL L-asparagine, 500 μg/mL ε-amino-n-caproic acid and penicillin/streptomycin. Prior to plating into 35 mm plates, thrombin was added (0.25 Units/mL) to initiate clot formation. Cells were incubated at 37° C. for 13 days at 5% CO₂ in a 37° C. humidified incubator.

At the end of the culture period plates were fixed with methanol:acetone (1:3), air dried and stored at -200° C. until staining. A peroxidase immunocytochemistry staining procedure was used (Zymed, Histostain-SP. San Francisco, Calif.) using a cocktail of primary monoclonal antibodies consisting of anti-CD41a, CD42 and CD61. Colonies were counted after staining and classified as negative, CFU-MK (small colonies, 1-2 foci and less that approx. 25 cells), BFU-MK (large, multi-foci colonies with >25 cells) or mixed colonies (mixture of both positive and negative cells.

Methylcellulose Assay

This assay reflects the ability of colony stimulating factors to stimulate normal bone marrow cells to produce different types of hematopoietic colonies in vitro (Bradley et al., Aust. Exp Biol. Sci. 44: 287-300, 1966), Pluznik et al., J. Cell Comp. Physio 66: 319-324, 1965).

Methods

Approximately 30 mL of fresh, normal, healthy bone marrow aspirate are obtained from individuals following informed consent. Under sterile conditions samples are diluted 1:5 with a 1× PBS (#14040.059 Life Technologies, Gaithersburg, Md.) solution in a 50 mL conical tube (#25339-50 Corning, Corning Md.). Ficoll (Histopaque 1077 Sigma H-8889) is layered under the diluted sample and centrifuged, 300×g for 30 min. The mononuclear cell band is removed and washed two times in 1× PBS and once with 1% BSA PBS (CellPro Co., Bothel, Wash.). Mononuclear cells are counted and CD34+ cells are selected using the Ceprate LC (CD34) Kit (CellPro Co., Bothel, Wash.) column. This fractionation is performed since all stem and progenitor cells within the bone marrow display CD34 surface antigen.

Cultures are set up in triplicate with a final volume of 1.0 mL in a 35×10 mm petri dish (Nunc#174926). Culture medium is purchased from Terry Fox Labs. (HCC-4230 medium (Terry Fox Labs, Vancouver, B.C., Canada) and erythropoietin (Amgen, Thousand Oaks, Calif.) is added to the culture media. 3,000-10,000 CD34+ cells are added per dish. Recombinant IL-3, purified from mammalian cells or E. coli, and multi-functional hematopoietic receptor agonist proteins, in conditioned media from transfected mammalian cells or purified from conditioned media from transfected mammalian cells or E. coli, are added to give final concentrations ranging from 0.001 nM to 10 nM. Recombinant hIL-3, GM-CSF, c-mpl ligand and multi-functional hematopoietic receptor agonist are supplied in house. G-CSF (Neupogen) is from Amgen (Thousand Oaks Calf.). Cultures are resuspended using a 3 cc syringe and 1.0 mL is dispensed per dish. Control (baseline response) cultures received no colony stimulating factors. Positive control cultures received conditioned media (PHA stimulated human cells: Terry Fox Lab. H2400). Cultures are incubated at 37° C., 5% CO₂ in humidified air. Hematopoietic colonies which are defined as greater than 50 cells are counted on the day of peak response (days 10-11) using a Nikon inverted phase microscope with a 40× objective combination. Groups of cells containing fewer than 50 cells are referred to as clusters. Alternatively colonies can be identified by spreading the colonies on a slide and stained or they can be picked, resuspended and spun onto cytospin slides for staining.

Human Cord Blood Hemopoietic Growth Factor Assays

Bone marrow cells are traditionally used for in vitro assays of hematopoietic colony stimulating factor (CSF) activity. However, human bone marrow is not always available, and there is considerable variability between donors. Umbilical cord blood is comparable to bone marrow as a source of hematopoietic stem cells and progenitors (Broxmeyer et al., PNAS USA 89: 4109-113, 1992; Mayani et al., Blood 81: 3252-3258, 1993). In contrast to bone marrow, cord blood is more readily available on a regular basis. There is also a potential to reduce assay variability by pooling cells obtained fresh from several donors, or to create a bank of cryopreserved cells for this purpose. By modifying the culture conditions, and/or analyzing for lineage specific markers, it is be possible to assay specifically for granulocyte/macrophage colonies (CFU-GM), for megakaryocyte CSF activity, or for high proliferative potential colony forming cell (HPP-CFC) activity.

Methods

Mononuclear cells (MNC) are isolated from cord blood within 24 hr. of collection, using a standard density gradient (1.077 g/mL Histopaque). Cord blood MNC have been further enriched for stem cells and progenitors by several procedures, including immunomagnetic selection for CD14-, CD34+ cells; panning for SBA-, CD34+ fraction using coated flasks from Applied Immune Science (Santa Clara, Calif.); and CD34+ selection using a CellPro (Bothell, Wash.) avidin column. Either freshly isolated or cryopreserved CD34+ cell enriched fractions are used for the assay. Duplicate cultures for each serial dilution of sample (concentration range from 1 pM to 1204 pM) are #prepared with 1×104 cells in 1 ml of 0.9% methycellulose containing medium without additional growth factors (Methocult H4230 from Stem Cell Technologies, Vancouver, BC.). In some experiments, Methocult H4330 containing erythropoietin (EPO) was used instead of Methocult H4230, or Stem Cell Factor (SCF), 50 ng/mL (Biosource International, Camarillo, Calif.) was added. After culturing for 7-9 days, colonies containing >30 cells are counted. In order to rule out subjective bias in scoring, assays are scored blind.

Additional details about recombinant DNA methods which may be used to create the variants, express them in bacteria, mammalian cells or insect cells, purification and refold of the desired proteins and assays for determining the bioactivity of the proteins may be found in co-filed Applications WO 95/00646, WO 94/12639, WO 94/12638, WO 95/20976, WO 95/21197, WO 95/20977, WO 95/21254 and US 08/383,035 which are hereby incorporated by reference in their entirety.

Further details known to those skilled in the art may be found in T. Maniatis, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, 1982) and references cited therein, incorporated herein by reference; and in J. Sambrook, et al., Molecular Cloning, A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory, 1989) and references cited therein, incorporated herein by reference.

                                      TABLE 1                                      __________________________________________________________________________     OLIGONUCLEOTIDES                                                               __________________________________________________________________________     c-mplNcoI                                                                            ACGTCCATGGCNTCNCCNGCNCCNCCTGCTTGTGCACTCCGAGTC                                  (SEQ ID NO:13)                                                           N = A, C, G or T                                                               Ecompl  ATGCACGAATTCCCTGACGCAGAGGGTGGA                                                                      (SEQ ID NO:14)                                    c-mplHindIII                                                                                  TGACAAGCTTACCTGACGCAGAGGGTGGACCCT                                                            (SEQ ID NO:15)                                    4L-5'          AATTCGGCAA (SEQ ID NO:16)                                       4L-3'          CATGTTGCCG (SEQ ID NO:17)                                       5L-5'          AATTCGGCGGCAA (SEQ ID NO:18)                                    5L-3'          CATGTTGCCGCCG (SEQ ID NO:19)                                    8L-5'          AATTCGGCGGCAACGGCGGCAA (SEQ ID NO:20)                           8L-3'          CATGTTGCCGCCGTTGCCGCCG  (SEQ TDNO:21)                           31-5'          CGATCCATGGAGGTTCACCCTTTGCCT (SEQ ID NO:22)                      31-3'          GATCAAGCTTATGGGCACTGGCTCAGTCT (SEQ ID NO:23)                    35-5'          CGATACATGTTGCCTACACCTGTCCTG (SEQ ID NO:24)                      35-3'          GATCAAGCTTAAGGGTGAACCTCTGGGCA (SEQ ID NO:25)                    39-5'          CGATCCATGGTCCTGCTGCCTGCTGTG (SEQ ID NO:26)                      39-3'          GATCAAGCTTAAGGTGTAGGCAAAGGGTG (SEQ ID NO:27)                    43-5'          CGATCCATGGCTGTGGACTTTAGCTTGGGA (SEQ ID NO:28)                   43-3'          GATCAAGCTTAAGGCAGCAGGACAGGTGT (SEQ ID NO:29)                    45-5'          CGATCCATGGACTTTAGCTTGGGAGAA (SEQ ID NO:30)                      45-3'          GATCAAGCTTACACAGCAGGCAGCAGGAC (SEQ ID NO:31)                    49-5'          CGATCCATGGGAGAATGGAAAACCCAG (SEQ ID NO:32)                      49-3'          GATCAAGCTTACAAGCTAAAGTCCACAGC (SEQ ID NO:33)                    82-5'          CGATCCATGGGACCCACTTGCCTCTCA (SEQ ID NO:34)                      82-3'          GATCAAGCTTACAGTTGTCCCCGTGCTGC (SEQ ID NO:35)                    109-5'        CAGTCCATGGGAACCCAGCTTCCTCCA (SEQ ID NO: 36)                      109-3'        GATCAAGCTTAAAGGAGGCTCTGCAGGGC (SEQ ID NO:37)                     116-5'        CGATCCATGGGCAGGACCACAGCTCAC (SEQ ID NO:38)                       116-3'        GATCAAGCTTACTGTGGAGGAAGCTGGGTT (SEQ ID NO: 39)                   120-5'        CGATCCATGGCTCACAAGGATCCCAATGCC (SEQ ID NO:40)                    120-3'        GATCAAGCTTATGTGGTCCTGCCCTGTGG (SEQ ID NO:41)                     123-5'        CGATCCATGGATCCCAATGCCATCTTCCTG (SEQ ID NO:42)                    123-3'        GATCAAGCTTACTTGTGAGCTGTGGTCCT (SEQ ID NO:43)                     126-5'        CGATCCATGGCCATCTTCCTGAGCTTCCAA                                                      (SEQ ID NO:44)                                              126-3'        GATCAAGCTTAATTGGGATCCTTGTGAGCTGT                                                       (SEQ ID NO:45)                                           SYNNOXA1.REQ                                                                                 AATTCCGTCG TAAACTGACC TTCTATCTGA AAACCTTGGA                                                  GAACGCGCAG GCTCAACAGT ACGTAGAGGG CGGTGGAGGC                                    TCC (SEQ ID NO:46)                                 SYNNOXA2.REQ                                                                                CCGGGGAGCC TCCACCGCCC TCTACGTACT GTTGAGCCTG                                                  CGCGTTCTCC AAGGTTTTCA GATAGAAGGT CAGTTTACGA                                    CGG (SEQ ID NO:47)                                  L1syn.for                                                                                      GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT                                               CTAACTGCTC TATAATGAT (SEQ ID NO:48)                 L1syn.rev                                                                                      CGATCATTAT AGAGCAGTTA GAGCCACCAC CCTGTTGTTC                                               CTGCGCTTGC TCAAGG (SEQ ID NO:49)                    L3syn.for                                                                                      GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT                                               CTGGCGGTGG CAGCGGCGGC GGTTCTAACT GCTCTATAAT                                    GAT (SEQ ID NO:50)                                  L3syn.rev                                                                                     CGATCATTAT AGAGCAGTTA GAACCGCCGC CGCTGCCACC                                               GCCAGAGCCA CCACCCTGTT GTTCCTGCGC TTGCTCAAGG                                    (SEQ ID NO:51)                                       35start.seq                                                                                  GATCGACCAT GGCTCTGGAC CCGAACAACC TC                                                         (SEQ ID NO:52)                                      34rev.seq                                                                                      CTCGATTACG TACAAAGGTG CAGGTGGT                                                            (SEQ ID NO:53)                                      70start.seq                                                                                  GATCGACCAT GGCTAATGCA TCAGGTATTG AG                                                         (SEQ ID NO:54)                                      69rev.seq                                                                                      CTCGATTACG TATTCTAAGT TCTTGACA (SEQ ID NO:55)                  91start.seq                                                                                  GATCGACCAT GGCTGCACCC TCTCGACATC CA                                                         (SEQ ID NO:56)                                      90rev.seq                                                                                      CTCGATTACG TAGGCCGTGG CAGAGGGC (SEQ ID NO:57)                  101start.seq                                                                                GATCGACCAT GGCTGCAGGT GACTGGCAAG AA                                                          (SEQ ID NO:58)                                      100rev.seq                                                                                    CTCGATTACG TACTTGATGA TGATTGGA (SEQ ID NO:59)                   L-11start.seq                                                                             GCTCTGAGAG CCGCCAGAGC CGCCAGAGGG                                                               CTGCGCAAGG TGGCGTAGAA CGCG (SEQ ID NO:60)           L-11stop.seq                                                                                CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG                                                             AGCTTCCTGC TCAAGTCTTT AGAG (SEQ ID NO:61)           P-b1start.seq                                                                              GGGCTGCGCA AGGTGGCG (SEQ ID NO:62)                                 P-b1stop.seq                                                                                ACACCATTGG GCCCTGCCAG C (SEQ ID NO:63)                            39start.seq                                                                                  GATCGACCAT GGCTTACAAG CTGTGCCACC CC                                                         (SEQ ID NO:64)                                      38stop.Seq                                                                                    CGATCGAAGC TTATTAGGTG GCACACAGCT TCTCCT                                                    (SEQ ID NO:65)                                      97start.seq                                                                                  GATCGACCAT GGCTCCCGAG TTGGGTCCCA CC                                                         (SEQ ID NO:66)                                      96stop.Seq                                                                                    CGATCGAAGC TTATTAGGAT ATCCCTTCCA GGGCCT                                                    (SEQ ID NO:67)                                      126start.seq                                                                                GATCGACCAT GGCTATGGCC CCTGCCCTGC AG                                                          (SEQ ID NO:68)                                      125stop.Seq                                                                                  CGATCGAAGC TTATTATCCC AGTTCTTCCA TCTGCT                                                     (SEQ ID NO:69)                                      133start.seq                                                                                GATCGACCAT GGCTACCCAG GGTGCCATGC CG                                                          (SEQ ID NO:70)                                      132stop.seq                                                                                  CGATCGAAGC TTATTAGGGC TGCAGGGCAG GGGCCA                                                     (SEQ ID NO:71)                                      142start.seq                                                                                GATCGACCAT GGCTTCTGCT TTCCAGCGCC GG                                                          (SEQ ID NO:72)                                      141stop.Seq                                                                                  CGATCGAAGC TTATTAGGCG AAGGCCGGCA TGGCAC                                                     (SEQ ID NO:73)                                      GLYXA1             GTAGAGGGCG GTGGAGGCTC C (SEQ ID NO:74)                      GLYXA2             CCGGGGAGCC TCCACCGCCC TCTAC (SEQ ID NO:75)                  1GGGSfor                                                                                        TTCTACGCCA CCTTGCGCAG CCCGGCGGCG GCTCTGACAT                                              GTCTACACCA TTG (SEQ ID NO:76)                       1GGGSrev                                                                                        CAATGGTGTA GACATGTCAG AGCCGCCGCC GGGCTGCGCA                                              AGGTGGCGTA GAA (SEQ ID NO:77)                       Synnoxa1.req                                                                                AATTCCGTCG TAAACTGACC TTCTATCTGA AAACCTTGGA                                                  GAACGCGCAG GCTCAACAGT ACGTAGAGGG CGGTGGAGGC                                    TCC (SEQ ID NO:240)                                 Synnoxa2.req                                                                                CCGGGGAGCC TCCACCGCCC TCTACGTACT GTTGAGCCTG                                                  CGCGTTCTCC AAGGTTTTCA GATAGAAGGT CAGTTTACGA                                    CGG (SEQ ID NO:241)                                 __________________________________________________________________________

                                      TABLE 2                                      __________________________________________________________________________     GENE SEQUENCES                                                                 __________________________________________________________________________     pMON30304                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGT (SEQ ID NO:78)                           pMON26458                                                                      TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTC            ACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGA            CTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTG            ACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCC            TGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCT            TCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTG            CTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTC                (SEQ ID NO:79)                                                                 pMON28548                                                                      TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTC            ACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGA            CTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTG            ACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCC            TGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCT            TCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTG            CTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCG            GCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTC            CCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTG            CCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTC            TGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCT            CTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTT            GGAACCCAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGC            TCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG                       (SEQ ID NO:80)                                                                 pMON28500                                                                      TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTC            ACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGA            CTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTG            ACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCC            TGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCT            TCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTG            CTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCA            ACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCA            TGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCT            GCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGG            GAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTC            ATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGA            ACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCC            AACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG              (SEQ ID NO:81)                                                                 pMON28501                                                                      TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTC            ACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGA            CTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTG            ACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCC            TGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCT            TCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTG            CTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCG            GCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTC            CCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTG            CCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTC            TGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCT            CTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTT            GGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCT            TCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAG            G (SEQ ID NO:82)                                                               pMON28502                                                                      TCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTC            ACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGA            CTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTG            ACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCC            TGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCT            TCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTG            CTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCG            GCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCT            TCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCT            GTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCAC            AGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACC            CACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAG            AGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCT            TCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCT            CTGCGTCAGG (SEQ ID NO:83)                                                      Syntan1                                                                        1  CATGGCTAAC TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA                      51  GACCACCTGC ACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC                     101                                                                                TCTATCCTGA TGGACCGAAA CCTTCGACTT CCAAACCTGG AGAGCTTCGT                     151                                                                                AAGGGCTGTC AAGAACTTAG AAAATGCATC AGGTATTGAG GCAATTCTTC                     201                                                                                GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCACC CTCTCGACAT                     251                                                                                CCAATCATCA TCAAGGCAGG TGACTGGCAA GAATTCCGGG AAAAACTGAC                     301                                                                                GTTCTATCTG GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT                     351                                                                                CTAACTGCTC TATAATGATC GATGAAATTA TACATCACTT AAAGAGACCA                     401                                                                                CCTGCACCTT TGCTGGACCC GAACAACCTC AATGACGAAG ACGTCTCTAT                     451                                                                                CCTGATGGAC CGAAACCTTC GACTTCCAAA CCTGGAGAGC TTCGTAAGGG                     501                                                                                CTGTCAAGAA CTTAGAAAAT GCATCAGGTA TTGAGGCAAT TCTTCGTAAT                     551                                                                                CTCCAACCAT GTCTGCCCTC TGCCACGGCC GCACCCTCTC GACATCCAAT                     601                                                                                CATCATCAAG GCAGGTGACT GGCAAGAATT CCGGGAAAAA CTGACGTTCT                     651                                                                                ATCTGGTTAC CCTTGAGCAA GCGCAGGAAC AACAGTAC (SEQ ID NO:84)                   Syntan3                                                                        1  CATGGCTAAC TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA                      51    GACCACCTGC ACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC                   101                                                                                  TCTATCCTGA TGGACCGAAA CCTTCGACTT CCAAACCTGG AGAGCTTCGT                   151                                                                                  AAGGGCTGTC AAGAACTTAG AAAATGCATC AGGTATTGAG GCAATTCTTC                   201                                                                                  GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCACC CTCTCGACAT                   251                                                                                  CCAATCATCA TCAAGGCAGG TGACTGGCAA GAATTCCGGG AAAAACTGAC                   301                                                                                  GTTCTATCTG GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT                   351                                                                                  CTGGCGGTGG CAGCGGCGGC GGTTCTAACT GCTCTATAAT GATCGATGAA                   401                                                                                  ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA                   451                                                                                  CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC CTTCGACTTC                   501                                                                                  CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA                   551                                                                                  GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC                   601                                                                                  GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG                   651                                                                                  AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG                   701                                                                                  GAACAACAGT AC (SEQ ID NO:85)                                             pMON31104                                                                      1  ATGGCTCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT                      51    GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA                   101                                                                                  AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA                   151                                                                                  CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT                   201                                                                                  CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG                   251                                                                                  TTACCCTTGA GCAAGCGCAG GAACAACAGG GTGGTGGCTC TAACTGCTCT                   301                                                                                  ATAATGATCG ATGAAATTAT ACATCACTTA AAGAGACCAC CTGCACCTTT                   351                                                                                  GTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT                   401                                                                                  CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC                   451                                                                                  ATGGCTACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG                   501                                                                                  GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT                   551                                                                                  CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC                   601                                                                                  TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG                   651                                                                                  CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC                   701                                                                                  ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT                   751                                                                                  CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG                   801                                                                                  CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG                   851                                                                                  AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC                   901                                                                                  GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT                   951                                                                                  GGCCCCTGCC CTGCAGCCCT AATAA (SEQ ID NO:86)                               pMON31105                                                                      1  ATGGCTAATG CATCAGGTAT TGAGGCAATT CTTCGTAATC TCCAACCATG                      51    TCTGCCCTCT GCCACGGCCG CACCCTCTCG ACATCCAATC ATCATCAAGG                   101                                                                                  CAGGTGACTG GCAAGAATTC CGGGAAAAAC TGACGTTCTA TCTGGTTACC                   151                                                                                  CTTGAGCAAG CGCAGGAACA ACAGGGTGGT GGCTCTAACT GCTCTATAAT                   201                                                                                  GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG                   251                                                                                  ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC                   301                                                                                  CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA                   351                                                                                  ATACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT                   401                                                                                  CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC                   451                                                                                  ATGGCTACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG                   501                                                                                  GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT                   551                                                                                  CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC                   601                                                                                  TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG                   651                                                                                  CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC                   701                                                                                  ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT                   751                                                                                  CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG                   801                                                                                  CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG                   851                                                                                  AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC                   901                                                                                  GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT                   951                                                                                  GGCCCCTGCC CTGCAGCCCT AATAA (SEQ ID NO:87)                               pMON31106                                                                      1  ATGGCTGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA                      51    AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC                   101                                                                                  AGGAACAACA GGGTGGTGGC TCTAACTGCT CTATAATGAT CGATGAAATT                   151                                                                                  ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT                   201                                                                                  CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA                   251                                                                                  ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT                   301                                                                                  ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC                   351                                                                                  CTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT                   401                                                                                  CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC                   451                                                                                  ATGGCTACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG                   501                                                                                  GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT                   551                                                                                  CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC                   601                                                                                  TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG                   651                                                                                  CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC                   701                                                                                  ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT                   751                                                                                  CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG                   801                                                                                  CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG                   851                                                                                  AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC                   901                                                                                  GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT                   951                                                                                  GGCCCCTGCC CTGCAGCCCT AATAA (SEQ ID NO:88)                               pMON31107                                                                      1  ATGGCTGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT                      51    GGTTACCCTT GAGCAAGCGC AGGAACAACA GGGTGGTGGC TCTAACTGCT                   101                                                                                  CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT                   151                                                                                  TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA                   201                                                                                  CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA                   251                                                                                  ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA                   301                                                                                  TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA                   351                                                                                  GTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT                   401                                                                                  CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC                   451                                                                                  ATGGCTACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG                   501                                                                                  GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT                   551                                                                                  CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC                   601                                                                                  TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG                   651                                                                                  CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC                   701                                                                                  ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT                   751                                                                                  CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG                   801                                                                                  CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG                   851                                                                                  AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC                   901                                                                                  GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT                   951                                                                                  GGCCCCTGCC CTGCAGCCCT AATAA (SEQ ID NO:89)                               pMON31108                                                                      1  ATGGCTCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT                      51    GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA                   101                                                                                  AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA                   151                                                                                  CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT                   201                                                                                  CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG                   251                                                                                  TTACCCTTGA GCAAGCGCAG GAACAACAGG GTGGTGGCTC TGGCGGTGGC                   301                                                                                  AGCGGCGGCG GTTCTAACTG CTCTATAATG ATCGATGAAA TTATACATCA                   351                                                                                  CTTAAAGAGA CCACCTGCAC CTTTGTACGT AGAGGGCGGT GGAGGCTCCC                   401                                                                                  CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT                   451                                                                                  AAAGAATCTC ATAAATCTCC AAACATGGCT ACCCAGGGTG CCATGCCGGC                   501                                                                                  CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC                   551                                                                                  ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG                   601                                                                                  CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT                   651                                                                                  AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC                   701                                                                                  TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA                   751                                                                                  CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC                   801                                                                                  CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT                   851                                                                                  ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC                   901                                                                                  ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG                   951                                                                                  GCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA                                (SEQ ID NO:90)                                                     pMON31109                                                                      1  ATGGCTAATG CATCAGGTAT TGAGGCAATT CTTCGTAATC TCCAACCATG                      51   TCTGCCCTCT GCCACGGCCG CACCCTCTCG ACATCCAATC ATCATCAAGG                    101                                                                                 CAGGTGACTG GCAAGAATTC CGGGAAAAAC TGACGTTCTA TCTGGTTACC                    151                                                                                 CTTGAGCAAG CGCAGGAACA ACAGGGTGGT GGCTCTGGCG GTGGCAGCGG                    201                                                                                 CGGCGGTTCT AACTGCTCTA TAATGATCGA TGAAATTATA CATCACTTAA                    251                                                                                 AGAGACCACC TGCACCTTTG CTGGACCCGA ACAACCTCAA TGACGAAGAC                    301                                                                                 GTCTCTATCC TGATGGACCG AAACCTTCGA CTTCCAAACC TGGAGAGCTT                    351                                                                                 CGTAAGGGCT GTCAAGAACT TAGAATACGT AGAGGGCGGT GGAGGCTCCC                    401                                                                                 CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT                    451                                                                                 AAAGAATCTC ATAAATCTCC AAACATGGCT ACCCAGGGTG CCATGCCGGC                    501                                                                                 CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC                    551                                                                                 ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG                    601                                                                                 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT                    651                                                                                 AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC                    701                                                                                 TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA                    751                                                                                 CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC                    801                                                                                 CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT                    851                                                                                 ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC                    901                                                                                 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG                    951                                                                                 GCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA                                 (SEQ ID NO:91)                                                     pMON31110                                                                      1  ATGGCTGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA                      51   AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC                    101                                                                                 AGGAACAACA GGGTGGTGGC TCTGGCGGTG GCAGCGGCGG CGGTTCTAAC                    151                                                                                 TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA GACCACCTGC                    201                                                                                 ACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC TCTATCCTGA                    251                                                                                 TGGACCGAAA CCTTCGACTT CCAAACCTGG AGAGCTTCGT AAGGGCTGTC                    301                                                                                 AAGAACTTAG AAAATGCATC AGGTATTGAG GCAATTCTTC GTAATCTCCA                    351                                                                                 ACCATGTCTG CCCTCTGCCA CGGCCTACGT AGAGGGCGGT GGAGGCTCCC                    401                                                                                 CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT                    451                                                                                 AAAGAATCTC ATAAATCTCC AAACATGGCT ACCCAGGGTG CCATGCCGGC                    501                                                                                 CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC                    551                                                                                 ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG                    601                                                                                 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT                    651                                                                                 AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC                    701                                                                                 TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA                    751                                                                                 CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC                    801                                                                                 CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT                    851                                                                                 ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC                    901                                                                                 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG                    951                                                                                 GCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA                                 (SEQ ID NO:92)                                                     pMON31111                                                                      1  ATGGCTGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT                      51    GGTTACCCTT GAGCAAGCGC AGGAACAACA GGGTGGTGGC TCTGGCGGTG                   101                                                                                  GCAGCGGCGG CGGTTCTAAC TGCTCTATAA TGATCGATGA AATTATACAT                   151                                                                                  CACTTAAAGA GACCACCTGC ACCTTTGCTG GACCCGAACA ACCTCAATGA                   201                                                                                  CGAAGACGTC TCTATCCTGA TGGACCGAAA CCTTCGACTT CCAAACCTGG                   251                                                                                  AGAGCTTCGT AAGGGCTGTC AAGAACTTAG AAAATGCATC AGGTATTGAG                   301                                                                                  GCAATTCTTC GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCACC                   351                                                                                  CTCTCGACAT CCAATCATCA TCAAGTACGT AGAGGGCGGT GGAGGCTCCC                   401                                                                                  CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT                   451                                                                                  AAAGAATCTC ATAAATCTCC AAACATGGCT ACCCAGGGTG CCATGCCGGC                   501                                                                                  CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC                   551                                                                                  ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG                   601                                                                                  CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT                   651                                                                                  AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC                   701                                                                                  TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA                   751                                                                                  CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC                   801                                                                                  CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT                   851                                                                                  ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC                   901                                                                                  ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG                   951                                                                                  GCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA                                 (SEQ ID NO:93)                                                    pMON13182                                                                      1  ATGGCTAACTGCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                       51     ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                  101                                                                                  CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                   151                                                                                  AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                   201                                                                                  TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                   251                                                                                  CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                   301                                                                                  TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                   351                                                                                  CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT                   401                                                                                  ACAAGCTGTG CCACCCCGAG GAGCTGGTGC TGCTCGGACA CTCTCTGGGC                   451                                                                                  ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC                   501                                                                                  AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC                   551                                                                                  TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA                   601                                                                                  CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA                   651                                                                                  AGAACTGGGA ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG                   701                                                                                  CCTTCGCCTC TGCTTTCCAG CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC                   751                                                                                  CATCTGCAGA GCTTCCTGGA GGTGTCGTAC CGCGTTCTAC GCCACCTTGC                   801                                                                                  GCAGCCCTCT GGCGGCTCTG GCGGCTCTCA GAGCTTCCTG CTCAAGTCTT                   851                                                                                  TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG                   901                                                                                  CTGTGTGCCA CCTAATAA (SEQ ID NO:94)                                       pMON13183                                                                      1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51    ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                   101                                                                                  CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                   151                                                                                  AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                   201                                                                                  TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                   251                                                                                  CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                   301                                                                                  TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                   351                                                                                  CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                   401                                                                                  CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTACAAG                   451                                                                                  CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC                   501                                                                                  CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT                   551                                                                                 GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG                    601                                                                                 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA                    651                                                                                 GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC                    701                                                                                 TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC                    751                                                                                 GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT                    801                                                                                 GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC                    851                                                                                 CCTCTGGCGG CTCTGGCGGC TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG                    901                                                                                 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG                    951                                                                                 TGCCACCTAA TAA (SEQ ID NO:95)                                             pMON13184                                                                      1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51   ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                    101                                                                                 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                    151                                                                                 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                    201                                                                                 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                    251                                                                                 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                    301                                                                                 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                    351                                                                                 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTC                    401                                                                                 CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT                    451                                                                                 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT                    501                                                                                 GCAGCCCACC CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT TTCCAGCGCC                    551                                                                                 GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CCTGGAGGTG                    601                                                                                 TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCTCTGGCG GCTCTGGCGG                    651                                                                                 CTCTCAGAGC TTCCTGCTCA AGTCTTTAGA GCAAGTGAGA AAGATCCAGG                    701                                                                                 GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CAAGCTGTGC                    751                                                                                 CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC                    801                                                                                 TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA                    851                                                                                 GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GCAGGCCCTG                    901                                                                                 GAAGGGATAT CCTAATAA (SEQ ID NO:96)                                        pMON13185                                                                      1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51   ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                    101                                                                                 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                    151                                                                                 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                    201                                                                                 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                    251                                                                                 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                    301                                                                                 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                    351                                                                                 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                    401                                                                                 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCCCGAG                    451                                                                                 TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC                    501                                                                                 CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC                    551                                                                                 CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA                    601                                                                                 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA                    651                                                                                 CCGCGTTCTA CGCCACCTTG CGCAGCCCTC TGGCGGCTCT GGCGGCTCTC                    701                                                                                 AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG TGAGAAAGAT CCAGGGCGAT                    751                                                                                 GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC ACCTACAAGC TGTGCCACCC                    801                                                                                 CGAGGAGCTG GTGCTGCTCG GACACTCTCT GGGCATCCCC TGGGCTCCCC                    851                                                                                 TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA                    901                                                                                 CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG                    951                                                                                 GATATCCTAA TAA (SEQ ID NO:97)                                             pMON13186                                                                      1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51     ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                  101                                                                                 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                    151                                                                                 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                    201                                                                                 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                    251                                                                                 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                    301                                                                                 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                    351                                                                                 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA                    401                                                                                 TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CTTCGCCTCT                    451                                                                                 GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG                    501                                                                                 CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCTCTG                    551                                                                                 GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG                    601                                                                                 AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC                    651                                                                                 CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG                    701                                                                                 GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG                    751                                                                                 GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT ACCAGGGGCT                    801                                                                                 CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC ACCTTGGACA                    851                                                                                 CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GCAGCAGATG                    901                                                                                 GAAGAACTGG GATAATAA (SEQ ID NO:98)                                        pMON13187                                                                      1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51   ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                    101                                                                                 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                    151                                                                                 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                    201                                                                                 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                    251                                                                                 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                    301                                                                                 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                    351                                                                                 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                    401                                                                                 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTATGGCC                    451                                                                                 CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCG CCTCTGCTTT                    501                                                                                 CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC                    551                                                                                 TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CTCTGGCGGC                    601                                                                                 TCTGGCGGCT CTCAGAGCTT CCTGCTCAAG TCTTTAGAGC AAGTGAGAAA                    651                                                                                 GATCCAGGGC GATGGCGCAG CGCTCCAGGA GAAGCTGTGT GCCACCTACA                    701                                                                                 AGCTGTGCCA CCCCGAGGAG CTGGTGCTGC TCGGACACTC TCTGGGCATC                    751                                                                                 CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG                    801                                                                                 CTGCTTGAGC CAACTCCATA GCGGCCTTTT CCTCTACCAG GGGCTCCTGC                    851                                                                                 AGGCCCTGGA AGGGATATCC CCCGAGTTGG GTCCCACCTT GGACACACTG                    901                                                                                 CAGCTGGACG TCGCCGACTT TGCCACCACC ATCTGGCAGC AGATGGAAGA                    951                                                                                 ACTGGGATAA TAA (SEQ ID NO:99)                                             pMON13188                                                                      1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51   ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                    101                                                                                 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                    151                                                                                 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                    201                                                                                 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                    251                                                                                 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                    301                                                                                 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                    351                                                                                 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA                    401                                                                                 CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA                    451                                                                                 GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG                    501                                                                                 CGTTCTACGC CACCTTGCGC AGCCCTCTGG CGGCTCTGGC GGCTCTCAGA                    551                                                                                 GCTTCCTGCT CAAGTCTTTA GAGCAAGTGA GAAAGATCCA GGGCGATGGC                    601                                                                                 GCAGCGCTCC AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGA                    651                                                                                 GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA                    701                                                                                 GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC                    751                                                                                CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT                     801                                                                                ATCCCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG                     851                                                                                ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT                     901                                                                                GCCCTGCAGC CCTAATAA (SEQ ID NO:100)                                        pMON13189                                                                      1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51  ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                     101                                                                                CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                     151                                                                                AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                     201                                                                                TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                     251                                                                                CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                     301                                                                                TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                     351                                                                                CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                     401                                                                                CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG                     451                                                                                GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT                     501                                                                                CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC                     551                                                                                TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TCAGAGCTTC                     601                                                                                CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC                     651                                                                                GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC                     701                                                                                TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC                     751                                                                                TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG                     801                                                                                CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC                     851                                                                                CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT                     901                                                                                GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT                     951                                                                                GCAGCCCTAA TAA (SEQ ID NO:101)                                             pMON13190                                                                      1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51  ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                     101                                                                                CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                     151                                                                                AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                     201                                                                                TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                     251                                                                                CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                     301                                                                                TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                     351                                                                                CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT                     401                                                                                CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG                     451                                                                                AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCTC                     501                                                                                TGGCGGCTCT GGCGGCTCTC AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG                     551                                                                                TGAGAAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC                     601                                                                                ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCT                     651                                                                                GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC                     701                                                                                TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT CTACCAGGGG                     751                                                                                CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTC CCACCTTGGA                     801                                                                                CACACTGCAG CTGGACGTCG CCGACTTTGC CACCACCATC TGGCAGCAGA                     851                                                                                TGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCA GGGTGCCATG                     901                                                                                CCGGCCTTCG CCTAATAA (SEQ ID NO:102)                                        pMON13191                                                                      1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51  ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                     101                                                                                CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                     151                                                                                AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                     201                                                                                TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                     251                                                                                CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                     301                                                                                  TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                   351                                                                                  CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                   401                                                                                  CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTCTGCT                   451                                                                                  TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT                   501                                                                                  CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCTCTGGCG                   551                                                                                  GCTCTGGCGG CTCTCAGAGC TTCCTGCTCA AGTCTTTAGA GCAAGTGAGA                   601                                                                                  AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA                   651                                                                                  CAAGCTGTGC CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA                   701                                                                                  TCCCCTGGGC TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA                   751                                                                                  GGCTGCTTGA GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT                   801                                                                                  GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GGGTCCCACC TTGGACACAC                   851                                                                                  TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA GCAGATGGAA                   901                                                                                  GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC                   951                                                                                  CTTCGCCTAA TAA (SEQ ID NO:103)                                           pMON13192                                                                      1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51    ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                   101                                                                                  CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                   151                                                                                  AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                   201                                                                                  TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                   251                                                                                  CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                   301                                                                                  TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                   351                                                                                  CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT                   401                                                                                  ACAAGCTGTG CCACCCCGAG GAGCTGGTGC TGCTCGGACA CTCTCTGGGC                   451                                                                                  ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC                   501                                                                                  AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC                   551                                                                                  TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA                   601                                                                                  CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA                   651                                                                                  AGAACTGGGA ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG                   701                                                                                  CCTTCGCCTC TGCTTTCCAG CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC                   751                                                                                  CATCTGCAGA GCTTCCTGGA GGTGTCGTAC CGCGTTCTAC GCCACCTTGC                   801                                                                                  GCAGCCCACA CCATTGGGCC CTGCCAGCTC CCTGCCCCAG AGCTTCCTGC                   851                                                                                  TCAAGTCTTT AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC                   901                                                                                  CAGGAGAAGC TGTGTGCCAC CTAATAA (SEQ ID NO:104)                            pMON13193                                                                      1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51    ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                   101                                                                                  CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                   151                                                                                  AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                   201                                                                                  TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                   251                                                                                  CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                   301                                                                                  TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                   351                                                                                  CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                   401                                                                                  CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTACAAG                   451                                                                                  CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC                   501                                                                                  CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT                   551                                                                                  GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG                   601                                                                                  GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA                   651                                                                                  GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC                   701                                                                                  TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC                   751                                                                                  GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT                   801                                                                                  GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC                   851                                                                                  CCACACCATT GGGCCCTGCC AGCTCCCTGC CCCAGAGCTT CCTGCTCAAG                   901                                                                                  TCTTTAGAGC AAGTGAGAAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA                   951                                                                                  GAAGCTGTGT GCCACCTAAT AA (SEQ ID NO:105)                                 pMON25190                                                                      1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51   ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                    101                                                                                 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                    151                                                                                 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                    201                                                                                 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                    251                                                                                 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                    301                                                                                 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                    351                                                                                 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTC                    401                                                                                 CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT                    451                                                                                 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT                    501                                                                                 GCAGCCCACC CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT TTCCAGCGCC                    551                                                                                 GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CCTGGAGGTG                    601                                                                                 TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCACACCAT TGGGCCCTGC                    651                                                                                 CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA                    701                                                                                 AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC                    751                                                                                 AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT                    801                                                                                 CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG                    851                                                                                 GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG                    901                                                                                 CAGGCCCTGG AAGGGATATC CTAATAA (SEQ ID NO:106)                             pMON25191                                                                      1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51   ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                    101                                                                                 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                    151                                                                                 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                    201                                                                                 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                    251                                                                                 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                    301                                                                                 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                    351                                                                                 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                    401                                                                                 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCCCGAG                    451                                                                                 TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC                    501                                                                                 CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC                    551                                                                                 CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA                    601                                                                                 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA                    651                                                                                 CCGCGTTCTA CGCCACCTTG CGCAGCCCAC ACCATTGGGC CCTGCCAGCT                    701                                                                                 CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT TAGAGCAAGT GAGAAAGATC                    751                                                                                 CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT                    801                                                                                 GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT                    851                                                                                 GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC                    901                                                                                 TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGCTCCTGCAGGC                     951                                                                                 CCTGGAAGGG ATATCCTAAT AA (SEQ ID NO:107)                                  pMON13194                                                                      1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51   ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                    101                                                                                 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                    151                                                                                 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                    201                                                                                 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                    251                                                                                 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                    301                                                                                 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                    351                                                                                 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA                    401                                                                                 TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CTTCGCCTCT                    451                                                                                 GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG                    501                                                                                CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCACAC                     551                                                                                CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CAAGTCTTTA                     601                                                                                GAGCAAGTGA GAAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT                     651                                                                                GTGTGCCACC TAqAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC                     701                                                                                ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC                     751                                                                                CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTA                     801                                                                                CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA                     851                                                                                CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG                     901                                                                                CAGCAGATGG AAGAACTGGG ATAATAA (SEQ ID NO:108)                              pMON13195                                                                      1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51  ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                     101                                                                                CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                     151                                                                                AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                     201                                                                                TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                     251                                                                                CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                     301                                                                                TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                     351                                                                                CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                     401                                                                                CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTATGGCC                     451                                                                                CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCG CCTCTGCTTT                     501                                                                                CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC                     551                                                                                TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CACACCATTG                     601                                                                                GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA                     651                                                                                AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG                     701                                                                                CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CGGACACTCT                     751                                                                                CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA                     801                                                                                GCTGGCAGGC TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG                     851                                                                                GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG TCCCACCTTG                     901                                                                                GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA                     951                                                                                GATGGAAGAA CTGGGATAAT AA (SEQ ID NO:109)                                   pMON13196                                                                      1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51  ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                     101                                                                                CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                     151                                                                                AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                     201                                                                                TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                     251                                                                                CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                     301                                                                                TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                     351                                                                                CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA                     401                                                                                CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA                     451                                                                                GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG                     501                                                                                CGTTCTACGC CACCTTGCGC AGCCCACACC ATTGGGCCCT GCCAGCTCCC                     551                                                                                TGCCCCAGAG CTTCCTGCTC AAGTCTTTAG AGCAAGTGAG AAAGATCCAG                     601                                                                                GGCGATGGCG CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG                     651                                                                                CCACCCCGAG GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG                     701                                                                                CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG                     751                                                                                AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC TGCAGGCCCT                     801                                                                                GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA CTGCAGCTGG                     851                                                                                ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AGAACTGGGA                     901                                                                                ATGGCCCCTG CCCTGCAGCC CTAATAA (SEQ ID NO:110)                              pMON13197                                                                      1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51    ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                   101                                                                                  CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                   151                                                                                  AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                   201                                                                                  TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                   251                                                                                  CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                   301                                                                                  TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                   351                                                                                  CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                   401                                                                                  CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG                   451                                                                                  GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT                   501                                                                                  CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC                   551                                                                                  TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CTCCCTGCCC                   601                                                                                  CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA                   651                                                                                  TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC                   701                                                                                  CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC                   751                                                                                  CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA                   801                                                                                  ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG                   851                                                                                  GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC                   901                                                                                  GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC                   951                                                                                  CCCTGCCCTG CAGCCCTAAT AA (SEQ ID NO:111)                                 pMON13198                                                                      1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51    ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                   101                                                                                  CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                   151                                                                                  AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                   201                                                                                  TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                   251                                                                                  CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                   301                                                                                  TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                   351                                                                                  CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT                   401                                                                                  CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG                   451                                                                                  AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCAC                   501                                                                                  ACCATTGGGC CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT                   551                                                                                  TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG                   601                                                                                  CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG                   651                                                                                  ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG                   701                                                                                  CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC                   751                                                                                  TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC                   801                                                                                  CACCTTGGAC ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT                   851                                                                                  GGCAGCAGAT GGAAGAACTG GGAATGGCCC CTGCCCTGCA GCCCACCCAG                   901                                                                                  GGTGCCATGC CGGCCTTCGC CTAATAA (SEQ ID NO:112)                            pMON13199                                                                      1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51    ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                   101                                                                                  CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                   151                                                                                  AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                   201                                                                                  TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                   251                                                                                  CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                   301                                                                                  TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                   351                                                                                  CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                   401                                                                                  CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTCTGCT                   451                                                                                  TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT                   501                                                                                  CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCACACCAT                   551                                                                                  TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG                   601                                                                                  CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG                   651                                                                                  TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT                   701                                                                                  CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG                   751                                                                                 CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA                    801                                                                                 GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT                    851                                                                                 TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG                    901                                                                                 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC                    951                                                                                 CATGCCGGCC TTCGCCTAAT AA (SEQ ID NO:113)                                  pMON31112                                                                      1  ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA                      51   GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG                    101                                                                                 ATATCCTAAT GGACAATAAC CTTCGTCGTC CAAACCTCGA GGCATTCAAC                    151                                                                                 CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA                    201                                                                                 AAATCTCCTG CCATGTCTGC CGCTAGCCAC GGCCGCACCC ACGCGACATC                    251                                                                                 CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC                    301                                                                                 TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG                    351                                                                                 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                    401                                                                                 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG                    451                                                                                 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT                    501                                                                                 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC                    551                                                                                 TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TCAGAGCTTC                    601                                                                                 CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC                    651                                                                                 GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC                    701                                                                                 TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC                    751                                                                                 TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG                    801                                                                                 CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC                    851                                                                                 CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT                    901                                                                                 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT                    951                                                                                 GCAGCCCTAA TAA (SEQ ID NO:114)                                            pMON31113                                                                      1  ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA                      51   GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG                    101                                                                                 ATATCCTGAT GGAAAATAAC CTTCGTCGTC CAAACCTCGA GGCATTCAAC                    151                                                                                 CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA                    201                                                                                 AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACCC ACGCGACATC                    251                                                                                 CAATCATCAT CCGTGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC                    301                                                                                 TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG                    351                                                                                 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                    401                                                                                 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG                    451                                                                                 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT                    501                                                                                 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC                    551                                                                                 TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CTCCCTGCCC                    601                                                                                 CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA                    651                                                                                 TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC                    701                                                                                 CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC                    751                                                                                 CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA                    801                                                                                 ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG                    851                                                                                 GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC                    901                                                                                 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC                    951                                                                                 CCCTGCCCTG CAGCCCTAAT AA (SEQ ID NO:115)                                  pMON31114                                                                      1  ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA                      51   GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG                    101                                                                                 ATATCCTGAT GGAAAATAAC CTTCGTCGTC CAAACCTCGA GGCATTCAAC                    151                                                                                 CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA                    201                                                                                AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACCC ACGCGACATC                     251                                                                                CAATCATCAT CCGTGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC                     301                                                                                TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG                     351                                                                                CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                     401                                                                                CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG                     451                                                                                GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT                     501                                                                                CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC                     551                                                                                TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TCAGAGCTTC                     601                                                                                CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC                     651                                                                                GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC                     701                                                                                TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC                     751                                                                                TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG                     801                                                                                CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC                     851                                                                                CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT                     901                                                                                GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT                     951                                                                                GCAGCCCTAA TAA (SEQ ID NO:116)                                             pMON31115                                                                      1  ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA                      51 GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG                      101                                                                                ATATCCTAAT GGACAATAAC CTTCGTCGTC CAAACCTCGA GGCATTCAAC                     151                                                                                CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA                     201                                                                                AAATCTCCTG CCATGTCTGC CGCTAGCCAC GGCCGCACCC ACGCGACATC                     251                                                                                CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC                     301                                                                                TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG                     351                                                                                CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                     401                                                                                CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG                     451                                                                                GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT                     501                                                                                CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC                     551                                                                                TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CTCCCTGCCC                     601                                                                                CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA                     651                                                                                TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC                     701                                                                                CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC                     751                                                                                CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA                     801                                                                                ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG                     851                                                                                GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC                     901                                                                                GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC                     951                                                                                CCCTGCCCTG CAGCCCTAAT AA (SEQ ID NO:117)                                   pMON28505                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGAGGTTCACCCTTTGCCTACACCTGTCCTGC            TGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACAT            TCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGC            CTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCC            TTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAG            CTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTC            AGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAAC            TGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCA (SEQ ID NO:118)                pMON28506                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGTTGCCTACACCTGTCCTGCTGCCTGCTGTGG            ACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGT            GACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTC            CTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGC            TTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCT            GCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGC            GGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACT            CCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCT (SEQ ID NO:119)                pMON28507                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGTCCTGCTGCCTGCTGTGGACTTTAGCTTGG            GAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCT            GGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTT            TCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGG            GCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAA            GGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCG            TCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTC            ACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCT (SEQ ID NO:120)                pMON28508                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGTGGACTTTAGCTTGGGAGAATGGAAAA            CCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGAT            GGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTC            CGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAG            CTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCT            GATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCG            CCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGA            GCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCT (SEQ ID NO:121)                pMON28509                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGACTTTAGCTTGGGAGAATGGAAAACCCAGA            TGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGC            ACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTC            CTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACA            AGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCT            TGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCT            TGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGT            GCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTG  (SEQ ID NO:122)               pMON28510                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCGGTTACCCTTGAGCAAGCGCAGGAACAACAG            TACGTAGAGGGCGGTGGAGGCTCCCCGGGGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCC            TCCGTCTAAAGAATCTCATAAACTCCAAACATGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGG            CACAGGACATTCTGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGA            CCCACTTGCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCA            GGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCATCTT            CCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGGGGTCCACCCTCT            GCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTGTGACCTCCGAGTCCTCAGT            AAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGACCAGTGCCCAGAGGTTCACCCTTTGCC            TACACCTGTCCTGCTGCCTGCTGTGGACTTTAGTTG  (SEQ ID NO:123)                          pMON28511                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGACCCACTTGCCTCTCATCCCTCCTGGGGC            AGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCC            ACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGA            GGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACA            TGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGT            CCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCT            GTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAG            CAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTG  (SEQ ID NO:124)               pMON28512                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAACCCAGCTTCCTCCACAGGGCAGGACCA            CAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTT            CCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCT            CCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGAC            TGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTT            GGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTG            CTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGC            TTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTT (SEQ ID NO:125)                pMON28513                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGCAGGACCACAGCTCACAAGGATCCCAATG            CCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTC            CACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGA            GTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTC            ACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGAT            GGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCA            CGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCC            TCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAG (SEQ ID NO:126)                pMON28514                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCACAAGGATCCCAATGCCATCTTCCTGA            GCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGT            CAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAA            CTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTA            CACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAA            GGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTG            GGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCC            TGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACA (SEQ ID NO:127)                pMON28515                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGATCCCAATGCCATCTTCCTGAGCTTCCAAC            ACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATT            CGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGT            GACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCC            TGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGA            CATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACT            TGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCC            TCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAG (SEQ ID NO:128)                pMON28516                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCATCTTCCTGAGCTTCCAACACCTGCTCC            GAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAA            CATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCAT            GTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTG            CTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGG            AGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCA            TCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAA            CCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAAT (SEQ ID NO:129)                pMON28519                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGAGGTTCACCCTTTGCCTACACCTGTCCTGC            TGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACAT            TCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGC            CTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCC            TTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAG            CTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTC            AGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGC            TTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCA (SEQ ID NO:130)                   pMON28520                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGTTGCCTACACCTGTCCTGCTGCCTGCTGTGG            ACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGT            GACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTC            CTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGC            TTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCT            GCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGC            AACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCC            ATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCT (SEQ ID NO:131)                   pMON28521                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGTCCTGCTGCCTGCTGTGGACTTTAGCTTGG            GAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCT            GGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTT            TCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGG            GCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAA            GGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCT            CCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACA            GCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCT (SEQ ID NO:132)                   pMON28522                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGTGGACTTTAGCTTGGGAGAATGGAAAA            CCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGAT            GGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTC            CGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAG            CTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCT            GATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCT            GCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCC            AGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCT (SEQ ID NO:133)                   pMON28523                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGACTTTAGCTTGGGAGAATGGAAAACCCAGA            TGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGC            ACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTC            CTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACA            AGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCT            TGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGT            GACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCC            CAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTG  (SEQ ID NO:134)                  pMON28524                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAGAATGGAAAACCCAGATGGAGGAGACCA            AGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACT            GGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCC            CTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATG            CCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTC            CACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTC            CTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACC            CTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTG (SEQ ID NO:135)                   pMON28525                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGACCCACTTGCCTCTCATCCCTCCTGGGGC            AGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCC            ACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGA            GGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGG            CGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCT            TCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTG            GACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAG            TGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTG (SEQ ID NO:136)                   pMON28526                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAACCCAGCTTCCTCCACAGGGCAGGACCA            CAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTT            CCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCG            CCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGA            GCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGG            AGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTG            GAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTT            CTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTT (SEQ ID NO:137)                   pMON28527                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGCAGGACCACAGCTCACAAGGATCCCAATG            CCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTC            CACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTC            CTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACC            CTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGA            GGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGG            GGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCC            TTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAG (SEQ ID NO:138)                   pMON28528                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCACAAGGATCCCAATGCCATCTTCCTGA            GCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGT            CAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTG            CTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACAC            CTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGC            ACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGA            CCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGC            AGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACA (SEQ ID NO:139)                   pMON28529                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGATCCCAATGCCATCTTCCTGAGCTTCCAAC            ACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATT            CGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGAC            TCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGC            TGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACAT            TCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGC            CTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCC            TTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAG (SEQ ID NO:140)                   pMON28530                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCATCTTCCTGAGCTTCCAACACCTGCTCC            GAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACAT            GGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTC            CTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTG            TGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGC            AGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCC            CTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCC            AGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAAT (SEQ ID NO:141)                   pMON28533                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTGACTTCCAAACCTG            GAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATGAGGCAATTCTTCGTAATCT            CCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGCATCCAATCATCATCAAGGCAGGTGACT            GGCAAGAATTCCGGGAAAAACTGACGTTCTATTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTAC            GTAGAGGGCGGTGGAGGCTCCCCGGTAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCG            TCTAAAGAATCTCATAAATCTCCAAACATGGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTG            CTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGG            AGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCA            TCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAA            CCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCA            ACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAA            TTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTA            AACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCA (SEQ ID NO:142)             pMON28534                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGTTGCCTACACCTGTCCTGCTGCCTGCTGTGG            ACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGT            GACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTC            CTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGC            TTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCT            GCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGC            GGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGC            TTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCT (SEQ ID               NO:143)                                                                        pMON28535                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGTCCTGCTGCCTGCTGTGGACTTTAGCTTGG            GAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCT            GGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTT            TCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGG            GCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAA            GGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGC            AACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCC            ATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCT (SEQ ID               NO:144)                                                                        pMON28536                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGTGGACTTTAGCTTGGGAGAATGGAAAA            CCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGAT            GGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTC            CGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAG            CTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCT            GATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCC            CCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACA            GCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCT                       (SEQ ID NO:145)                                                                pMON28537                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGACTTTAGCTTGGGAGAATGGAAAACCCAGA            TGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGC            ACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTC            CTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACA            AGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCT            TGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCG            CCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGAC            TGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTG                       (SEQ ID NO:146)                                                                pMON28538                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAGAATGGAAAACCCAGATGGAGGAGACCA            AGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACT            GGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCC            CTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATG            CCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTC            CACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGT            GACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCC            CAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTG                       (SEQ ID NO:147)                                                                pMON28539                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGACCCACTTGCCTCTCATCCCTCCTGGGGC            AGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCC            ACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGA            GGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACG            GCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGA            CTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTG            CTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACA            TTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTG                       (SEQ ID NO:148)                                                                pMON28540                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAACCCAGCTTCCTCCACAGGGCAGGACCA            CAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTT            CCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCG            TCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTC            ACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGA            CTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTG            ACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCC            TGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTT                       (SEQ ID NO:149)                                                                pMON28541                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGCAGGACCACAGCTCACAAGGATCCCAATG            CCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTC            CACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGT            GACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGqAGACTGAGCCAGTGCC            CAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAA            AACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTG            ATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGG            TCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAG                       (SEQ ID NO:150)                                                                pMON28542                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCACAAGGATCCCAATGCCATCTTCCTGA            GCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGT            CAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTC            CTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACC            CTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGA            GGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGG            GGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCC            TTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACA                       (SEQ ID NO:151)                                                                pMON28543                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGATCCCAATGCCATCTTCCTGAGCTTCCAAC            ACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATT            CGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAA            CTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTA            CACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAA            GGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTG            GGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCC            TGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAG                       (SEQ ID NO:152)                                                                pMON28544                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCATCTTCCTGAGCTTCCAACACCTGCTCC            GAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAA            CGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGT            GACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCC            TGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGA            CATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACT            TGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCC            TCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAAT                       (SEQ ID NO:153)                                                                pMON28545                                                                      GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGG            ACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCT            GGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAAT            CTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTG            ACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACA            GTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT            CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGATCCCAATGCCATCTTCCTGAGCTTCCAAC            ACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATT            CGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGT            GACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCC            TGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGA            CATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACT            TGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCC            TCCTTGGAACCCAGGGCAGGACCACAGCTCACAAG  (SEQ ID NO:154)                           pMON15981                                                                      1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51  ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                     101                                                                                CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                     151                                                                                AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                     201                                                                                TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                     251                                                                                CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                     301                                                                                TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                     351                                                                                CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                     401                                                                                CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTTACAAG                     451                                                                               CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC                      501                                                                               CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT                      551                                                                               GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG                      601                                                                               GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA                      651                                                                               GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC                      701                                                                               TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC                      751                                                                               GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT                      801                                                                               GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC                      851                                                                               CCGGCGGCGG CTCTGACATG GCTACACCAT TAGGCCCTGC CAGCTCCCTG                      901                                                                               CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGGA AGATCCAGGG                      951                                                                               CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAA TAA;                                     (SEQ ID NO:155)                                                       pMON15982                                                                      1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                      101                                                                               CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                      151                                                                               AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                      201                                                                               TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                      251                                                                               CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                      301                                                                               TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                      351                                                                               CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                      401                                                                               CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTCCCGAG                      451                                                                               TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC                      501                                                                               CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC                      551                                                                               CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA                      601                                                                               GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA                      651                                                                               CCGCGTTCTA CGCCACCTTG CGCAGCCCqG CGGCGGCTCT GACATGGCTA                      701                                                                               CACCATTAGG CCCTGCCAGC TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT                      751                                                                               TTAGAGCAAG TGAGGAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA                      801                                                                               GCTGTGTGCC ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG                      851                                                                               GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG                      901                                                                               GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT                      951                                                                               CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCTAA TAA;                                     (SEQ ID NO:156)                                                       pMON15965                                                                      1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                      101                                                                               CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                      151                                                                               AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                      201                                                                               TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                      251                                                                               CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                      301                                                                               TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                      351                                                                               CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                      401                                                                               CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTTCTGCT                      451                                                                               TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT                      501                                                                               CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCGGCGGCG                      551                                                                               GCTCTGACAT GGCTACACCA TTAGGCCCTG CCAGCTCCCT GCCCCAGAGC                      601                                                                               TTCCTGCTCA AGTCTTTAGA GCAAGTGAGG AAGATCCAGG GCGATGGCGC                      651                                                                               AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CAAGCTGTGC CACCCCGAGG                      701                                                                               AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC                      751                                                                               TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA                      801                                                                               TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT                      851                                                                               CCCCCGAGTT GGGTCCCACC TTGGACACAC TGCAGCTGGA CGTCGCCGAC                      901                                                                               TTTGCCACCA CCATCTGGCA GCAGATGGAA GAACTGGGAA TGGCCCCTGC                      951                                                                               CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CTTCGCCTAA TAA                                      (SEQ ID NO:157)                                                       pMON15966                                                                      1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51   ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                    101                                                                                 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                    151                                                                                 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                    201                                                                                 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                    251                                                                                 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                    301                                                                                 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                    351                                                                                 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                    401                                                                                 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTATGGCC                    451                                                                                 CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCG CCTCTGCTTT                    501                                                                                 CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC                    551                                                                                 TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CGGCGGCGGC                    601                                                                                 TCTGACATGG CTACACCATT AGGCCCTGCC AGCTCCCTGC CCCAGAGCTT                    651                                                                                 CCTGCTCAAG TCTTTAGAGC AAGTGAGGAA GATCCAGGGC GATGGCGCAG                    701                                                                                 CGCTCCAGGA GAAGCTGTGT GCCACCTACA AGCTGTGCCA CCCCGAGGAG                    751                                                                                 CTGGTGCTGC TCGGACACTC TCTGGGCATC CCCTGGGCTC CCCTGAGCTC                    801                                                                                 CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC CAACTCCATA                    851                                                                                 GCGGCCTTTT CCTCTACCAG GGGCTCCTGC AGGCCCTGGA AGGGATATCC                    901                                                                                 CCCGAGTTGG GTCCCACCTT GGACACACTG CAGCTGGACG TCGCCGACTT                    951                                                                                 TGCCACCACC ATCTGGCAGC AGATGGAAGA ACTGGGATAA TAA                                       (SEQ ID NO:158)                                                    pMON15967                                                                      1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51   ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                    101                                                                                 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                    151                                                                                 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                    201                                                                                 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                    251                                                                                 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                    301                                                                                 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                    351                                                                                 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                    401                                                                                 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTACCCAG                    451                                                                                 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT                    501                                                                                 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC                    551                                                                                 TACGCCACCT TGCGCAGCCC GGCGGCGGCT CTGACATGGC TACACCATTA                    601                                                                                 GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA                    651                                                                                 AGTGAGGAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG                    701                                                                                 CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CGGACACTCT                    751                                                                                 CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA                    801                                                                                 GCTGGCAGGC TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG                    851                                                                                 GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG TCCCACCTTG                    901                                                                                 GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA                    951                                                                                 GATGGAAGAA CTGGGAATGG CCCCTGCCCT GCAGCCCTAA TAA                                       (SEQ ID NO:159)                                                    pMON15960                                                                      1  ATGGCTACAC CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT                      51   CAAGTCTTTA GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC                    101                                                                                 AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGA GGAGCTGGTG                    151                                                                                 CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC                    201                                                                                 CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC                    251                                                                                 TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG                    301                                                                                 TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC                    351                                                                                 CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC                    401                                                                                 CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA                    451                                                                                 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA                    501                                                                                 CCGCGTTCTA CGCCACCTTG CGCAGCCCGG CGGCGGCTCT GACATGGCTA                    551                                                                                 CACCATTGGG CCCTGCCAGC TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT                    601                                                                                 TTAGAGCAAG TGAGGAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA                    651                                                                                 GCTGTGTGCC ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG                    701                                                                                 GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG                    751                                                                                 GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT                    801                                                                                 CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTC                    851                                                                                 CCACCTTGGA CACACTGCAG CTGGACGTCG CCGACTTTGC CACCACCATC                    901                                                                                 TGGCAGCAGA TGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCA                    1001                                                                                TCCTGGTTGC TAGCCATCTG CAGAGCTTCC TGGAGGTGTC GTACCGCGTT                    1051                                                                                CTACGCCACC TTGCGCAGCC CTGATAA (SEQ ID NO:160)                             PM0N32132                                                                      TCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTC            ACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGA            CTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTG            ACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCC            TGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCT            TCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTG            CTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG                      (SEQ ID NO:249)                                                                PMON32133                                                                      TCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTC            ACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGA            CTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTG            ACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCC            TGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGGG            CAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAG            GTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG (SEQ ID NO:250)                  pMON32134                                                                      TCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTC            ACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGA            CTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTG            ACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCC            TGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCT            TCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTG            CTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG                      (SEQ ID NO:251)                                                                Pmon13181                                                                      1  CCATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG                      51   AGACCACCTG CACCTTTGCT GGACCCGAAC AACCTCAATG ACGAAGACGT                    101                                                                                 CTCTATCCTG ATGGATCGAA ACCTTCGACT TCCAAACCTG GAGAGCTTCG                    151                                                                                 TAAGGGCTGT CAAGAACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT                    201                                                                                 CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA                    251                                                                                 TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA                    301                                                                                 CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GTACGTAgag                    351                                                                                 ggcggtggag gctcCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA                    401                                                                                 CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGTAAGGTA                    451                                                                                 CCGCATGCAA GCTT (SEQ ID NO:257)                                           Pmon13180.Seg                                                                  1  CCATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG                      51   AGACCACCTG CACCTTTGCT GGACCCGAAC AACCTCAATG ACGAAGACGT                    101                                                                                 CTCTATCCTG ATGGATCGAA ACCTTCGACT TCCAAACCTG GAGAGCTTCG                    151                                                                                 TAAGGGCTGT CAAGAACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT                    201                                                                                 CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA                    251                                                                                 TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA                    301                                                                                 CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GTACGTAgag                    351                                                                                 ggcggtggag gctcCCCGGG TGGTGGTTCT GGCGGCGGCT CCAACATGTA                    401                                                                                 AGGTACCGCA TGCAAGCTT (SEQ ID NO:258)                                      pmon16017.seq                                                                  1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51   ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                    101                                                                                 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                    151                                                                                 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                    201                                                                                 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                    251                                                                                 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                    301                                                                                 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                    351                                                                                 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                    401                                                                                 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTTAGGC                    451                                                                                 CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT TAGAGCAAGT                    501                                                                                 GAGGAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA                    551                                                                                 CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG                    601                                                                                 GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT                    651                                                                                 GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC                    701                                                                                 TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC                    751                                                                                 ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT                    801                                                                                 GGAAGAACTG GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC                    851                                                                                 CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT                    901                                                                                 AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC TACGCCACCT                    951                                                                                 TGCGCAGCCC GACATGGCTA CACCA (SEQ ID NO:259)                               pmon16018.seq                                                                  1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51   ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                    101                                                                                 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                    151                                                                                 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                    201                                                                                 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                    251                                                                                 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                    301                                                                                 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                    351                                                                                 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                    401                                                                                 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCAGAGC                    451                                                                                 TTCCTGCTCA AGTCTTTAGA GCAAGTGAGG AAGATCCAGG GCGATGGCGC                    501                                                                                 AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CAAGCTGTGC CACCCCGAGG                    551                                                                                 AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC                    601                                                                                 TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA                    651                                                                                 TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT                    701                                                                                 CCCCCGAGTT GGGTCCCACC TTGGACACAC TGCAGCTGGA CGTCGCCGAC                    751                                                                                 TTTGCCACCA CCATCTGGCA GCAGATGGAA GAACTGGGAA TGGCCCCTGC                    801                                                                                 CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC                    851                                                                                 GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG                    901                                                                                 GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCGACA TGGCTACACC                    951                                                                                 ATTAGGCCCT GCCAGCTCCC TGCCC (SEQ ID NO:260)                               pmon16019.seq                                                                  1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                      101                                                                               CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                      151                                                                               AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                      201                                                                               TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                      251                                                                               CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                      301                                                                               TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                      351                                                                               CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                      401                                                                               CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTTCCTG                      451                                                                               CTCAAGTCTT TAGAGCAAGT GAGGAAGATC CAGGGCGATG GCGCAGCGCT                      501                                                                               CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG                      551                                                                               TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC                      601                                                                               CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG                      651                                                                               CCTTTTCCTC TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG                      701                                                                               AGTTGGGTCC CACCTTGGAC ACACTGCAGC TGGACGTCGC CGACTTTGCC                      751                                                                               ACCACCATCT GGCAGCAGAT GGAAGAACTG GGAATGGCCC CTGCCCTGCA                      801                                                                               GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG                      851                                                                               CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG                      901                                                                               TACCGCGTTC TACGCCACCT TGCGCAGCCC GACATGGCTA CACCATTAGG                      951                                                                               CCCTGCCAGC TCCCTGCCCC AGAGC (SEQ ID NO:261)                                 pmon16020.seq                                                                  1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                      101                                                                               CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                      151                                                                               AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                      201                                                                               TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                      251                                                                               CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                      301                                                                               TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                      351                                                                               CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                      401                                                                               CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTGAGCAA                      451                                                                               GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC                      501                                                                               CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC                      551                                                                               TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG                      601                                                                               CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG                      651                                                                               GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG                      701                                                                               ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG                      751                                                                               ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT                      801                                                                               GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG                      851                                                                               CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC                      901                                                                               CTTGCGCAGC CCGACATGGC TACACCATTA GGCCCTGCCA GCTCCCTGCC                      951                                                                               CCAGAGCTTC CTGCTCAAGT CTTTA (SEQ ID NO:262)                                 pmon16021.seq                                                                  1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                      101                                                                               CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                      151                                                                               AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                      201                                                                               TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                      251                                                                               CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                      301                                                                               TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                      351                                                                               CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                      401                                                                               CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCTGCTC                      451                                                                               GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA                      501                                                                               GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC                      551                                                                               TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT                      601                                                                               CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT                      651                                                                               CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC                      701                                                                                 AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG                    751                                                                                 GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT                    801                                                                                 TCTACGCCAC CTTGCGCAGC CCGACATGGC TACACCATTA GGCCCTGCCA                    851                                                                                 GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA AGTGAGGAAG                    901                                                                                 ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAA                    951                                                                                 GCTGTGCCAC CCCGAGGAGC TGGTG (SEQ ID NO:263)                               pmon16022.seq                                                                  1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51   ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                    101                                                                                 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                    151                                                                                 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                    201                                                                                 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                    251                                                                                 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                    301                                                                                 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                    351                                                                                 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                    401                                                                                 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCCCCTG                    451                                                                                 AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT                    501                                                                                 CCATAGCGGC CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA                    551                                                                                 TATCCCCCGA GTTGGGTCCC ACCTTGGACA CACTGCAGCT GGACGTCGCC                    601                                                                                 GACTTTGCCA CCACCATCTG GCAGCAGATG GAAGAACTGG GAATGGCCCC                    651                                                                                 TGCCCTGCAG CCCACCCAGG GTGCCATGCC GGCCTTCGCC TCTGCTTTCC                    701                                                                                 AGCGCCGGGC AGGAGGGGTC CTGGTTGCTA GCCATCTGCA GAGCTTCCTG                    751                                                                                 GAGGTGTCGT ACCGCGTTCT ACGCCACCTT GCGCAGCCCG ACATGGCTAC                    801                                                                                 ACCATTAGGC CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT                    851                                                                                 TAGAGCAAGT GAGGAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG                    901                                                                                 CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG                    951                                                                                 ACACTCTCTG GGCATCCCCT GGGCT (SEQ ID NO:264)                               pmon16023.seq                                                                  1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51   ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                    101                                                                                 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                    151                                                                                 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                    201                                                                                 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                    251                                                                                 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                    301                                                                                 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                    351                                                                                 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                    401                                                                                 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCAGGCC                    451                                                                                 CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTA                    501                                                                                 CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA                    551                                                                                 CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG                    601                                                                                 CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC CCACCCAGGG                    651                                                                                 TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC                    701                                                                                 TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA                    751                                                                                 CGCCACCTTG CGCAGCCCGA CATGGCTACA CCATTAGGCC CTGCCAGCTC                    801                                                                                 CCTGCCCCAG AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGGAAGATCC                    851                                                                                 AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CTACAAGCTG                    901                                                                                 TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG                    951                                                                                 GGCTCCCCTG AGCTCCTGCC CCAGC (SEQ ID NO:265)                               pmon16024.seq                                                                  1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51   ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                    101                                                                                 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                    151                                                                                  AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                   201                                                                                  TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                   251                                                                                  CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                   301                                                                                  TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                   351                                                                                  CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                   401                                                                                  CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCTGCAG                   451                                                                                  CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG                   501                                                                                  GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG                   551                                                                                 ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG                    601                                                                                 ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT                    651                                                                                 GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG                    701                                                                                 CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC                    751                                                                                 CTTGCGCAGC CCGACATGGC TACACCATTA GGCCCTGCCA GCTCCCTGCC                    801                                                                                 CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA AGTGAGGAAG ATCCAGGGCG                    851                                                                                 ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCAC                    901                                                                                 CCCGAGGAGC TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC                    951                                                                                 CCTGAGCTCC TGCCCCAGCC AGGCC (SEQ ID NO:266)                               pmon16025.seq                                                                  1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51   ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                    101                                                                                 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                    151                                                                                 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                    201                                                                                 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                    251                                                                                 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                    301                                                                                 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                    351                                                                                 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                    401                                                                                 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCTGGCA                    451                                                                                 GGCTGCTTGA GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT                    501                                                                                 GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GGGTCCCACC TTGGACACAC                    551                                                                                 TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA GCAGATGGAA                    601                                                                                 GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC                    651                                                                                 CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC                    701                                                                                 ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG                    751                                                                                 CAGCCCGACA TGGCTACACC ATTAGGCCCT GCCAGCTCCC TGCCCCAGAG                    801                                                                                 CTTCCTGCTC AAGTCTTTAG AGCAAGTGAG GAAGATCCAG GGCGATGGCG                    851                                                                                 CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG CCACCCCGAG                    901                                                                                 GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG                    951                                                                                 CTCCTGCCCC AGCCAGGCCC TGCAG (SEQ ID NO:267)                               pmon16026.seq                                                                  1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51   ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                    101                                                                                 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                    151                                                                                 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                    201                                                                                 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                    251                                                                                 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                    301                                                                                 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                    351                                                                                 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                    401                                                                                 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTGAACTG                    451                                                                                 GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC                    501                                                                                 CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC                    551                                                                                 AGAGCTTCCT GGAGGTGTCG TACCGCGTTC TACGCCACCT TGCGCAGCCC                    601                                                                                 GACATGGCTA CACCATTAGG CCCTGCCAGC TCCCTGCCCC AGAGCTTCCT                    651                                                                                 GCTCAAGTCT TTAGAGCAAG TGAGGAAGAT CCAGGGCGAT GGCGCAGCGC                    701                                                                                 TCCAGGAGAA GCTGTGTGCC ACCTACAAGC TGTGCCACCC CGAGGAGCTG                    751                                                                                 GTGCTGCTCG GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG                    801                                                                                 CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG                    851                                                                                 GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCCCC                    901                                                                                 GAGTTGGGTC CCACCTTGGA CACACTGCAG CTGGACGTCG CCGACTTTGC                    951                                                                                 CACCACCATC TGGCAGCAGA TGGAA (SEQ ID NO:268)                               pmon16027.seq                                                                  1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51   ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                    101                                                                                 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                    151                                                                                 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                    201                                                                                 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                    251                                                                                 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                    301                                                                                 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                    351                                                                                 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                    401                                                                                 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTGGAATG                    451                                                                                 GCCCCTGCCC TGCAGCCCAC CCAGGGTGCC ATGCCGGCCT TCGCCTCTGC                    501                                                                                 TTTCCAGCGC CGGGCAGGAG GGGTCCTGGT TGCTAGCCAT CTGCAGAGCT                    551                                                                                 TCCTGGAGGT GTCGTACCGC GTTCTACGCC ACCTTGCGCA GCCCGACATG                    601                                                                                 GCTACACCAT TAGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA                    651                                                                                 GTCTTTAGAG CAAGTGAGGA AGATCCAGGG CGATGGCGCA GCGCTCCAGG                    701                                                                                 AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG                    751                                                                                 CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG                    801                                                                                 CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT                    851                                                                                 TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG                    901                                                                                 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC                    951                                                                                 CATCTGGCAG CAGATGGAAG AACTG (SEQ ID NO:269)                               pmon16028.seq                                                                  1  ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG                      51   ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT                    101                                                                                 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA                    151                                                                                 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG                    201                                                                                 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC                    251                                                                                 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG                    301                                                                                 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG                    351                                                                                 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC                    401                                                                                 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTAGCTTC                    451                                                                                 CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCGACATGGC                    501                                                                                 TACACCATTA GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT                    551                                                                                 CTTTAGAGCA AGTGAGGAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG                    601                                                                                 AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT                    651                                                                                 CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC                    701                                                                                 AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG CGGCCTTTTC                    751                                                                                 CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG                    801                                                                                 TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA                    851                                                                                 TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GCAGCCCACC                    901                                                                                 CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT TTCCAGCGCC GGGCAGGAGG                    951                                                                                 GGTCCTGGTT GCTAGCCATC TGCAG (SEQ ID NO:270)                               1     ATGGCTGGAC CCACTTGCCT CTCATCCCTC CTGGGGCAGC TTTCTGGACA                   51   GGTCCGTCTC CTCCTTGGGG CCCTGCAGAG CCTCCTTGGA ACCCAGCTTC                    101                                                                                 CTCCACAGGG CAGGACCACA GCTCACAAGG ATCCCAATGC CATCTTCCTG                    151                                                                                 AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG CGTTTCCTGA TGCTTGTAGG                    201                                                                                 AGGGTCCACC CTCGCCGTCA GGGAATTCGG CGGCAACATG GCGTCTCCGG                    251                                                                                 CGCCGCCTGC TGCTGACCTC CGAGTCCTCA GTAAACTGCT TCGTGACTCC                    301                                                                                 CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC                    351                                                                                 TACACCTGTC CTGCTGCCTG CTGTGGACTT TAGCTTGGGA GAATGGAAAA                    401                                                                                 CCCAGATGGA GGAGACCAAG GCACAGGACA TTCTGGGAGC AGTGACCCTT                    451                                                                                CTGCTGGAGG GAGTGATGGC AGCACGGGGA CAACTG                                               (SEQ ID NO:286)                                                     1   ATGGCTGGCA GGACCACAGC TCACAAGGAT CCCAATGCCA TCTTCCTGAG                     51  CTTCCAACAC CTGCTCCGAG GAAAGGTGCG TTTCCTGATG CTTGTAGGAG                     101                                                                                GGTCCACCCT CGCCGTCAGG GAATTCGGCG GCAACATGGC GTCTCCGGCG                     151                                                                                CCGCCTGCTG CTGACCTCCG AGTCCTCAGT AAACTGCTTC GTGACTCCCA                     201                                                                                TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AGAGGTTCAC CCTTTGCCTA                     251                                                                                CACCTGTCCT GCTGCCTGCT GTGGACTTTA GCTTGGGAGA ATGGAAAACC                     301                                                                                CAGATGGAGG AGACCAAGGC ACAGGACATT CTGGGAGCAG TGACCCTTCT                     351                                                                                GCTGGAGGGA GTGATGGCAG CACGGGGACA ACTGGGACCC ACTTGCCTCT                     401                                                                                CATCCCTCCT GGGGCAGCTT TCTGGACAGG TCCGTCTCCT CCTTGGGGCC                     451                                                                                CTGCAGAGCC TCCTTGGAAC CCAGCTTCCT CCACAG                                               (SEQ ID NO:287)                                                     __________________________________________________________________________

                                      TABLE 3                                      __________________________________________________________________________     PROTEIN SEQUENCES                                                              __________________________________________________________________________     pMON26458pep                                                                   SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis                   ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu                   LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla                   GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln                   LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu                   LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla                   HisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg                   PheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPhe                                  (SEQ ID NO:161)                                                                pMON28548pep                                                                   SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis                   ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu                   LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla                   GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln                   LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu                   LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla                   HisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg                   PheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAla                   SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis                   ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu                   LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla                   GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln                   LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu                   LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnGlyArgThrThrAlaHisLysAspPro                   AsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeu                   ValGlyGlySerThrLeuCysValArg (SEQ ID NO:162)                                    pMON28500                                                                      SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeu             HisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaVal             AspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAla             ValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSer             LeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThr             GlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGln             HisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGlu             PheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArg             AspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProVal             LeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGln             AspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyPro             ThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGln             SerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIle             PheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThr             LeuCysValArg (SEQ ID NO:163)                                                   pMON28501                                                                      SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis                   ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu                   LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla                   GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln                   LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu                   LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla                   HisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg                   PheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAla                   SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis                   ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu                   LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla                   GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln                   LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu                   LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla                   HisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg                   PheLeuMetLeuValGlyGlySerThrLeuCysValArg (SEQ ID NO:164)                        pMON28502                                                                      SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis                   ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu                   LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla                   GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln                   LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu                   LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla                   HisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg                   PheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGly                   AsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArg                   AspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThr                   ProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGlu                   ThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAla                   ArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnVal                   ArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArg                   ThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGly                   LysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg                               (SEQ ID NO:165)                                                                13182.Pept                                                                     Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Tyr Lys Leu Cys                    His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro                    Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala                    Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly                    Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr                    Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile                    Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro                    Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg                    Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu                    Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly                    Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val                    Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys                    Ala Thr (SEQ ID NO:166)                                                        13183.Pept                                                                     Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro                    Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Tyr Lys Leu Cys                    His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro                    Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala                    Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly                    Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr                    Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile                    Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro                    Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg                    Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu                    Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly                    Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val                    Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys                    Ala Thr (SEQ ID NO:167)                                                        13184.Pept                                                                     Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Pro Glu Leu Gly                    Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr                    Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu                    Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln                    Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe                    Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser                    Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu                    Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys                    Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu                    Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys                    Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His                    Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly                    Ile Ser (SEQ ID NO:168)                                                        13185.Pept                                                                     Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro                    Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Pro Glu Leu Gly                    Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr                    Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu                    Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln                    Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe                    Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser                    Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu                    Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys                    Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu                    Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys                    Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His                    Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly                    Ile Ser (SEQ ID NO:169)                                                        13186.Pept                                                                     Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Met Ala Pro Ala                    Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe                    Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser                    Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro                    Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu                    Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu                    Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val                    Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser                    Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu                    His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu                    Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu                    Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu                    Leu Gly (SEQ ID NO:170)                                                        13187.Pept                                                                     Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro                    Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Met Ala Pro Ala                    Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe                    Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser                    Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro                    Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu                    Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu                    Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val                    Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser                    Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu                    His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu                    Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu                    Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu                    Leu Gly (SEQ ID NO:171)                                                        13188.Pept                                                                     Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Gln Gly Ala                    Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val                    Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg                    Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser                    Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln                    Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys                    Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly                    Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln                    Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr                    Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly                    Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr                    Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu                    Gln Pro (SEQ ID NO:172)                                                        13189.Pept                                                                     Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro                    Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala                    Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val                    Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg                    Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser                    Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln                    Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys                    Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly                    Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln                    Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr                    Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly                    Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr                    Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu                    Gln Pro (SEQ ID NO:173)                                                        13190.Pept                                                                     Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Ser Ala Phe Gln                    Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe                    Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser                    Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu                    Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys                    Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu                    Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys                    Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His                    Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly                    Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp                    Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu                    Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala                    Phe Ala (SEQ ID NO:174)                                                        13191.Pept                                                                     Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro                    Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Ser Ala Phe Gln                    Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe                    Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser                    Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu                    Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys                    Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu                    Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys                    Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His                    Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly                    Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp                    Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu                    Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala                    Phe Ala (SEQ ID NO:175)                                                        13192.Pept                                                                     Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Tyr Lys Leu Cys                    His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro                    Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala                    Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly                    Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr                    Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile                    Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro                    Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg                    Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu                    Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr Pro Leu                    Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu                    Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu                    Lys Leu Cys Ala Thr (SEQ ID NO:176)                                            13193.Pept                                                                     Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro                    Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Tyr Lys Leu Cys                    His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro                    Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala                    Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly                    Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr                    Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile                    Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro                    Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg                    Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu                    Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr Pro Leu                    Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu                    Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu                    Lys Leu Cys Ala Thr (SEQ ID NO:177)                                            25190.Pept                                                                     Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Pro Glu Leu Gly                    Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr                    Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu                    Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln                    Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe                    Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr                    Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys                    Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu                    Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu                    Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu                    Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser                    Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala                    Leu Glu Gly Ile Ser (SEQ ID NO:178)                                            pMON25191.Pep                                                                  Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro                    Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Pro Glu Leu Gly                    Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr                    Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu                    Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln                    Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe                    Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr                    Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys                    Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu                    Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu                    Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu                    Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser                    Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala                    Leu Glu Gly Ile Ser (SEQ ID NO:179)                                            13194.Pept                                                                     Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Met Ala Pro Ala                    Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe                    Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser                    Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro                    Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu                    Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala                    Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu                    Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro                    Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu                    Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln                    Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr                    Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln                    Met Glu Glu Leu Gly (SEQ ID NO:180)                                            13195.Pept                                                                     Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro                    Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Met Ala Pro Ala                    Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe                    Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser                    Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro                    Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu                    Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala                    Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu                    Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro                    Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu                    Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln                    Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr                    Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln                    Met Glu Glu Leu Gly (SEQ ID NO:181)                                            13196.Pept                                                                     Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Gln Gly Ala                    Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val                    Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg                    Val Leu Arg His Leu Ala Gln Pro Thr Pro Leu Gly Pro Ala Ser                    Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg                    Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala                    Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His                    Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln                    Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu                    Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro                    Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp                    Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala                    Pro Ala Leu Gln Pro (SEQ ID NO:182)                                            13197.Pept                                                                     Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro                    Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala                    Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val                    Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg                    Val Leu Arg His Leu Ala Gln Pro Thr Pro Leu Gly Pro Ala Ser                    Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg                    Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala                    Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His                    Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln                    Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu                    Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro                    Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp                    Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala                    Pro Ala Leu Gln Pro (SEQ ID NO:183)                                            13198.Pept                                                                     Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Ser Ala Phe Gln                    Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe                    Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr                    Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys                    Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu                    Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu                    Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu                    Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser                    Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala                    Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu                    Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met                    Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala                    Met Pro Ala Phe Ala (SEQ ID NO:184)                                            13199.Pept                                                                     Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro                    Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Ser Ala Phe Gln                    Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe                    Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr                    Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys                    Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu                    Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu                    Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu                    Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser                    Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala                    Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu                    Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met                    Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala                    Met Pro Ala Phe Ala (SEQ ID NO:185)                                            31104.Pep                                                                      Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met                    Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala                    Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg                    Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg                    His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu                    Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln                    Gln Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile Ile                    His His Leu Lys Arg Pro Pro Ala Pro Leu Tyr Val Glu Gly Gly                    Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn                    Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala                    Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg                    Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu                    Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly                    Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val                    Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys                    Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly                    His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser                    Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly                    Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser                    Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala                    Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met                    Ala Pro Ala Leu Gln Pro (SEQ ID NO:186)                                        31105.Pep                                                                      Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys                    Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile                    Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr                    Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gly Ser                    Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Tyr Val Glu Gly Gly                    Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn                    Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala                    Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg                    Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu                    Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly                    Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val                    Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys                    Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly                    His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser                    Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly                    Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser                    Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala                    Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met                    Ala Pro Ala Leu Gln Pro (SEQ ID NO:187)                                        31106.Pep                                                                      Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln                    Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln                    Ala Gln Glu Gln Gln Gly Gly Gly Ser Asn Cys Ser Ile Met Ile                    Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu                    Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp                    Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val                    Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn                    Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Tyr Val Glu Gly Gly                    Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn                    Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala                    Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg                    Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu                    Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly                    Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val                    Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys                    Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly                    His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser                    Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly                    Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser                    Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala                    Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met                    Ala Pro Ala Leu Gln Pro (SEQ ID NO:188)                                        31107.Pep                                                                      Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu                    Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gly Ser Asn                    Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro                    Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val                    Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser                    Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu                    Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala                    Ala Pro Ser Arg His Pro Ile Ile Ile Lys Thr Val Glu Gly Gly                    Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn                    Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala                    Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg                    Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu                    Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly                    Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val                    Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys                    Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly                    His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser                    Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly                    Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser                    Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala                    Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met                    Ala Pro Ala Leu Gln Pro (SEQ ID NO:189)                                        31108.Pep                                                                      Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met                    Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala                    Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg                    Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg                    His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu                    Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln                    Gln Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys                    Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro                    Ala Pro Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro                    Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu                    Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala                    Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala                    Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg                    His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe                    Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly                    Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His                    Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp                    Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly                    Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu                    Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu                    Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp                    Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro                        (SEQ ID NO:190)                                                                31109.Pep                                                                      Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys                    Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile                    Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr                    Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gly Ser                    Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp                    Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp                    Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg                    Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys                    Asn Leu Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro                    Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu                    Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala                    Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala                    Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg                    His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe                    Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly                    Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His                    Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp                    Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly                    Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu                    Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu                    Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp                    Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro                        (SEQ ID NO:191)                                                                31110.Pep                                                                      Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln                    Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln                    Ala Gln Glu Gln Gln Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly                    Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu                    Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp                    Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn                    Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser                    Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser                    Ala Thr Ala Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro                    Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu                    Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala                    Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala                    Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg                    His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe                    Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly                    Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His                    Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp                    Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly                    Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu                    Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu                    Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp                    Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro                        (SEQ ID NO:192)                                                                31111.Pep                                                                      Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu                    Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gly Ser Gly                    Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu                    Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro                    Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn                    Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn                    Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln                    Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile                    Ile Ile Lys Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro                    Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu                    Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala                    Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala                    Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg                    His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe                    Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly                    Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His                    Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp                    Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly                    Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu                    Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu                    Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp                    Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro                        (SEQ ID NO:193)                                                                pMON15981                                                                      MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAla                   ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsn                   LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer                   GlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro                   SerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr                   PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly                   SerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGlu                   SerHisLysSerProAsnMetAlaTyrLysLeuCysHisProGluGluLeuValLeuLeu                   GlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGln                   LeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln                   AlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVal                   AlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeu                   GlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGly                   ValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHis                   LeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeu                   ProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAla                   AlaLeuGlnGluLysLeuCysAlaThr (SEQ ID NO:194)                                    pMON15982                                                                      MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAla                   ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsn                   LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer                   GlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro                   SerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr                   PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly                   SerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGlu                   SerHisLysSerProAsnMetAlaProGluLeuGlyProThrLeuAspThrLeuGlnLeu                   AspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaPro                   AlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAla                   GlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeu                   ArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSer                   SerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAsp                   GlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeu                   ValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGln                   AlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGly                   LeuLeuGlnAlaLeuGluGlyIleSer (SEQ ID NO:195)                                    pMON15965                                                                      MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAla                   ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsn                   LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer                   GlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro                   SerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr                   PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly                   SerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGlu                   SerHisLysSerProAsnMetAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuVal                   AlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGln                   ProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSer                   PheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGln                   GluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHis                   SerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAla                   GlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeu                   GluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAsp                   PheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro                   ThrGlnGlyAlaMetProAlaPheAla (SEQ ID NO:196)                                    pMON15966                                                                      MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAla                   ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsn                   LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer                   GlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro                   SerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr                   PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly                   SerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGlu                   SerHisLysSerProAsnMetAlaMetAlaProAlaLeuGlnProThrGlnGlyAlaMet                   ProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeu                   GlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGly                   SerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLys                   SerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCys                   AlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIle                   ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSer                   GlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSer                   ProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThr                   IleTrpGlnGlnMetGluGluLeuGly (SEQ ID NO:197)                                    pMON15967                                                                      MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAla                   ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsn                   LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer                   GlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro                   SerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr                   PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly                   SerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGlu                   SerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe                   GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSer                   TyrArgValLeuArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeu                   GlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLys                   IleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHis                   ProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSer                   CysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe                   LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeu                   AspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGlu                   LeuGlyMetAlaProAlaLeuGlnPro (SEQ ID NO:198)                                    pMON31112.pep                                                                  MetAlaAsnCysSerAsnMetIleAspGluIleIleThrHisLeuLysGlnProProLeu                   ProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetAspAsnAsn                   LeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSer                   AlaIleGluSerIleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaPro                   ThrArgHisProIleHisIleLysAspGlyAspTrpAsnGluPheArgArgLysLeuThr                   PheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGly                   SerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGlu                   SerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe                   GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSer                   TyrArgValLeuArgHisLeuAlaGlnProSerGlyGlySerGlyGlySerGlnSerPhe                   LeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGlu                   LysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSer                   LeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGly                   CysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGlu                   GlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPhe                   AlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro                      (SEQ ID NO:199)                                                                pMON31113.pep                                                                  MetAlaAsnCysSerAsnMetIleAspGluIleIleThrHisLeuLysGlnProProLeu                   ProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetGluAsnAsn                   LeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSer                   AlaIleGluSerIleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaPro                   ThrArgHisProIleIleIleArgAspGlyAspTrpAsnGluPheArgArgLysLeuThr                   PheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGly                   SerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGlu                   SerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe                   GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSer                   TyrArgValLeuArgHisLeuAlaGlnProThrProLeuGlyProAlaSerSerLeuPro                   GlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAla                   LeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeu                   GlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGln                   LeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln                   AlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVal                   AlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeu                   GlnPro (SEQ ID NO:200)                                                         pMON31114.pep                                                                  MetAlaAsnCysSerAsnMetIleAspGluIleIleThrHisLeuLysGlnProProLeu                   ProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetGluAsnAsn                   LeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSer                   AlaIleGluSerIleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaPro                   ThrArgHisProIleIleIleArgAspGlyAspTrpAsnGluPheArgArgLysLeuThr                   PheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGly                   SerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGlu                   SerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe                   GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSer                   TyrArgValLeuArgHisLeuAlaGlnProSerGlyGlySerGlyGlySerGlnSerPhe                   LeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGlu                   LysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSer                   LeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGly                   CysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGlu                   GlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPhe                   AlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro                      (SEQ ID NO:201)                                                                pMON31115.pep                                                                  MetAlaAsnCysSerAsnMetIleAspGluIleIleThrHisLeuLysGlnProProLeu                   ProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetAspAsnAsn                   LeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSer                   AlaIleGluSerIleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaPro                   ThrArgHisProIleHisIleLysAspGlyAspTrpAsnGluPheArgArgLysLeuThr                   PheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGly                   SerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGlu                   SerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe                   GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSer                   TyrArgValLeuArgHisLeuAlaGlnProThrProLeuGlyProAlaSerSerLeuPro                   GlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAla                   LeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeu                   GlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGluAlaLeuGln                   LeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln                   AlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVal                   AlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeu                   GlnPro (SEQ ID NO:202)                                                         pMON28505                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGluAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetGluValHisProLeuProThrProValLeuLeuProAlaVal                   AspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGluAspIleLeu                   GlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThr                   CysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeu                   GlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspPro                   AsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeu                   ValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaPro                   ProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSer                   ArgLeuSerGlnCysPro (SEQ ID NO:203)                                             pMON28506                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGluAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetLeuProThrProValLeuLeuProAlaValAspPheSerLeu                   GlyGluTrpLysThrGlnMetGluGluThrLysAlaGluAspIleLeuGlyAlaValThr                   LeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSer                   LeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeu                   GlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePhe                   LeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySer                   ThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAsp                   LeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGln                   CysProGluValHisPro (SEQ ID NO:204)                                             pMON28507                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLys                   ThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGlu                   GlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGln                   LeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeu                   ProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGln                   HisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysVal                   ArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeu                   SerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluVal                   HisProLeuProThrPro (SEQ ID NO:205)                                             pMON28508                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGluAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu                   GluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla                   AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGln                   ValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGly                   ArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArg                   GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly                   GlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeu                   ArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuPro                   ThrProValLeuLeuPro (SEQ ID NO:206)                                             pMON28509                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGluAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThr                   LysAlaGluAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArg                   GlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArg                   LeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThr                   ThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLys                   ValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsn                   MetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAsp                   SerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrPro                   ValLeuLeuProAlaVal (SEQ ID NO:207)                                             pMON28510                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAsp                   IleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGly                   ProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGly                   AlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys                   AspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeu                   MetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerPro                   AlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeu                   HisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuPro                   AlaValAspPheSerLeu (SEQ ID NO:208)                                             pMON28511                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGly                   GlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGln                   GlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeu                   ArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPhe                   GlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeu                   LeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeu                   ProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMet                   GluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMet                   AlaAlaArgGlyGlnLeu (SEQ ID NO:209)                                             pMON28512                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys                   AspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeu                   MetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerPro                   AlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeu                   HisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuPro                   AlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAsp                   IleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGly                   ProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGly                   AlaLeuGlnSerLeuLeu (SEQ ID NO:210)                                             pMON28513                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeu                   SerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThr                   LeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeu                   ArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCys                   ProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGly                   GluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeu                   LeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeu                   LeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGly                   ThrGlnLeuProProGln (SEQ ID NO:211)                                             pMON28514                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHis                   LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg                   GluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSer                   LysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHis                   ProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThr                   GlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGly                   ValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeu                   SerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuPro                   ProGlnGlyArgThrThr (SEQ ID NO:212)                                             pMON28515                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArg                   GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly                   GlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeu                   ArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuPro                   ThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu                   GluThrLysAlaGluAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla                   AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGln                   ValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGly                   ArgThrThrAlaHisLys (SEQ ID NO:213)                                             pMON28516                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysVal                   ArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMet                   AlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer                   HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProVal                   LeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLys                   AlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGly                   GlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeu                   LeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThr                   AlaHisLysAspProAsn (SEQ ID NO:214)                                             pMON28519                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetGluValHisProLeuProThrProValLeuLeuProAlaVal                   AspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeu                   GlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThr                   CysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeu                   GlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspPro                   AsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeu                   ValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProPro                   AlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArg                   LeuSerGlnCysPro (SEQ ID NO:215)                                                pMON28520                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetLeuProThrProValLeuLeuProAlaValAspPheSerLeu                   GlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThr                   LeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSer                   LeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeu                   GlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePhe                   LeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySer                   ThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeu                   ArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCys                   ProGluValHisPro (SEQ ID NO:216)                                                pMON28521                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLys                   ThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGlu                   GlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGln                   LeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeu                   ProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGln                   HisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysVal                   ArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSer                   LysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHis                   ProLeuProThrPro (SEQ ID NO:217)                                                pMON28522                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu                   GluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla                   AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGln                   ValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGly                   ArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArg                   GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly                   AsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArg                   AspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThr                   ProValLeuLeuPro (SEQ ID NO:218)                                                pMON28523                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGluAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThr                   LysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArg                   GlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArg                   LeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThr                   ThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLys                   ValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMet                   AlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer                   HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProVal                   LeuLeuProAlaVal (SEQ ID NO:219)                                                pMON28524                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGluAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAsp                   IleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGly                   ProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGly                   AlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys                   AspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeu                   MetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAla                   ProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHis                   SerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAla                   ValAspPheSerLeu (SEQ ID NO:220)                                                pMON28525                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGly                   GlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGln                   GlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeu                   ArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPhe                   GlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeu                   ArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuPro                   ThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu                   GluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla                   AlaArgGlyGlnLeu (SEQ ID NO:221)                                                pMON28526                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys                   AspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeu                   MetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAla                   ProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHis                   SerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAla                   ValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIle                   LeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyPro                   ThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAla                   LeuGlnSerLeuLeu (SEQ ID NO:222)                                                pMON28527                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeu                   SerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThr                   LeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArg                   ValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysPro                   GluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGlu                   TrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeu                   LeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeu                   GlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThr                   GlnLeuProProGln (SEQ ID NO:223)                                                pMON28528                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHis                   LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg                   GluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLys                   LeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisPro                   LeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGln                   MetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyVal                   MetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSer                   GlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProPro                   GlnGlyArgThrThr (SEQ ID NO:224)                                                pMON28529                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArg                   GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly                   AsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArg                   AspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThr                   ProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGlu                   ThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAla                   ArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnVal                   ArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArg                   ThrThrAlaHisLys (SEQ ID NO:225)                                                pMON28530                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGluAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysVal                   ArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAla                   SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis                   ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu                   LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla                   GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln                   LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu                   LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla                   HisLysAspProAsn (SEQ ID NO:226)                                                pMON28533                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetGluValHisProLeuProThrProValLeuLeuProAlaVal                   AspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeu                   GlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThr                   CysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeu                   GlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspPro                   AsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeu                   ValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSer                   ProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisVal                   LeuHisSerArgLeuSerGlnCysPro (SEQ ID NO:227)                                    pMON28534                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetLeuProThrProValLeuLeuProAlaValAspPheSerLeu                   GlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThr                   LeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSer                   LeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeu                   GlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePhe                   LeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySer                   ThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProPro                   AlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArg                   LeuSerGlnCysProGluValHisPro (SEQ ID NO:228)                                    pMON28535                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLys                   ThrGlnMetGluGluThrLysAlaGluAspIleLeuGlyAlaValThrLeuLeuLeuGlu                   GlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGln                   LeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeu                   ProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGln                   HisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysVal                   ArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeu                   ArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCys                   ProGluValHisProLeuProThrPro (SEQ ID NO:229)                                    pMON28536                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGluAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu                   GluThrLysAlaGluAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla                   AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGln                   ValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGly                   ArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArg                   GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly                   GlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSer                   LysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHis                   ProLeuProThrProValLeuLeuPro (SEQ ID NO:230)                                    pMON28537                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThr                   LysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArg                   GlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArg                   LeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThr                   ThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLys                   ValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsn                   GlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeu                   LeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeu                   ProThrProValLeuLeuProAlaVal (SEQ ID NO:231)                                    pMON28538                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPh&ArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGluAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetGlyGluTrpLysThrGlnMetGluGluThrLysAlaGluAsp                   IleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGly                   ProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGly                   AlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys                   AspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeu                   MetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMet                   AlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer                   HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProVal                   LeuLeuProAlaValAspPheSerLeu (SEQ ID NO:232)                                    pMON28539                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGluAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGly                   GlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGln                   GlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeu                   ArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPhe                   GlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeu                   SerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluVal                   HisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLys                   ThrGlnMetGluGluThrLysAlaGluAspIleLeuGlyAlaValThrLeuLeuLeuGlu                   GlyValMetAlaAlaArgGlyGlnLeu (SEQ ID NO:233)                                    pMON28540                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys                   AspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeu                   MetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMet                   AlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer                   HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProVal                   LeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLys                   AlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGly                   GlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeu                   LeuLeuGlyAlaLeuGlnSerLeuLeu (SEQ ID NO:234)                                    pMON28541                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeu                   SerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThr                   LeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAla                   CysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeu                   SerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPhe                   SerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAla                   ValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeu                   SerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSer                   LeuLeuGlyThrGlnLeuProProGln (SEQ ID NO:235)                                    pMON28542                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHis                   LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg                   GluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArg                   ValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysPro                   GluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGlu                   TrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeu                   LeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeu                   GlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThr                   GlnLeuProProGlnGlyArgThrThr (SEQ ID NO:236)                                    pMON28543                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGluAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArg                   GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly                   GlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSer                   LysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHis                   ProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThr                   GlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGly                   ValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeu                   SerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuPro                   ProGlnGlyArgThrThrAlaHisLys (SEQ ID NO: 237)                                   pMON28544                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysVal                   ArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGly                   GlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeu                   ArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuPro                   ThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu                   GluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla                   AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGln                   ValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGly                   ArgThrThrAlaHisLysAspProAsn (SEQ ID NO: 238)                                   pMON28545                                                                      AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro                   LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeu                   ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly                   IleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer                   ArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe                   TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer                   ProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSer                   HisLysSerProAsnMetAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArg                   GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly                   GlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeu                   ArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuPro                   ThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu                   GluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla                   AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGln                   ValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnGlyArgThrThrAla                   HisLys (SEQ ID NO:239)                                                         pMON32132                                                                      SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis                   ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu                   LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla                   GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln                   LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu                   LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla                   HisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg                   PheLeuMetLeuValGlyGlySerThrLeuCysValArg (SEQ ID NO: 252)                       PMON32133                                                                      SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis                   ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu                   LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla                   GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln                   LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu                   LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnGlyArgThrThrAlaHisLysAspPro                   AsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeu                   ValGlyGlySerThrLeuCysValArg (SEQ ID NO:253)                                    PMON32134                                                                      SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis                   ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu                   LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla                   GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln                   LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu                   LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla                   HisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg                   PheLeuMetLeuValGlyGlySerThrLeuCysValArg (SEQ ID NO:254)                        pmon16017.pep                                                                    1                                                                              Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu                   16                                                                               Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp                  31                                                                               Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn                  46                                                                               Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser                  61                                                                               Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser                  76                                                                               Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly                  91                                                                               Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr                 106                                                                               Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly                 121                                                                               Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser                 136                                                                               Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Leu Gly                 151                                                                               Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu                 166                                                                               Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys                 181                                                                               Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu                 196                                                                               Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys                 211                                                                               Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His                 226                                                                               Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly                 241                                                                               Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp                 256                                                                               Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu                 271                                                                               Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala                 286                                                                               Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala                 301                                                                               Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg                 316                                                                               His Leu Ala Gln Pro Asp Met Ala Thr Pro (SEQ ID NO:271)                     pmon16018.pep                                                                    1                                                                              Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu                   16                                                                               Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp                  31                                                                               Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn                  46                                                                               Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser                  61                                                                               Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser                  76                                                                              Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly                   31                                                                              Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr                  106                                                                              Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly                  121                                                                              Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser                  136                                                                              Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Leu Gly                  151                                                                              Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu                  176                                                                              Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys                  191                                                                              Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu                  206                                                                              Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys                  221                                                                              Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His                  236                                                                              Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly                  251                                                                              Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp                  266                                                                              Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu                  281                                                                              Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala                  296                                                                              Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala                  311                                                                              Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg                  326                                                                              His Leu Ala Gln Pro Asp Met Ala Thr Pro (SEQ ID NO:272)                      pmon16019.pep                                                                    1                                                                              Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu                   16                                                                              Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp                   31                                                                              Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn                   46                                                                              Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser                   61                                                                              Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser                   76                                                                              Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly                   91                                                                              Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr                  106                                                                              Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly                  121                                                                              Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser                  136                                                                              Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Phe Leu                  151                                                                              Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala                  166                                                                              Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro                  181                                                                              Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala                  196                                                                              Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys                  211                                                                              Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu                  226                                                                              Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp                  241                                                                              Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln                  256                                                                              Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln                  271                                                                              Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly                  286                                                                              Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser                  301                                                                              Tyr Arg Val Leu Arg His Leu Ala Gln Pro Asp Met Ala Thr Pro                  316                                                                              Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser (SEQ ID NO:273)                      pmon16020.pep                                                                    1                                                                              Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu                   16                                                                              Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp                   31                                                                              Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn                   46                                                                              Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser                   61                                                                              Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser                   76                                                                              Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly                   91                                                                              Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr                  106                                                                              Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly                  121                                                                              Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser                  136                                                                              Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Glu Gln                  151                                                                              Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu                  166                                                                              Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu                  181                                                                              Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro                  196                                                                              Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser                  211                                                                              Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile                  226                                                                              Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val                  241                                                                              Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly                  256                                                                              Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe                  271                                                                              Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser                  286                                                                              His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His                  301                                                                              Leu Ala Gln Pro Asp Met Ala Thr Pro Leu Gly Pro Ala Ser Ser                  316                                                                              Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu (SEQ ID NO:274)                      pmon16021.pep                                                                    1 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu                 16 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp                 31 Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn                 46 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser                 61 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser                 76 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly                 91 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr                106 Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly                121 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser                136 Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Leu Leu                151 Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro                166 Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser                181 Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile                196 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val                211 Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly                226 Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe                241 Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser                256 His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His                271 Leu Ala Gln Pro Asp Met Ala Thr Pro Leu Gly Pro Ala Ser Ser                286 Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys                301 Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr                316 Tyr Lys Leu Cys His Pro Glu Glu Leu Val (SEQ ID NO:275)                    pmon16022.pep                                                                    1 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu                 16 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp                 31 Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn                 46 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser                 61 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser                 76 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly                 91 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr                106 Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly                121 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser                136 Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Pro Leu                151 Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser                166 Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala                181 Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu                196 Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met                211 Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala                226 Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val                241 Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg                256 Val Leu Arg His Leu Ala Gln Pro Asp Met Ala Thr Pro Leu Gly                271 Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu                286 Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys                301 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu                316 Leu Gly His Ser Leu Gly Ile Pro Trp Ala (SEQ ID NO:276)                    pmon16023.pep                                                                    1                                                                              Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu                   16                                                                               Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp                  31                                                                               Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn                  46                                                                               Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser                  61                                                                               Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser                  76                                                                               Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly                  91                                                                               Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr                 106                                                                               Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly                 121                                                                               Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser                 136                                                                               Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Gln Ala                 151                                                                               Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe                 166                                                                               Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu                 181                                                                               Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe                 196                                                                               Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro                 211                                                                               Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala                 226                                                                               Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln                 241                                                                               Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln                 256                                                                               Pro Asp Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln                 271                                                                               Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly                 286                                                                               Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu                 301                                                                               Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile                 316                                                                               Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser (SEQ ID NO:277)                     pmon16024.pep                                                                    1                                                                              Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu                   16                                                                               Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp                  31                                                                               Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn                  46                                                                               Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser                  61                                                                               Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser                  76                                                                               Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly                  91                                                                               Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr                 106                                                                               Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly                 121                                                                               Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser                 136                                                                               Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Leu Gln                 151                                                                               Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr                 166                                                                               Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly                 181                                                                               Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr                 196                                                                               Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu                 211                                                                               Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln                 226                                                                               Arg Arg Ala Gly Gly Valleu Val Ala Ser His Leu Gln Ser Phe                  241                                                                               Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Asp                 256                                                                               Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe                 271                                                                               Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly                 286                                                                               Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His                 301                                                                               Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp                 316                                                                               Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala (SEQ ID NO:278)                     pmon16025.pep                                                                    1                                                                              Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu                   16                                                                               Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp                  31                                                                               Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn                  46                                                                               Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser                  61                                                                               Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser                  76                                                                               Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly                  91                                                                              Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr                  106                                                                              Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly                  121                                                                              Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser                  136                                                                              Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Leu Ala                  151                                                                              Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly                  166                                                                              Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr                  181                                                                              Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile                  196                                                                              Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro                  211                                                                              Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg                  226                                                                              Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu                  241                                                                              Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Asp Met Ala                  256                                                                              Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu                  271                                                                              Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala                  286                                                                              Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu                  301                                                                              Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro                  316                                                                              Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln (SEQ ID NO:279)                      pmon16026.pep                                                                    1                                                                              Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu                   16                                                                              Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp                   31                                                                              Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn                   46                                                                              Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser                   61                                                                              Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser                   76                                                                              Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly                   91                                                                              Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr                  106                                                                              Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly                  121                                                                              Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser                  136                                                                              Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Glu Leu                  151                                                                              Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala                  166                                                                              Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala                  181                                                                              Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg                  196                                                                              His Leu Ala Gln Pro Asp Met Ala Thr Pro Leu Gly Pro Ala Ser                  211                                                                              Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg                  226                                                                              Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala                  241                                                                              Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His                  256                                                                              Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln                  271                                                                              Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu                  286                                                                              Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro                  301                                                                              Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp                  316                                                                              Phe Ala Thr Thr Ile Trp Gln Gln Met Glu (SEQ ID NO:280)                      pmon16027.pep                                                                    1                                                                              Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu                   16                                                                              Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp                   31                                                                              Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn                   46                                                                              Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser                   61                                                                              Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser                   76                                                                              Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly                   91                                                                              Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr                  106                                                                              Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly                  121                                                                              Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser                  136                                                                              Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Gly Met                  151                                                                              Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala                  166                                                                              Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His                  181                                                                              Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu                  196                                                                              Ala Gln Pro Asp Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu                  211                                                                              Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile                  226                                                                               Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr                 241                                                                               Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu                 256                                                                               Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu                 271                                                                               Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu                 286                                                                               Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu                 301                                                                               Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala                 316                                                                               Thr Thr Ile Trp Gln Gln Met Glu Glu Leu (SEQ ID NO:281)                     pmon16028.pep                                                                    1                                                                              Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu                   16                                                                               Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp                  31                                                                               Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn                  46                                                                               Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser                  61                                                                               Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser                  76                                                                               Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly                  91                                                                               Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr                 106                                                                               Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly                 121                                                                               Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser                 136                                                                               Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Ser Phe                 151                                                                               Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Asp                 166                                                                               Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe                 181                                                                               Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly                 196                                                                               Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His                 211                                                                               Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp                 226                                                                               Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly                 241                                                                               Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu                 256                                                                               Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu                 271                                                                               Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp                 286                                                                               Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr                 301                                                                               Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala                 316                                                                               Gly Gly Val Leu Val Ala Ser His Leu Gln (SEQ ID NO:282)                     MetAlaGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHis                   LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuAlaValArg                   GluPheGlyGlyAsnMetAlaSerProAlaProProAlaAlaAspLeuArgValLeuSer                   LysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHis                   ProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThr                   GlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGly                   ValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeu                   SerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuPro                   ProGln (SEQ ID NO:284);                                                        MetAlaGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeu                   LeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThr                   AlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysVal                   ArgPheLeuMetLeuValGlyGlySerThrLeuAlaValArgGluPheGlyGlyAsnMet                   AlaSerProAlaProProAlaAlaAspLeuArgValLeuSerLysLeuLeuArgAspSer                   HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProVal                   LeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLys                   AlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGly                   GlnLeu (SEQ ID NO:285)                                                         __________________________________________________________________________

The following examples will illustrate the invention in greater detail although it will be understood that the invention is not limited to these specific examples.

EXAMPLE 1 Construction of Parental BHK Expression Vector

A. Removal of AflIII site from mammalian expression plasmid.

A new mammalian expression vector was constructed to accept NcoI-HindIII or AflIII-HindIII gene fragments in-frame and 3' to the hIL-3 receptor agonist pMON13146 (WO 94/12638) gene and a mouse IgG2b linker fragment. First, the single AflIII site was removed from pMON3934, which is a derivative of pMON3359. pMON3359 is a pUC18-based vector containing a mammalian expression cassette. The cassette includes a herpes simplex viral promoter IE110 (-800 to +120) followed by a modified human IL-3 signal peptide sequence and an SV40 late poly-adenylation (poly-A) signal which has been subcloned into the pUC18 polylinker (See Hippenmeyer et al., Bio/Technology, 1993, pp.1037-1041). The modified human IL-3 signal sequence, which facilitates secretion of gene products outside of the cell, is flanked by a BamHI site on the 5' end and a unique NcoI site on the 3' end. A unique HindIII site is 3' to the NcoI site and 5' to the poly-A sequence. The DNA sequence encoding the signal peptide is shown below (restriction enzyme sites are indicated above). The ATG (methionine) codon within the NcoI site is in-frame with the initiator ATG of the signal peptide (underlined); BamHI NcoI 5'GGATCCACCATGAGCCTGCCCGTCCTGCTCCTGCTCCAACTCCTGGTCCGCCCCGCCATGG (SEQ ID NO:255)

The single AflIII site was removed from pMON3934 by digestion with AflIII followed by filling in the overhangs by addition of a DNA polymerase and nucleotides. The digested DNA fragment was purified via Magic PCR Clean up kit (Promega) and ligated with T4 DNA ligase. The ligation reaction was transformed into DH5α ™ and the cells were plated onto LB-agar plus ampicillin. Individual colonies were screened for the loss of the AflIII site by restriction analysis with AflIII and HindIII which results in a single fragment if the AflIII site was removed. The resulting plasmid was designated pMON30275.

B. Transfer of hIL-3 receptor agonist pMON13416/IgG2b cassette into pMON30275.

The NcoI-HindIII fragment (ca. 425 bp) from pMON30245 was ligated to the NcoI-HindIII fragment (ca. 3800 bp) of the pMON30275. pMON30245 (WO 94/12638) contains the gene coding for hIL-3 receptor agonist pMON13416 joined to a mouse IgG2b hinge fragment. Immediately 3' to the IgG2b hinge and 5' to the HindIII site is an AflIII site. Genes can be cloned into the AflIII-HindIII sites as NcoI-HindIII or AflIII-HindIII fragments in frame with the hIL-3 variant pMON13416/IgG2b hinge to create novel chimeras. The NcoI site and the AflIII site have compatible overhangs and will ligate but both recognition sites are lost. The plasmid, pMON30304 containing the DNA sequence of (SEQ ID NO:78), coding for hIL-3 variant pMON13416 joined with a mouse IgG2b hinge region, was a result of this cloning.

EXAMPLE 2

Construction of an intermediate plasmid containing one copy of the c-mpl ligand (1-153) gene of the dimer template

In order to generate a plasmid DNA with the coding sequence of c-mpl (1-153) ligand followed by a unique EcoRI restriction site, the gene is isolated via reverse transcriptase/polymerase chain reaction (RT/PCR). Human fetal (lot #38130) and adult liver (lot #46018) A+RNA are obtained from Clontech (Palo Alto, Calif.) for source of c-mpl ligand messenger RNA (mRNA). The first strand cDNA reactions are carried out using a cDNA Cycle™ Kit obtained from Invitrogen (San Diego, Calif.). In the RT reaction, random primers and oligo dT primer are used to generate cDNA from a combination of human and fetal liver mRNA. For amplification of c-mpl ligand gene fragment encoding amino acids 1-153, the RT product serves as the template for PCR with a combination of the primers, Forward primer: c-mplNcoI (SEQ ID NO:13) and Reverse primer: Ecompl. The c-mplNcoI primer anneals to the c-mpl ligand gene (bases #279-311 based on c-mpl ligand sequence from Gene bank accession #L33410 or de Sauvage et al., Nature 369: 533-538 (1994)) and encodes a NcoI restriction enzyme site immediately 5' to the first codon (Ser+1) of c-mpl ligand. The NcoI restriction enzyme site codes for methionine and alanine codons prior to Ser+1 and includes codon degeneracy for the Ala codon and the first four codons (Ser, Pro, Ala, & Pro) of c-mpl ligand. The Ecompl primer anneals to bases #720-737 of c-mpl ligand and encodes an EcoRI site (GAATTC) in-frame with the c-mpl ligand gene immediately following Arg-153. The EcoRI site creates Glu and Phe codons following Arg-153. The ca. 480 bp PCR product was purified, digested with NcoI and EcoRI and ligated to the NcoI-EcoRI vector fragment of pMON3993 (ca. 4550 bp.). pMON3993 was a derivative of pMON3359 (described in Example 1). The human IL-3 signal peptide sequence, which had been subcloned as a BamHI fragment into the unique BamHI site between the IE110 promoter and poly-A signal, contains an NcoI site at its 3' end and is followed by a unique EcoRI site. The plasmid, pMON26458 containing the DNA sequence of (SEQ ID NO:79), coding for c-mpl ligand amino acids 1-153 (SEQ ID NO:161), was the result of this cloning.

EXAMPLE 3

Construction of the parental plasmids containing the second genes of the dimer templates

For amplification of c-mpl ligand gene fragments starting at amino acid 1 (Ser) with a termination codon following amino acid 153 (Arg), the RT reaction from Example 2 serves as the template for PCR with a combination of the following primers; c-mplNcoI (SEQ ID NO:13) (forward primer) and c-mplHindIII (SEQ ID NO:15) (reverse primer). The c-mplNcoI (SEQ ID NO:13) primer is described in Example 2. The c-mplHindIII (SEQ ID NO:15) primer, which anneals to bases #716-737 of c-mpl ligand, adds both a termination codon and a HindIII restriction enzyme site immediately following the final codon, Arg¹⁵³.

Two types of PCR products are generated from the RT cDNA samples, one with a deletion of the codons for amino acids 112-115 and one without the deletion of these codons. The c-mpl ligand PCR products (ca. 480 bp) are digested with NcoI and HindIII restriction enzymes for transfer to a mammalian expression vector, pMON3934. pMON3934 is digested with NcoI and HindIII (ca. 3800 bp) and will accept the PCR products.

Plasmid, pMON32132 (SEQ ID NO:249), coding for c-mpl ligand amino acids 1-153 (SEQ ID NO:252) was a result of this cloning. Plasmid, pMON32134 (SEQ ID NO:250), coding for c-mpl ligand amino acids 1-153 (SEQ ID NO:253) was a result of this cloning. Plasmid, pMON32133 (SEQ ID NO:251), coding for c-mpl ligand amino acids 1-153 with a deletion of codons 112-115 (Δ112-115) (SEQ ID NO:254) was also a result of this cloning.

EXAMPLE 4

Generation of PCR dimer template 5L with a Δ112-115 deletion in the second c-mpl ligand gene

A PCR template for generating novel forms of c-mpl ligand is constructed by ligating the 3.7 Kbp BstXI/EcoRI fragment of pMON26458 to the 1 Kbp NcoI/BstXI fragment from pMON32133 (containing a deletion of amino acids 112-115) along with the EcoRI/AflIII 5L synthetic oligonucleotide linker 5L-5' (SEQ ID NO:18) and 5L-3' (SEQ ID NO:19).

The EcoRI end of the linker will ligate to the EcoRI end of pMON26458. The AflIII end of the linker will ligate to the NcoI site of pMON32133, and neither restriction site will be retained upon ligation. The BstXI sites of pMON26458 and pMON32133 will ligate as well. Plasmid, pMON28548, is a result of the cloning and contains the DNA sequence of (SEQ ID NO:80) which encodes amino acids 1-153 c-mpl ligand fused via a GluPheGlyGlyAsnMetAla (SEQ ID NO:222) linker to amino acids 1-153 c-mpl ligand that contains a deletion of amino acids 112-115 (SEQ ID NO:162).

EXAMPLE 5 Generation of PCR Dimer Template 4L

A PCR template for generating novel forms of c-mpl ligand is constructed by ligating the 3.7 Kbp BstXI/EcoRI fragment of pMON26458 to the 1 Kbp NcoI/BstXI fragment from pMON32132 along with the EcoRI/AflIII 4L synthetic oligonucleotide linker 4L-5' (SEQ ID NO:16) and 4L-3' (SEQ ID NO:17).

The EcoRI end of the linker will ligate to the EcoRI end of pMON26458. The AflIII end of the linker will ligate to the NcoI site of pMON32132, and neither restriction site will be retained upon ligation. The BstXI sites of pMON26458 and pMON32132 will ligate as well. The plasmid, pMON28500, is a result of the cloning and contains the DNA sequence of (SEQ ID NO:82) which encodes amino acids 1-153 c-mpl ligand fused via a GluPheGlyAsnMetAla (SEQ ID NO:223) linker (4L) to amino acids 1-153 c-mpl ligand (SEQ ID NO:163).

EXAMPLE 6 Generation of PCR Dimer Template 5L

A PCR template for generating novel forms of c-mpl ligand is constructed by ligating the 3.7 Kbp BstXI/EcoRI fragment of pMON26458 to the 1 Kbp NcoI/BstXI fragment from pMON32132 along with the EcoRI/AflIII 5L synthetic oligonucleotide linker 5L-5' (SEQ ID NO:18) and 5L-3' (SEQ ID NO:19).

The EcoRI end of the linker will ligate to the EcoRI end of pMON26458. The AflIII end of the linker will ligate to the NcoI site of pMON32132, and neither restriction site will be retained upon ligation. The BstXI sites of pMON26458 and pMON32132 will ligate as well. Plasmid, pMON28501 is a result of the cloning and contains the DNA sequence of (SEQ ID NO: 82) which encodes amino acids 1-153 c-mpl ligand fused via a GluPheGlyGlyAsnMetAla (SEQ ID NO:222) linker (5L) to amino acids 1-153 c-mpl ligand (SEQ ID NO:164).

EXAMPLE 7 Generation of PCR Dimer Templates 8L

A PCR template for generating novel forms of c-mpl ligand is constructed by ligating the 3.7 Kbp BstXI/EcoRI fragment of pMON26458 to the 1 Kbp NcoI/BstXI fragment from pMON32134 along with the EcoRI/AflIII 8L synthetic oligonucleotide linker 8L-5' (SEQ ID NO:20) and 8L-3' (SEQ ID NO:21).

The EcoRI end of the linker will ligate to the EcoRI end of pMON26458. The AflIII end of the linker will ligate to the NcoI site of pMON32134, and neither restriction site will be retained upon ligation. The BstXI sites of pMON26458 and pMON32134 will ligate as well. Plasmid, pMON28502 is a result of the cloning which contains the DNA sequence of (SEQ ID NO:83) and encodes amino acids 1-153 c-mpl ligand fused via a GluPheGlyGlyAsnGlyGlyAsnMetAla (SEQ ID NO:224) linker (8L) to amino acids 1-153 c-mpl ligand (SEQ ID NO:165).

EXAMPLES 8-44

Generation of novel c-mpl ligand genes with new N-terminus and C-terminus

A. PCR generation of genes encoding novel c-mpl ligand receptor agonists.

Genes encoding novel c-mpl ligand receptor agonists were generated using Method III (Horlick et al., Prot. Eng. 5:427-433, 1992). The PCR reactions were carried out using dimer templates, pMONs 28500, 28501, 28502 or 28548 and one of the sets of synthetic primer sets below (The first number refers to the position of the first amino acid in the original sequence. For example, the 31-5' and 31-3' refers to the 5' and 3' oligo primers, receptively, for the sequence beginning at the codon corresponding to residue 31 of the original sequence.).

31-5' (SEQ ID NO:22) and 31-3' (SEQ ID NO:23), 35-5' (SEQ ID NO:24) and 35-3' (SEQ ID NO:25), 39-5' (SEQ ID NO:26) and 39-3' (SEQ ID NO:27), 43-5' (SEQ ID NO:28) and 43-3' (SEQ ID NO:29), 45-5' (SEQ ID NO:30) and 45-3' (SEQ ID NO:31), 49-5' (SEQ ID NO:32) and 49-3' (SEQ ID NO:33), 82-5' (SEQ ID NO:34) and 82-3' (SEQ ID NO:35), 109-5' (SEQ ID NO:36) and 109-3' (SEQ ID NO:37), 115-5' (SEQ ID NO:38) and 115-3' (SEQ ID NO:39), 120-5' (SEQ ID NO:40) and 120-3' (SEQ ID NO:41), 123-5' (SEQ ID NO:42) and 123-3' (SEQ ID NO:43), 126-5' (SEQ ID NO:44) and 126-3' (SEQ ID NO:45).

The templates and oligonucleotide sets used in the PCR reactions are shown in Table 4. The products that were generated were about 480 bp and were purified via Magic PCR Clean up kits (Promega).

B. Subcloning of novel c-mpl receptor agonist gene products into mammalian expression vector for generation of chimeras.

The c-mpl receptor agonist gene PCR products were digested with NcoI and HindIII or AflIII and HindIII restriction enzymes (ca. 470 bp) for transfer to a mammalian expression vector. The expression vector, pMON30304, was digested with NcoI and HindIII (ca. 4200 bp) and accepts the PCR products as NcoI-HindIII or AflIII-HindIII fragments. The restriction digest of the PCR product and the resulting plasmids are shown in Table 4.

                                      TABLE 4                                      __________________________________________________________________________                         PCR Product                                                                               Resulting                                                                           Breakpoint                                               PCR Product                                                                          Restriction                                                                               Plasmid                                                                             in c-mpl                                   Example #                                                                             PCR template                                                                          Primer set                                                                           Digest Linker                                                                             pMON ligand                                     __________________________________________________________________________     Example 8                                                                             pMON28501                                                                             31    NcoI/HindIII                                                                          5L  28505                                                                               30-31                                      Example 9                                                                              pMON28501                                                                                      AflIII/HindIII                                                                             28506                                                                               34-35                                 Example 10                                                                             pMON28501                                                                                        NcoI/HindIII                                                                             28507                                                                               38-39                                 Example 11                                                                             pMON28501                                                                                        NcoI/HindIII                                                                             28508                                                                               42-43                                 Example 12                                                                             pMON28501                                                                                        NcoI/HindIII                                                                             28509                                                                               44-45                                 Example 13                                                                             pMON28501                                                                                        NcoI/HindIII                                                                             28510                                                                               48-49                                 Example 14                                                                             pMON28501                                                                                        NcoI/HindIII                                                                             28511                                                                               81-82                                 Example 15                                                                             PMON28501                                                                                  109                                                                                  NcoI/HindIII                                                                             28512                                                                              108-109                                Example 16                                                                             PMON28501                                                                                  116                                                                                  NcoI/HindIII                                                                             28513                                                                              115-116                                Example 17                                                                             pMON28501                                                                                  120                                                                                  NcoI/HindIII                                                                             28514                                                                              119-120                                Example 18                                                                             pMON28501                                                                                  123                                                                                  NcoI/HindIII                                                                             28515                                                                              122-123                                Example 19                                                                             PMON28501                                                                                  126                                                                                  NcoI/HindIII                                                                             28516                                                                              125-126                                Example 20                                                                             pMON28500                                                                                        NcoI/HindIII                                                                             28519                                                                               30-31                                 Example 21                                                                             pMON28500                                                                                      AflIII/HindIII                                                                             28520                                                                               34-35                                 Example 22                                                                             pMON28500                                                                                        NcoI/HindIII                                                                             28521                                                                               38-39                                 Example 23                                                                             pMON28500                                                                                        NcoI/HindIII                                                                             28522                                                                               42-43                                 Example 24                                                                             pMON28500                                                                                        NcoI/HindIII                                                                             28523                                                                               44-45                                 Example 25                                                                             pMON28500                                                                                        NcoI/HindIII                                                                             28524                                                                               48-49                                 Example 26                                                                             PMON28500                                                                                        NcoI/HindIII                                                                             28525                                                                               81-82                                 Example 27                                                                             pMON28500                                                                                  109                                                                                  NcoI/HindIII                                                                             28526                                                                              108-109                                Example 28                                                                             pMON28500                                                                                  116                                                                                  NcoI/HindIII                                                                             28527                                                                              115-116                                Example 29                                                                             pMON28500                                                                                  120                                                                                  NcoI/HindIII                                                                             28528                                                                              119-120                                Example 30                                                                             pMON28500                                                                                  123                                                                                  NcoI/HindIII                                                                             28529                                                                              122-123                                Example 31                                                                             pMON28500                                                                                  126                                                                                  NcoI/HindIII                                                                             28530                                                                              125-126                                Example 32                                                                             pMON28502                                                                                        NcoIIHindIII                                                                             28533                                                                               30-31                                 Example 33                                                                             pMON28502                                                                                      AflIII/HindIII                                                                             28534                                                                               34-35                                 Example 34                                                                             pMON28502                                                                                        NcoI/HindIII                                                                             28535                                                                               38-39                                 Example 35                                                                             pMON28502                                                                                        NcoI/HindIII                                                                             28536                                                                               42-43                                 Example 36                                                                              pMON28502                                                                                 45                                                                                   NcoI/HindIII                                                                        8L                                                                                  28537                                                                                44-45                                Example 37                                                                              pMON28502                                                                                 49                                                                                   NcoI/HindIII                                                                        8L                                                                                  28538                                                                                48-49                                Example 38                                                                              pMON28502                                                                                 82                                                                                   NcoI/HindIII                                                                        8L                                                                                  28539                                                                                81-82                                Example 39                                                                             pMON28502                                                                                 109                                                                                   NcoI/HindIII                                                                        8L                                                                                  28540                                                                               108-109                               Example 40                                                                              pMON28502                                                                                116                                                                                   NcoI/HindIII                                                                        8L                                                                                  28541                                                                               115-116                               EXAMPLE 41                                                                              pMON28502                                                                                120                                                                                   NcoI/HindIII                                                                        8L                                                                                  28542                                                                               119-120                               Example 42                                                                              pMON28502                                                                                123                                                                                   NcoI/HindIII                                                                        8L                                                                                  28543                                                                               122-123                               Example 43                                                                              pMON28502                                                                                126                                                                                   NcoI/HindIII                                                                        8L                                                                                  28544                                                                               125-126                               Example 44                                                                              pMON28548                                                                                123                                                                                   NcoI/HindIII                                                                        5L                                                                                  28545                                                                               122-123                               __________________________________________________________________________

EXAMPLE 45 Construction of pMON15960

Construction of pMON15960, an intermediate plasmid used for constructing plasmids containing DNA sequences encoding G-CSF Ser¹⁷ with a new N-terminus and C-terminus. Plasmid pACYC177 (Chang, A. C. Y. and Cohen, S. N. J. Bacteriol. 134:1141-1156, 1978) DNA was digested with restriction enzymes HindIII and BamHI, resulting in a 3092 base pair HindIII, BamHI fragment. Plasmid, pMON13037 (WO 95/21254), DNA was digested with BglII and FspI, resulting in a 616 base pair BglII, FspI fragment. A second sample of plasmid, pMON13037, DNA was digested with NcoI and HindIII, resulting in a 556 base pair NcoI, HindIII fragment. The synthetic DNA oligonucleotides 1GGGSfor (SEQ ID NO:76) and 1GGGSrev (SEQ ID NO:77) were annealed to each other, and then digested with AflIII and FspI, resulting in a 21 base pair AflIII, FspI fragment. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and analyzed by restriction analysis to confirm the correct insert.

EXAMPLE 46 Construction of pMON15981

Construction of pMON15981, a plasmid containing DNA sequences encoding a multi-functional hematopoietic receptor agonist. Plasmid, pMON15960, DNA was digested with restriction enzyme SmaI and used as template in a PCR reaction using synthetic DNA oligonucleotides 38 stop (SEQ ID NO:65) and 39 start (SEQ ID NO:64) as primers, resulting in the amplification of a DNA fragment of 576 base pairs. The amplified fragment was digested with restriction enzymes HindIII and NcoI, resulting in a HindIII, NcoI fragment of 558 base pairs. Plasmid, pMON13181, DNA was digested with HindIII and AflIII, resulting in a HindIII, AflIII fragment of 4068 base pairs. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The plasmid, pMON15981, contains the DNA sequence of (SEQ ID NO:155) which encodes the following amino acid sequence:

    MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAla                   ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsn                   LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer                   GlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro                   SerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr                   PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly                   SerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGlu                   SerHisLysSerProAsnMetAlaTyrLysLeuCysHisProGluGluLeuValLeuLeu                   GlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGln                   LeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln                   AlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVal                   AlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeu                   GlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGly                   ValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHis                   LeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeu                   ProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAla                   AlaLeuGlnGluLysLeuCysAlaThr   (SEQ ID NO:195)                             

EXAMPLE 47 Construction of pMON15982

Construction of pMON15982, a plasmid containing DNA sequences encoding a multi-functional hematopoietic receptor agonist. Plasmid, pMON15960, DNA was digested with restriction enzyme SmaI and used as template in a PCR reaction using synthetic DNA oligonucleotides 96 stop (SEQ ID NO:67) and 97 start (SEQ ID NO:66) as primers, resulting in the amplification of a DNA fragment of 576 base pairs. The amplified fragment was digested with restriction enzymes HindIII and NcoI, resulting in a HindIII, NcoI fragment of 558 base pairs. Plasmid, pMON13181, DNA was digested with HindIII and AflIII, resulting in a HindIII, AflIII fragment of 4068 base pairs. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The plasmid, pMON15982, contains the DNA sequence of (SEQ ID NO:157) which encodes the following amino acid sequence:

    MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAla                   ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsn                   LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer                   GlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro                   SerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr                   PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly                   SerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGlu                   SerHisLysSerProAsnMetAlaProGluLeuGlyProThrLeuAspThrLeuGlnLeu                   AspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaPro                   AlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAla                   GlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeu                   ArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSer                   SerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAsp                   GlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeu                   ValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGln                   AlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGly                   LeuLeuGlnAlaLeuGluGlyIleSer   (SEQ ID NO:196)                             

EXAMPLE 48 Construction of pMON15965

Construction of pMON15965, a plasmid containing DNA sequences encoding a multi-functional hematopoietic receptor agonist. Plasmid, pMON15960, DNA was digested with restriction enzyme SmaI and used as template in a PCR reaction using synthetic DNA oligonucleotides 142 stop (SEQ ID NO:73) and 141 start (SEQ ID NO:72) as primers, resulting in the amplification of a DNA fragment of 576 base pairs. The amplified fragment was digested with restriction enzymes HindIII and NcoI, resulting in a HindIII, NcoI fragment of 558 base pairs. Plasmid, pMON13181, DNA was digested with HindIII and AflIII, resulting in a HindIII, AflIII fragment of 4068 base pairs. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The plasmid, pMON15965, contains the DNA sequence of (SEQ ID NO:157) which encodes the following amino acid sequence:

    MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAla                   ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsn                   LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer                   GlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro                   SerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr                   PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly                   SerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGlu                   SerHisLysSerProAsnMetAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuVal                   AlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGln                   ProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSer                   PheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGln                   GluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHis                   SerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGluAlaLeuGlnLeuAla                   GlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeu                   GluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAsp                   PheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro                   ThrGlnGlyAlaMetProAlaPheAla (SEQ ID NO:196)                               

EXAMPLE 49 Construction of pMON15966

Construction of pMON15966, a plasmid containing DNA sequences encoding a multi-functional hematopoietic receptor agonist. Plasmid, pMON15960, DNA was digested with restriction enzyme SmaI and used as template in a PCR reaction using synthetic DNA oligonucleotides 126 stop (SEQ ID NO:68) and 125 start (SEQ ID NO:69) as primers, resulting in the amplification of a DNA fragment of 576 base pairs. The amplified fragment was digested with restriction enzymes HindIII and NcoI, resulting in a HindIII, NcoI fragment of 558 base pairs. Plasmid, pMON13181, DNA was digested with HindIII and AflIII, resulting in a HindIII, AflIII fragment of 4068 base pairs. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The plasmid, pMON15966, contains the DNA sequence of (SEQ ID NO:158) which encodes the following amino acid sequence:

    MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAla                   ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsn                   LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer                   GlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro                   SerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr                   PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly                   SerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGlu                   SerHisLysSerProAsnMetAlaMetAlaProAlaLeuGlnProThrGlnGlyAlaMet                   ProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeu                   GlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGly                   SerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLys                   SerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCys                   AlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIle                   ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSer                   GlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSer                   ProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThr                   IleTrpGlnGlnMetGluGluLeuGly (SEQ ID NO:197)                               

EXAMPLE 50 Construction of pMON15967

Construction of pMON15967, a plasmid containing DNA sequences encoding a multi-functional hematopoietic receptor agonist. Plasmid, pMON15960, DNA was digested with restriction enzyme SmaI and used as template in a PCR reaction using synthetic DNA oligonucleotides 132 stop (SEQ ID NO:71) and 133 start (SEQ ID NO:70) as primers, resulting in the amplification of a DNA fragment of 576 base pairs. The amplified fragment was digested with restriction enzymes HindIII and NcoI, resulting in a HindIII, NcoI fragment of 558 base pairs. Plasmid, pMON13181, DNA was digested with HindIII and AflIII, resulting in a HindIII, AflIII fragment of 4068 base pairs. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The plasmid, pMON15967, contains the DNA sequence of (SEQ ID NO: 159) which encodes the following amino acid sequence:

    MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAla                   ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsn                   LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer                   GlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro                   SerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr                   PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly                   SerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGlu                   SerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe                   GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSer                   TyrArgValLeuArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeu                   GlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLys                   IleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHis                   ProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSer                   CysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe                   LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeu                   AspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGlu                   LeuGlyMetAlaProAlaLeuGlnPro SEQ ID NO:198                                 

EXAMPLE 51

Construction of pMON13180, an intermediate plasmid used for constructing Dlasmids that contain DNA sequence encoding multi-functional hematopoietic receptor agonists.

Plasmid, pMON13046 (WO 95/21254), DNA was digested with restriction endonucleases XmaI and SnaBI, resulting in a 4018 base pair vector fragment. The 4018 base pair XmaI-SnaBI fragment was purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.) in which the 25 base pair XmaI-SnaBI insert fragment is not retained. The complimentary pair of synthetic oligonucleotides, glyxal (SEQ ID NO:74) and glyxa2 (SEQ ID NO:75), were designed to remove sequence encoding a factor Xa cleavage site. When properly assembled these oligonucleotides also result in XmaI and SnaBI ends. The primers, Glyxa1 and glyxa2, were annealed in annealing buffer (20 mM Tris-HCl pH7.5, 10 mM MgCl₂, 50 mM NaCl) by heating at 70° C. for ten minutes and allowed to slow cool. The 4018 base pair XmaI-SnaBI fragment from pMON13046 was ligated with the assembled oligonucleotides using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated from the transformants and analyzed using a PCR based assay. Plasmid DNA from selected transformants was sequenced to confirm the correct insertion of the oligonucleotides. The resulting plasmid was designated pMON13180 and contains the DNA sequence of (SEQ ID NO:258).

EXAMPLE 52

Construction of pMON13181. an intermediate plasmid used for constructing plasmids that contain DNA sequences encoding multi-functional hematopoietic receptor agonists.

Plasmid, pMON13047 (WO 95/21254), DNA was digested with restriction endonucleases XmaI and SnaBI, resulting in a 4063 base pair vector fragment. The 4063 base pair XmaI-SnaBI fragment was purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.) in which the 25 base pair XmaI-SnaBI insert fragment is not retained. The complimentary pair of synthetic oligonucleotides, glyxal (SEQ ID NO:74) and glyxa2 (SEQ ID NO:75), were designed to remove sequence encoding the factor Xa cleavage site. When properly assembled these oligonucleotides also result in XmaI and SnaBI ends. Glyxal and glyxa2 were annealed in annealing buffer by heating at 70° C. for ten minutes and allowed to slow cool. The 4063 base pair XmaI-SnaBI fragment from pMON13047 was ligated with the assembled oligonucleotides using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated from the transformants and analyzed using a PCR based assay. Plasmid DNA from selected transformants was sequenced to confirm the correct insertion of the oligonucleotides. The resulting plasmid was designated pMON13181 and contains the DNA sequence of (SEQ ID NO:257).

EXAMPLE 53 Construction of pMON13182

The new N-terminus/C-terminus gene in pMON13182 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 39 start (SEQ ID NO:64) and L-11 start (SEQ ID NO:60). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 38 stop (SEQ ID NO:65) and L-11 stop (SEQ ID NO:61). The full-length new N terminus/C-terminus G-CSF Ser¹⁷ gene was created and amplified from the annealed Fragments Start and Stop using primers 39 start and 38 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON13182.

E. coli strain JM101 was transformed with pMON13182 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13182, contains the DNA sequence of (SEQ ID NO:94) which encodes the following amino acid sequence:

    Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Tyr Lys Leu Cys                    His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro                    Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala                    Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly                    Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr                    Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile                    Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro                    Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg                    Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu                    Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly                    Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val                    Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys                    Ala Thr (SEQ ID NO:166)                                                   

EXAMPLE 54 Construction of pMON13183

The new N-terminus/C-terminus gene in pMON13183 was created using Method I as described in Materials and Methods. "Fragment Start" was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 39 start (SEQ ID NO:64) and L-11 start (SEQ ID NO:60). Fragment Stop was created and amplified from G-CSF Ser17 sequence in pMON13037 using the primer set, 38 stop (SEQ ID NO:65) and L-l1 stop (SEQ ID NO:61). The full-length new N terminus/C-terminus G-CSF Ser¹⁷ gene was created and amplified from the annealed Fragments Start and Stop using 39 start and 38 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON13183.

E. coli strain JM101 was transformed with pMON13183 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13183, contains the DNA sequence of (SEQ ID NO:95) which encodes the following amino acid sequence:

    Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro                    Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Tyr Lys Leu Cys                    His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro                    Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala                    Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly                    Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr                    Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile                    Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro                    Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg                    Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu                    Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly                    Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val                    Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys                    Ala Thr  (SEQ ID NO:167)                                                  

EXAMPLE 55 Construction of pMON13184

The new N-terminus/C-terminus gene in pMON13184 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 97 start (SEQ ID NO:66) and L-11 start (SEQ ID NO:60). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 96 stop (SEQ ID NO:67) and L-11 stop (SEQ ID NO:61). The full-length new N terminus/C-terminus G-CSF Ser¹⁷ gene was created and amplified from the annealed Fragments Start and Stop using 97 start and 96 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON13184.

E. coli strain JM101 was transformed with pMON13184 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13184, contains the DNA sequence of (SEQ ID NO:96) which encodes the following amino acid sequence:

    Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Pro Glu Leu Gly                    Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr                    Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu                    Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln                    Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe                    Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser                    Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu                    Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys                    Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu                    Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys                    Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His                    Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly                    Ile Ser (SEQ ID NO:168)                                                   

EXAMPLE 56 Construction of pMON13185

The new N-terminus/C-terminus gene in pMON13185 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 97 start (SEQ ID NO:66) and L-11 start (SEQ ID NO:60). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 96 stop (SEQ ID NO:67 and L-11 stop (SEQ ID NO:61). The full-length new N terminus/C-terminus G-CSF Ser¹⁷ gene was created and amplified from the annealed Fragments Start and Stop using 97 start and 96 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON13185.

E. coli strain JM101 was transformed with pMON13185 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13185, contains the DNA sequence of (SEQ ID NO:67) which encodes the following amino acid sequence:

    Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Pne Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro                    Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Pro Glu Leu Gly                    Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr                    Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu                    Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln                    Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe                    Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser                    Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu                    Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys                    Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu                    Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys                    Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His                    Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly                    Ile Ser (SEQ ID NO:169)                                                   

EXAMPLE 57 Construction of pMON13186

The new N-terminus/C-terminus gene in pMON13186 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 126 start (SEQ ID NO:68) and L-11 start (SEQ ID NO:60). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 125 stop (SEQ ID NO:69) and L-11 stop (SEQ ID NO:61). The full-length new N terminus/C-terminus G-CSF Ser¹⁷ gene was created and amplified from the annealed Fragments Start and Stop using 126 start and 125 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON13186.

E. coli strain JM101 was transformed with pMON13186 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13186, contains the DNA sequence of (SEQ ID NO:98) which encodes the following amino acid sequence:

    Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Met Ala Pro Ala                    Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe                    Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser                    Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro                    Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu                    Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu                    Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val                    Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser                    Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu                    His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu                    Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu                    Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu                    Leu Gly (SEQ ID NO:170)                                                   

EXAMPLE 58 Construction of pMON13187

The new N-terminus/C-terminus gene in pMON13187 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 126 start (SEQ ID NO:68) and L-11 start (SEQ ID NO:60). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 125 stop (SEQ ID NO:69) and L-11 stop (SEQ ID NO:61). The full-length new N terminus/C-terminus G-CSF Ser¹⁷ gene was created and amplified from the annealed Fragments Start and Stop using 126 start and 125 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON13187.

E. coli strain JM101 was transformed with pMON13187 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13187, contains the DNA sequence of (SEQ ID NO:99) which encodes the following amino acid sequence:

    Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro                    Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Met Ala Pro Ala                    Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe                    Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser                    Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro                    Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu                    Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu                    Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val                    Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser                    Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu                    His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu                    Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu                    Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu                    Leu Gly  (SEQ ID NO:171)                                                  

EXAMPLE 59 Construction of pMON13188

The new N-terminus/C-terminus gene in pMON13188 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 133 start (SEQ ID NO:70) and L-11 start (SEQ ID NO:60). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 132 stop (SEQ ID NO:71) and L-11 stop (SEQ ID NO:61). The full-length new N terminus/C-terminus G-CSF Ser¹⁷ gene was created and amplified from the annealed Fragments Start and Stop using 133 start and 132 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON13188.

E. coli strain JM101 was transformed with pMON13188 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13188, contains the DNA sequence of (SEQ ID NO:100) which encodes the following amino acid sequence:

    Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Gln Gly Ala                    Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val                    Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg                    Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser                    Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln                    Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys                    Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly                    Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln                    Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr                    Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly                    Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr                    Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu                    Gln Pro (SEQ ID NO:172)                                                   

EXAMPLE 60 Construction of pMON13189

The new N-terminus/C-terminus gene in pMON13189 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 133 start (SEQ ID NO:70) and L-11 start (SEQ ID NO:60). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 132 stop (SEQ ID NO:71) and L-11 stop (SEQ ID NO:61). The full-length new N terminus/C-terminus G-CSF Ser¹⁷ gene was created and amplified from the annealed Fragments Start and Stop using 133 start and 132 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON13189.

E. coli strain JM101 was transformed with pMON13189 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13189, contains the DNA sequence of (SEQ ID NO:101) which encodes the following amino acid sequence:

    Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro                    Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala                    Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val                    Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg                    Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser                    Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln                    Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys                    Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly                    Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln                    Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr                    Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly                    Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr                    Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu                    Gln Pro   (SEQ ID NO:173)                                                 

EXAMPLE 61 Construction of pMON13190

The new N-terminus/C-terminus gene in pMON13190 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 142 start (SEQ ID NO:72) and L-11 start (SEQ ID NO:60). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 141 stop (SEQ ID NO:73) and L-11 stop (SEQ ID NO:61). The full-length new N terminus/C-terminus G-CSF Ser¹⁷ gene was created and amplified from the annealed Fragments Start and Stop using 142 start and 141 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON13190.

E. coli strain JM101 was transformed with pMON13190 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13190, contains the DNA sequence of (SEQ ID NO:102) which encodes the following amino acid sequence:

    Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Ser Ala Phe Gln                    Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe                    Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser                    Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu                    Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys                    Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu                    Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys                    Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His                    Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly                    Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp                    Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu                    Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala                    Phe Ala (SEQ ID NO:174)                                                   

EXAMPLE 62 Construction of pMON13191

The new N-terminus/C-terminus gene in pMON13191 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 142 start (SEQ ID NO:72) and L-11 start (SEQ ID NO:60). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 141 stop (SEQ ID NO:73) and L-11 stop (SEQ ID NO:61). The full-length new N terminus/C-terminus G-CSF Ser¹⁷ gene was created and amplified from the annealed Fragments Start and Stop using 142 start and 141 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and HindIII and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON13191.

E. coli strain JM101 was transformed with pMON13191 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13191, contains the DNA sequence of (SEQ ID NO:103) which encodes the following amino acid sequence:

    Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro                    Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Ser Ala Phe Gln                    Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe                    Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser                    Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu                    Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys                    Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu                    Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys                    Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His                    Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly                    Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp                    Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu                    Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala                    Phe Ala (SEQ ID NO:175)                                                   

EXAMPLE 63 Construction of pMON13192

The new N-terminus/C-terminus gene in pMON13192 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF sequence in pMON13037 using the primer set, 39 start (SEQ ID NO:64) and P-bl start (SEQ ID NO:62). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 38 stop (SEQ ID NO:65) and P-bl stop (SEQ ID NO:63). Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser¹⁷ gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full-length new N-terminus/C-terminus G-CSF Ser¹⁷ gene was isolated using Geneclean (Bio101, Vista, Calif.). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13192.

E. coli strain JM101 was transformed with pMON13192 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13192, contains the DNA sequence of (SEQ ID NO:104) which encodes the following amino acid sequence:

13192.Pept

    Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Tyr Lys Leu Cys                    His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro                    Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala                    Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly                    Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr                    Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile                    Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro                    Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg                    Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu                    Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr Pro Leu                    Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu                    Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu                    Lys Leu Cys Ala Thr (SEQ ID NO:176)                                       

EXAMPLE 64 Construction of pMON13193

The new N-terminus/C-terminus gene in pMON13193 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 39 start (SEQ ID NO:64) and P-bl start (SEQ ID NO:62). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 38 stop (SEQ ID NO:65) and P-bl stop (SEQ ID NO:63). Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser¹⁷ gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full-length new N-terminus/C-terminus G-CSF Ser¹⁷ gene was isolated using Geneclean (Bio101, Vista, Calif.). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13193.

E. coli strain JM101 was transformed with pMON13193 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13193, contains the DNA sequence of (SEQ ID NO:105) encodes the following amino acid sequence:

    Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro                    Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Tyr Lys Leu Cys                    His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro                    Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala                    Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly                    Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr                    Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile                    Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro                    Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg                    Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu                    Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr Pro Leu                    Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu                    Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu                    Lys Leu Cys Ala Thr (SEQ ID NO:177)                                       

EXAMPLE 65 Construction of pMON25190

The new N-terminus/C-terminus gene in pMON25190 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF sequence in pMON13037 using the primer set, 97 start (SEQ ID NO:66) and P-bl start (SEQ ID NO:62). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 96 stop (SEQ ID NO:67) and P-bl stop (SEQ ID NO:63). Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser¹⁷ gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full-length new N-terminus/C-terminus G-CSF Ser¹⁷ gene was isolated using Geneclean (Bio101, Vista, Calif.). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON25190.

E. coli strain JM101 was transformed with pMON25190 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON25190, contains the DNA sequence of (SEQ ID NO:106) which encodes the following amino acid sequence:

    Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Pro Glu Leu Gly                    Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr                    Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu                    Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln                    Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe                    Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr                    Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys                    Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu                    Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu                    Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu                    Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser                    Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala                    Leu Glu Gly Ile Ser  (SEQ ID NO:178)                                      

EXAMPLE 66 Construction of pMON25191

The new N-terminus/C-terminus gene in pMON25191 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 97 start (SEQ ID NO:66) and P-bl start (SEQ ID NO:62). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 96 stop (SEQ ID NO:98) and P-bl stop (SEQ ID NO:63). Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser¹⁷ gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full-length new N-terminus/C-terminus G-CSF Ser¹⁷ gene was isolated using Geneclean (Bio101, Vista, Calif.). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON25191.

E. coli strain JM101 was transformed with pMON25191 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON25191, contains the DNA sequence of (SEQ ID NO:107) which encodes the following amino acid sequence:

    Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro                    Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Pro Glu Leu Gly                    Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr                    Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu                    Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln                    Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe                    Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr                    Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys                    Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu                    Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu                    Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu                    Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser                    Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala                    Leu Glu Gly Ile Ser (SEQ ID NO:179)                                       

EXAMPLE 67 Construction of pMON13194

The new N-terminus/C-terminus gene in pMON13194 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 126 start (SEQ ID NO:68) and P-bl start (SEQ ID NO:62). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 125 stop (SEQ ID NO:67) and P-bl stop (SEQ ID NO:63). Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser¹⁷ gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full-length new N-terminus/C-terminus G-CSF Ser¹⁷ gene was isolated using Geneclean (Bio101, Vista, Calif.). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13194.

E. coli strain JM101 was transformed with pMON13194 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13194, contains the DNA sequence of (SEQ ID NO:108) which encodes the following amino acid sequence:

    Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Met Ala Pro Ala                    Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe                    Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser                    Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro                    Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu                    Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala                    Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu                    Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro                    Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu                    Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln                    Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr                    Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln                    Met Glu Glu Leu Gly (SEQ ID NO:180)                                       

EXAMPLE 68 Construction of pMON13195

The new N-terminus/C-terminus gene in pMON13195 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 126 start (SEQ ID NO:68) and P-bl start (SEQ ID NO:62). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 125 stop (SEQ ID NO:69) and P-bl stop (SEQ ID NO:63). Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser¹⁷ gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full-length new N-terminus/C-terminus G-CSF Ser¹⁷ gene was isolated using Geneclean (Bio101, Vista, Calif.). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13195.

E. coli strain JM101 was transformed with pMON13195 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13195, contains the DNA sequence of (SEQ ID NO:109) which encodes the following amino acid sequence:

    Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro                    Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Met Ala Pro Ala                    Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe                    Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser                    Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro                    Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu                    Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala                    Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu                    Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro                    Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu                    Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln                    Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr                    Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln                    Met Glu Glu Leu Gly (SEQ ID NO:181)                                       

EXAMPLE 69 Construction of pMON13196

The new N-terminus/C-terminus gene in pMON13196 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF sequence in pMON13037 using the primer set, 133 start (SEQ ID NO:70) and P-bl start (SEQ ID NO:62). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 132 stop (SEQ ID NO:71) and P-bl stop (SEQ ID NO:63). Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser¹⁷ gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full-length new N-terminus/C-terminus G-CSF Ser¹⁷ gene was isolated using Geneclean (Bio101, Vista, Calif.). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13196.

E. coli strain JM101 was transformed with pMON13196 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13196, contains the DNA sequence of (SEQ ID NO:110) which encodes the following amino acid sequence:

    Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Gln Gly Ala                    Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val                    Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg                    Val Leu Arg His Leu Ala Gln Pro Thr Pro Leu Gly Pro Ala Ser                    Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg                    Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala                    Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His                    Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln                    Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu                    Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro                    Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp                    Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala                    Pro Ala Leu Gln Pro (SEQ ID NO:182)                                       

EXAMPLE 70 Construction of pMON13197

The new N-terminus/C-terminus gene in pMON13197 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 133 start (SEQ ID NO:70) and P-bl start (SEQ ID NO:62). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 132 stop (SEQ ID NO:71) and P-bl stop (SEQ ID NO:63). Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser¹⁷ gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full-length new N-terminus/C-terminus G-CSF Ser¹⁷ gene was isolated using Geneclean (Bio101, Vista, Calif.). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13197.

E. coli strain JM101 was transformed with pMON13197 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13197, contains the DNA sequence of (SEQ ID NO:lll) which encodes the following amino acid sequence:

    Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Tyr Lys Leu Cys                    His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro                    Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala                    Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly                    Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr                    Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile                    Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro                    Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg                    Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu                    Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr Pro Leu                    Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu                    Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu                    Lys Leu Cys Ala Thr (SEQ ID NO:183)                                       

EXAMPLE 71 Construction of pMON13198

The new N-terminus/C-terminus gene in pMON13198 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF sequence in pMON13037 using the primer set, 142 start (SEQ ID NO:72) and P-bl start (SEQ ID NO:62). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 141 stop (SEQ ID NO:73) and P-bl stop (SEQ ID NO:63). Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser¹⁷ gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full-length new N-terminus/C-terminus G-CSF Ser¹⁷ gene was isolated using Geneclean (Bio101, Vista, Calif.). The intermediate plasmid, pMON13180, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13198.

E. coli strain JM101 was transformed with pMON13198 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13198, contains the DNA sequence of (SEQ ID NO:112) which encodes the following amino acid sequence:

    Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Ser Ala Phe Gln                    Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe                    Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr                    Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys                    Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu                    Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu                    Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu                    Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser                    Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala                    Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu                    Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met                    Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala                    Met Pro Ala Phe Ala (SEQ ID NO:184)                                       

EXAMPLE 72 Construction of pMON13199

The new N-terminus/C-terminus gene in pMON13199 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 142 start (SEQ ID NO:72) and P-bl start (SEQ ID NO:62). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 141 stop (SEQ ID NO:73) and P-bl stop (SEQ ID NO:63). Fragment Start was digested with restriction endonuclease NcoI, and Fragment Stop was digested with restriction endonuclease HindIII. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair NcoI-HindIII vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser¹⁷ gene and was digested with restriction endonucleases NcoI and HindIII. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full-length new N-terminus/C-terminus G-CSF Ser¹⁷ gene was isolated using Geneclean (Bio101, Vista, Calif.). The intermediate plasmid, pMON13181, was digested with restriction endonucleases HindIII and AflIII, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, Wis.). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13199.

E. coli strain JM101 was transformed with pMON13199 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13199, contains the DNA sequence of (SEQ ID NO:113) which encodes the following amino acid sequence:

    Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile                    Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr                    Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp                    Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu                    Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro                    Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro                    Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Ser Ala Phe Gln                    Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe                    Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr                    Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys                    Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu                    Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu                    Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu                    Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser                    Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala                    Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu                    Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met                    Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala                    Met Pro Ala Phe Ala (SEQ ID NO:185)                                       

EXAMPLE 73 Construction of Tandemly-Duplicated Plasmid Template, Syntan1

To create the tandemly-duplicated hIL-3 receptor agonist pMON13416 template, Syntan1, three DNAs were joined by means of ligation using T4 DNA ligase (Boehringer Mannheim). The three DNAs are: 1) pMON13046, containing hIL-3 receptor agonist pMON13416, digested with BstEII and SnaBI; 2) the annealed complimentary pair of synthetic oligonucleotides, L1syn.for (SEQ ID NO:48) and L1syn.rev (SEQ ID NO:49), which contain sequence encoding the linker that connects the C-terminal and N-terminal ends of the original protein and a small amount of surrounding pMON13416 sequence and which when properly assembled result in BstEII and ClaI ends; and 3) a portion of hIL-3 receptor agonist pMON13416 digested from pMON13046 with ClaT (DNA had been grown in the dam- cells, DM1 (Life Technologies)) and SnaBI. The digested DNAs were resolved on a 0.9% TAE gel, stained with ethidium bromide and isolated using Geneclean (Bio101).

A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Miniprep DNA was isolated from the transformants, and the transformants were screened using a PCR based assay. Plasmid DNA from selected transformants was sequenced to obtain the correct template. The resulting plasmid was designated syntan1 and contains the DNA sequence of (SEQ ID NO:84).

EXAMPLE 74 Construction of Tandemly-Duplicated Template, Syntan3

To create the tandemly-duplicated hIL-3 receptor agonist pMON13416 template, syntan3, three DNAs were joined by means of ligation using T4 DNA ligase (Boehringer Mannheim). The three DNAs are: 1) pMON13046, containing hIL-3 receptor agonist pMON13416, digested with BstEII and SnaBI; 2) the annealed complimentary pair of synthetic oligonucleotides, L3syn.for (SEQ ID NO:50) and L3syn.rev (SEQ ID NO:51), which contain sequence encoding the linker that connects the C-terminal and N-terminal ends of the original protein and a small amount of surrounding pMON13416 sequence and which when properly assembled result in BstEII and SnaBI ends; and 3) a portion of hIL-3 receptor agonist pMON13416 digested from pMON13046 with ClaI (DNA had been grown in the dam- cells, DM1 (Life Technologies)) and SnaBI. The digested DNAs were resolved on a 0.9% TAE gel, stained with ethidium bromide and isolated using Geneclean (Bio101).

A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Miniprep DNA was isolated from the transformants, and the transformants were screened using a PCR based assay. Plasmid DNA from selected transformants was sequenced to obtain the correct template. The resulting plasmid was designated syntan3 and contains the DNA sequence of (SEQ ID NO:85).

EXAMPLE 75 Construction of pMON31104

The new N-terminus/C-terminus gene in pMON31104 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntan1, using the primer set 35 start (SEQ ID NO:52) and 34 rev (SEQ ID NO:53).

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and SnaBI. The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (Bio101, Vista, Calif.). The purified digested DNA fragment was ligated into the expression vector,pMON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). The pMON13189 DNA had been previously digested with NcoI and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (Bio101, Vista, Calif.) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31104.

E. coli strain JM101 was transformed with pMON31104 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON31104, contains the DNA sequence of (SEQ ID NO:86) which encodes the following amino acid sequence:

    Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met                    Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala                    Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg                    Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg                    His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu                    Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln                    Gln Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile Ile                    His His Leu Lys Arg Pro Pro Ala Pro Leu Tyr Val Glu Gly Gly                    Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn                    Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala                    Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg                    Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu                    Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly                    Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val                    Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys                    Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly                    His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser                    Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly                    Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser                    Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala                    Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met                    Ala Pro Ala Leu Gln Pro (SEQ ID NO:186)                                   

EXAMPLE 76 Construction of pMON31105

The new N-terminus/C-terminus gene in pMON31105 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntan1, using the primer set 70 start (SEQ ID NO:54) and 69 rev (SEQ ID NO:55).

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and SnaBI. The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (Bio101, Vista, Calif.). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). The pMON13189 DNA had been previously digested with NcoI and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (Bio101, Vista, Calif.) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31105.

E. coli strain JM101 was transformed with pMON31105 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON31105, contains the DNA sequence of (SEQ ID NO:87) which encodes the protein with the following amino acid sequence:

    Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys                    Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile                    Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr                    Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gly Ser                    Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg                    Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp                    Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu                    Ser Phe Val Arg Ala Val Lys Asn Leu Glu Tyr Val Glu Gly Gly                    Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn                    Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala                    Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg                    Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu                    Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly                    Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val                    Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys                    Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly                    His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser                    Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly                    Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser                    Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala                    Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met                    Ala Pro Ala Leu Gln Pro (SEQ ID NO:187)                                   

EXAMPLE 77 Construction of pMON31106

The new N-terminus/C-terminus gene in pMON31106 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntan1, using the primer set 91 start (SEQ ID NO:56) and 90 rev (SEQ ID NO:57).

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and SnaBI. The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (Bio101, Vista, Calif.). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). The pMON13189 DNA had been previously digested with NcoI and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (Bio101, Vista, Calif.) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31106.

E. coli strain JM101 was transformed with pMON31106 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON31106, contains the DNA sequence of (SEQ ID NO:80) which encodes the protein with the following amino acid sequence:

    Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln                    Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln                    Ala Gln Glu Gln Gln Gly Gly Gly Ser Asn Cys Ser Ile Met Ile                    Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu                    Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp                    Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val                    Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn                    Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Tyr Val Glu Gly Gly                    Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn                    Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala                    Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg                    Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu                    Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly                    Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val                    Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys                    Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly                    His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser                    Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly                    Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser                    Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala                    Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met                    Ala Pro Ala Leu Gln Pro  (SEQ ID NO:188)                                  

EXAMPLE 78 Construction of pMON31107

The new N-terminus/C-terminus gene in pMON31107 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntan1, using the primer set 101 start (SEQ ID NO:58) and 100 rev (SEQ ID NO:59).

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and SnaBI. The digested The DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (Bio101, Vista, Calif.). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). The pMON13189 DNA had been previously digested with NcoI and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (Bio101, Vista, Calif.) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31107.

E. coli strain JM101 was transformed with pMON31107 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON31107, contains the DNA sequence of (SEQ ID NO:89) which encodes the following amino acid sequence:

    Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu                    Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gly Ser Asn                    Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro                    Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val                    Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser                    Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu                    Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala                    Ala Pro Ser Arg His Pro Ile Ile Ile Lys Tyr Val Glu Gly Gly                    Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn                    Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala                    Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg                    Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu                    Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly                    Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val                    Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys                    Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly                    His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser                    Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly                    Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser                    Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala                    Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met                    Ala Pro Ala Leu Gln Pro (SEQ ID NO:189)                                   

EXAMPLE 79 Construction of pMON31108

The new N-terminus/C-terminus gene in pMON31108 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntan3, using the primer set 35 start (SEQ ID NO:52) and 34 rev (SEQ ID NO:53).

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and SnaBI. The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (Bio101, Vista, Calif.). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). The pMON13189 DNA had been previously digested with NcoI and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (Bio101, Vista, Calif.) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31108.

E. coli strain JM101 was transformed with pMON31108 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON31108, contains the DNA sequence of (SEQ ID NO:90) which encodes the following amino acid sequence:

    Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met                    Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala                    Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg                    Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg                    His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu                    Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln                    Gln Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys                    Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro                    Ala Pro Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro                    Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu                    Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala                    Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala                    Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg                    His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe                    Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly                    Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His                    Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp                    Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly                    Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu                    Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu                    Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp                    Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro                        (SEQ ID NO:190)                                                           

EXAMPLE 80 Construction of pMON31109

The new N-terminus/C-terminus gene in pMON31109 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntan3, using the primer set 70 start (SEQ ID NO:54) and 69 rev (SEQ ID NO:55).

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and SnaBI. The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (Bio101, Vista, Calif.). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). The pMON13189 DNA had been previously digested with NcoI and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (Bio101, Vista, Calif.) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31109.

E. coli strain JM101 was transformed with pMON31109 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON31109, contains the DNA sequence of (SEQ ID NO:91) which encodes the following amino acid sequence:

    Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys                    Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile                    Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr                    Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gly Ser                    Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp                    Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp                    Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg                    Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys                    Asn Leu Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro                    Ser Gly Pro Ile Ser Phr Ile Asn Pro Ser Pro Pro Ser Lys Glu                    Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala                    Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala                    Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg                    His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe                    Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly                    Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His                    Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp                    Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly                    Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu                    Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu                    Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp                    Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro                        (SEQ ID NO:191)                                                           

EXAMPLE 81 Construction of pMON31110

The new N-terminus/C-terminus gene in pMON31110 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntan3, using the primer set 91 start (SEQ ID NO:56) and 90 rev (SEQ ID NO:57).

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and SnaBI. The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (Bio101, Vista, Calif.). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). The pMON13189 DNA had been previously digested with NcoI and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (Bio101, Vista, Calif.) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31110.

E. coli strain JM101 was transformed with pMON31110 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON31110, contains the DNA sequence of (SEQ ID NO:92) which encodes the following amino acid sequence:

    Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln                    Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln                    Ala Gln Glu Gln Gln Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly                    Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu                    Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp                    Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn                    Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser                    Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser                    Ala Thr Ala Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro                    Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu                    Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala                    Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala                    Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg                    His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe                    Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly                    Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His                    Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp                    Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly                    Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu                    Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu                    Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp                    Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro                        (SEQ ID NO:192)                                                           

EXAMPLE 82 Construction of pMON31111

The new N-terminus/C-terminus gene in pMON31111 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntan3, using the primer set 101 start (SEQ ID NO:58) and 100 rev (SEQ ID NO:59).

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases NcoI and SnaBI. The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (Bio101, Vista, Calif.). The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, Ind.). The pMON13189 DNA had been previously digested with NcoI and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (Bio101, Vista, Calif.) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, Md.). Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31111.

E. coli strain JM101 was transformed with pMON31111 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON31111, contains the DNA sequence of (SEQ ID NO:93) which encodes the following amino acid sequence:

    Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu                    Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gly Ser Gly                    Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu                    Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro                    Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn                    Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn                    Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln                    Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile                    Ile Ile Lys Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro                    Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu                    Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala                    Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala                    Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg                    His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe                    Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly                    Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His                    Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp                    Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly                    Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu                    Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu                    Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp                    Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro                        (SEQ ID NO:193)                                                           

EXAMPLE 83 Construction of pMON31112

Construction of pMON31112, a plasmid containing DNA sequence encoding a multi-functional hematopoietic receptor agonist which activates the hIL-3 receptor and G-CSF receptor. Plasmid, pMON13189 DNA was digested with restriction enzymes NcoI and XmaI resulting in an NcoI, XmaI vector fragment that was isolated and purified from a 0.8% agarose gel. The DNA from a second plasmid, pMON13222 (WO 94/12639, U.S. Ser. No. 08/411,796) was digested with NcoI and EcoRI resulting in a 281 base pair NcoI, EcoRI fragment. This fragment was isolated and purified from a 1.0% agarose gel. Two oligonucleotides SYNNOXA1.REQ (SEQ ID NO:240) and SYNNOXA2.REQ (SEQ ID NO:241) were annealed and ligated with the 281 base pair DNA fragment from pMON13222 to the DNA vector fragment from pMON13189. A portion of the ligation mixture was then transformed into E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis to show the presence of an EcoRV fragment, and sequenced to confirm the correct inserts.

The plasmid, pMON31112, contains the DNA sequence of (SEQ ID NO:114) which encodes the following amino acid sequence:

    MetAlaAsnCysSerAsnMetIleAspGluIleIleThrHisLeuLysGlnProPro                      LeuProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetAsp                      AsnAsnLeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGln                      AsnAlaSerAlaIleGluSerIleLeuLysAsnLeuLeuProCysLeuProLeuAla                      ThrAlaAlaProThrArgHisProIleHisIleLysAspGlyAspTrpAsnGluPhe                      ArgArGlysLeuThrPheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyr                      ValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsn                      ProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAla                      MetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSer                      HisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro                      SerGlyGlySerGlyGlySerGlnSerPheLeuLeuLysSerLeuGluGlnValArg                      LysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeu                      CysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaPro                      LeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis                      SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGlu                      LeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIle                      TrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro                                  (SEQ ID NO:199)                                                           

Construction of pMON31113

Construction of pMON31113, a plasmid containing DNA sequence encoding a multi-functional hematopoietic receptor agonist which activates the hIL-3 receptor and G-CSF receptor. Plasmid, pMON13197 DNA was digested with restriction enzymes NcoI and XmaI resulting in an NcoI, XmaI vector fragment that was isolated and purified from a 0.8% agarose gel. The DNA from a second plasmid, pMON13239 (WO 94/12639, U.S. Ser. No. 08/411,796) was digested with NcoI and EcoRI resulting in a 281 base pair NcoI, EcoRI fragment. This fragment was isolated and purified from a 1.0% agarose gel. Two oligonucleotides SYNNOXA1.REQ (SEQ ID NO:240) and SYNNOXA2.REQ (SEQ ID NO:241) were annealed and ligated with the 281 base pair DNA fragment from pMON13239 to the DNA vector fragment from pMON13197. A portion of the ligation mixture was then transformed into E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis to show the presence of an EcoRV fragment, and sequenced to confirm the correct inserts.

The plasmid, pMON31113, contains the DNA sequence of (SEQ ID NO:115) which encodes the following amino acid sequence:

    MetAlaAsnCysSerAsnMetIleAspGluIleIleThrHisLeuLysGlnProPro                      LeuProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetGlu                      AsnAsnLeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGln                      AsnAlaSerAlaIleGluSerIleLeuLysAsnLeuLeuProCysLeuProLeuAla                      ThrAlaAlaProThrArgHisProIleIleIleArgAspGlyAspTrpAsnGluPhe                      ArgArgLysLeuThrPheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyr                      ValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsn                      ProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAla                      MetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSer                      HisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro                      ThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGlu                      GlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThr                      TyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIlePro                      TrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSer                      GlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIle                      SerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAla                      ThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro                         (SEQ ID NO:200)                                                           

EXAMPLE 85 Construction of pMON31114

Construction of pMON31114, a plasmid containing DNA sequence encoding a multi-functional hematopoietic receptor agonist which activates the hIL-3 receptor and G-CSF receptor. Plasmid, pMON13189 DNA was digested with restriction enzymes NcoI and XmaI resulting in an NcoI, XmaI vector fragment that was isolated and purified from a 0.8% agarose gel. The DNA from a second plasmid, pMON13239 (WO 94/12639, U.S. Ser. No. 08/411,796), was digested with NcoI and EcoRI resulting in a 281 base pair NcoI, EcoRI fragment. This fragment was isolated and purified from a 1.0% agarose gel. Two oligonucleotides SYNNOXA1.REQ (SEQ ID NO:240) and SYNNOXA2.REQ (SEQ ID NO:241) were annealed and ligated with the 281 base pair DNA fragment from pMON13239 to the DNA vector fragment from pMON13189. A portion of the ligation mixture was then transformed into E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis to show the presence of an EcoRV fragment, and sequenced to confirm the correct inserts.

The plasmid, pMON31114, contains the DNA sequence of (SEQ ID NO:116) which encodes the following amino acid sequence:

    MetAlaAsnCysSerAsnMetIleAspGluIleIleThrHisLeuLysGlnProPro                      LeuProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspI1eLeuMetGlu                      AsnAsnLeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGln                      AsnAlaSerAlaIleGluSerIleLeuLysAsnLeuLeuProcysLeuProLeuAla                      ThrAlaAlaProThrArgHisProIleIleIleArgAspGlyAspTrpAsnGluPhe                      ArgArgLysLeuThrPheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyr                      ValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsn                      ProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAla                      MetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSer                      HisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro                      SerGlyGlySerGlyGlySerGlnSerPheLeuLeuLysSerLeuGluGlnValArg                      LysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeu                      CysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaPro                      LeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis                      SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGlu                      LeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIle                      TrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro                                  (SEQ ID NO:201)                                                           

EXAMPLE 86 Construction of pMON31115

Construction of pMON31115, a plasmid containing DNA sequence encoding a multi-functional hematopoietic receptor agonist which activates the hIL-3 receptor and G-CSF receptor. Plasmid, pMON13197 DNA was digested with restriction enzymes NcoI and XmaI resulting in an NcoI, XmaI vector fragment that was isolated and purified from a 0.8% agarose gel. The DNA from a second plasmid, pMON13222, was digested with NcoI and EcoRI resulting in a 281 base pair NcoI, EcoRI fragment. This fragment was isolated and purified from a 1.0% agarose gel. Two oligonucleotides SYNNOXA1.REQ (SEQ ID NO:240) and SYNNOXA2.REQ (SEQ ID NO:241) were annealed and ligated with the 281 base pair DNA fragment from pMON13222 to the DNA vector fragment from pMON13197. A portion of the ligation mixture was then transformed into E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis to show the presence of an EcoRV fragment, and sequenced to confirm the correct inserts.

The plasmid, pMON31115, contains the DNA sequence of (SEQ ID NO:117) which encodes the following amino acid sequence:

    MetAlaAsnCysSerAsnMetIleAspGluIleIleThrHisLeuLysGlnProPro                      LeuProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetAsp                      AsnAsnLeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGln                      AsnAlaSerAlaIleGluSerIleLeuLysAsnLeuLeuProCysLeuProLeuAla                      ThrAlaAlaProThrArgHisProIleHisIleLysAspGlyAspTrpAsnGluPhe                      ArgArgLysLeuThrPheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyr                      ValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsn                      ProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAla                      MetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSer                      HisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro                      ThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGlu                      GlnValargLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThr                      TyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIlePro                      TrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSer                      GlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIle                      SerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAla                      ThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro                         (SEQ ID NO:202)                                                           

EXAMPLE 87

Determination of the in vitro activity of multi-functional hematopoietic receptor agonist proteins

The protein concentration of the multi-functional hematopoietic receptor agonist protein can be determined using a sandwich ELISA based on an affinity purified polyclonal antibody. Alternatively the protein concentration can be determined by amino acid composition analysis. The bioactivity of the multi-functional hematopoietic receptor agonist can be determined in a number of in vitro assays. For example a multi-functional hematopoietic receptor agonist which binds the hIL-3 receptor and G-CSF receptor can be assayed in cell proliferation assays using cell lines expressing the hIL-3 and/or G-CSF receptors. One such assay is the AML-193 cell proliferation assay. AML-193 cells respond to IL-3 and G-CSF which allows for the combined bioactivity of the IL-3/G-CSF multi-functional hematopoietic receptor agonist to be determined. Another such assay is the TF1 cell proliferation assay.

In addition other factor dependent cell lines, such as M-NFS-60 (ATCC. CRL 1838) or 32D which are murine IL-3 dependent cell line, may be used. The activity of IL-3 is species specific whereas G-CSF is not, therefore the bioactivity of the G-CSF component of the IL-3/G-CSF multi-functional hematopoietic receptor agonist can be determined independently. Cell lines, such as BHK or murine Baf/3, which do not express the receptor for a given ligand can be transfected with a plasmid containing a gene encoding the desired receptor. An example of such a cell line is BaF3 transfected with the hG-CSF receptor (BaF3/hG-CSF). The activity of the multi-functional hematopoietic receptor agonist in these cell lines can be compared with hIL-3 or G-CSF alone or together. The bioactivity of examples of multi-functional hematopoietic receptor agonists of the present invention assayed in the BaF3/hG-CSF cell proliferation and TF1 cell proliferation assays is shown in Table 5 and Table 6. The bioactivity of the multi-functional hematopoietic receptor agonist is expressed as relative activity compared with a standard protein pMON13056 (WO 95/21254). The bioactivity of examples of multi-functional hematopoietic receptor agonists of the present invention assayed in the BaF3/c-mpl cell proliferation and TF1 cell proliferation assays is shown in Table 7 and Table 8.

                  TABLE 5                                                          ______________________________________                                         CELL PROLIFERATIVE ACTIVITY                                                    OF DUAL IL-3/G-CSF RECEPTOR AGONISTS                                                      BaF3/hG-CSF receptor                                                                         TF1                                                                  cell proliferation                                                                            cell proliferation                                                                           assay                              pMON       relative activity*                                                                              relative activity*                                 ______________________________________                                         13182      0.015         1.1                                                   13183                    0.02                                                                                                nd                               13184                    0.01                                                                                               0.3                               13185                   0.023                                                                                               0.36                              13186                    0.36                                                                                               0.45                              13187                    0.07                                                                                               0.26                              13188                    0.64                                                                                               1.3                               13189                    0.58                                                                                               1.37                              13190                   0.045                                                                                               1.2                               13191                    0.14                                                                                               2.7                               13192                    0.09                                                                                               2.2                               13193                    0.06                                                                                               3.0                               25190                                          nd                              25191                    0.43                                                                                               1.2                               13194                                          nd                              13195                    1.3                                                                                                 4.3                              13196                    0.66                                                                                               0.5                               13197                    0.6                                                                                                 0.77                             13198                    0.6                                                                                                 0.5                              13199                                          nd                              15982                    0.7                                                                                                 1.9                              15981                   0.068                                                                                               1.2                               15965                    0.7                                                                                                 0.82                             15966                    0.36                                                                                               1.48                              15967                    0.62                                                                                               1.37                              ______________________________________                                          nd = not determined                                                            *The bioactivity of the multifunctional hematopoietic receptor agonist is      expressed as relative activity compared with a standard protein pMON13056      n = 3 or greater                                                         

                  TABLE 6                                                          ______________________________________                                         CELL PROLIFERATIVE ACTIVITY                                                    OF DUAL IL-3/G-CSF RECEPTOR AGONISTS                                                      BaF3/hG-CSF receptor                                                                         TF1                                                              cell proliferation                                                                              cell proliferation                                            assay                          assay                                pMON                  relative activity                                                                      relative activity                                ______________________________________                                         31104      +             +                                                     31105                   +                                                                                                     +                               31106                   +                                                                                                     +                               31107                  nd                                                                                                   nd                                31108                   +                                                                                                     +                               31109                   +                                                                                                     +                               31110                  nd                                                                                                   nd                                31111                  nd                                                                                                   nd                                31112                   +                                                                                                     +                               31113                   +                                                                                                     +                               31114                   +                                                                                                     +                               31115                   +                                                                                                     +                               31116                  nd                                                                                                   nd                                31117                  nd                                                                                                   nd                                ______________________________________                                          nd = not determined                                                            † The bioactivity (n = 1 or 2) of the multifunctional hematopoieti      receptor agonist is expressed as relative activity compared with a             standard protein pMON13056.                                                    "+" indicates that the molecule was comparable to pMON13056.             

                  TABLE 7                                                          ______________________________________                                         CELL PROLIFERATION ACTIVITY                                                               Baf3/c-mpl receptor                                                                          TF1                                                                   cell proliferation                                                                          cell proliferation                                           assay                            assay                              pMON       activity*                     activity                              ______________________________________                                         28505      -             +                                                     28506                    +                           -                         28507                    +                           -                         28508                    +                           -                         28509                    +                           -                         28510                    +                           -                         28511                                             +                            28512                                             +                            28513                                             +                            28514                                             +                            28519                    +                           -                         28520                    +                           -                         28521                    +                           -                         28522                    +                           -                         28523                    +                           -                         28524                    +                           -                         28525                                             +                            28526                                             +                            28533                                              +                           28534                    +                           -                         28535                    +                           -                         28536                    +                           -                         28537                                          +                               28538                    +                           -                         28539                                             +                            28540                                             +                            28541                                             +                            28542                                             +                            28543                                             +                            28544                                             +                            28545                                             +                            ______________________________________                                          *Activity measured in the Baf3 cell line transfected with the cmpl             receptor, relative to cmpl ligand (1-153).                                     † Activity measured relative to pMON13056.                        

In a similar manner other factor dependent cell lines known to those skilled in the art can be used to measure the bioactivity of the desired multi-functional hematopoietic receptor agonist. The methylcellulose assay can be used to determine the effect of the multi-functional hematopoietic receptor agonists on the expansion of the hematopoietic progenitor cells and the pattern of the different types of hematopoietic colonies in vitro. The methylcellulose assay can provide an estimate of precursor frequency since one measures the frequency of progenitors per 100,000 input cells. Long term, stromal dependent cultures have been used to delineate primitive hematopoietic progenitors and stem cells. This assay can be used to determine whether the multi-functional hematopoietic receptor agonist stimulates the expansion of very primitive progenitors and/or stem cells. In addition, limiting dilution cultures can be performed which will indicate the frequency of primitive progenitors stimulated by the multi-functional hematopoietic receptor agonist.

                  TABLE 8                                                          ______________________________________                                                                c-mpl receptor agonist                                            IL-3 agonist activity                                                                       activity                                                          (AML cell    (Baf/3-c-mpl cell                                       pMON #    proliferation assay)                                                                        proliferation assay                                     ______________________________________                                         28505     +            -                                                       28506                   -      +                                               28507                   -      +                                               28508                   -      +                                               28509                   -      +                                               28510                   -      +                                               28511                                         +                                28512                                         +                                28513                                         +                                28514                                         +                                28515                                         +                                28519                   -      +                                               28520                   -      +                                               28521                   -      +                                               28522                   -      +                                               28523                   -      +                                               28524                   -      +                                               28525                                         +                                28526                                         +                                28527                                         +                                28528                                         +                                28529                                         +                                28535                   -     +                                                28539                                          +                               28540                                          +                               28541                                          +                               28542                                          +                               28545                                          +                               ______________________________________                                    

EXAMPLE 88

G-CSF variants which contain single or multiple amino acid substitutions were made using PCR mutagenesis techniques as described in WO 94/12639 and WO 94/12638. These and other variants (i.e. amino acid substitutions, insertions or deletions and N-terminal or C-terminal extensions) could also be made, by one skilled in the art, using a variety of other methods including synthetic gene assembly or site-directed mutagenesis (see Taylor et al., Nucl. Acids Res., 13: 7864-8785 [1985]; Kunkel et al., Proc. Natl. Acad. Sci. USA, 82: 488-492 [1985]; Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., [1989], (WO 94/12639) and (WO 94/12638)). These substitutions can be made one at a time or in combination with other amino acid substitutions, and/or deletions, and/or insertions and/or extensions. After sequence verification of the changes, the plasmid DNA can be transfected into an appropriate mammalian cell, insect cell or bacterial strain such as E. coli for production. Known variants of G-CSF, which are active, include substitutions at positions 1 (Thr to Ser, Arg or Gly, 2 (Pro to Leu), 3 (Leu to Arg or Ser) and 17 (Cys to Ser) and deletions of amino acids 1-11 (Kuga et al. Biochemicla and Biophysical Research Comm. 159:103-111 (1989)). These G-CSF amino acid substitution variants can be used as the template to create the G-CSF receptor agonists in which a new N-terminus and new C-terminus are created. Examples of G-CSF amino acid substitution variants are shown in Table 9.

EXAMPLE 89

Bioactivity determination of G-CSF amino acid substitution variants

The G-CSF amino acid substitution variants can be assayed for cell proliferation activity using the Baf/3 cell line transfected with the human G-CSF receptor. The bioactivity of examples of G-CSF amino acid substitution variants is shown in Table 9 relative to native human G-CSF. A "+" indicates a comparable activity to native and a "-" indicates significantly reduced or no measurable activity.

                  TABLE 9                                                          ______________________________________                                         CELL PROLIFERATION ACTIVITY OF G-CSF VARIANTS IN BAF3                          CELL LINE TRANSFECTED WITH THE HUMAN G-CSF RECEPTOR                            aa position                                                                             native aa     mutant aa                                                                               activity*                                      ______________________________________                                         13       Phe           Ser      +                                              13                    Phe                                                                                                    +                                13                    Phe                                                                                                    +                                13                    Phe                                                                                                    +                                16                    Lys                                                                                                    +                                16                    Lys                                                                                                    +                                16                    Lys                                                                                                    +                                16                    Lys                                                                                                    +                                18                    Leu                                                                                                    +                                18                    Leu                                                                                                    +                                18                    Leu                                                                                                    +                                18                    Leu                                                                                                    +                                18                    Leu                                                                                                    +                                19                    Glu                                                                                      -  Ala                                         19                    Glu                                                                                      -  Thr                                         19                    Glu                                                                                      -  Arg                                         19                    Glu                                                                                      -  Pro                                         19                    Glu                                                                                      -  Leu                                         19                    Glu                                                                                      -  Ser                                         22                    Arg                                                                                                    +                                22                    Arg                                                                                                    +                                22                    Arg                                                                                                    +                                22                    Arg                                                                                                    +                                24                    Ile                                                                                                    +                                24                    Ile                                                                                                    +                                24                    Ile                                                                                                    +                                27                     Asp                                                                                                    +                               30                     Ala                                                                                                    +                               30                     Ala                                                                                                    +                               34                     Lys                                                                                                    +                               43                     His                                                                                                    +                               43                     His                                                                                                    +                               43                     His                                                                                                    +                               43                     His                                                                                                    +                               43                     His                                                                                                    +                               43                     His                                                                                                    +                               43                     His                                                                                                    +                               43                     His                                                                                                    +                               43                     His                                                                                                    +                               44                     Pro                                                                                                    +                               44                     Pro                                                                                                    +                               44                     Pro                                                                                                    +                               44                     Pro                                                                                                    +                               44                     Pro                                                                                                    +                               44                     Pro                                                                                                    +                               44                     Pro                                                                                                    +                               44                     Pro                                                                                                    +                               44                     Pro                                                                                                    +                               46                     Glu                                                                                                    +                               46                     Glu                                                                                                    +                               47                     Leu                                                                                                    +                               49                     Leu                                                                                                    +                               49                     Leu                                                                                                    +                               49                     Leu                                                                                                    +                               50                     Leu                                                                                                    +                               54                     Leu                                                                                                    +                               67                    Gln                                                                                                     +                               67                    Gln                                                                                                     +                               67                    Gln                                                                                                     +                               70                    Gln                                                                                                     +                               70                    Gln                                                                                                     +                               70                    Gln                                                                                                     +                               70                    Gln                                                                                                     +                               104                   Asp                                                                                                     +                               104                   Asp                                                                                                     +                               108                   Leu                                                                                                     +                               108                   Leu                                                                                                     +                               108                   Leu                                                                                                     +                               108                   Leu                                                                                                     +                               108                   Leu                                                                                                     +                               108                   Leu                                                                                                     +                               115                   Thr                                                                                                     +                               115                   Thr                                                                                                     +                               115                   Thr                                                                                                     +                               144                   Phe                                                                                                     +                               144                   Phe                                                                                                     +                               144                   Phe                                                                                                     +                               144                   Phe                                                                                                     +                               144                   Phe                                                                                                     +                               146                   Arg                                                                                                     +                               147                   Arg                                                                                                     +                               156                   His                                                                                      -    Asp                                       156                   His                                                                                                     +                               156                   His                                                                                                     +                               159                   Ser                                                                                                     +                               159                   Ser                                                                                                     +                               159                   Ser                                                                                                     +                               159                   Ser                                                                                                     +                               159                   Ser                                                                                                     +                               162                   Glu                                                                                      -    Gly                                       162                   Glu                                                                                                     +                               162                   Glu                                                                                                     +                               163                   Val                                                                                                     +                               163                   Val                                                                                                     +                               163                   Val                                                                                                     +                               165                   Tyr                                                                                                    nd                               169                   Ser                                                                                                     +                               169                   Ser                                                                                                     +                               169                   Ser                                                                                                     +                               170                   His                                                                                                     +                               170                   His                                                                                                     +                               ______________________________________                                          *activity relative to native hGCSF                                             nd = not determined                                                      

EXAMPLE 90 Cysteine Substitution Variants

The multi-functional receptor agonists may comprise sequence rearranged c-mpl receptor agonist, which also have the substitution of the cysteine residues at position 7 and/or 151 with an another amino acid, which can be prepared by the methods described in Examples 1-89 and by other methods known to those skilled in the art. One such c-mpl receptor agonist has the breakpoint at 115/116 and alanine at positions 7 and 151. This c-mpl receptor agonist has the following amino acid:

    MetAlaGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHis                   LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuAlaValArg                   GluPheGlyGlyAsnMetAlaSerProAlaProProAlaAlaAspLeuArgValLeuSer                   LysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHis                   ProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThr                   GlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGly                   ValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeu                   SerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuPro              

ProGln (SEQ ID NO:284), and is encoded by the following DNA sequence;

      1                                                                               ATGGCTGGCA GGACCACAGC TCACAAGGAT CCCAATGCCA TCTTCCTGAG                       51                                                                                 CTTCCAACAC CTGCTCCGAG GAAAGGTGCG TTTCCTGATG CTTGTAGGAG                    101                                                                                 GGTCCACCCT CGCCGTCAGG GAATTCGGCG GCAACATGGC GTCTCCGGCG                    151                                                                                 CCGCCTGCTG CTGACCTCCG AGTCCTCAGT AAACTGCTTC GTGACTCCCA                    201                                                                                 TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AGAGGTTCAC CCTTTGCCTA                    251                                                                                 CACCTGTCCT GCTGCCTGCT GTGGACTTTA GCTTGGGAGA ATGGAAAACC                    301                                                                                 CAGATGGAGG AGACCAAGGC ACAGGACATT CTGGGAGCAG TGACCCTTCT                    351                                                                                 GCTGGAGGGA GTGATGGCAG CACGGGGACA ACTGGGACCC ACTTGCCTCT                    401                                                                                 CATCCCTCCT GGGGCAGCTT TCTGGACAGG TCCGTCTCCT CCTTGGGGCC                    451                                                                                 CTGCAGAGCC TCCTTGGAAC CCAGCTTCCT CCACAG                                                 (SEQ ID NO:287).                                            

Another c-mpl receptor agonist has the breakpoint at 81/82 and alanine at positions 7 and 151. This c-mpl receptor agonist has the following amino acid;

    MetAlaGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeu                   LeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThr                   AlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysVal                   ArgPheLeuMetLeuValGlyGlySerThrLeuAlaValArgGluPheGlyGlyAsnMet                   AlaSerProAlaProProAlaAlaAspLeuArgValLeuSerLysLeuLeuArgAspSer                   HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProVal                   LeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLys                   AlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGly              

GlnLeu, (SEQ ID NO:285), and is encoded by the following DNA sequence;

      1                                                                               ATGGCTGGAC CCACTTGCCT CTCATCCCTC CTGGGGCAGC TTTCTGGACA                       51                                                                                GGTCCGTCTC CTCCTTGGGG CCCTGCAGAG CCTCCTTGGA ACCCAGCTTC                     101                                                                                CTCCACAGGG CAGGACCACA GCTCACAAGG ATCCCAATGC CATCTTCCTG                     151                                                                                AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG CGTTTCCTGA TGCTTGTAGG                     201                                                                                AGGGTCCACC CTCGCCGTCA GGGAATTCGG CGGCAACATG GCGTCTCCGG                     251                                                                                CGCCGCCTGC TGCTGACCTC CGAGTCCTCA GTAAACTGCT TCGTGACTCC                     301                                                                                CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC                     351                                                                                TACACCTGTC CTGCTGCCTG CTGTGGACTT TAGCTTGGGA GAATGGAAAA                     401                                                                                CCCAGATGGA GGAGACCAAG GCACAGGACA TTCTGGGAGC AGTGACCCTT                     451                                                                                CTGCTGGAGG GAGTGATGGC AGCACGGGGA CAACTG                                                  (SEQ ID NO:286)                                             

EXAMPLES 91-103

The plasmids in Table 10 contain genes encoding multi-functional hematopoietic receptor agonists comprising a sequence rearranged G-CSF receptor agonists that were made by the method of Horlich et al (Protein Eng. 5:427-431, 1992). As described in Materials and Methods, the tandem repeat of the G-CSF Ser¹⁷ gene was maintained on a pACYC177 based plasmid (Chang and Cohen, J. Bacteriol. 1341141-1156, 1978), containing the sequence; GAG ATG GCT, encoding; Asp Met Ala, following immediately downstream of amino acid 174 of the first copy of the G-CSF Ser¹⁷ gene and immediately preceeding amino acid 1 of the second copy of the G-CSF Ser¹⁷ gene. The resulting sequence rearranged G-CSF receptor agonists have the linker; Asp Met Ala, between the original C-terminus and original N-terminus of G-CSF Ser¹⁷. The sequence rearranged G-CSF receptor agonists encoded by the plasmids of Table 10 were identified using a G-CSF receptor binding screen (Wantanabe et al. Analyt. Biochem 195:38-44, 1991). The multi-functional receptor agonists shown in Table 10 had G-CSF receptor binding comparable to or better than native recombinant hG-CSF.

                  TABLE 10                                                         ______________________________________                                         plasmid                        protein                                         designation                                                                              breakpoint                                                                              gene sequence                                                                                sequence                                      ______________________________________                                         pMON16017                                                                              2-3        SEQ ID NO:294                                                                              SEQ ID NO:306                                   pMON16018                                                                                  10-11       SEQ ID NO:288                                                                          SEQ ID NO:300                                  pMON16019                                                                                  12-13       SEQ ID NO:291                                                                          SEQ ID NO:303                                  pMON16021                                                                                  48-49       SEQ ID NO:295                                                                          SEQ ID NO:307                                  pMON16022                                                                                  59-60       SEQ ID NO:296                                                                          SEQ ID NO:308                                  pMON16023                                                                                  66-67       SEQ ID NO:297                                                                          SEQ ID NO:309                                  pMON16024                                                                                  68-69       SEQ ID NO:298                                                                          SEQ ID NO:310                                  pMON16025                                                                                  122-123                                                                                  SEQ ID NO:289                                                                            SEQ ID NO:301                                  pMON16028                                                                                  158-159                                                                                  SEQ ID NO:292                                                                            SEQ ID NO:304                                  pMON16025                                                                                  70-71       SEQ ID NO:299                                                                          SEQ ID NO:311                                  pMON16027                                                                                  124-125                                                                                  SEQ ID NO:290                                                                            SEQ ID NO:302                                  pMON16020                                                                                  18-19       SEQ ID NO:293                                                                          SEQ ID NO:305                                  pMON16029                                                                                  169-170                                                                                  SEQ ID NO:313                                                                            SEQ ID NO:312                                  ______________________________________                                    

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

More details concerning the molecular biology techniques, protein purification and bioassays can be found in WO 94/12639, WO 94/12638, WO 95/20976, WO 95/21197, WO 95/20977, WO 95/21254, are hereby incorporated by reference in their entirety.

All references, patents or applications cited herein are incorporated by reference in their entirety as if written herein.

Various other examples will be apparent to the person skilled in the art after reading the present disclosure without departing from the spirit and scope of the invention. It is intended that all such other examples be included within the scope of the appended claims.

    __________________________________________________________________________     #             SEQUENCE LISTING                                                 - (1) GENERAL INFORMATION:                                                     -    (iii) NUMBER OF SEQUENCES: 313                                            - (2) INFORMATION FOR SEQ ID NO:1:                                             -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 174 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: protein                                              -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 1                                                      #/note= "Xaa at position 1 is Thr,                                                            Ser, Arg, - # Tyr or Gly;"                                      -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 2                                                      #/note= "Xaa at position 2 is Pro or                                                          Leu;"                                                           -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 3                                                      #/note= "Xaa at position 3 is Leu,                                             #or Ser;"      Arg, Tyr                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 13                                                     #/note= "Xaa at position 13 is Phe,                                                           Ser, His, - # Thr or Pro;"                                      -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 16                                                     #/note= "Xaa at position 16 is Lys,                                                           Pro, Ser, - # thr or His;"                                      -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 17                                                     #/note= "Xaa at position 17 is Cys,                                                           Ser, Gly, - # Ala, Ile, Tyr or Arg;"                            -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 18                                                     #/note= "Xaa at position 18 is Leu,                                                           Thr, Pro, - # His, Ile or Cys;"                                 -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 22                                                     #/note= "Xaa at position 22 is Arg,                                                           Tyr, Ser, - # Thr or Ala;"                                      -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 24                                                     #/note= "Xaa at position 24 is Ile,                                            #or Leu;"      Pro, Tyr                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 27                                                     #/note= "Xaa at position 27 is Asp,                                                           or Gly;"                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 30                                                     #/note= "Xaa at position 30 is Ala,                                            #or Gly;"      Ile, Leu                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 34                                                     #/note= "Xaa at position 34 is Lys                                                            or Ser;"                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 36                                                     #/note= "Xaa at position 36 is Cys                                                            or Ser;"                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 42                                                     #/note= "Xaa at position 42 is Cys                                                            or Ser;"                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 43                                                     #/note= "Xaa at position 43 is His,                                                           Thr, Gly, - # Val, Lys, Trp, Ala, Arg, Cys, or Leu;"            -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 44                                                     #/note= "Xaa at position 44 is Pro,                                                           Gly, Arg, - # Asp, Val, Ala, His, Trp, Gln, or Thr;"            -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 46                                                     #/note= "Xaa at position 46 is Glu,                                                           Arg, Phe, - # Arg, Ile or Ala;"                                 -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 47                                                     #/note= "Xaa at position 47 is Leu                                                            or Thr;"                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 49                                                     #/note= "Xaa at position 49 is Leu,                                            #or Ser;"      Phe, Arg                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 50                                                     #/note= "Xaa at position 50 is Leu,                                                           Ile, His, - # Pro or Tyr;"                                      -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 54                                                     #/note= "Xaa at position 54 is Leu                                                            or His;"                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 64                                                     #/note= "Xaa at position 64 is Cys                                                            or Ser;"                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 67                                                     #/note= "Xaa at position 67 is Gln,                                            #or Cys;"      Lys, Leu                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 70                                                     #/note= "Xaa at position 70 is Gln,                                                           Pro, Leu, - # Arg or Ser;"                                      -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 74                                                     #/note= "Xaa at position 74 is Cys                                                            or Ser;"                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 104                                                    #/note= "Xaa at position 104 is Asp,                                           #Val;"         Gly or                                                          -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 108                                                    #/note= "Xaa at position 108 is Leu,                                                          Ala, Val, - # Arg, Trp, Gln or Gly;"                            -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 115                                                    #/note= "Xaa at position 115 is Thr,                                           #or Ala;"      His, Leu                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 120                                                    #/note= "Xaa at position 120 is Gln,                                                          Gly, Arg, - # Lys or His"                                       -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 123                                                    #/note= "Xaa at position 123 is Glu,                                           #or Thr"       Arg, Phe                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 144                                                    #/note= "Xaa at position 144 is Phe,                                                          His, Arg, - # Pro, Leu, Gln or Glu;"                            -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 146                                                    #/note= "Xaa at position146 is Arg                                                            or Gln;"                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 147                                                    #/note= "Xaa ap position 147 is Arg                                                           or Gln;"                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 156                                                    #/note= "Xaa at position 156 is His,                                           #Ser;"         Gly or                                                          -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 159                                                    #/note= "Xaa at position 159 is Ser,                                                          Arg, Thr, - # Tyr, Val or Gly;"                                 -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 162                                                    #/note= "Xaa at position 162 is Glu,                                           #or Trp;"      Leu, Gly                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 163                                                    #/note= "Xaa at position 163 is Val,                                           #or Ala;"      Gly, Arg                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 169                                                    #/note= "Xaa at position 169 is Arg,                                                          Ser, Leu, - # Arg or Cys;"                                      -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 170                                                    #/note= "Xaa at position 170 is His,                                           #Ser;"         Arg or                                                          -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:                                  - Xaa Xaa Xaa Gly Pro Ala Ser Ser Leu Pro Gl - #n Ser Xaa Leu Leu Xaa          #                15                                                            - Xaa Xaa Glu Gln Val Xaa Lys Xaa Gln Gly Xa - #a Gly Ala Xaa Leu Gln          #            30                                                                - Glu Xaa Leu Xaa Ala Thr Tyr Lys Leu Xaa Xa - #a Xaa Glu Xaa Xaa Val          #        45                                                                    - Xaa Xaa Gly His Ser Xaa Gly Ile Pro Trp Al - #a Pro Leu Ser Ser Xaa          #    60                                                                        - Pro Ser Xaa Ala Leu Xaa Leu Ala Gly Xaa Le - #u Ser Gln Leu His Ser          #80                                                                            - Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Al - #a Leu Glu Gly Ile Ser          #                95                                                            - Pro Glu Leu Gly Pro Thr Leu Xaa Thr Leu Gl - #n Xaa Asp Val Ala Asp          #           110                                                                - Phe Ala Xaa Thr Ile Trp Gln Gln Met Glu Xa - #a Xaa Gly Met Ala Pro          #       125                                                                    - Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Al - #a Phe Ala Ser Ala Xaa          #   140                                                                        - Gln Xaa Xaa Ala Gly Gly Val Leu Val Ala Se - #r Xaa Leu Gln Xaa Phe          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Leu Xaa Xaa Ser Tyr Arg Val Leu Xaa Xaa Le - #u Ala Gln Pro                  #               170                                                            - (2) INFORMATION FOR SEQ ID NO:2:                                             -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 133 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: protein                                              -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 17                                                     #/note= "Xaa at position 17 is Ser,                                                           Lys, Gly, - # Asp, Met, Gln, or Arg;"                           -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 18                                                     #/note= "Xaa at position 18 is Asn,                                                           His, Leu, - # Ile, Phe, Arg, or Gln;"                           -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 19                                                     #/note= "Xaa at position 19 is Met,                                                           Phe, Ile, - # Arg, Gly, Ala, or Cys;"                           -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 20                                                     #/note= "Xaa at position 20 is Ile,                                                           Cys, Gln, - # Glu, Arg, Pro, or Ala;"                           -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 21                                                     #/note= "Xaa at position 21 is Asp,                                            #Val;"         Phe, Lys, - # Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or         -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 22                                                     #/note= "Xaa at position 22 is Glu,                                            #Gly;"         Trp, Pro, - # Ser, Ala, His, Asp, Asn, Gln, Leu, Val or         -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 23                                                     #/note= "Xaa at position 23 is Ile,                                                           Val, Ala, - # Gly, Trp, Lys, Phe, Leu, Ser, or Arg;"            -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 24                                                     #/note= "Xaa at position 24 is Ile,                                                           Gly, Val, - # Arg, Ser, Phe, Leu;"                              -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 25                                                     #/note= "Xaa at position 25 is Thr,                                                           His, Gly, - # Gln, Arg, Pro, or Ala;"                           -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 26                                                     #/note= "Xaa at position 26 is His,                                                           Thr, Phe, - # Gly, Arg, Ala, Trp;"                              -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 27                                                     #/note= "Xaa at position 27 is Leu,                                                           Gly, Arg, - # Thr, Ser, or Ala;"                                -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 28                                                     #/note= "Xaa at position 28 is Lys,                                                           Arg, Leu, - # Gln, Gly, Pro, Val or Trp;"                       -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 29                                                     #/note= "Xaa at position 29 is Gln,                                                           Asn, Leu, - # Pro, Arg, or Val;"                                -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 30                                                     #/note= "Xaa at position 30 is Pro,                                                           His, Thr, - # Gly, Asp, Gln, Ser, Leu, or L..."                 -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 31                                                     #/note= "Xaa at position 31 is Pro,                                                           Asp, Gly, - # Ala, Arg, Leu, or Gln;"                           -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 32                                                     #/note= "Xaa at position 32 is Leu,                                                           Val, Arg, - # Gln, Asn, Gly, Ala, or Glu;"                      -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 33                                                     #/note= "Xaa at position 33 is Pro,                                                           Leu, Gln, - # Ala, Thr, or Glu;"                                -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 34                                                     #/note= "Xaa at position 34 is Leu,                                                           Val, Gly, - # Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile       - # or Met;"                                                                   -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 35                                                     #/note= "Xaa at position 35 is Leu,                                                           Ala, Gly, - # Asn, Pro, Gln, or Val;"                           -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 36                                                     #/note= "Xaa at position 36 is Asp,                                            #Val;"         Leu, or                                                         -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 37                                                     #/note= "Xaa at position 37 is Phe,                                                           Ser, Pro, - # Trp, or Ile;"                                     -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 38                                                     #/note= "Xaa at position 38 is Asn,                                                           or Ala;"                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 40                                                     #/note= "Xaa at position 40 is Leu,                                            #Arg;"         Trp, or                                                         -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 41                                                     #/note= "Xaa at position 41 is Asn,                                                           Cys, Arg, - # Leu, His, Met, or pro;"                           -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 42                                                     #/note= "Xaa at position 42 is Gly,                                                           Asp, Ser, - # Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr       - #, Ile, Met                                                                                 or Ala;"                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 43                                                     #/note= "Xaa at position 43 is Glu,                                                           Asn, Tyr, - # Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly       - #, or Ser;"                                                                  -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 44                                                     #/note= "Xaa at position 44 is Asp,                                                           Ser, Leu, - # Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala       - # or Pro;"                                                                   -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 45                                                     #/note= "Xaa at position 45 is Gln,                                                           Pro, Phe, - # Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg       - #, Ser, Ala,                                                                 #or His;"      Ile, Glu                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 46                                                     #/note= "Xaa at position 46 is Asp,                                                           Phe, Ser, - # Thr, Cys, Glu, Asn, Gln, Lys, His, Ala, Tyr       - #, Ile, Val                                                                                 or Gly;"                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 47                                                     #/note= "Xaa at position 47 is Ile,                                                           Gly, Val, - # Ser, Arg, Pro, or His;"                           -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 48                                                     #/note= "Xaa at position 48 is Leu,                                                           Ser, Cys, - # Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met       - #, Val or                                                                                   Asn;"                                                           -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 49                                                     #/note= "Xaa at position 49 is Met,                                                           Arg, Ala, - # Gly, Pro, Asn, His, or Asp;"                      -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 50                                                     #/note= "Xaa at position 50 is Glu,                                                           Leu, Thr, - # Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His       - #, Phe, Met                                                                                 or Gln;"                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 51                                                     #/note= "Xaa at position 51 is Asn,                                                           Arg, Met, - # Pro, Ser, Thr, or his;"                           -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 52                                                     #/note= "Xaa at position 52 is Asn,                                                           His, Arg, - # Leu, Gly, Ser, or Thr;"                           -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 53                                                     #/note= "Xaa at position 53 is Leu,                                                           Thr, Ala, - # Gly, Glu, Pro, Lys, Ser, or M..."                 -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 54                                                     #/note= "Xaa at position 54 is Arg,                                            #Leu;"         Asp, Ile, - # Ser, Val, Thr, Gln, Asn, Lys, His, Ala or         -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 55                                                     #/note= "Xaa at position 55 is Arg,                                                           Thr, Val, - # Ser, Leu, or Gly;"                                -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 56                                                     #/note= "Xaa at position 56 is Pro,                                                           Gly, Cys, - # Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe       - #, Leu, Val                                                                                 or Lys;"                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 57                                                     #/note= "Xaa at position 57 is Asn                                                            or Gly;"                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 58                                                     #/note= "Xaa at position 58 is Leu,                                                           Ser, Asp, - # Arg, Gln, Val, or Cys;"                           -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 59                                                     #/note= "Xaa at position 59 is Glu,                                                           Tyr, His, - # Leu, Pro, or Arg;"                                -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 60                                                     #/note= "Xaa at position 60 is Ala,                                                           Ser, Pro, - # Tyr, Asn, or Thr;"                                -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 61                                                     #/note= "Xaa at position 61 is Phe,                                                           Asn, Glu, - # Pro, Lys, Arg, or Ser;"                           -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 62                                                     #/note= "Xaa at position 62 is Asn,                                                           His, Val, - # Arg, Pro, Thr, Asp, or Ile;"                      -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 63                                                     #/note= "Xaa at position 63 is Arg,                                                           Tyr, Trp, - # Lys, Ser, His, Pro, or Val;"                      -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 64                                                     #/note= "Xaa at position 64 is Ala,                                                           Asn, Pro, - # Ser, or Lys;"                                     -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 65                                                     #/note= "Xaa at position 65 is Val,                                                           Thr, Pro, - # His, Leu, Phe, or Ser;"                           -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 66                                                     #/note= "Xaa at position 66 is Lys,                                                           Ile, Arg, - # Val, Asn, Glu, or Ser;"                           -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 67                                                     #/note= "Xaa at postion 67 is Ser,                                                            Ala, Phe, - # Val, Gly, Asn, Ile, Pro, or His;"                 -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 68                                                     #/note= "Xaa at position 68 is Leu,                                                           Val, Trp, - # Ser, Ile, Phe, Thr, or His;"                      -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 69                                                     #/note= "Xaa at position 69 is Gln,                                                           Ala, Pro, - # Thr, Glu, Arg, Trp, Gly, or L..."                 -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 70                                                     #/note= "Xaa at position 70 is Asn,                                                           Leu, Val, - # Trp, pro, or Ala;"                                -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 71                                                     #/note= "Xaa at position 71 is Ala,                                                           Met, Leu, - # Pro, Arg, Glu, Thr, Gln, Trp, or Asn;"            -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 72                                                     #/note= "Xaa at position 72 is Ser,                                                           Glu, Met, - # Ala, His, Asn, Arg, or Asp;"                      -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 73                                                     #/note= "Xaa at position 73 is Ala,                                                           Glu, Asp, - # Leu, Ser, Gly, Thr, or Arg;"                      -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 74                                                     #/note= "Xaa at position 74 is Ile,                                                           Met, Thr, - # Pro, Arg, Gly, Ala;"                              -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 75                                                     #/note= "Xaa at position 75 is Glu,                                                           Lys, Gly, - # Asp, Pro, Trp, Arg, Ser, Gln, or Leu;"            -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 76                                                     #/note= "Xaa at position 76 is Ser,                                                           Val, Ala, - # Asn, Trp, Glu, Pro, Gly, or A..."                 -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 77                                                     #/note= "Xaa at position 77 is Ile,                                                           Ser, Arg, - # Thr, or Leu;"                                     -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 78                                                     #/note= "Xaa at position 78 is Leu,                                                           Ala, Ser, - # Glu, Phe, Gly, or Arg;"                           -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 79                                                     #/note= "Xaa at position 79 is Lys,                                                           Thr, Asn, - # Met, Arg, Ile, Gly, or Asp;"                      -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 80                                                     #/note= "Xaa position at 80 is Asn,                                                           Trp, Val, - # Gly, Thr, Leu, Glu, or Arg;"                      -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 81                                                     #/note= "Xaa at position 81 is Leu,                                                           Gln, Gly, - # Ala, Trp, Arg, Val, or Lys;"                      -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 82                                                     #/note= "Xaa at position 82 is Leu,                                                           Gln, Lys, - # Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala       - #, Tyr, Phe,                                                                 #or Val;"      Ile, Met                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 83                                                     #/note= "Xaa at position 83 is Pro,                                                           Ala, Thr, - # Trp, Arg, or Met;"                                -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 84                                                     #/note= "Xaa at position 84 is Cys,                                                           Glu, Gly, - # Arg, Met, or Val;"                                -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 85                                                     #/note= "Xaa at position 85 is Leu,                                                           Asn, Val, - # or Gln;"                                          -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 86                                                     #/note= "Xaa at position 86 is Pro,                                                           Cys, Arg, - # Ala, or Lys;"                                     -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 87                                                     #/note= "Xaa at position 87 is Leu,                                                           Ser, Trp, - # or Gly;"                                          -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 88                                                     #/note= "Xaa at position 88 is Ala,                                                           Lys, Arg, - # Val, or Trp;"                                     -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 89                                                     #/note= "Xaa at position 89 is Thr,                                                           Asp, Cys, - # Leu, Val, Glu, His, Asn, or S..."                 -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 90                                                     #/note= "Xaa at position 90 is Ala,                                                           Pro, Ser, - # Thr, Gly, Asp, Ile, or ,Met;"                     -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 91                                                     #/note= "Xaa at position 91 is Ala,                                                           Pro, Ser, - # Thr, Phe, Leu, Asp, or His;"                      -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 92                                                     #/note= "Xaa at position 92 is Pro,                                                           Phe, Arg, - # Ser, Lys, His, Ala, Gly, Ile or Leu;"             -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 93                                                     #/note= "Xaa at position 93 is Thr,                                                           Asp, Ser, - # Asn, Pro, Ala, Leu, or Arg;"                      -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 94                                                     #/note= "Xaa at position 94 is Arg,                                                           Ile, Ser, - # Glu, Leu, Val, Gln, Lys, His, Ala, or Pro;"       -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 95                                                     #/note= "Xaa at position 95 is His,                                                           Gln, Pro, - # Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala       - #, Trp, Phe,                                                                 #Tyr;"         Ile, or                                                         -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 96                                                     #/note= "Xaa at position 96 is Pro,                                                           Lys, Tyr, - # Gly, Ile, or Thr;"                                -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 97                                                     #/note= "Xaa at position 97 is Ile,                                                           Val, Lys, - # Ala, or Asn;"                                     -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 98                                                     #/note= "Xaa at position 98 is His,                                                           Ile, Asn, - # Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met       - #, Val, Lys,                                                                                Arg, Tyr, - # or Pro;"                                          -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 99                                                     #/note= "Xaa at position 99 is Ile,                                                           Leu, Arg, - # Asp, Val, Pro, Gln, Gly, Ser, Phe, or His;"       -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 100                                                    #/note= "Xaa at position 100 is Lys,                                                          Tyr, Leu, - # His, Arg, Ile, Ser, Gln, or ..."                  -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 101                                                    #/note= "Xaa at position is Asp,                                                              Pro, Met, - # Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala       - #, Gly, Ile,                                                                 #Gln;"         Leu, or                                                         -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 102                                                    #/note= "Xaa at position 102 is Gly,                                                          Leu, Glu, - # Lys, Ser, Tyr, or Pro;"                           -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 103                                                    #/note= "Xaa at position 103 is Asp,                                                          or Ser;"                                                        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 104                                                    #/note= "Xaa at position 104 is Trp,                                                          Val, Cys, - # Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe       - #, or Gly;"                                                                  -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 105                                                    #/note= "Xaa at position 105 is Asn,                                                          Pro, Ala, - # Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp       - #, or His;"                                                                  -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 106                                                    #/note= "Xaa at position 106 is Glu,                                                          Ser, Ala, - # Lys, Thr, Ile, Gly, or Pro;"                      -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 108                                                    #/note= "Xaa at position 108 is Arg,                                                          Lys, Asp, - # Leu, Thr, Ile, Gln, His, Ser, Ala or Pro;"        -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 109                                                    #/note= "Xaa at position 109 is Arg,                                                          Thr, Pro, - # Glu, Tyr, Leu, Ser, or Gly;"                      -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 110                                                    #/note= "Xaa at position 110 is Lys,                                                          Ala, Asn, - # Thr, Leu, Arg, Gln, His, Glu, Ser, or Trp;"       -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 111                                                    #/note= "Xaa at position 111 is Leu,                                                          Ile, Arg, - # Asp, or Met;"                                     -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 112                                                    #/note= "Xaa at position 112 is Thr,                                                          Val, Gln, - # Tyr, Glu, His, Ser, or Phe;"                      -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 113                                                    #/note= "Xaa at position 113 is Phe,                                                          Ser, Cys, - # His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val       - # or Asn;"                                                                   -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 114                                                    #/note= "Xaa at position 114 is Tyr,                                                          Cys, His, - # Ser, Trp, Arg, or Leu;"                           -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 115                                                    #/note= "Xaa at position 115 is Leu,                                                          Asn, Val, - # Pro, Arg, Ala, His, Thr, Trp, or Met;"            -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 116                                                    #/note= "Xaa at position 116 is Lys,                                                          Leu, Pro, - # Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn       - #, His, Ala,                                                                                Tyr, Phe, - # Gln, or Ile;"                                     -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 117                                                    #/note= "Xaa at position 117 is Thr,                                                          Ser, Asn, - # Ile, Trp, Lys, or Pro;"                           -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 118                                                    #/note= "Xaa at position 118 is Leu,                                                          Ser, Pro, - # Ala, Glu, Cys, Asp, or Tyr;"                      -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 119                                                    #/note= "Xaa at position 119 is Glu,                                                          Ser, Lys, - # Pro, leu, Thr, Tyr, or Arg;"                      -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 120                                                    #/note= "Xaa at position 120 is Asn,                                                          Ala, Pro, - # Leu, His, Val, or Gln;"                           -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 121                                                    #/note= "Xaa at position 121 is Ala,                                                          Ser, Ile, - # Asn, Pro, Lys, Asp, or Gly;"                      -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 122                                                    #/note= "Xaa at position 122 is Gln,                                                          Ser, Met, - # Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;"       -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 123                                                    #/note= "Xaa at position 123 is Ala,                                                          Met, Glu, - # His, Ser, Pro, Tyr, or Leu;"                      -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:                                  - Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Th - #r Ser Trp Val Asn Cys          #                15                                                            - Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa - #a Xaa Xaa Xaa Xaa Xaa          #            30                                                                - Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xa - #a Xaa Xaa Xaa Xaa Xaa          #        45                                                                    - Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa - #a Xaa Xaa Xaa Xaa Xaa          #    60                                                                        - Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa - #a Xaa Xaa Xaa Xaa Xaa          #80                                                                            - Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa - #a Xaa Xaa Xaa Xaa Xaa          #                95                                                            - Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ph - #e Xaa Xaa Xaa Xaa Xaa          #           110                                                                - Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa - #a Gln Gln Thr Thr Leu          #       125                                                                    - Ser Leu Ala Ile Phe                                                              130                                                                        - (2) INFORMATION FOR SEQ ID NO:3:                                             -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 332 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: protein                                              -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 112                                                    #/note= "position 112 is deleted or                                                           Leu, Ala, - # Val, Ile, Pro, Phe, Trp, or M..."                 -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 113                                                    #/note= "position 113 is deleted or                                                           Pro, Phe, - # Ala, Leu, Ile, Trp, or Met"                       -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 114                                                    #/note= "position 114 is deleted or                                                           Pro, Phe, - # Ala, Val, Leu, Ile, Trp or Met"                   -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 115                                                    #/note= "position 115 is deleted or                                                           Gln, Gly, - # Ser, Thr, Tyr or Asn"                             -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:                                  - Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu          #                15                                                            - Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val          #            30                                                                - His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu          #        45                                                                    - Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu          #    60                                                                        - Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln          #80                                                                            - Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln          #                95                                                            - Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Xaa          #           110                                                                - Xaa Xaa Xaa Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe          #       125                                                                    - Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu          #   140                                                                        - Val Gly Gly Ser Thr Leu Cys Val Arg Arg Al - #a Pro Pro Thr Thr Ala          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Val Pro Ser Arg Thr Ser Leu Val Leu Thr Le - #u Asn Glu Leu Pro Asn          #               175                                                            - Arg Thr Ser Gly Leu Leu Glu Thr Asn Phe Th - #r Ala Ser Ala Arg Thr          #           190                                                                - Thr Gly Ser Gly Leu Leu Lys Trp Gln Gln Gl - #y Phe Arg Ala Lys Ile          #       205                                                                    - Pro Gly Leu Leu Asn Gln Thr Ser Arg Ser Le - #u Asp Gln Ile Pro Gly          #   220                                                                        - Tyr Leu Asn Arg Ile His Glu Leu Leu Asn Gl - #y Thr Arg Gly Leu Phe          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Pro Gly Pro Ser Arg Arg Thr Leu Gly Ala Pr - #o Asp Ile Ser Ser Gly          #               255                                                            - Thr Ser Asp Thr Gly Ser Leu Pro Pro Asn Le - #u Gln Pro Gly Tyr Ser          #           270                                                                - Pro Ser Pro Thr His Pro Pro Thr Gly Gln Ty - #r Thr Leu Phe Pro Leu          #       285                                                                    - Pro Pro Thr Leu Pro Thr Pro Val Val Gln Le - #u His Pro Leu Leu Pro          #   300                                                                        - Asp Pro Ser Ala Pro Thr Pro Thr Pro Thr Se - #r Pro Leu Leu Asn Thr          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Ser Tyr Thr His Ser Gln Asn Leu Ser Gln Gl - #u Gly                          #               330                                                            - (2) INFORMATION FOR SEQ ID NO:4:                                             -      (i) SEQUENCE CHARACTERISTICS:                                                     (A) LENGTH: 5 base p - #airs                                                   (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:                                  #             5                                                                - (2) INFORMATION FOR SEQ ID NO:5:                                             -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 3 amino                                                            (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (ix) FEATURE:                                                                      (A) NAME/KEY: Peptide                                                          (B) LOCATION: 1                                                      #/note= "where x=(glyglyglyglyser)n                                                           and where - # n is an interger"                                 -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:                                  - Xaa Ala Ala                                                                  - (2) INFORMATION FOR SEQ ID NO:6:                                             -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 3 amino                                                            (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (ix) FEATURE:                                                                      (A) NAME/KEY: Peptide                                                          (B) LOCATION: 1                                                      -     (ix) FEATURE:                                                                      (A) NAME/KEY: Peptide                                                          (B) LOCATION: 1                                                      #/note= "where XaaR INFORMATION:                                                              =(glyglyg - #lyglyglyser)n and where n is an integer"           -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:                                  - Xaa Ala Ala                                                                  1                                                                              - (2) INFORMATION FOR SEQ ID NO:7:                                             -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 3 amino                                                            (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (ix) FEATURE:                                                                      (A) NAME/KEY: Peptide                                                          (B) LOCATION: 1                                                      #/note= "where xaa = (gly(n)ser)m                                                             and where - # n is an integer and m is an int..."               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:                                  - Xaa Ala Ala                                                                  1                                                                              - (2) INFORMATION FOR SEQ ID NO:8:                                             -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 3 amino                                                            (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (ix) FEATURE:                                                                      (A) NAME/KEY: Peptide                                                          (B) LOCATION: 1                                                      #/note= "where Xaa=(alaglyser)n and                                            #is an integer"where n                                                         -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:                                  - Xaa Ala Ala                                                                  1                                                                              - (2) INFORMATION FOR SEQ ID NO:9:                                             -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 36 amino                                                           (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: protein                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:                                  - Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gl - #y Ser Glu Gly Gly Gly          #                15                                                            - Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Se - #r Glu Gly Gly Gly Ser          #            30                                                                - Gly Gly Gly Ser                                                                      35                                                                     - (2) INFORMATION FOR SEQ ID NO:10:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 24 amino                                                           (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:                                 - Ile Ser Glu Pro Ser Gly Pro Ile Ser Thr Il - #e Asn Pro Ser Pro Pro          #                15                                                            - Ser Lys Glu Ser His Lys Ser Pro                                                          20                                                                 - (2) INFORMATION FOR SEQ ID NO:11:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 28 amino                                                           (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:                                 - Ile Glu Gly Arg Ile Ser Glu Pro Ser Gly Pr - #o Ile Ser Thr Ile Asn          #                15                                                            - Pro Ser Pro Pro Ser Lys Glu Ser His Lys Se - #r Pro                          #            25                                                                - (2) INFORMATION FOR SEQ ID NO:12:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 4 amino                                                            (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:                                 - Gly Gly Gly Ser                                                              1                                                                              - (2) INFORMATION FOR SEQ ID NO:13:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 45 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:                                 #45                CNGC NCCNCCTGCT TGTGCACTCC GAGTC                            - (2) INFORMATION FOR SEQ ID NO:14:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 30 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:                                 #           30     ACGC AGAGGGTGGA                                             - (2) INFORMATION FOR SEQ ID NO:15:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 33 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:                                 #         33       CGCA GAGGGTGGAC CCT                                         - (2) INFORMATION FOR SEQ ID NO:16:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 10 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:                                 #        10                                                                    - (2) INFORMATION FOR SEQ ID NO:17:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 10 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:                                 #        10                                                                    - (2) INFORMATION FOR SEQ ID NO:18:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 13 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:                                 #      13                                                                      - (2) INFORMATION FOR SEQ ID NO:19:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 13 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:                                 #      13                                                                      - (2) INFORMATION FOR SEQ ID NO:20:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 22 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:                                 #                 22GGC AA                                                     - (2) INFORMATION FOR SEQ ID NO:21:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 22 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:                                 #                 22CGC CG                                                     - (2) INFORMATION FOR SEQ ID NO:22:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 27 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:                                 #             27   ACCC TTTGCCT                                                - (2) INFORMATION FOR SEQ ID NO:23:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 29 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:                                 #            29    ACTG GCTCAGTCT                                              - (2) INFORMATION FOR SEQ ID NO:24:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 27 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:                                 #             27   CACC TGTCCTG                                                - (2) INFORMATION FOR SEQ ID NO:25:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 29 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:                                 #            29    GAAC CTCTGGGCA                                              - (2) INFORMATION FOR SEQ ID NO:26:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 27 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:                                 #             27   TGCC TGCTGTG                                                - (2) INFORMATION FOR SEQ ID NO:27:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 29 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:                                 #            29    TAGG CAAAGGGTG                                              - (2) INFORMATION FOR SEQ ID NO:28:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 30 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:                                 #           30     ACTT TAGCTTGGGA                                             - (2) INFORMATION FOR SEQ ID NO:29:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 29 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:                                 #            29    GCAG GACAGGTGT                                              - (2) INFORMATION FOR SEQ ID NO:30:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 27 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:                                 #             27   GCTT GGGAGAA                                                - (2) INFORMATION FOR SEQ ID NO:31:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 29 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:                                 #            29    CAGG CAGCAGGAC                                              - (2) INFORMATION FOR SEQ ID NO:32:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 27 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:                                 #             27   GGAA AACCCAG                                                - (2) INFORMATION FOR SEQ ID NO:33:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 29 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:                                 #            29    TAAA GTCCACAGC                                              - (2) INFORMATION FOR SEQ ID NO:34:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 27 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:                                 #             27   CTTG CCTCTCA                                                - (2) INFORMATION FOR SEQ ID NO:35:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 29 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:                                 #            29    GTCC CCGTGCTGC                                              - (2) INFORMATION FOR SEQ ID NO:36:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 27 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:                                 #             27   AGCT TCCTCCA                                                - (2) INFORMATION FOR SEQ ID NO:37:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 29 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:                                 #            29    GGCT CTGCAGGGC                                              - (2) INFORMATION FOR SEQ ID NO:38:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 27 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:                                 #             27   CCAC AGCTCAC                                                - (2) INFORMATION FOR SEQ ID NO:39:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 30 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:                                 #           30     GAGG AAGCTGGGTT                                             - (2) INFORMATION FOR SEQ ID NO:40:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 30 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:                                 #           30     AGGA TCCCAATGCC                                             - (2) INFORMATION FOR SEQ ID NO:41:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 29 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:                                 #            29    TCCT GCGCTGTGG                                              - (2) INFORMATION FOR SEQ ID NO:42:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 30 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:                                 #           30     ATGC CATCTTCCTG                                             - (2) INFORMATION FOR SEQ ID NO:43:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 29 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:                                 #            29    GAGC TGTGGTCCT                                              - (2) INFORMATION FOR SEQ ID NO:44:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 30 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:                                 #           30     TCCT GAGCTTCCAA                                             - (2) INFORMATION FOR SEQ ID NO:45:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 32 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:                                 #          32      GATC CTTGTGAGCT GT                                          - (2) INFORMATION FOR SEQ ID NO:46:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 83 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "SYNTHETIC"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:                                 - AATTCCGTCG TAAACTGACC TTCTATCTGA AAACCTTGGA GAACGCGCAG GC - #TCAACAGT          60                                                                           #                83AGGC TCC                                                    - (2) INFORMATION FOR SEQ ID NO:47:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 83 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:                                 - CCGGGGAGCC TCCACCGCCC TCTACGTACT GTTGAGCCTG CGCGTTCTCC AA - #GGTTTTCA          60                                                                           #                83ACGA CGG                                                    - (2) INFORMATION FOR SEQ ID NO:48:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 59 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:                                 - GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT CTAACTGCTC TA - #TAATGAT           59                                                                           - (2) INFORMATION FOR SEQ ID NO:49:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 56 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:                                 - CGATCATTAT AGAGCAGTTA GAGCCACCAC CCTGTTGTTC CTGCGCTTGC TC - #AAGG              56                                                                           - (2) INFORMATION FOR SEQ ID NO:50:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 80 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:                                 - GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT CTGGCGGTGG CA - #GCGGCGGC          60                                                                           # 80               TAAT                                                        - (2) INFORMATION FOR SEQ ID NO:51:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 80 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:                                 - CGATCATTAT AGAGCAGTTA GAACCGCCGC CGCTGCCACC GCCAGAGCCA CC - #ACCCTGTT          60                                                                           # 80               AAGG                                                        - (2) INFORMATION FOR SEQ ID NO:52:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 30 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:                                 #           30     GGAC CCGAACAACC                                             - (2) INFORMATION FOR SEQ ID NO:53:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 28 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:                                 #             28   GGTG CAGGTGGT                                               - (2) INFORMATION FOR SEQ ID NO:54:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 32 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:                                 #          32      TGCA TCAGGTATTG AG                                          - (2) INFORMATION FOR SEQ ID NO:55:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 28 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:                                 #             28   AAGT TCTTGACA                                               - (2) INFORMATION FOR SEQ ID NO:56:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 32 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:                                 #          32      ACCC TCTCGACATC CA                                          - (2) INFORMATION FOR SEQ ID NO:57:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 28 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:                                 #             28   GTGG CAGAGGGC                                               - (2) INFORMATION FOR SEQ ID NO:58:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 32 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:                                 #          32      AGGT GACTGGCAAG AA                                          - (2) INFORMATION FOR SEQ ID NO:59:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 28 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:                                 #             28   ATGA TGATTGGA                                               - (2) INFORMATION FOR SEQ ID NO:60:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 54 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:                                 - GCTCTGAGAG CCGCCAGAGC CGCCAGAGGG CTGCGCAAGG TGGCGTAGAA CG - #CG                54                                                                           - (2) INFORMATION FOR SEQ ID NO:61:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 54 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:                                 - CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AG - #AG                54                                                                           - (2) INFORMATION FOR SEQ ID NO:62:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 18 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:                                 #  18              CG                                                          - (2) INFORMATION FOR SEQ ID NO:63:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 21 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:                                 #21                CCAG C                                                      - (2) INFORMATION FOR SEQ ID NO:64:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 32 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:                                 #          32      CAAG CTGTGCCACC CC                                          - (2) INFORMATION FOR SEQ ID NO:65:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 36 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:                                 #       36         GGTG GCACACAGCT TCTCCT                                      - (2) INFORMATION FOR SEQ ID NO:66:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 32 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:                                 #          32      CGAG TTGGGTCCCA CC                                          - (2) INFORMATION FOR SEQ ID NO:67:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 36 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:                                 #       36         GGAT ATCCCTTCCA GGGCCT                                      - (2) INFORMATION FOR SEQ ID NO:68:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 32 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:                                 #          32      GGCC CCTGCCCTGC AG                                          - (2) INFORMATION FOR SEQ ID NO:69:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 36 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:                                 #       36         TCCC AGTTCTTCCA TCTGCT                                      - (2) INFORMATION FOR SEQ ID NO:70:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 32 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:                                 #          32      CCAG GGTGCCATGC CG                                          - (2) INFORMATION FOR SEQ ID NO:71:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 36 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:                                 #       36         GGGC TGCAGGGCAG GGGCCA                                      - (2) INFORMATION FOR SEQ ID NO:72:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 36 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:                                 #       36         GGGC TGCAGGGCAG GGGCCA                                      - (2) INFORMATION FOR SEQ ID NO:73:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 36 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:                                 #       36         GGCG AAGGCCGGCA TGGCAC                                      - (2) INFORMATION FOR SEQ ID NO:74:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 21 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:                                 #21                GCTC C                                                      - (2) INFORMATION FOR SEQ ID NO:75:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 25 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:                                 #               25 GCCC TCTAC                                                  - (2) INFORMATION FOR SEQ ID NO:76:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 53 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:                                 - TTCTACGCCA CCTTGCGCAG CCCGGCGGCG GCTCTGACAT GTCTACACCA TT - #G                 53                                                                           - (2) INFORMATION FOR SEQ ID NO:77:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 53 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:                                 - CAATGGTGTA GACATGTCAG AGCCGCCGCC GGGCTGCGCA AGGTGGCGTA GA - #A                 53                                                                           - (2) INFORMATION FOR SEQ ID NO:78:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 439 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:                                 - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           #439               TGT                                                         - (2) INFORMATION FOR SEQ ID NO:79:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 465 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:                                 - TCCCCAGCTC CACCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TG - #ACTCCCAT          60                                                                           - GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC AC - #CTGTCCTG         120                                                                           - CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GA - #CCAAGGCA         180                                                                           - CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC AC - #GGGGACAA         240                                                                           - CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CC - #GTCTCCTC         300                                                                           - CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GA - #CCACAGCT         360                                                                           - CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AA - #AGGTGCGT         420                                                                           #                 465GG GTCCACCCTC TGCGTCAGGG AATTC                            - (2) INFORMATION FOR SEQ ID NO:80:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 927 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:                                 - TCCCCAGCTC CACCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TG - #ACTCCCAT          60                                                                           - GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC AC - #CTGTCCTG         120                                                                           - CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GA - #CCAAGGCA         180                                                                           - CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC AC - #GGGGACAA         240                                                                           - CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CC - #GTCTCCTC         300                                                                           - CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GA - #CCACAGCT         360                                                                           - CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AA - #AGGTGCGT         420                                                                           - TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTCGGCGG CA - #ACATGGCG         480                                                                           - TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TG - #ACTCCCAT         540                                                                           - GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC AC - #CTGTCCTG         600                                                                           - CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GA - #CCAAGGCA         660                                                                           - CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC AC - #GGGGACAA         720                                                                           - CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CC - #GTCTCCTC         780                                                                           - CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGGGCAGGA CCACAGCTCA CA - #AGGATCCC         840                                                                           - AATGCCATCT TCCTGAGCTT CCAACACCTG CTCCGAGGAA AGGTGCGTTT CC - #TGATGCTT         900                                                                           #            927   TCTG CGTCAGG                                                - (2) INFORMATION FOR SEQ ID NO:81:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 936 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:                                 - TCCCCAGCTC CACCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TG - #ACTCCCAT          60                                                                           - GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC AC - #CTGTCCTG         120                                                                           - CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GA - #CCAAGGCA         180                                                                           - CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC AC - #GGGGACAA         240                                                                           - CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CC - #GTCTCCTC         300                                                                           - CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GA - #CCACAGCT         360                                                                           - CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AA - #AGGTGCGT         420                                                                           - TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTCGGCAA CA - #TGGCGTCT         480                                                                           - CCCGCTCCGC CTGCTTGTGA CCTCCGAGTC CTCAGTAAAC TGCTTCGTGA CT - #CCCATGTC         540                                                                           - CTTCACAGCA GACTGAGCCA GTGCCCAGAG GTTCACCCTT TGCCTACACC TG - #TCCTGCTG         600                                                                           - CCTGCTGTGG ACTTTAGCTT GGGAGAATGG AAAACCCAGA TGGAGGAGAC CA - #AGGCACAG         660                                                                           - GACATTCTGG GAGCAGTGAC CCTTCTGCTG GAGGGAGTGA TGGCAGCACG GG - #GACAACTG         720                                                                           - GGACCCACTT GCCTCTCATC CCTCCTGGGG CAGCTTTCTG GACAGGTCCG TC - #TCCTCCTT         780                                                                           - GGGGCCCTGC AGAGCCTCCT TGGAACCCAG CTTCCTCCAC AGGGCAGGAC CA - #CAGCTCAC         840                                                                           - AAGGATCCCA ATGCCATCTT CCTGAGCTTC CAACACCTGC TCCGAGGAAA GG - #TGCGTTTC         900                                                                           #      936         GGTC CACCCTCTGC GTCAGG                                      - (2) INFORMATION FOR SEQ ID NO:82:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 939 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:                                 - TCCCCAGCTC CACCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TG - #ACTCCCAT          60                                                                           - GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC AC - #CTGTCCTG         120                                                                           - CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GA - #CCAAGGCA         180                                                                           - CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC AC - #GGGGACAA         240                                                                           - CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CC - #GTCTCCTC         300                                                                           - CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GA - #CCACAGCT         360                                                                           - CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AA - #AGGTGCGT         420                                                                           - TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTCGGCGG CA - #ACATGGCG         480                                                                           - TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TG - #ACTCCCAT         540                                                                           - GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC AC - #CTGTCCTG         600                                                                           - CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GA - #CCAAGGCA         660                                                                           - CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC AC - #GGGGACAA         720                                                                           - CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CC - #GTCTCCTC         780                                                                           - CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GA - #CCACAGCT         840                                                                           - CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AA - #AGGTGCGT         900                                                                           #   939            GAGG GTCCACCCTC TGCGTCAGG                                   - (2) INFORMATION FOR SEQ ID NO:83:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 948 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:                                 - TCCCCAGCGC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TG - #ACTCCCAT          60                                                                           - GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC AC - #CTGTCCTG         120                                                                           - CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GA - #CCAAGGCA         180                                                                           - CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC AC - #GGGGACAA         240                                                                           - CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CC - #GTCTCCTC         300                                                                           - CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GA - #CCACAGCT         360                                                                           - CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AA - #AGGTGCGT         420                                                                           - TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTCGGCGG CA - #ACGGCGGC         480                                                                           - AACATGGCGT CCCCAGCGCC GCCTGCTTGT GACCTCCGAG TCCTCAGTAA AC - #TGCTTCGT         540                                                                           - GACTCCCATG TCCTTCACAG CAGACTGAGC CAGTGCCCAG AGGTTCACCC TT - #TGCCTACA         600                                                                           - CCTGTCCTGC TGCCTGCTGT GGACTTTAGC TTGGGAGAAT GGAAAACCCA GA - #TGGAGGAG         660                                                                           - ACCAAGGCAC AGGACATTCT GGGAGCAGTG ACCCTTCTGC TGGAGGGAGT GA - #TGGCAGCA         720                                                                           - CGGGGACAAC TGGGACCCAC TTGCCTCTCA TCCCTCCTGG GGCAGCTTTC TG - #GACAGGTC         780                                                                           - CGTCTCCTCC TTGGGGCCCT GCAGAGCCTC CTTGGAACCC AGCTTCCTCC AC - #AGGGCAGG         840                                                                           - ACCACAGCTC ACAAGGATCC CAATGCCATC TTCCTGAGCT TCCAACACCT GC - #TCCGAGGA         900                                                                           #               948TGCT TGTAGGAGGG TCCACCCTCT GCGTCAGG                         - (2) INFORMATION FOR SEQ ID NO:84:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 688 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:                                 - CATGGCTAAC TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA GA - #CCACCTGC          60                                                                           - ACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC TCTATCCTGA TG - #GACCGAAA         120                                                                           - CCTTCGACTT CCAAACCTGG AGAGCTTCGT AAGGGCTGTC AAGAACTTAG AA - #AATGCATC         180                                                                           - AGGTATTGAG GCAATTCTTC GTAATCTCCA ACCATGTCTG CCCTCTGCCA CG - #GCCGCACC         240                                                                           - CTCTCGACAT CCAATCATCA TCAAGGCAGG TGACTGGCAA GAATTCCGGG AA - #AAACTGAC         300                                                                           - GTTCTATCTG GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT CT - #AACTGCTC         360                                                                           - TATAATGATC GATGAAATTA TACATCACTT AAAGAGACCA CCTGCACCTT TG - #CTGGACCC         420                                                                           - GAACAACCTC AATGACGAAG ACGTCTCTAT CCTGATGGAC CGAAACCTTC GA - #CTTCCAAA         480                                                                           - CCTGGAGAGC TTCGTAAGGG CTGTCAAGAA CTTAGAAAAT GCATCAGGTA TT - #GAGGCAAT         540                                                                           - TCTTCGTAAT CTCCAACCAT GTCTGCCCTC TGCCACGGCC GCACCCTCTC GA - #CATCCAAT         600                                                                           - CATCATCAAG GCAGGTGACT GGCAAGAATT CCGGGAAAAA CTGACGTTCT AT - #CTGGTTAC         660                                                                           #            688   GAAC AACAGTAC                                               - (2) INFORMATION FOR SEQ ID NO:85:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 712 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "SYNTHETIC"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:                                 - CATGGCTAAC TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA GA - #CCACCTGC          60                                                                           - ACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC TCTATCCTGA TG - #GACCGAAA         120                                                                           - CCTTCGACTT CCAAACCTGG AGAGCTTCGT AAGGGCTGTC AAGAACTTAG AA - #AATGCATC         180                                                                           - AGGTATTGAG GCAATTCTTC GTAATCTCCA ACCATGTCTG CCCTCTGCCA CG - #GCCGCACC         240                                                                           - CTCTCGACAT CCAATCATCA TCAAGGCAGG TGACTGGCAA GAATTCCGGG AA - #AAACTGAC         300                                                                           - GTTCTATCTG GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT CT - #GGCGGTGG         360                                                                           - CAGCGGCGGC GGTTCTAACT GCTCTATAAT GATCGATGAA ATTATACATC AC - #TTAAAGAG         420                                                                           - ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CT - #ATCCTGAT         480                                                                           - GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AG - #AACTTAGA         540                                                                           - AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CC - #TCTGCCAC         600                                                                           - GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AA - #TTCCGGGA         660                                                                           - AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT AC - #                 712                                                                           - (2) INFORMATION FOR SEQ ID NO:86:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 975 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:                                 - ATGGCTCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC          60                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         120                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         180                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         240                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGG GTGGTGGCTC TA - #ACTGCTCT         300                                                                           - ATAATGATCG ATGAAATTAT ACATCACTTA AAGAGACCAC CTGCACCTTT GT - #ACGTAGAG         360                                                                           - GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CC - #CGTCTCCT         420                                                                           - CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGGCTACCC AGGGTGCCAT GC - #CGGCCTTC         480                                                                           - GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GC - #AGAGCTTC         540                                                                           - CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CT - #CTGGCGGC         600                                                                           - TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CG - #ATGGCGCA         660                                                                           - GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GC - #TGGTGCTG         720                                                                           - CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CC - #AGGCCCTG         780                                                                           - CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GG - #GGCTCCTG         840                                                                           - CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GC - #AGCTGGAC         900                                                                           - GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GG - #CCCCTGCC         960                                                                           #   975                                                                        - (2) INFORMATION FOR SEQ ID NO:87:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 975 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:                                 - ATGGCTCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC          60                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         120                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         180                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         240                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGG GTGGTGGCTC TA - #ACTGCTCT         300                                                                           - ATAATGATCG ATGAAATTAT ACATCACTTA AAGAGACCAC CTGCACCTTT GT - #ACGTAGAG         360                                                                           - GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CC - #CGTCTCCT         420                                                                           - CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGGCTACCC AGGGTGCCAT GC - #CGGCCTTC         480                                                                           - GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GC - #AGAGCTTC         540                                                                           - CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CT - #CTGGCGGC         600                                                                           - TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CG - #ATGGCGCA         660                                                                           - GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GC - #TGGTGCTG         720                                                                           - CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CC - #AGGCCCTG         780                                                                           - CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GG - #GGCTCCTG         840                                                                           - CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GC - #AGCTGGAC         900                                                                           - GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GG - #CCCCTGCC         960                                                                           #   975                                                                        - (2) INFORMATION FOR SEQ ID NO:88:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 975 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:                                 - ATGGCTGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AG - #AATTCCGG          60                                                                           - GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GG - #GTGGTGGC         120                                                                           - TCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT         180                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         240                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         300                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CT - #ACGTAGAG         360                                                                           - GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CC - #CGTCTCCT         420                                                                           - CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGGCTACCC AGGGTGCCAT GC - #CGGCCTTC         480                                                                           - GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GC - #AGAGCTTC         540                                                                           - CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CT - #CTGGCGGC         600                                                                           - TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CG - #ATGGCGCA         660                                                                           - GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GC - #TGGTGCTG         720                                                                           - CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CC - #AGGCCCTG         780                                                                           - CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GG - #GGCTCCTG         840                                                                           - CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GC - #AGCTGGAC         900                                                                           - GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GG - #CCCCTGCC         960                                                                           #   975                                                                        - (2) INFORMATION FOR SEQ ID NO:89:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 975 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:                                 - ATGGCTGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GG - #TTACCCTT          60                                                                           - GAGCAAGCGC AGGAACAACA GGGTGGTGGC TCTAACTGCT CTATAATGAT CG - #ATGAAATT         120                                                                           - ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CA - #ATGACGAA         180                                                                           - GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CT - #TCGTAAGG         240                                                                           - GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TC - #TCCAACCA         300                                                                           - TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GT - #ACGTAGAG         360                                                                           - GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CC - #CGTCTCCT         420                                                                           - CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGGCTACCC AGGGTGCCAT GC - #CGGCCTTC         480                                                                           - GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GC - #AGAGCTTC         540                                                                           - CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CT - #CTGGCGGC         600                                                                           - TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CG - #ATGGCGCA         660                                                                           - GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GC - #TGGTGCTG         720                                                                           - CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CC - #AGGCCCTG         780                                                                           - CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GG - #GGCTCCTG         840                                                                           - CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GC - #AGCTGGAC         900                                                                           - GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GG - #CCCCTGCC         960                                                                           #   975                                                                        - (2) INFORMATION FOR SEQ ID NO:90:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 999 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:                                 - ATGGCTCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC          60                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         120                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         180                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         240                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGG GTGGTGGCTC TG - #GCGGTGGC         300                                                                           - AGCGGCGGCG GTTCTAACTG CTCTATAATG ATCGATGAAA TTATACATCA CT - #TAAAGAGA         360                                                                           - CCACCTGCAC CTTTGTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GT - #CTGGTCCA         420                                                                           - ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AA - #ACATGGCT         480                                                                           - ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AG - #GGGTCCTG         540                                                                           - GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CC - #ACCTTGCG         600                                                                           - CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AG - #AGCAAGTG         660                                                                           - AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CT - #ACAAGCTG         720                                                                           - TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GG - #CTCCCCTG         780                                                                           - AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CC - #ATAGCGGC         840                                                                           - CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GT - #TGGGTCCC         900                                                                           - ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GC - #AGCAGATG         960                                                                           #   999            CCCC TGCCCTGCAG CCCTAATAA                                   - (2) INFORMATION FOR SEQ ID NO:91:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 999 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:                                 - ATGGCTAATG CATCAGGTAT TGAGGCAATT CTTCGTAATC TCCAACCATG TC - #TGCCCTCT          60                                                                           - GCCACGGCCG CACCCTCTCG ACATCCAATC ATCATCAAGG CAGGTGACTG GC - #AAGAATTC         120                                                                           - CGGGAAAAAC TGACGTTCTA TCTGGTTACC CTTGAGCAAG CGCAGGAACA AC - #AGGGTGGT         180                                                                           - GGCTCTGGCG GTGGCAGCGG CGGCGGTTCT AACTGCTCTA TAATGATCGA TG - #AAATTATA         240                                                                           - CATCACTTAA AGAGACCACC TGCACCTTTG CTGGACCCGA ACAACCTCAA TG - #ACGAAGAC         300                                                                           - GTCTCTATCC TGATGGACCG AAACCTTCGA CTTCCAAACC TGGAGAGCTT CG - #TAAGGGCT         360                                                                           - GTCAAGAACT TAGAATACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GT - #CTGGTCCA         420                                                                           - ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AA - #ACATGGCT         480                                                                           - ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AG - #GGGTCCTG         540                                                                           - GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CC - #ACCTTGCG         600                                                                           - CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AG - #AGCAAGTG         660                                                                           - AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CT - #ACAAGCTG         720                                                                           - TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GG - #CTCCCCTG         780                                                                           - AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CC - #ATAGCGGC         840                                                                           - CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GT - #TGGGTCCC         900                                                                           - ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GC - #AGCAGATG         960                                                                           #   999            CCCC TGCCCTGCAG CCCTAATAA                                   - (2) INFORMATION FOR SEQ ID NO:92:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 999 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:                                 - ATGGCTGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AG - #AATTCCGG          60                                                                           - GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GG - #GTGGTGGC         120                                                                           - TCTGGCGGTG GCAGCGGCGG CGGTTCTAAC TGCTCTATAA TGATCGATGA AA - #TTATACAT         180                                                                           - CACTTAAAGA GACCACCTGC ACCTTTGCTG GACCCGAACA ACCTCAATGA CG - #AAGACGTC         240                                                                           - TCTATCCTGA TGGACCGAAA CCTTCGACTT CCAAACCTGG AGAGCTTCGT AA - #GGGCTGTC         300                                                                           - AAGAACTTAG AAAATGCATC AGGTATTGAG GCAATTCTTC GTAATCTCCA AC - #CATGTCTG         360                                                                           - CCCTCTGCCA CGGCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GT - #CTGGTCCA         420                                                                           - ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AA - #ACATGGCT         480                                                                           - ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AG - #GGGTCCTG         540                                                                           - GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CC - #ACCTTGCG         600                                                                           - CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AG - #AGCAAGTG         660                                                                           - AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CT - #ACAAGCTG         720                                                                           - TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GG - #CTCCCCTG         780                                                                           - AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CC - #ATAGCGGC         840                                                                           - CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GT - #TGGGTCCC         900                                                                           - ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GC - #AGCAGATG         960                                                                           #   999            CCCC TGCCCTGCAG CCCTAATAA                                   - (2) INFORMATION FOR SEQ ID NO:93:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 999 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:                                 - ATGGCTGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GG - #TTACCCTT          60                                                                           - GAGCAAGCGC AGGAACAACA GGGTGGTGGC TCTGGCGGTG GCAGCGGCGG CG - #GTTCTAAC         120                                                                           - TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA GACCACCTGC AC - #CTTTGCTG         180                                                                           - GACCCGAACA ACCTCAATGA CGAAGACGTC TCTATCCTGA TGGACCGAAA CC - #TTCGACTT         240                                                                           - CCAAACCTGG AGAGCTTCGT AAGGGCTGTC AAGAACTTAG AAAATGCATC AG - #GTATTGAG         300                                                                           - GCAATTCTTC GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCACC CT - #CTCGACAT         360                                                                           - CCAATCATCA TCAAGTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GT - #CTGGTCCA         420                                                                           - ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AA - #ACATGGCT         480                                                                           - ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AG - #GGGTCCTG         540                                                                           - GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CC - #ACCTTGCG         600                                                                           - CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AG - #AGCAAGTG         660                                                                           - AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CT - #ACAAGCTG         720                                                                           - TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GG - #CTCCCCTG         780                                                                           - AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CC - #ATAGCGGC         840                                                                           - CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GT - #TGGGTCCC         900                                                                           - ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GC - #AGCAGATG         960                                                                           #   999            CCCC TGCCCTGCAG CCCTAATAA                                   - (2) INFORMATION FOR SEQ ID NO:94:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 918 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:                                 - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT ACAAGCTGTG CC - #ACCCCGAG         420                                                                           - GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CT - #CCTGCCCC         480                                                                           - AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TT - #TCCTCTAC         540                                                                           - CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CT - #TGGACACA         600                                                                           - CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AG - #AACTGGGA         660                                                                           - ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTC TG - #CTTTCCAG         720                                                                           - CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGA GG - #TGTCGTAC         780                                                                           - CGCGTTCTAC GCCACCTTGC GCAGCCCTCT GGCGGCTCTG GCGGCTCTCA GA - #GCTTCCTG         840                                                                           - CTCAAGTCTT TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT CC - #AGGAGAAG         900                                                                           # 918              AA                                                          - (2) INFORMATION FOR SEQ ID NO:95:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 963 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:                                 - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GGCTTACAAG CTGTGCCACC CCGAGGAGCT GG - #TGCTGCTC         480                                                                           - GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GG - #CCCTGCAG         540                                                                           - CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GC - #TCCTGCAG         600                                                                           - GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GC - #TGGACGTC         660                                                                           - GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CC - #CTGCCCTG         720                                                                           - CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GG - #CAGGAGGG         780                                                                           - GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TC - #TACGCCAC         840                                                                           - CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC TCTCAGAGCT TCCTGCTCAA GT - #CTTTAGAG         900                                                                           - CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TG - #CCACCTAA         960                                                                           #            963                                                               - (2) INFORMATION FOR SEQ ID NO:96:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 918 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:                                 - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTC CCGAGTTGGG TC - #CCACCTTG         420                                                                           - GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GA - #TGGAAGAA         480                                                                           - CTGGGAATGG CCCCTGCCCT GCAGCCCACC CAGGGTGCCA TGCCGGCCTT CG - #CCTCTGCT         540                                                                           - TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CC - #TGGAGGTG         600                                                                           - TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCTCTGGCG GCTCTGGCGG CT - #CTCAGAGC         660                                                                           - TTCCTGCTCA AGTCTTTAGA GCAAGTGAGA AAGATCCAGG GCGATGGCGC AG - #CGCTCCAG         720                                                                           - GAGAAGCTGT GTGCCACCTA CAAGCTGTGC CACCCCGAGG AGCTGGTGCT GC - #TCGGACAC         780                                                                           - TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GC - #AGCTGGCA         840                                                                           - GGCTGCTTGA GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GC - #AGGCCCTG         900                                                                           # 918              AA                                                          - (2) INFORMATION FOR SEQ ID NO:97:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 963 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:                                 - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GGCTCCCGAG TTGGGTCCCA CCTTGGACAC AC - #TGCAGCTG         480                                                                           - GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AA - #TGGCCCCT         540                                                                           - GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GC - #GCCGGGCA         600                                                                           - GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CC - #GCGTTCTA         660                                                                           - CGCCACCTTG CGCAGCCCTC TGGCGGCTCT GGCGGCTCTC AGAGCTTCCT GC - #TCAAGTCT         720                                                                           - TTAGAGCAAG TGAGAAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GC - #TGTGTGCC         780                                                                           - ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCT GG - #GCATCCCC         840                                                                           - TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CT - #TGAGCCAA         900                                                                           - CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GA - #TATCCTAA         960                                                                           #            963                                                               - (2) INFORMATION FOR SEQ ID NO:98:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 918 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:                                 - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA TGGCCCCTGC CC - #TGCAGCCC         420                                                                           - ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AG - #GGGTCCTG         480                                                                           - GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CC - #ACCTTGCG         540                                                                           - CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AG - #AGCAAGTG         600                                                                           - AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CT - #ACAAGCTG         660                                                                           - TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GG - #CTCCCCTG         720                                                                           - AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CC - #ATAGCGGC         780                                                                           - CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GT - #TGGGTCCC         840                                                                           - ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GC - #AGCAGATG         900                                                                           # 918              AA                                                          - (2) INFORMATION FOR SEQ ID NO:99:                                            -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 963 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:                                 - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GGCTATGGCC CCTGCCCTGC AGCCCACCCA GG - #GTGCCATG         480                                                                           - CCGGCCTTCG CCTCTGCTTT CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TA - #GCCATCTG         540                                                                           - CAGAGCTTCC TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CT - #CTGGCGGC         600                                                                           - TCTGGCGGCT CTCAGAGCTT CCTGCTCAAG TCTTTAGAGC AAGTGAGAAA GA - #TCCAGGGC         660                                                                           - GATGGCGCAG CGCTCCAGGA GAAGCTGTGT GCCACCTACA AGCTGTGCCA CC - #CCGAGGAG         720                                                                           - CTGGTGCTGC TCGGACACTC TCTGGGCATC CCCTGGGCTC CCCTGAGCTC CT - #GCCCCAGC         780                                                                           - CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC CAACTCCATA GCGGCCTTTT CC - #TCTACCAG         840                                                                           - GGGCTCCTGC AGGCCCTGGA AGGGATATCC CCCGAGTTGG GTCCCACCTT GG - #ACACACTG         900                                                                           - CAGCTGGACG TCGCCGACTT TGCCACCACC ATCTGGCAGC AGATGGAAGA AC - #TGGGATAA         960                                                                           #            963                                                               - (2) INFORMATION FOR SEQ ID NO:100:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 918 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA CCCAGGGTGC CA - #TGCCGGCC         420                                                                           - TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TC - #TGCAGAGC         480                                                                           - TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTCTGG CG - #GCTCTGGC         540                                                                           - GGCTCTCAGA GCTTCCTGCT CAAGTCTTTA GAGCAAGTGA GAAAGATCCA GG - #GCGATGGC         600                                                                           - GCAGCGCTCC AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGA GG - #AGCTGGTG         660                                                                           - CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC CA - #GCCAGGCC         720                                                                           - CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTA CC - #AGGGGCTC         780                                                                           - CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA CCTTGGACAC AC - #TGCAGCTG         840                                                                           - GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AA - #TGGCCCCT         900                                                                           # 918              AA                                                          - (2) INFORMATION FOR SEQ ID NO:101:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 963 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CT - #CTGCTTTC         480                                                                           - CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GG - #AGGTGTCG         540                                                                           - TACCGCGTTC TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TC - #AGAGCTTC         600                                                                           - CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC GC - #TCCAGGAG         660                                                                           - AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CG - #GACACTCT         720                                                                           - CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA GC - #TGGCAGGC         780                                                                           - TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GG - #CCCTGGAA         840                                                                           - GGGATATCCC CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CG - #CCGACTTT         900                                                                           - GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GC - #AGCCCTAA         960                                                                           #            963                                                               - (2) INFORMATION FOR SEQ ID NO:102:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 918 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT CTGCTTTCCA GC - #GCCGGGCA         420                                                                           - GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CC - #GCGTTCTA         480                                                                           - CGCCACCTTG CGCAGCCCTC TGGCGGCTCT GGCGGCTCTC AGAGCTTCCT GC - #TCAAGTCT         540                                                                           - TTAGAGCAAG TGAGAAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GC - #TGTGTGCC         600                                                                           - ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCT GG - #GCATCCCC         660                                                                           - TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CT - #TGAGCCAA         720                                                                           - CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GA - #TATCCCCC         780                                                                           - GAGTTGGGTC CCACCTTGGA CACACTGCAG CTGGACGTCG CCGACTTTGC CA - #CCACCATC         840                                                                           - TGGCAGCAGA TGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCA GG - #GTGCCATG         900                                                                           # 918              AA                                                          - (2) INFORMATION FOR SEQ ID NO:103:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 963 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "SYNTHETIC"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GGCTTCTGCT TTCCAGCGCC GGGCAGGAGG GG - #TCCTGGTT         480                                                                           - GCTAGCCATC TGCAGAGCTT CCTGGAGGTG TCGTACCGCG TTCTACGCCA CC - #TTGCGCAG         540                                                                           - CCCTCTGGCG GCTCTGGCGG CTCTCAGAGC TTCCTGCTCA AGTCTTTAGA GC - #AAGTGAGA         600                                                                           - AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CA - #AGCTGTGC         660                                                                           - CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TC - #CCCTGAGC         720                                                                           - TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA TA - #GCGGCCTT         780                                                                           - TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GG - #GTCCCACC         840                                                                           - TTGGACACAC TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA GC - #AGATGGAA         900                                                                           - GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CT - #TCGCCTAA         960                                                                           #            963                                                               - (2) INFORMATION FOR SEQ ID NO:104:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 927 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT ACAAGCTGTG CC - #ACCCCGAG         420                                                                           - GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CT - #CCTGCCCC         480                                                                           - AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TT - #TCCTCTAC         540                                                                           - CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CT - #TGGACACA         600                                                                           - CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AG - #AACTGGGA         660                                                                           - ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTC TG - #CTTTCCAG         720                                                                           - CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGA GG - #TGTCGTAC         780                                                                           - CGCGTTCTAC GCCACCTTGC GCAGCCCACA CCATTGGGCC CTGCCAGCTC CC - #TGCCCCAG         840                                                                           - AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGAAAGATCC AGGGCGATGG CG - #CAGCGCTC         900                                                                           #            927   CCAC CTAATAA                                                - (2) INFORMATION FOR SEQ ID NO:105:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 972 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GGCTTACAAG CTGTGCCACC CCGAGGAGCT GG - #TGCTGCTC         480                                                                           - GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GG - #CCCTGCAG         540                                                                           - CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GC - #TCCTGCAG         600                                                                           - GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GC - #TGGACGTC         660                                                                           - GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CC - #CTGCCCTG         720                                                                           - CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GG - #CAGGAGGG         780                                                                           - GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TC - #TACGCCAC         840                                                                           - CTTGCGCAGC CCACACCATT GGGCCCTGCC AGCTCCCTGC CCCAGAGCTT CC - #TGCTCAAG         900                                                                           - TCTTTAGAGC AAGTGAGAAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA GA - #AGCTGTGT         960                                                                           #      972                                                                     - (2) INFORMATION FOR SEQ ID NO:106:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 927 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTC CCGAGTTGGG TC - #CCACCTTG         420                                                                           - GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GA - #TGGAAGAA         480                                                                           - CTGGGAATGG CCCCTGCCCT GCAGCCCACC CAGGGTGCCA TGCCGGCCTT CG - #CCTCTGCT         540                                                                           - TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CC - #TGGAGGTG         600                                                                           - TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCACACCAT TGGGCCCTGC CA - #GCTCCCTG         660                                                                           - CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CG - #ATGGCGCA         720                                                                           - GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GC - #TGGTGCTG         780                                                                           - CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CC - #AGGCCCTG         840                                                                           - CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GG - #GGCTCCTG         900                                                                           #            927   TATC CTAATAA                                                - (2) INFORMATION FOR SEQ ID NO:107:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 972 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GGCTCCCGAG TTGGGTCCCA CCTTGGACAC AC - #TGCAGCTG         480                                                                           - GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AA - #TGGCCCCT         540                                                                           - GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GC - #GCCGGGCA         600                                                                           - GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CC - #GCGTTCTA         660                                                                           - CGCCACCTTG CGCAGCCCAC ACCATTGGGC CCTGCCAGCT CCCTGCCCCA GA - #GCTTCCTG         720                                                                           - CTCAAGTCTT TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT CC - #AGGAGAAG         780                                                                           - CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG AC - #ACTCTCTG         840                                                                           - GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GG - #CAGGCTGC         900                                                                           - TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC TCCTGCAGGC CC - #TGGAAGGG         960                                                                           #      972                                                                     - (2) INFORMATION FOR SEQ ID NO:108:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 927 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA TGGCCCCTGC CC - #TGCAGCCC         420                                                                           - ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AG - #GGGTCCTG         480                                                                           - GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CC - #ACCTTGCG         540                                                                           - CAGCCCACAC CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CA - #AGTCTTTA         600                                                                           - GAGCAAGTGA GAAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GT - #GTGCCACC         660                                                                           - TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CA - #TCCCCTGG         720                                                                           - GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GA - #GCCAACTC         780                                                                           - CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT AT - #CCCCCGAG         840                                                                           - TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CA - #CCATCTGG         900                                                                           #            927   TGGG ATAATAA                                                - (2) INFORMATION FOR SEQ ID NO:109:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 972 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "DNA (synthetic)"PTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GGCTATGGCC CCTGCCCTGC AGCCCACCCA GG - #GTGCCATG         480                                                                           - CCGGCCTTCG CCTCTGCTTT CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TA - #GCCATCTG         540                                                                           - CAGAGCTTCC TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CA - #CACCATTG         600                                                                           - GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA AG - #TGAGAAAG         660                                                                           - ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAA GC - #TGTGCCAC         720                                                                           - CCCGAGGAGC TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CC - #TGAGCTCC         780                                                                           - TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG CG - #GCCTTTTC         840                                                                           - CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG TC - #CCACCTTG         900                                                                           - GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GA - #TGGAAGAA         960                                                                           #      972                                                                     - (2) INFORMATION FOR SEQ ID NO:110:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 927 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA CCCAGGGTGC CA - #TGCCGGCC         420                                                                           - TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TC - #TGCAGAGC         480                                                                           - TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCACACC AT - #TGGGCCCT         540                                                                           - GCCAGCTCCC TGCCCCAGAG CTTCCTGCTC AAGTCTTTAG AGCAAGTGAG AA - #AGATCCAG         600                                                                           - GGCGATGGCG CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG CC - #ACCCCGAG         660                                                                           - GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CT - #CCTGCCCC         720                                                                           - AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TT - #TCCTCTAC         780                                                                           - CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CT - #TGGACACA         840                                                                           - CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AG - #AACTGGGA         900                                                                           #            927   AGCC CTAATAA                                                - (2) INFORMATION FOR SEQ ID NO:111:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 972 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CT - #CTGCTTTC         480                                                                           - CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GG - #AGGTGTCG         540                                                                           - TACCGCGTTC TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CT - #CCCTGCCC         600                                                                           - CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA TG - #GCGCAGCG         660                                                                           - CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GG - #TGCTGCTC         720                                                                           - GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GG - #CCCTGCAG         780                                                                           - CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GC - #TCCTGCAG         840                                                                           - GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GC - #TGGACGTC         900                                                                           - GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CC - #CTGCCCTG         960                                                                           #      972                                                                     - (2) INFORMATION FOR SEQ ID NO:112:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 927 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT CTGCTTTCCA GC - #GCCGGGCA         420                                                                           - GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CC - #GCGTTCTA         480                                                                           - CGCCACCTTG CGCAGCCCAC ACCATTGGGC CCTGCCAGCT CCCTGCCCCA GA - #GCTTCCTG         540                                                                           - CTCAAGTCTT TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT CC - #AGGAGAAG         600                                                                           - CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG AC - #ACTCTCTG         660                                                                           - GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GG - #CAGGCTGC         720                                                                           - TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC TCCTGCAGGC CC - #TGGAAGGG         780                                                                           - ATATCCCCCG AGTTGGGTCC CACCTTGGAC ACACTGCAGC TGGACGTCGC CG - #ACTTTGCC         840                                                                           - ACCACCATCT GGCAGCAGAT GGAAGAACTG GGAATGGCCC CTGCCCTGCA GC - #CCACCCAG         900                                                                           #            927   TCGC CTAATAA                                                - (2) INFORMATION FOR SEQ ID NO:113:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 972 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ACCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GGCTTCTGCT TTCCAGCGCC GGGCAGGAGG GG - #TCCTGGTT         480                                                                           - GCTAGCCATC TGCAGAGCTT CCTGGAGGTG TCGTACCGCG TTCTACGCCA CC - #TTGCGCAG         540                                                                           - CCCACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GT - #CTTTAGAG         600                                                                           - CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TG - #CCACCTAC         660                                                                           - AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CC - #CCTGGGCT         720                                                                           - CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CC - #AACTCCAT         780                                                                           - AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CC - #CCGAGTTG         840                                                                           - GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CA - #TCTGGCAG         900                                                                           - CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CA - #TGCCGGCC         960                                                                           #      972                                                                     - (2) INFORMATION FOR SEQ ID NO:114:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 963 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:                                - ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GC - #CACCGCTG          60                                                                           - CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTAAT GG - #ACAATAAC         120                                                                           - CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA AGTCTCTGCA GA - #ATGCATCA         180                                                                           - GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CGCTAGCCAC GG - #CCGCACCC         240                                                                           - ACGCGACATC CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TA - #AACTGACC         300                                                                           - TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CT - #CTGCTTTC         480                                                                           - CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GG - #AGGTGTCG         540                                                                           - TACCGCGTTC TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TC - #AGAGCTTC         600                                                                           - CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC GC - #TCCAGGAG         660                                                                           - AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CG - #GACACTCT         720                                                                           - CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA GC - #TGGCAGGC         780                                                                           - TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GG - #CCCTGGAA         840                                                                           - GGGATATCCC CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CG - #CCGACTTT         900                                                                           - GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GC - #AGCCCTAA         960                                                                           #            963                                                               - (2) INFORMATION FOR SEQ ID NO:115:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 972 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:                                - ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GC - #CACCGCTG          60                                                                           - CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTGAT GG - #AAAATAAC         120                                                                           - CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA AGTCTCTGCA GA - #ATGCATCA         180                                                                           - GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CCCTGGCCAC GG - #CCGCACCC         240                                                                           - ACGCGACATC CAATCATCAT CCGTGACGGT GACTGGAATG AATTCCGTCG TA - #AACTGACC         300                                                                           - TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CT - #CTGCTTTC         480                                                                           - CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GG - #AGGTGTCG         540                                                                           - TACCGCGTTC TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CT - #CCCTGCCC         600                                                                           - CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA TG - #GCGCAGCG         660                                                                           - CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GG - #TGCTGCTC         720                                                                           - GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GG - #CCCTGCAG         780                                                                           - CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GC - #TCCTGCAG         840                                                                           - GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GC - #TGGACGTC         900                                                                           - GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CC - #CTGCCCTG         960                                                                           #      972                                                                     - (2) INFORMATION FOR SEQ ID NO:116:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 963 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:                                - ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GC - #CACCGCTG          60                                                                           - CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTGAT GG - #AAAATAAC         120                                                                           - CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA AGTCTCTGCA GA - #ATGCATCA         180                                                                           - GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CCCTGGCCAC GG - #CCGCACCC         240                                                                           - ACGCGACATC CAATCATCAT CCGTGACGGT GACTGGAATG AATTCCGTCG TA - #AACTGACC         300                                                                           - TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CT - #CTGCTTTC         480                                                                           - CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GG - #AGGTGTCG         540                                                                           - TACCGCGTTC TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TC - #AGAGCTTC         600                                                                           - CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC GC - #TCCAGGAG         660                                                                           - AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CG - #GACACTCT         720                                                                           - CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA GC - #TGGCAGGC         780                                                                           - TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GG - #CCCTGGAA         840                                                                           - GGGATATCCC CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CG - #CCGACTTT         900                                                                           - GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GC - #AGCCCTAA         960                                                                           #            963                                                               - (2) INFORMATION FOR SEQ ID NO:117:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 972 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:                                - ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GC - #CACCGCTG          60                                                                           - CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTAAT GG - #ACAATAAC         120                                                                           - CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA AGTCTCTGCA GA - #ATGCATCA         180                                                                           - GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CGCTAGCCAC GG - #CCGCACCC         240                                                                           - ACGCGACATC CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TA - #AACTGACC         300                                                                           - TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CT - #CTGCTTTC         480                                                                           - CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GG - #AGGTGTCG         540                                                                           - TACCGCGTTC TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CT - #CCCTGCCC         600                                                                           - CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA TG - #GCGCAGCG         660                                                                           - CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GG - #TGCTGCTC         720                                                                           - GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GG - #CCCTGCAG         780                                                                           - CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GC - #TCCTGCAG         840                                                                           - GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GC - #TGGACGTC         900                                                                           - GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CC - #CTGCCCTG         960                                                                           #      972                                                                     - (2) INFORMATION FOR SEQ ID NO:118:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 918 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGA GGTTCACCCT TTGCCTACAC CTGTCCTGCT GC - #CTGCTGTG         480                                                                           - GACTTTAGCT TGGGAGAATG GAAAACCCAG ATGGAGGAGA CCAAGGCACA GG - #ACATTCTG         540                                                                           - GGAGCAGTGA CCCTTCTGCT GGAGGGAGTG ATGGCAGCAC GGGGACAACT GG - #GACCCACT         600                                                                           - TGCCTCTCAT CCCTCCTGGG GCAGCTTTCT GGACAGGTCC GTCTCCTCCT TG - #GGGCCCTG         660                                                                           - CAGAGCCTCC TTGGAACCCA GCTTCCTCCA CAGGGCAGGA CCACAGCTCA CA - #AGGATCCC         720                                                                           - AATGCCATCT TCCTGAGCTT CCAACACCTG CTCCGAGGAA AGGTGCGTTT CC - #TGATGCTT         780                                                                           - GTAGGAGGGT CCACCCTCTG CGTCAGGGAA TTCGGCGGCA ACATGGCGTC TC - #CCGCTCCG         840                                                                           - CCTGCTTGTG ACCTCCGAGT CCTCAGTAAA CTGCTTCGTG ACTCCCATGT CC - #TTCACAGC         900                                                                           # 918              CA                                                          - (2) INFORMATION FOR SEQ ID NO:119:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 918 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGTT GCCTACACCT GTCCTGCTGC CTGCTGTGGA CT - #TTAGCTTG         480                                                                           - GGAGAATGGA AAACCCAGAT GGAGGAGACC AAGGCACAGG ACATTCTGGG AG - #CAGTGACC         540                                                                           - CTTCTGCTGG AGGGAGTGAT GGCAGCACGG GGACAACTGG GACCCACTTG CC - #TCTCATCC         600                                                                           - CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT CTCCTCCTTG GGGCCCTGCA GA - #GCCTCCTT         660                                                                           - GGAACCCAGC TTCCTCCACA GGGCAGGACC ACAGCTCACA AGGATCCCAA TG - #CCATCTTC         720                                                                           - CTGAGCTTCC AACACCTGCT CCGAGGAAAG GTGCGTTTCC TGATGCTTGT AG - #GAGGGTCC         780                                                                           - ACCCTCTGCG TCAGGGAATT CGGCGGCAAC ATGGCGTCTC CCGCTCCGCC TG - #CTTGTGAC         840                                                                           - CTCCGAGTCC TCAGTAAACT GCTTCGTGAC TCCCATGTCC TTCACAGCAG AC - #TGAGCCAG         900                                                                           # 918              CT                                                          - (2) INFORMATION FOR SEQ ID NO:120:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 918 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGT CCTGCTGCCT GCTGTGGACT TTAGCTTGGG AG - #AATGGAAA         480                                                                           - ACCCAGATGG AGGAGACCAA GGCACAGGAC ATTCTGGGAG CAGTGACCCT TC - #TGCTGGAG         540                                                                           - GGAGTGATGG CAGCACGGGG ACAACTGGGA CCCACTTGCC TCTCATCCCT CC - #TGGGGCAG         600                                                                           - CTTTCTGGAC AGGTCCGTCT CCTCCTTGGG GCCCTGCAGA GCCTCCTTGG AA - #CCCAGCTT         660                                                                           - CCTCCACAGG GCAGGACCAC AGCTCACAAG GATCCCAATG CCATCTTCCT GA - #GCTTCCAA         720                                                                           - CACCTGCTCC GAGGAAAGGT GCGTTTCCTG ATGCTTGTAG GAGGGTCCAC CC - #TCTGCGTC         780                                                                           - AGGGAATTCG GCGGCAACAT GGCGTCTCCC GCTCCGCCTG CTTGTGACCT CC - #GAGTCCTC         840                                                                           - AGTAAACTGC TTCGTGACTC CCATGTCCTT CACAGCAGAC TGAGCCAGTG CC - #CAGAGGTT         900                                                                           # 918              CT                                                          - (2) INFORMATION FOR SEQ ID NO:121:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 918 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CC - #AGATGGAG         480                                                                           - GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AG - #TGATGGCA         540                                                                           - GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TT - #CTGGACAG         600                                                                           - GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCC TC - #CACAGGGC         660                                                                           - AGGACCACAG CTCACAAGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CC - #TGCTCCGA         720                                                                           - GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GG - #AATTCGGC         780                                                                           - GGCAACATGG CGTCTCCCGC TCCGCCTGCT TGTGACCTCC GAGTCCTCAG TA - #AACTGCTT         840                                                                           - CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC CAGAGGTTCA CC - #CTTTGCCT         900                                                                           # 918              CT                                                          - (2) INFORMATION FOR SEQ ID NO:122:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 918 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGA CTTTAGCTTG GGAGAATGGA AAACCCAGAT GG - #AGGAGACC         480                                                                           - AAGGCACAGG ACATTCTGGG AGCAGTGACC CTTCTGCTGG AGGGAGTGAT GG - #CAGCACGG         540                                                                           - GGACAACTGG GACCCACTTG CCTCTCATCC CTCCTGGGGC AGCTTTCTGG AC - #AGGTCCGT         600                                                                           - CTCCTCCTTG GGGCCCTGCA GAGCCTCCTT GGAACCCAGC TTCCTCCACA GG - #GCAGGACC         660                                                                           - ACAGCTCACA AGGATCCCAA TGCCATCTTC CTGAGCTTCC AACACCTGCT CC - #GAGGAAAG         720                                                                           - GTGCGTTTCC TGATGCTTGT AGGAGGGTCC ACCCTCTGCG TCAGGGAATT CG - #GCGGCAAC         780                                                                           - ATGGCGTCTC CCGCTCCGCC TGCTTGTGAC CTCCGAGTCC TCAGTAAACT GC - #TTCGTGAC         840                                                                           - TCCCATGTCC TTCACAGCAG ACTGAGCCAG TGCCCAGAGG TTCACCCTTT GC - #CTACACCT         900                                                                           # 918              TG                                                          - (2) INFORMATION FOR SEQ ID NO:123:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 907 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCGGTTAC CCTTGAGCAA GCGCAGGAAC AACAGTACGT AGAGGGCGGT GG - #AGGCTCCC         360                                                                           - CGGGGAACCG TCTGGTCCAA TCTCTACTAT CAACCCGTCT CCTCCGTCTA AA - #GAATCTCA         420                                                                           - TAAACTCCAA ACATGGGAGA ATGGAAAACC CAGATGGAGG AGACCAAGGC AC - #AGGACATT         480                                                                           - CTGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA CT - #GGGACCCA         540                                                                           - CTTGCTCTCA TCCCTCCTGG GGCAGCTTTC TGGACAGGTC CGTCTCCTCC TT - #GGGGCCCT         600                                                                           - GCAGGCCTCC TTGGAACCCA GCTTCCTCCA CAGGGCAGGA CCACAGCTCA CA - #AGGATCCC         660                                                                           - AATGCATCTT CCTGAGCTTC CAACACCTGC TCCGAGGAAA GGTGCGTTTC CT - #GATGCTTG         720                                                                           - TAGGGGGTCC ACCCTCTGCG TCAGGGAATT CGGCGGCAAC ATGGCGTCTC CC - #GCTCCGCC         780                                                                           - TGCTGTGACC TCCGAGTCCT CAGTAAACTG CTTCGTGACT CCCATGTCCT TC - #ACAGCAGA         840                                                                           - CTGACCAGTG CCCAGAGGTT CACCCTTTGC CTACACCTGT CCTGCTGCCT GC - #TGTGGACT         900                                                                           #         907                                                                  - (2) INFORMATION FOR SEQ ID NO:124:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 918 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGG ACCCACTTGC CTCTCATCCC TCCTGGGGCA GC - #TTTCTGGA         480                                                                           - CAGGTCCGTC TCCTCCTTGG GGCCCTGCAG AGCCTCCTTG GAACCCAGCT TC - #CTCCACAG         540                                                                           - GGCAGGACCA CAGCTCACAA GGATCCCAAT GCCATCTTCC TGAGCTTCCA AC - #ACCTGCTC         600                                                                           - CGAGGAAAGG TGCGTTTCCT GATGCTTGTA GGAGGGTCCA CCCTCTGCGT CA - #GGGAATTC         660                                                                           - GGCGGCAACA TGGCGTCTCC CGCTCCGCCT GCTTGTGACC TCCGAGTCCT CA - #GTAAACTG         720                                                                           - CTTCGTGACT CCCATGTCCT TCACAGCAGA CTGAGCCAGT GCCCAGAGGT TC - #ACCCTTTG         780                                                                           - CCTACACCTG TCCTGCTGCC TGCTGTGGAC TTTAGCTTGG GAGAATGGAA AA - #CCCAGATG         840                                                                           - GAGGAGACCA AGGCACAGGA CATTCTGGGA GCAGTGACCC TTCTGCTGGA GG - #GAGTGATG         900                                                                           # 918              TG                                                          - (2) INFORMATION FOR SEQ ID NO:125:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 848 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AG - #CTCACAAG         480                                                                           - GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GC - #GTTTCCTG         540                                                                           - ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCGGCAACAT GG - #CGTCTCCC         600                                                                           - GCTCCGCCTG CTTGTGACCT CCGAGTCCTC AGTAAACTGC TTCGTGACTC CC - #ATGTCCTT         660                                                                           - CACAGCAGAC TGAGCCAGTG CCCAGAGGTT CACCCTTTGC CTACACCTGT CC - #TGCTGCCT         720                                                                           - GCTGTGGACT TTAGCTTGGG AGAATGGAAA ACCCAGATGG AGGAGACCAA GG - #CACAGGAC         780                                                                           - ATTCTGGGAG CAGTGACCCT TCTGCTGGAG GGAGTGATGG CAGCACGGGG AC - #AACTGGGA         840                                                                           #         848                                                                  - (2) INFORMATION FOR SEQ ID NO:126:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 918 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGG CAGGACCACA GCTCACAAGG ATCCCAATGC CA - #TCTTCCTG         480                                                                           - AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG CGTTTCCTGA TGCTTGTAGG AG - #GGTCCACC         540                                                                           - CTCTGCGTCA GGGAATTCGG CGGCAACATG GCGTCTCCCG CTCCGCCTGC TT - #GTGACCTC         600                                                                           - CGAGTCCTCA GTAAACTGCT TCGTGACTCC CATGTCCTTC ACAGCAGACT GA - #GCCAGTGC         660                                                                           - CCAGAGGTTC ACCCTTTGCC TACACCTGTC CTGCTGCCTG CTGTGGACTT TA - #GCTTGGGA         720                                                                           - GAATGGAAAA CCCAGATGGA GGAGACCAAG GCACAGGACA TTCTGGGAGC AG - #TGACCCTT         780                                                                           - CTGCTGGAGG GAGTGATGGC AGCACGGGGA CAACTGGGAC CCACTTGCCT CT - #CATCCCTC         840                                                                           - CTGGGGCAGC TTTCTGGACA GGTCCGTCTC CTCCTTGGGG CCCTGCAGAG CC - #TCCTTGGA         900                                                                           # 918              AG                                                          - (2) INFORMATION FOR SEQ ID NO:127:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 918 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:127:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGC TCACAAGGAT CCCAATGCCA TCTTCCTGAG CT - #TCCAACAC         480                                                                           - CTGCTCCGAG GAAAGGTGCG TTTCCTGATG CTTGTAGGAG GGTCCACCCT CT - #GCGTCAGG         540                                                                           - GAATTCGGCG GCAACATGGC GTCTCCCGCT CCGCCTGCTT GTGACCTCCG AG - #TCCTCAGT         600                                                                           - AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AG - #AGGTTCAC         660                                                                           - CCTTTGCCTA CACCTGTCCT GCTGCCTGCT GTGGACTTTA GCTTGGGAGA AT - #GGAAAACC         720                                                                           - CAGATGGAGG AGACCAAGGC ACAGGACATT CTGGGAGCAG TGACCCTTCT GC - #TGGAGGGA         780                                                                           - GTGATGGCAG CACGGGGACA ACTGGGACCC ACTTGCCTCT CATCCCTCCT GG - #GGCAGCTT         840                                                                           - TCTGGACAGG TCCGTCTCCT CCTTGGGGCC CTGCAGAGCC TCCTTGGAAC CC - #AGCTTCCT         900                                                                           # 918              CA                                                          - (2) INFORMATION FOR SEQ ID NO:128:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 918 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CC - #TGCTCCGA         480                                                                           - GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GG - #AATTCGGC         540                                                                           - GGCAACATGG CGTCTCCCGC TCCGCCTGCT TGTGACCTCC GAGTCCTCAG TA - #AACTGCTT         600                                                                           - CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC CAGAGGTTCA CC - #CTTTGCCT         660                                                                           - ACACCTGTCC TGCTGCCTGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CC - #AGATGGAG         720                                                                           - GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AG - #TGATGGCA         780                                                                           - GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TT - #CTGGACAG         840                                                                           - GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCC TC - #CACAGGGC         900                                                                           # 918              AG                                                          - (2) INFORMATION FOR SEQ ID NO:129:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 918 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGC CATCTTCCTG AGCTTCCAAC ACCTGCTCCG AG - #GAAAGGTG         480                                                                           - CGTTTCCTGA TGCTTGTAGG AGGGTCCACC CTCTGCGTCA GGGAATTCGG CG - #GCAACATG         540                                                                           - GCGTCTCCCG CTCCGCCTGC TTGTGACCTC CGAGTCCTCA GTAAACTGCT TC - #GTGACTCC         600                                                                           - CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC TA - #CACCTGTC         660                                                                           - CTGCTGCCTG CTGTGGACTT TAGCTTGGGA GAATGGAAAA CCCAGATGGA GG - #AGACCAAG         720                                                                           - GCACAGGACA TTCTGGGAGC AGTGACCCTT CTGCTGGAGG GAGTGATGGC AG - #CACGGGGA         780                                                                           - CAACTGGGAC CCACTTGCCT CTCATCCCTC CTGGGGCAGC TTTCTGGACA GG - #TCCGTCTC         840                                                                           - CTCCTTGGGG CCCTGCAGAG CCTCCTTGGA ACCCAGCTTC CTCCACAGGG CA - #GGACCACA         900                                                                           # 918              AT                                                          - (2) INFORMATION FOR SEQ ID NO:130:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 915 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGA GGTTCACCCT TTGCCTACAC CTGTCCTGCT GC - #CTGCTGTG         480                                                                           - GACTTTAGCT TGGGAGAATG GAAAACCCAG ATGGAGGAGA CCAAGGCACA GG - #ACATTCTG         540                                                                           - GGAGCAGTGA CCCTTCTGCT GGAGGGAGTG ATGGCAGCAC GGGGACAACT GG - #GACCCACT         600                                                                           - TGCCTCTCAT CCCTCCTGGG GCAGCTTTCT GGACAGGTCC GTCTCCTCCT TG - #GGGCCCTG         660                                                                           - CAGAGCCTCC TTGGAACCCA GCTTCCTCCA CAGGGCAGGA CCACAGCTCA CA - #AGGATCCC         720                                                                           - AATGCCATCT TCCTGAGCTT CCAACACCTG CTCCGAGGAA AGGTGCGTTT CC - #TGATGCTT         780                                                                           - GTAGGAGGGT CCACCCTCTG CGTCAGGGAA TTCGGCAACA TGGCGTCTCC CG - #CTCCGCCT         840                                                                           - GCTTGTGACC TCCGAGTCCT CAGTAAACTG CTTCGTGACT CCCATGTCCT TC - #ACAGCAGA         900                                                                           #   915                                                                        - (2) INFORMATION FOR SEQ ID NO:131:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 915 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGTT GCCTACACCT GTCCTGCTGC CTGCTGTGGA CT - #TTAGCTTG         480                                                                           - GGAGAATGGA AAACCCAGAT GGAGGAGACC AAGGCACAGG ACATTCTGGG AG - #CAGTGACC         540                                                                           - CTTCTGCTGG AGGGAGTGAT GGCAGCACGG GGACAACTGG GACCCACTTG CC - #TCTCATCC         600                                                                           - CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT CTCCTCCTTG GGGCCCTGCA GA - #GCCTCCTT         660                                                                           - GGAACCCAGC TTCCTCCACA GGGCAGGACC ACAGCTCACA AGGATCCCAA TG - #CCATCTTC         720                                                                           - CTGAGCTTCC AACACCTGCT CCGAGGAAAG GTGCGTTTCC TGATGCTTGT AG - #GAGGGTCC         780                                                                           - ACCCTCTGCG TCAGGGAATT CGGCAACATG GCGTCTCCCG CTCCGCCTGC TT - #GTGACCTC         840                                                                           - CGAGTCCTCA GTAAACTGCT TCGTGACTCC CATGTCCTTC ACAGCAGACT GA - #GCCAGTGC         900                                                                           #   915                                                                        - (2) INFORMATION FOR SEQ ID NO:132:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 915 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGT CCTGCTGCCT GCTGTGGACT TTAGCTTGGG AG - #AATGGAAA         480                                                                           - ACCCAGATGG AGGAGACCAA GGCACAGGAC ATTCTGGGAG CAGTGACCCT TC - #TGCTGGAG         540                                                                           - GGAGTGATGG CAGCACGGGG ACAACTGGGA CCCACTTGCC TCTCATCCCT CC - #TGGGGCAG         600                                                                           - CTTTCTGGAC AGGTCCGTCT CCTCCTTGGG GCCCTGCAGA GCCTCCTTGG AA - #CCCAGCTT         660                                                                           - CCTCCACAGG GCAGGACCAC AGCTCACAAG GATCCCAATG CCATCTTCCT GA - #GCTTCCAA         720                                                                           - CACCTGCTCC GAGGAAAGGT GCGTTTCCTG ATGCTTGTAG GAGGGTCCAC CC - #TCTGCGTC         780                                                                           - AGGGAATTCG GCAACATGGC GTCTCCCGCT CCGCCTGCTT GTGACCTCCG AG - #TCCTCAGT         840                                                                           - AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AG - #AGGTTCAC         900                                                                           #   915                                                                        - (2) INFORMATION FOR SEQ ID NO:133:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 915 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CC - #AGATGGAG         480                                                                           - GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AG - #TGATGGCA         540                                                                           - GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TT - #CTGGACAG         600                                                                           - GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCC TC - #CACAGGGC         660                                                                           - AGGACCACAG CTCACAAGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CC - #TGCTCCGA         720                                                                           - GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GG - #AATTCGGC         780                                                                           - AACATGGCGT CTCCCGCTCC GCCTGCTTGT GACCTCCGAG TCCTCAGTAA AC - #TGCTTCGT         840                                                                           - GACTCCCATG TCCTTCACAG CAGACTGAGC CAGTGCCCAG AGGTTCACCC TT - #TGCCTACA         900                                                                           #   915                                                                        - (2) INFORMATION FOR SEQ ID NO:134:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 915 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGA CTTTAGCTTG GGAGAATGGA AAACCCAGAT GG - #AGGAGACC         480                                                                           - AAGGCACAGG ACATTCTGGG AGCAGTGACC CTTCTGCTGG AGGGAGTGAT GG - #CAGCACGG         540                                                                           - GGACAACTGG GACCCACTTG CCTCTCATCC CTCCTGGGGC AGCTTTCTGG AC - #AGGTCCGT         600                                                                           - CTCCTCCTTG GGGCCCTGCA GAGCCTCCTT GGAACCCAGC TTCCTCCACA GG - #GCAGGACC         660                                                                           - ACAGCTCACA AGGATCCCAA TGCCATCTTC CTGAGCTTCC AACACCTGCT CC - #GAGGAAAG         720                                                                           - GTGCGTTTCC TGATGCTTGT AGGAGGGTCC ACCCTCTGCG TCAGGGAATT CG - #GCAACATG         780                                                                           - GCGTCTCCCG CTCCGCCTGC TTGTGACCTC CGAGTCCTCA GTAAACTGCT TC - #GTGACTCC         840                                                                           - CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC TA - #CACCTGTC         900                                                                           #   915                                                                        - (2) INFORMATION FOR SEQ ID NO:135:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 915 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:135:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGG AGAATGGAAA ACCCAGATGG AGGAGACCAA GG - #CACAGGAC         480                                                                           - ATTCTGGGAG CAGTGACCCT TCTGCTGGAG GGAGTGATGG CAGCACGGGG AC - #AACTGGGA         540                                                                           - CCCACTTGCC TCTCATCCCT CCTGGGGCAG CTTTCTGGAC AGGTCCGTCT CC - #TCCTTGGG         600                                                                           - GCCCTGCAGA GCCTCCTTGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AG - #CTCACAAG         660                                                                           - GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GC - #GTTTCCTG         720                                                                           - ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCAACATGGC GT - #CTCCCGCT         780                                                                           - CCGCCTGCTT GTGACCTCCG AGTCCTCAGT AAACTGCTTC GTGACTCCCA TG - #TCCTTCAC         840                                                                           - AGCAGACTGA GCCAGTGCCC AGAGGTTCAC CCTTTGCCTA CACCTGTCCT GC - #TGCCTGCT         900                                                                           #   915                                                                        - (2) INFORMATION FOR SEQ ID NO:136:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 915 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGG ACCCACTTGC CTCTCATCCC TCCTGGGGCA GC - #TTTCTGGA         480                                                                           - CAGGTCCGTC TCCTCCTTGG GGCCCTGCAG AGCCTCCTTG GAACCCAGCT TC - #CTCCACAG         540                                                                           - GGCAGGACCA CAGCTCACAA GGATCCCAAT GCCATCTTCC TGAGCTTCCA AC - #ACCTGCTC         600                                                                           - CGAGGAAAGG TGCGTTTCCT GATGCTTGTA GGAGGGTCCA CCCTCTGCGT CA - #GGGAATTC         660                                                                           - GGCAACATGG CGTCTCCCGC TCCGCCTGCT TGTGACCTCC GAGTCCTCAG TA - #AACTGCTT         720                                                                           - CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC CAGAGGTTCA CC - #CTTTGCCT         780                                                                           - ACACCTGTCC TGCTGCCTGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CC - #AGATGGAG         840                                                                           - GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AG - #TGATGGCA         900                                                                           #   915                                                                        - (2) INFORMATION FOR SEQ ID NO:137:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 915 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AG - #CTCACAAG         480                                                                           - GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GC - #GTTTCCTG         540                                                                           - ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCAACATGGC GT - #CTCCCGCT         600                                                                           - CCGCCTGCTT GTGACCTCCG AGTCCTCAGT AAACTGCTTC GTGACTCCCA TG - #TCCTTCAC         660                                                                           - AGCAGACTGA GCCAGTGCCC AGAGGTTCAC CCTTTGCCTA CACCTGTCCT GC - #TGCCTGCT         720                                                                           - GTGGACTTTA GCTTGGGAGA ATGGAAAACC CAGATGGAGG AGACCAAGGC AC - #AGGACATT         780                                                                           - CTGGGAGCAG TGACCCTTCT GCTGGAGGGA GTGATGGCAG CACGGGGACA AC - #TGGGACCC         840                                                                           - ACTTGCCTCT CATCCCTCCT GGGGCAGCTT TCTGGACAGG TCCGTCTCCT CC - #TTGGGGCC         900                                                                           #   915                                                                        - (2) INFORMATION FOR SEQ ID NO:138:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 915 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGG CAGGACCACA GCTCACAAGG ATCCCAATGC CA - #TCTTCCTG         480                                                                           - AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG CGTTTCCTGA TGCTTGTAGG AG - #GGTCCACC         540                                                                           - CTCTGCGTCA GGGAATTCGG CAACATGGCG TCTCCCGCTC CGCCTGCTTG TG - #ACCTCCGA         600                                                                           - GTCCTCAGTA AACTGCTTCG TGACTCCCAT GTCCTTCACA GCAGACTGAG CC - #AGTGCCCA         660                                                                           - GAGGTTCACC CTTTGCCTAC ACCTGTCCTG CTGCCTGCTG TGGACTTTAG CT - #TGGGAGAA         720                                                                           - TGGAAAACCC AGATGGAGGA GACCAAGGCA CAGGACATTC TGGGAGCAGT GA - #CCCTTCTG         780                                                                           - CTGGAGGGAG TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC AT - #CCCTCCTG         840                                                                           - GGGCAGCTTT CTGGACAGGT CCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CC - #TTGGAACC         900                                                                           #   915                                                                        - (2) INFORMATION FOR SEQ ID NO:139:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 915 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGC TCACAAGGAT CCCAATGCCA TCTTCCTGAG CT - #TCCAACAC         480                                                                           - CTGCTCCGAG GAAAGGTGCG TTTCCTGATG CTTGTAGGAG GGTCCACCCT CT - #GCGTCAGG         540                                                                           - GAATTCGGCA ACATGGCGTC TCCCGCTCCG CCTGCTTGTG ACCTCCGAGT CC - #TCAGTAAA         600                                                                           - CTGCTTCGTG ACTCCCATGT CCTTCACAGC AGACTGAGCC AGTGCCCAGA GG - #TTCACCCT         660                                                                           - TTGCCTACAC CTGTCCTGCT GCCTGCTGTG GACTTTAGCT TGGGAGAATG GA - #AAACCCAG         720                                                                           - ATGGAGGAGA CCAAGGCACA GGACATTCTG GGAGCAGTGA CCCTTCTGCT GG - #AGGGAGTG         780                                                                           - ATGGCAGCAC GGGGACAACT GGGACCCACT TGCCTCTCAT CCCTCCTGGG GC - #AGCTTTCT         840                                                                           - GGACAGGTCC GTCTCCTCCT TGGGGCCCTG CAGAGCCTCC TTGGAACCCA GC - #TTCCTCCA         900                                                                           #   915                                                                        - (2) INFORMATION FOR SEQ ID NO:140:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 915 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CC - #TGCTCCGA         480                                                                           - GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GG - #AATTCGGC         540                                                                           - AACATGGCGT CTCCCGCTCC GCCTGCTTGT GACCTCCGAG TCCTCAGTAA AC - #TGCTTCGT         600                                                                           - GACTCCCATG TCCTTCACAG CAGACTGAGC CAGTGCCCAG AGGTTCACCC TT - #TGCCTACA         660                                                                           - CCTGTCCTGC TGCCTGCTGT GGACTTTAGC TTGGGAGAAT GGAAAACCCA GA - #TGGAGGAG         720                                                                           - ACCAAGGCAC AGGACATTCT GGGAGCAGTG ACCCTTCTGC TGGAGGGAGT GA - #TGGCAGCA         780                                                                           - CGGGGACAAC TGGGACCCAC TTGCCTCTCA TCCCTCCTGG GGCAGCTTTC TG - #GACAGGTC         840                                                                           - CGTCTCCTCC TTGGGGCCCT GCAGAGCCTC CTTGGAACCC AGCTTCCTCC AC - #AGGGCAGG         900                                                                           #   915                                                                        - (2) INFORMATION FOR SEQ ID NO:141:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 915 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGC CATCTTCCTG AGCTTCCAAC ACCTGCTCCG AG - #GAAAGGTG         480                                                                           - CGTTTCCTGA TGCTTGTAGG AGGGTCCACC CTCTGCGTCA GGGAATTCGG CA - #ACATGGCG         540                                                                           - TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TG - #ACTCCCAT         600                                                                           - GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC AC - #CTGTCCTG         660                                                                           - CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GA - #CCAAGGCA         720                                                                           - CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC AC - #GGGGACAA         780                                                                           - CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CC - #GTCTCCTC         840                                                                           - CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GA - #CCACAGCT         900                                                                           #   915                                                                        - (2) INFORMATION FOR SEQ ID NO:142:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 921 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - GACTTCCAAA CCTGGAGAGC TTCGTAAGGG CTGTCAAGAA CTTAGAAAAT GC - #ATCAGGTA         180                                                                           - TGAGGCAATT CTTCGTAATC TCCAACCATG TCTGCCCTCT GCCACGGCCG CA - #CCCTCTCG         240                                                                           - CATCCAATCA TCATCAAGGC AGGTGACTGG CAAGAATTCC GGGAAAAACT GA - #CGTTCTAT         300                                                                           - TGGTTACCCT TGAGCAAGCG CAGGAACAAC AGTACGTAGA GGGCGGTGGA GG - #CTCCCCGG         360                                                                           - TAACCGTCTG GTCCAATCTC TACTATCAAC CCGTCTCCTC CGTCTAAAGA AT - #CTCATAAA         420                                                                           - TCTCCAAACA TGGAGGTTCA CCCTTTGCCT ACACCTGTCC TGCTGCCTGC TG - #TGGACTTT         480                                                                           - AGCTTGGGAG AATGGAAAAC CCAGATGGAG GAGACCAAGG CACAGGACAT TC - #TGGGAGCA         540                                                                           - GTGACCCTTC TGCTGGAGGG AGTGATGGCA GCACGGGGAC AACTGGGACC CA - #CTTGCCTC         600                                                                           - TCATCCCTCC TGGGGCAGCT TTCTGGACAG GTCCGTCTCC TCCTTGGGGC CC - #TGCAGAGC         660                                                                           - CTCCTTGGAA CCCAGCTTCC TCCACAGGGC AGGACCACAG CTCACAAGGA TC - #CCAATGCC         720                                                                           - ATCTTCCTGA GCTTCCAACA CCTGCTCCGA GGAAAGGTGC GTTTCCTGAT GC - #TTGTAGGA         780                                                                           - GGGTCCACCC TCTGCGTCAG GGAATTCGGC GGCAACGGCG GCAACATGGC GT - #CCCCAGCG         840                                                                           - CCGCCTGCTT GTGACCTCCG AGTCCTCAGT AAACTGCTTC GTGACTCCCA TG - #TCCTTCAC         900                                                                           #                 921CC A                                                      - (2) INFORMATION FOR SEQ ID NO:143:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 927 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGTT GCCTACACCT GTCCTGCTGC CTGCTGTGGA CT - #TTAGCTTG         480                                                                           - GGAGAATGGA AAACCCAGAT GGAGGAGACC AAGGCACAGG ACATTCTGGG AG - #CAGTGACC         540                                                                           - CTTCTGCTGG AGGGAGTGAT GGCAGCACGG GGACAACTGG GACCCACTTG CC - #TCTCATCC         600                                                                           - CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT CTCCTCCTTG GGGCCCTGCA GA - #GCCTCCTT         660                                                                           - GGAACCCAGC TTCCTCCACA GGGCAGGACC ACAGCTCACA AGGATCCCAA TG - #CCATCTTC         720                                                                           - CTGAGCTTCC AACACCTGCT CCGAGGAAAG GTGCGTTTCC TGATGCTTGT AG - #GAGGGTCC         780                                                                           - ACCCTCTGCG TCAGGGAATT CGGCGGCAAC GGCGGCAACA TGGCGTCCCC AG - #CGCCGCCT         840                                                                           - GCTTGTGACC TCCGAGTCCT CAGTAAACTG CTTCGTGACT CCCATGTCCT TC - #ACAGCAGA         900                                                                           #            927   AGGT TCACCCT                                                - (2) INFORMATION FOR SEQ ID NO:144:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 927 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGT CCTGCTGCCT GCTGTGGACT TTAGCTTGGG AG - #AATGGAAA         480                                                                           - ACCCAGATGG AGGAGACCAA GGCACAGGAC ATTCTGGGAG CAGTGACCCT TC - #TGCTGGAG         540                                                                           - GGAGTGATGG CAGCACGGGG ACAACTGGGA CCCACTTGCC TCTCATCCCT CC - #TGGGGCAG         600                                                                           - CTTTCTGGAC AGGTCCGTCT CCTCCTTGGG GCCCTGCAGA GCCTCCTTGG AA - #CCCAGCTT         660                                                                           - CCTCCACAGG GCAGGACCAC AGCTCACAAG GATCCCAATG CCATCTTCCT GA - #GCTTCCAA         720                                                                           - CACCTGCTCC GAGGAAAGGT GCGTTTCCTG ATGCTTGTAG GAGGGTCCAC CC - #TCTGCGTC         780                                                                           - AGGGAATTCG GCGGCAACGG CGGCAACATG GCGTCCCCAG CGCCGCCTGC TT - #GTGACCTC         840                                                                           - CGAGTCCTCA GTAAACTGCT TCGTGACTCC CATGTCCTTC ACAGCAGACT GA - #GCCAGTGC         900                                                                           #            927   TGCC TACACCT                                                - (2) INFORMATION FOR SEQ ID NO:145:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 927 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CC - #AGATGGAG         480                                                                           - GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AG - #TGATGGCA         540                                                                           - GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TT - #CTGGACAG         600                                                                           - GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCC TC - #CACAGGGC         660                                                                           - AGGACCACAG CTCACAAGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CC - #TGCTCCGA         720                                                                           - GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GG - #AATTCGGC         780                                                                           - GGCAACGGCG GCAACATGGC GTCCCCAGCG CCGCCTGCTT GTGACCTCCG AG - #TCCTCAGT         840                                                                           - AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AG - #AGGTTCAC         900                                                                           #            927   TCCT GCTGCCT                                                - (2) INFORMATION FOR SEQ ID NO:146:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 927 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGA CTTTAGCTTG GGAGAATGGA AAACCCAGAT GG - #AGGAGACC         480                                                                           - AAGGCACAGG ACATTCTGGG AGCAGTGACC CTTCTGCTGG AGGGAGTGAT GG - #CAGCACGG         540                                                                           - GGACAACTGG GACCCACTTG CCTCTCATCC CTCCTGGGGC AGCTTTCTGG AC - #AGGTCCGT         600                                                                           - CTCCTCCTTG GGGCCCTGCA GAGCCTCCTT GGAACCCAGC TTCCTCCACA GG - #GCAGGACC         660                                                                           - ACAGCTCACA AGGATCCCAA TGCCATCTTC CTGAGCTTCC AACACCTGCT CC - #GAGGAAAG         720                                                                           - GTGCGTTTCC TGATGCTTGT AGGAGGGTCC ACCCTCTGCG TCAGGGAATT CG - #GCGGCAAC         780                                                                           - GGCGGCAACA TGGCGTCCCC AGCGCCGCCT GCTTGTGACC TCCGAGTCCT CA - #GTAAACTG         840                                                                           - CTTCGTGACT CCCATGTCCT TCACAGCAGA CTGAGCCAGT GCCCAGAGGT TC - #ACCCTTTG         900                                                                           #            927   TGCC TGCTGTG                                                - (2) INFORMATION FOR SEQ ID NO:147:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 927 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:147:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGG AGAATGGAAA ACCCAGATGG AGGAGACCAA GG - #CACAGGAC         480                                                                           - ATTCTGGGAG CAGTGACCCT TCTGCTGGAG GGAGTGATGG CAGCACGGGG AC - #AACTGGGA         540                                                                           - CCCACTTGCC TCTCATCCCT CCTGGGGCAG CTTTCTGGAC AGGTCCGTCT CC - #TCCTTGGG         600                                                                           - GCCCTGCAGA GCCTCCTTGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AG - #CTCACAAG         660                                                                           - GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GC - #GTTTCCTG         720                                                                           - ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCGGCAACGG CG - #GCAACATG         780                                                                           - GCGTCCCCAG CGCCGCCTGC TTGTGACCTC CGAGTCCTCA GTAAACTGCT TC - #GTGACTCC         840                                                                           - CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC TA - #CACCTGTC         900                                                                           #            927   ACTT TAGCTTG                                                - (2) INFORMATION FOR SEQ ID NO:148:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 927 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:148:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGG ACCCACTTGC CTCTCATCCC TCCTGGGGCA GC - #TTTCTGGA         480                                                                           - CAGGTCCGTC TCCTCCTTGG GGCCCTGCAG AGCCTCCTTG GAACCCAGCT TC - #CTCCACAG         540                                                                           - GGCAGGACCA CAGCTCACAA GGATCCCAAT GCCATCTTCC TGAGCTTCCA AC - #ACCTGCTC         600                                                                           - CGAGGAAAGG TGCGTTTCCT GATGCTTGTA GGAGGGTCCA CCCTCTGCGT CA - #GGGAATTC         660                                                                           - GGCGGCAACG GCGGCAACAT GGCGTCCCCA GCGCCGCCTG CTTGTGACCT CC - #GAGTCCTC         720                                                                           - AGTAAACTGC TTCGTGACTC CCATGTCCTT CACAGCAGAC TGAGCCAGTG CC - #CAGAGGTT         780                                                                           - CACCCTTTGC CTACACCTGT CCTGCTGCCT GCTGTGGACT TTAGCTTGGG AG - #AATGGAAA         840                                                                           - ACCCAGATGG AGGAGACCAA GGCACAGGAC ATTCTGGGAG CAGTGACCCT TC - #TGCTGGAG         900                                                                           #            927   GGGG ACAACTG                                                - (2) INFORMATION FOR SEQ ID NO:149:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 927 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:149:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AG - #CTCACAAG         480                                                                           - GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GC - #GTTTCCTG         540                                                                           - ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCGGCAACGG CG - #GCAACATG         600                                                                           - GCGTCCCCAG CGCCGCCTGC TTGTGACCTC CGAGTCCTCA GTAAACTGCT TC - #GTGACTCC         660                                                                           - CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC TA - #CACCTGTC         720                                                                           - CTGCTGCCTG CTGTGGACTT TAGCTTGGGA GAATGGAAAA CCCAGATGGA GG - #AGACCAAG         780                                                                           - GCACAGGACA TTCTGGGAGC AGTGACCCTT CTGCTGGAGG GAGTGATGGC AG - #CACGGGGA         840                                                                           - CAACTGGGAC CCACTTGCCT CTCATCCCTC CTGGGGCAGC TTTCTGGACA GG - #TCCGTCTC         900                                                                           #            927   AGAG CCTCCTT                                                - (2) INFORMATION FOR SEQ ID NO:150:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 927 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:150:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGG CAGGACCACA GCTCACAAGG ATCCCAATGC CA - #TCTTCCTG         480                                                                           - AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG CGTTTCCTGA TGCTTGTAGG AG - #GGTCCACC         540                                                                           - CTCTGCGTCA GGGAATTCGG CGGCAACGGC GGCAACATGG CGTCCCCAGC GC - #CGCCTGCT         600                                                                           - TGTGACCTCC GAGTCCTCAG TAAACTGCTT CGTGACTCCC ATGTCCTTCA CA - #GCAGACTG         660                                                                           - AGCCAGTGCC CAGAGGTTCA CCCTTTGCCT ACACCTGTCC TGCTGCCTGC TG - #TGGACTTT         720                                                                           - AGCTTGGGAG AATGGAAAAC CCAGATGGAG GAGACCAAGG CACAGGACAT TC - #TGGGAGCA         780                                                                           - GTGACCCTTC TGCTGGAGGG AGTGATGGCA GCACGGGGAC AACTGGGACC CA - #CTTGCCTC         840                                                                           - TCATCCCTCC TGGGGCAGCT TTCTGGACAG GTCCGTCTCC TCCTTGGGGC CC - #TGCAGAGC         900                                                                           #            927   TTCC TCCACAG                                                - (2) INFORMATION FOR SEQ ID NO:151:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 927 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:151:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGC TCACAAGGAT CCCAATGCCA TCTTCCTGAG CT - #TCCAACAC         480                                                                           - CTGCTCCGAG GAAAGGTGCG TTTCCTGATG CTTGTAGGAG GGTCCACCCT CT - #GCGTCAGG         540                                                                           - GAATTCGGCG GCAACGGCGG CAACATGGCG TCCCCAGCGC CGCCTGCTTG TG - #ACCTCCGA         600                                                                           - GTCCTCAGTA AACTGCTTCG TGACTCCCAT GTCCTTCACA GCAGACTGAG CC - #AGTGCCCA         660                                                                           - GAGGTTCACC CTTTGCCTAC ACCTGTCCTG CTGCCTGCTG TGGACTTTAG CT - #TGGGAGAA         720                                                                           - TGGAAAACCC AGATGGAGGA GACCAAGGCA CAGGACATTC TGGGAGCAGT GA - #CCCTTCTG         780                                                                           - CTGGAGGGAG TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC AT - #CCCTCCTG         840                                                                           - GGGCAGCTTT CTGGACAGGT CCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CC - #TTGGAACC         900                                                                           #            927   GCAG GACCACA                                                - (2) INFORMATION FOR SEQ ID NO:152:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 927 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:152:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CC - #TGCTCCGA         480                                                                           - GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GG - #AATTCGGC         540                                                                           - GGCAACGGCG GCAACATGGC GTCCCCAGCG CCGCCTGCTT GTGACCTCCG AG - #TCCTCAGT         600                                                                           - AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AG - #AGGTTCAC         660                                                                           - CCTTTGCCTA CACCTGTCCT GCTGCCTGCT GTGGACTTTA GCTTGGGAGA AT - #GGAAAACC         720                                                                           - CAGATGGAGG AGACCAAGGC ACAGGACATT CTGGGAGCAG TGACCCTTCT GC - #TGGAGGGA         780                                                                           - GTGATGGCAG CACGGGGACA ACTGGGACCC ACTTGCCTCT CATCCCTCCT GG - #GGCAGCTT         840                                                                           - TCTGGACAGG TCCGTCTCCT CCTTGGGGCC CTGCAGAGCC TCCTTGGAAC CC - #AGCTTCCT         900                                                                           #            927   CAGC TCACAAG                                                - (2) INFORMATION FOR SEQ ID NO:153:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 927 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:153:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGC CATCTTCCTG AGCTTCCAAC ACCTGCTCCG AG - #GAAAGGTG         480                                                                           - CGTTTCCTGA TGCTTGTAGG AGGGTCCACC CTCTGCGTCA GGGAATTCGG CG - #GCAACGGC         540                                                                           - GGCAACATGG CGTCCCCAGC GCCGCCTGCT TGTGACCTCC GAGTCCTCAG TA - #AACTGCTT         600                                                                           - CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC CAGAGGTTCA CC - #CTTTGCCT         660                                                                           - ACACCTGTCC TGCTGCCTGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CC - #AGATGGAG         720                                                                           - GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AG - #TGATGGCA         780                                                                           - GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TT - #CTGGACAG         840                                                                           - GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCC TC - #CACAGGGC         900                                                                           #            927   AGGA TCCCAAT                                                - (2) INFORMATION FOR SEQ ID NO:154:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 906 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:154:                                - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT          60                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CC - #GAAACCTT         120                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT         180                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT         240                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC         300                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC         360                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT         420                                                                           - CATAAATCTC CAAACATGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CC - #TGCTCCGA         480                                                                           - GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GG - #AATTCGGC         540                                                                           - GGCAACATGG CGTCTCCCGC TCCGCCTGCT TGTGACCTCC GAGTCCTCAG TA - #AACTGCTT         600                                                                           - CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC CAGAGGTTCA CC - #CTTTGCCT         660                                                                           - ACACCTGTCC TGCTGCCTGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CC - #AGATGGAG         720                                                                           - GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AG - #TGATGGCA         780                                                                           - GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TT - #CTGGACAG         840                                                                           - GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGGGCAG GA - #CCACAGCT         900                                                                           #          906                                                                 - (2) INFORMATION FOR SEQ ID NO:155:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 993 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:155:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GTCTTACAAG CTGTGCCACC CCGAGGAGCT GG - #TGCTGCTC         480                                                                           - GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GG - #CCCTGCAG         540                                                                           - CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GC - #TCCTGCAG         600                                                                           - GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GC - #TGGACGTC         660                                                                           - GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CC - #CTGCCCTG         720                                                                           - CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GG - #CAGGAGGG         780                                                                           - GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TC - #TACGCCAC         840                                                                           - CTTGCGCAGC CCGGCGGCGG CTCTGACATG GCTACACCAT TAGGCCCTGC CA - #GCTCCCTG         900                                                                           - CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGGA AGATCCAGGG CG - #ATGGCGCA         960                                                                           #        993       TGTG TGCCACCTAA TAA                                         - (2) INFORMATION FOR SEQ ID NO:156:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 993 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:156:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GTCTCCCGAG TTGGGTCCCA CCTTGGACAC AC - #TGCAGCTG         480                                                                           - GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AA - #TGGCCCCT         540                                                                           - GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GC - #GCCGGGCA         600                                                                           - GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CC - #GCGTTCTA         660                                                                           - CGCCACCTTG CGCAGCCCGG CGGCGGCTCT GACATGGCTA CACCATTAGG CC - #CTGCCAGC         720                                                                           - TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG TGAGGAAGAT CC - #AGGGCGAT         780                                                                           - GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC ACCTACAAGC TGTGCCACCC CG - #AGGAGCTG         840                                                                           - GTGCTGCTCG GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CC - #CCAGCCAG         900                                                                           - GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT CT - #ACCAGGGG         960                                                                           #        993       AAGG GATATCCTAA TAA                                         - (2) INFORMATION FOR SEQ ID NO:157:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 993 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:157:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GTCTTCTGCT TTCCAGCGCC GGGCAGGAGG GG - #TCCTGGTT         480                                                                           - GCTAGCCATC TGCAGAGCTT CCTGGAGGTG TCGTACCGCG TTCTACGCCA CC - #TTGCGCAG         540                                                                           - CCCGGCGGCG GCTCTGACAT GGCTACACCA TTAGGCCCTG CCAGCTCCCT GC - #CCCAGAGC         600                                                                           - TTCCTGCTCA AGTCTTTAGA GCAAGTGAGG AAGATCCAGG GCGATGGCGC AG - #CGCTCCAG         660                                                                           - GAGAAGCTGT GTGCCACCTA CAAGCTGTGC CACCCCGAGG AGCTGGTGCT GC - #TCGGACAC         720                                                                           - TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GC - #AGCTGGCA         780                                                                           - GGCTGCTTGA GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GC - #AGGCCCTG         840                                                                           - GAAGGGATAT CCCCCGAGTT GGGTCCCACC TTGGACACAC TGCAGCTGGA CG - #TCGCCGAC         900                                                                           - TTTGCCACCA CCATCTGGCA GCAGATGGAA GAACTGGGAA TGGCCCCTGC CC - #TGCAGCCC         960                                                                           #        993       CGGC CTTCGCCTAA TAA                                         - (2) INFORMATION FOR SEQ ID NO:158:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 993 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:158:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GTCTATGGCC CCTGCCCTGC AGCCCACCCA GG - #GTGCCATG         480                                                                           - CCGGCCTTCG CCTCTGCTTT CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TA - #GCCATCTG         540                                                                           - CAGAGCTTCC TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CG - #GCGGCGGC         600                                                                           - TCTGACATGG CTACACCATT AGGCCCTGCC AGCTCCCTGC CCCAGAGCTT CC - #TGCTCAAG         660                                                                           - TCTTTAGAGC AAGTGAGGAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA GA - #AGCTGTGT         720                                                                           - GCCACCTACA AGCTGTGCCA CCCCGAGGAG CTGGTGCTGC TCGGACACTC TC - #TGGGCATC         780                                                                           - CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG CT - #GCTTGAGC         840                                                                           - CAACTCCATA GCGGCCTTTT CCTCTACCAG GGGCTCCTGC AGGCCCTGGA AG - #GGATATCC         900                                                                           - CCCGAGTTGG GTCCCACCTT GGACACACTG CAGCTGGACG TCGCCGACTT TG - #CCACCACC         960                                                                           #        993       AAGA ACTGGGATAA TAA                                         - (2) INFORMATION FOR SEQ ID NO:159:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 993 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:159:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GTCTACCCAG GGTGCCATGC CGGCCTTCGC CT - #CTGCTTTC         480                                                                           - CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GG - #AGGTGTCG         540                                                                           - TACCGCGTTC TACGCCACCT TGCGCAGCCC GGCGGCGGCT CTGACATGGC TA - #CACCATTA         600                                                                           - GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA AG - #TGAGGAAG         660                                                                           - ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAA GC - #TGTGCCAC         720                                                                           - CCCGAGGAGC TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CC - #TGAGCTCC         780                                                                           - TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG CG - #GCCTTTTC         840                                                                           - CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG TC - #CCACCTTG         900                                                                           - GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GA - #TGGAAGAA         960                                                                           #        993       CCCT GCAGCCCTAA TAA                                         - (2) INFORMATION FOR SEQ ID NO:160:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 1027 base                                                          (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:160:                                - ATGGCTACAC CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CA - #AGTCTTTA          60                                                                           - GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GT - #GTGCCACC         120                                                                           - TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CA - #TCCCCTGG         180                                                                           - GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GA - #GCCAACTC         240                                                                           - CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT AT - #CCCCCGAG         300                                                                           - TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CA - #CCATCTGG         360                                                                           - CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC CCACCCAGGG TG - #CCATGCCG         420                                                                           - GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CC - #ATCTGCAG         480                                                                           - AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCGG CG - #GCGGCTCT         540                                                                           - GACATGGCTA CACCATTGGG CCCTGCCAGC TCCCTGCCCC AGAGCTTCCT GC - #TCAAGTCT         600                                                                           - TTAGAGCAAG TGAGGAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GC - #TGTGTGCC         660                                                                           - ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCT GG - #GCATCCCC         720                                                                           - TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CT - #TGAGCCAA         780                                                                           - CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GA - #TATCCCCC         840                                                                           - GAGTTGGGTC CCACCTTGGA CACACTGCAG CTGGACGTCG CCGACTTTGC CA - #CCACCATC         900                                                                           - TGGCAGCAGA TGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCA TC - #CTGGTTGC         960                                                                           - TAGCCATCTG CAGAGCTTCC TGGAGGTGTC GTACCGCGTT CTACGCCACC TT - #GCGCAGCC        1020                                                                           #        1027                                                                  - (2) INFORMATION FOR SEQ ID NO:161:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 155 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:161:                                - Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu          #                15                                                            - Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val          #            30                                                                - His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu          #        45                                                                    - Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu          #    60                                                                        - Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln          #80                                                                            - Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln          #                95                                                            - Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Leu          #           110                                                                - Pro Pro Gln Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe          #       125                                                                    - Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu          #   140                                                                        - Val Gly Gly Ser Thr Leu Cys Val Arg Glu Ph - #e                              145                 1 - #50                 1 - #55                            - (2) INFORMATION FOR SEQ ID NO:162:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 309 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:162:                                - Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu          #                15                                                            - Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val          #            30                                                                - His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu          #        45                                                                    - Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu          #    60                                                                        - Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln          #80                                                                            - Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln          #                95                                                            - Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Leu          #           110                                                                - Pro Pro Gln Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe          #       125                                                                    - Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu          #   140                                                                        - Val Gly Gly Ser Thr Leu Cys Val Arg Glu Ph - #e Gly Gly Asn Met Ala          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu          #               175                                                            - Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val          #           190                                                                - His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu          #       205                                                                    - Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu          #   220                                                                        - Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln          #               255                                                            - Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Gly          #           270                                                                - Arg Thr Thr Ala His Lys Asp Pro Asn Ala Il - #e Phe Leu Ser Phe Gln          #       285                                                                    - His Leu Leu Arg Gly Lys Val Arg Phe Leu Me - #t Leu Val Gly Gly Ser          #   300                                                                        - Thr Leu Cys Val Arg                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:163:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 312 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:163:                                - Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu          #                15                                                            - Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val          #            30                                                                - His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu          #        45                                                                    - Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu          #    60                                                                        - Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln          #80                                                                            - Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln          #                95                                                            - Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Leu          #           110                                                                - Pro Pro Gln Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe          #       125                                                                    - Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu          #   140                                                                        - Val Gly Gly Ser Thr Leu Cys Val Arg Glu Ph - #e Gly Asn Met Ala Ser          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Le - #u Ser Lys Leu Leu Arg          #               175                                                            - Asp Ser His Val Leu His Ser Arg Leu Ser Gl - #n Cys Pro Glu Val His          #           190                                                                - Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Va - #l Asp Phe Ser Leu Gly          #       205                                                                    - Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Al - #a Gln Asp Ile Leu Gly          #   220                                                                        - Ala Val Thr Leu Leu Leu Glu Gly Val Met Al - #a Ala Arg Gly Gln Leu          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gl - #n Leu Ser Gly Gln Val          #               255                                                            - Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Le - #u Gly Thr Gln Leu Pro          #           270                                                                - Pro Gln Gly Arg Thr Thr Ala His Lys Asp Pr - #o Asn Ala Ile Phe Leu          #       285                                                                    - Ser Phe Gln His Leu Leu Arg Gly Lys Val Ar - #g Phe Leu Met Leu Val          #   300                                                                        - Gly Gly Ser Thr Leu Cys Val Arg                                              305                 3 - #10                                                    - (2) INFORMATION FOR SEQ ID NO:164:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 313 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:164:                                - Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu          #                15                                                            - Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val          #            30                                                                - His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu          #        45                                                                    - Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu          #    60                                                                        - Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln          #80                                                                            - Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln          #                95                                                            - Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Leu          #           110                                                                - Pro Pro Gln Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe          #       125                                                                    - Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu          #   140                                                                        - Val Gly Gly Ser Thr Leu Cys Val Arg Glu Ph - #e Gly Gly Asn Met Ala          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu          #               175                                                            - Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val          #           190                                                                - His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu          #       205                                                                    - Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu          #   220                                                                        - Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln          #               255                                                            - Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Leu          #           270                                                                - Pro Pro Gln Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe          #       285                                                                    - Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu          #   300                                                                        - Val Gly Gly Ser Thr Leu Cys Val Arg                                          305                 3 - #10                                                    - (2) INFORMATION FOR SEQ ID NO:165:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 316 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:165:                                - Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu          #                15                                                            - Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val          #            30                                                                - His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu          #        45                                                                    - Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu          #    60                                                                        - Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln          #80                                                                            - Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln          #                95                                                            - Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Leu          #           110                                                                - Pro Pro Gln Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe          #       125                                                                    - Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu          #   140                                                                        - Val Gly Gly Ser Thr Leu Cys Val Arg Glu Ph - #e Gly Gly Asn Gly Gly          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Asn Met Ala Ser Pro Ala Pro Pro Ala Cys As - #p Leu Arg Val Leu Ser          #               175                                                            - Lys Leu Leu Arg Asp Ser His Val Leu His Se - #r Arg Leu Ser Gln Cys          #           190                                                                - Pro Glu Val His Pro Leu Pro Thr Pro Val Le - #u Leu Pro Ala Val Asp          #       205                                                                    - Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Gl - #u Glu Thr Lys Ala Gln          #   220                                                                        - Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Gl - #u Gly Val Met Ala Ala          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Arg Gly Gln Leu Gly Pro Thr Cys Leu Ser Se - #r Leu Leu Gly Gln Leu          #               255                                                            - Ser Gly Gln Val Arg Leu Leu Leu Gly Ala Le - #u Gln Ser Leu Leu Gly          #           270                                                                - Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Al - #a His Lys Asp Pro Asn          #       285                                                                    - Ala Ile Phe Leu Ser Phe Gln His Leu Leu Ar - #g Gly Lys Val Arg Phe          #   300                                                                        - Leu Met Leu Val Gly Gly Ser Thr Leu Cys Va - #l Arg                          305                 3 - #10                 3 - #15                            - (2) INFORMATION FOR SEQ ID NO:166:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 302 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:166:                                - Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro          #                15                                                            - Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser          #            30                                                                - Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val          #        45                                                                    - Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu          #    60                                                                        - Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg          #80                                                                            - His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys          #                95                                                            - Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr          #           110                                                                - Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gl - #y Ser Gly Gly Gly Ser          #       125                                                                    - Asn Met Ala Tyr Lys Leu Cys His Pro Glu Gl - #u Leu Val Leu Leu Gly          #   140                                                                        - His Ser Leu Gly Ile Pro Trp Ala Pro Leu Se - #r Ser Cys Pro Ser Gln          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Le - #u His Ser Gly Leu Phe          #               175                                                            - Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gl - #y Ile Ser Pro Glu Leu          #           190                                                                - Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Va - #l Ala Asp Phe Ala Thr          #       205                                                                    - Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Me - #t Ala Pro Ala Leu Gln          #   220                                                                        - Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Se - #r Ala Phe Gln Arg Arg          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Ala Gly Gly Val Leu Val Ala Ser His Leu Gl - #n Ser Phe Leu Glu Val          #               255                                                            - Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pr - #o Ser Gly Gly Ser Gly          #           270                                                                - Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Gl - #u Gln Val Arg Lys Ile          #       285                                                                    - Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Le - #u Cys Ala Thr                  #   300                                                                        - (2) INFORMATION FOR SEQ ID NO:167:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 317 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:167:                                - Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro          #                15                                                            - Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser          #            30                                                                - Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val          #        45                                                                    - Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu          #    60                                                                        - Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg          #80                                                                            - His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys          #                95                                                            - Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr          #           110                                                                - Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pr - #o Ser Gly Pro Ile Ser          #       125                                                                    - Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Se - #r His Lys Ser Pro Asn          #   140                                                                        - Met Ala Tyr Lys Leu Cys His Pro Glu Glu Le - #u Val Leu Leu Gly His          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Se - #r Cys Pro Ser Gln Ala          #               175                                                            - Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu Hi - #s Ser Gly Leu Phe Leu          #           190                                                                - Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Il - #e Ser Pro Glu Leu Gly          #       205                                                                    - Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Al - #a Asp Phe Ala Thr Thr          #   220                                                                        - Ile Trp Gln Gln Met Glu Glu Leu Gly Met Al - #a Pro Ala Leu Gln Pro          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Al - #a Phe Gln Arg Arg Ala          #               255                                                            - Gly Gly Val Leu Val Ala Ser His Leu Gln Se - #r Phe Leu Glu Val Ser          #           270                                                                - Tyr Arg Val Leu Arg His Leu Ala Gln Pro Se - #r Gly Gly Ser Gly Gly          #       285                                                                    - Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gl - #n Val Arg Lys Ile Gln          #   300                                                                        - Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cy - #s Ala Thr                      305                 3 - #10                 3 - #15                            - (2) INFORMATION FOR SEQ ID NO:168:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 302 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:168:                                - Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro          #                15                                                            - Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser          #            30                                                                - Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val          #        45                                                                    - Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu          #    60                                                                        - Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg          #80                                                                            - His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys          #                95                                                            - Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr          #           110                                                                - Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gl - #y Ser Gly Gly Gly Ser          #       125                                                                    - Asn Met Ala Pro Glu Leu Gly Pro Thr Leu As - #p Thr Leu Gln Leu Asp          #   140                                                                        - Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gl - #n Met Glu Glu Leu Gly          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Al - #a Met Pro Ala Phe Ala          #               175                                                            - Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Le - #u Val Ala Ser His Leu          #           190                                                                - Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Le - #u Arg His Leu Ala Gln          #       205                                                                    - Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Ph - #e Leu Leu Lys Ser Leu          #   220                                                                        - Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Al - #a Ala Leu Gln Glu Lys          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Gl - #u Glu Leu Val Leu Leu          #               255                                                            - Gly His Ser Leu Gly Ile Pro Trp Ala Pro Le - #u Ser Ser Cys Pro Ser          #           270                                                                - Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gl - #n Leu His Ser Gly Leu          #       285                                                                    - Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Gl - #u Gly Ile Ser                  #   300                                                                        - (2) INFORMATION FOR SEQ ID NO:169:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 317 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:169:                                - Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro          #                15                                                            - Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser          #            30                                                                - Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val          #        45                                                                    - Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu          #    60                                                                        - Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg          #80                                                                            - His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys          #                95                                                            - Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr          #           110                                                                - Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pr - #o Ser Gly Pro Ile Ser          #       125                                                                    - Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Se - #r His Lys Ser Pro Asn          #   140                                                                        - Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Th - #r Leu Gln Leu Asp Val          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Me - #t Glu Glu Leu Gly Met          #               175                                                            - Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Me - #t Pro Ala Phe Ala Ser          #           190                                                                - Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Va - #l Ala Ser His Leu Gln          #       205                                                                    - Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Ar - #g His Leu Ala Gln Pro          #   220                                                                        - Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Le - #u Leu Lys Ser Leu Glu          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Al - #a Leu Gln Glu Lys Leu          #               255                                                            - Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Gl - #u Leu Val Leu Leu Gly          #           270                                                                - His Ser Leu Gly Ile Pro Trp Ala Pro Leu Se - #r Ser Cys Pro Ser Gln          #       285                                                                    - Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Le - #u His Ser Gly Leu Phe          #   300                                                                        - Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gl - #y Ile Ser                      305                 3 - #10                 3 - #15                            - (2) INFORMATION FOR SEQ ID NO:170:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 302 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:170:                                - Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro          #                15                                                            - Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser          #            30                                                                - Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val          #        45                                                                    - Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu          #    60                                                                        - Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg          #80                                                                            - His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys          #                95                                                            - Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr          #           110                                                                - Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gl - #y Ser Gly Gly Gly Ser          #       125                                                                    - Asn Met Ala Met Ala Pro Ala Leu Gln Pro Th - #r Gln Gly Ala Met Pro          #   140                                                                        - Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gl - #y Gly Val Leu Val Ala          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Ser His Leu Gln Ser Phe Leu Glu Val Ser Ty - #r Arg Val Leu Arg His          #               175                                                            - Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Se - #r Gln Ser Phe Leu Leu          #           190                                                                - Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gl - #y Asp Gly Ala Ala Leu          #       205                                                                    - Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cy - #s His Pro Glu Glu Leu          #   220                                                                        - Val Leu Leu Gly His Ser Leu Gly Ile Pro Tr - #p Ala Pro Leu Ser Ser          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cy - #s Leu Ser Gln Leu His          #               255                                                            - Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gl - #n Ala Leu Glu Gly Ile          #           270                                                                - Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Le - #u Gln Leu Asp Val Ala          #       285                                                                    - Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Gl - #u Glu Leu Gly                  #   300                                                                        - (2) INFORMATION FOR SEQ ID NO:171:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 317 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:171:                                - Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro          #                15                                                            - Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser          #            30                                                                - Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val          #        45                                                                    - Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu          #    60                                                                        - Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg          #80                                                                            - His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys          #                95                                                            - Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr          #           110                                                                - Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pr - #o Ser Gly Pro Ile Ser          #       125                                                                    - Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Se - #r His Lys Ser Pro Asn          #   140                                                                        - Met Ala Met Ala Pro Ala Leu Gln Pro Thr Gl - #n Gly Ala Met Pro Ala          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gl - #y Val Leu Val Ala Ser          #               175                                                            - His Leu Gln Ser Phe Leu Glu Val Ser Tyr Ar - #g Val Leu Arg His Leu          #           190                                                                - Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gl - #n Ser Phe Leu Leu Lys          #       205                                                                    - Ser Leu Glu Gln Val Arg Lys Ile Gln Gly As - #p Gly Ala Ala Leu Gln          #   220                                                                        - Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys Hi - #s Pro Glu Glu Leu Val          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Leu Leu Gly His Ser Leu Gly Ile Pro Trp Al - #a Pro Leu Ser Ser Cys          #               255                                                            - Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Le - #u Ser Gln Leu His Ser          #           270                                                                - Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Al - #a Leu Glu Gly Ile Ser          #       285                                                                    - Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gl - #n Leu Asp Val Ala Asp          #   300                                                                        - Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Gl - #u Leu Gly                      305                 3 - #10                 3 - #15                            - (2) INFORMATION FOR SEQ ID NO:172:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 302 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:172:                                - Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro          #                15                                                            - Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser          #            30                                                                - Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val          #        45                                                                    - Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu          #    60                                                                        - Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg          #80                                                                            - His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys          #                95                                                            - Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr          #           110                                                                - Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gl - #y Ser Gly Gly Gly Ser          #       125                                                                    - Asn Met Ala Thr Gln Gly Ala Met Pro Ala Ph - #e Ala Ser Ala Phe Gln          #   140                                                                        - Arg Arg Ala Gly Gly Val Leu Val Ala Ser Hi - #s Leu Gln Ser Phe Leu          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Glu Val Ser Tyr Arg Val Leu Arg His Leu Al - #a Gln Pro Ser Gly Gly          #               175                                                            - Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Se - #r Leu Glu Gln Val Arg          #           190                                                                - Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Gl - #u Lys Leu Cys Ala Thr          #       205                                                                    - Tyr Lys Leu Cys His Pro Glu Glu Leu Val Le - #u Leu Gly His Ser Leu          #   220                                                                        - Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pr - #o Ser Gln Ala Leu Gln          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gl - #y Leu Phe Leu Tyr Gln          #               255                                                            - Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pr - #o Glu Leu Gly Pro Thr          #           270                                                                - Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Ph - #e Ala Thr Thr Ile Trp          #       285                                                                    - Gln Gln Met Glu Glu Leu Gly Met Ala Pro Al - #a Leu Gln Pro                  #   300                                                                        - (2) INFORMATION FOR SEQ ID NO:173:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 317 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:173:                                - Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro          #                15                                                            - Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser          #            30                                                                - Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val          #        45                                                                    - Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu          #    60                                                                        - Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg          #80                                                                            - His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys          #                95                                                            - Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr          #           110                                                                - Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pr - #o Ser Gly Pro Ile Ser          #       125                                                                    - Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Se - #r His Lys Ser Pro Asn          #   140                                                                        - Met Ala Thr Gln Gly Ala Met Pro Ala Phe Al - #a Ser Ala Phe Gln Arg          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Arg Ala Gly Gly Val Leu Val Ala Ser His Le - #u Gln Ser Phe Leu Glu          #               175                                                            - Val Ser Tyr Arg Val Leu Arg His Leu Ala Gl - #n Pro Ser Gly Gly Ser          #           190                                                                - Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Le - #u Glu Gln Val Arg Lys          #       205                                                                    - Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Ly - #s Leu Cys Ala Thr Tyr          #   220                                                                        - Lys Leu Cys His Pro Glu Glu Leu Val Leu Le - #u Gly His Ser Leu Gly          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Se - #r Gln Ala Leu Gln Leu          #               255                                                            - Ala Gly Cys Leu Ser Gln Leu His Ser Gly Le - #u Phe Leu Tyr Gln Gly          #           270                                                                - Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Gl - #u Leu Gly Pro Thr Leu          #       285                                                                    - Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Al - #a Thr Thr Ile Trp Gln          #   300                                                                        - Gln Met Glu Glu Leu Gly Met Ala Pro Ala Le - #u Gln Pro                      305                 3 - #10                 3 - #15                            - (2) INFORMATION FOR SEQ ID NO:174:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 302 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:174:                                - Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro          #                15                                                            - Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser          #            30                                                                - Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val          #        45                                                                    - Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu          #    60                                                                        - Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg          #80                                                                            - His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys          #                95                                                            - Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr          #           110                                                                - Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gl - #y Ser Gly Gly Gly Ser          #       125                                                                    - Asn Met Ala Ser Ala Phe Gln Arg Arg Ala Gl - #y Gly Val Leu Val Ala          #   140                                                                        - Ser His Leu Gln Ser Phe Leu Glu Val Ser Ty - #r Arg Val Leu Arg His          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Se - #r Gln Ser Phe Leu Leu          #               175                                                            - Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gl - #y Asp Gly Ala Ala Leu          #           190                                                                - Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cy - #s His Pro Glu Glu Leu          #       205                                                                    - Val Leu Leu Gly His Ser Leu Gly Ile Pro Tr - #p Ala Pro Leu Ser Ser          #   220                                                                        - Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cy - #s Leu Ser Gln Leu His          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gl - #n Ala Leu Glu Gly Ile          #               255                                                            - Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Le - #u Gln Leu Asp Val Ala          #           270                                                                - Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Gl - #u Glu Leu Gly Met Ala          #       285                                                                    - Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pr - #o Ala Phe Ala                  #   300                                                                        - (2) INFORMATION FOR SEQ ID NO:175:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 317 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:175:                                - Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro          #                15                                                            - Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser          #            30                                                                - Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val          #        45                                                                    - Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu          #    60                                                                        - Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg          #80                                                                            - His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys          #                95                                                            - Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr          #           110                                                                - Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pr - #o Ser Gly Pro Ile Ser          #       125                                                                    - Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Se - #r His Lys Ser Pro Asn          #   140                                                                        - Met Ala Ser Ala Phe Gln Arg Arg Ala Gly Gl - #y Val Leu Val Ala Ser          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - His Leu Gln Ser Phe Leu Glu Val Ser Tyr Ar - #g Val Leu Arg His Leu          #               175                                                            - Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gl - #n Ser Phe Leu Leu Lys          #           190                                                                - Ser Leu Glu Gln Val Arg Lys Ile Gln Gly As - #p Gly Ala Ala Leu Gln          #       205                                                                    - Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys Hi - #s Pro Glu Glu Leu Val          #   220                                                                        - Leu Leu Gly His Ser Leu Gly Ile Pro Trp Al - #a Pro Leu Ser Ser Cys          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Le - #u Ser Gln Leu His Ser          #               255                                                            - Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Al - #a Leu Glu Gly Ile Ser          #           270                                                                - Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gl - #n Leu Asp Val Ala Asp          #       285                                                                    - Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Gl - #u Leu Gly Met Ala Pro          #   300                                                                        - Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Al - #a Phe Ala                      305                 3 - #10                 3 - #15                            - (2) INFORMATION FOR SEQ ID NO:176:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 305 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:176:                                - Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro          #                15                                                            - Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser          #            30                                                                - Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val          #        45                                                                    - Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu          #    60                                                                        - Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg          #80                                                                            - His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys          #                95                                                            - Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr          #           110                                                                - Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gl - #y Ser Gly Gly Gly Ser          #       125                                                                    - Asn Met Ala Tyr Lys Leu Cys His Pro Glu Gl - #u Leu Val Leu Leu Gly          #   140                                                                        - His Ser Leu Gly Ile Pro Trp Ala Pro Leu Se - #r Ser Cys Pro Ser Gln          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Le - #u His Ser Gly Leu Phe          #               175                                                            - Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gl - #y Ile Ser Pro Glu Leu          #           190                                                                - Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Va - #l Ala Asp Phe Ala Thr          #       205                                                                    - Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Me - #t Ala Pro Ala Leu Gln          #   220                                                                        - Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Se - #r Ala Phe Gln Arg Arg          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Ala Gly Gly Val Leu Val Ala Ser His Leu Gl - #n Ser Phe Leu Glu Val          #               255                                                            - Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pr - #o Thr Pro Leu Gly Pro          #           270                                                                - Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Ly - #s Ser Leu Glu Gln Val          #       285                                                                    - Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gl - #n Glu Lys Leu Cys Ala          #   300                                                                        - Thr                                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:177:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 320 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:177:                                - Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro          #                15                                                            - Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser          #            30                                                                - Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val          #        45                                                                    - Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu          #    60                                                                        - Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg          #80                                                                            - His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys          #                95                                                            - Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr          #           110                                                                - Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pr - #o Ser Gly Pro Ile Ser          #       125                                                                    - Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Se - #r His Lys Ser Pro Asn          #   140                                                                        - Met Ala Tyr Lys Leu Cys His Pro Glu Glu Le - #u Val Leu Leu Gly His          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Se - #r Cys Pro Ser Gln Ala          #               175                                                            - Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu Hi - #s Ser Gly Leu Phe Leu          #           190                                                                - Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Il - #e Ser Pro Glu Leu Gly          #       205                                                                    - Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Al - #a Asp Phe Ala Thr Thr          #   220                                                                        - Ile Trp Gln Gln Met Glu Glu Leu Gly Met Al - #a Pro Ala Leu Gln Pro          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Al - #a Phe Gln Arg Arg Ala          #               255                                                            - Gly Gly Val Leu Val Ala Ser His Leu Gln Se - #r Phe Leu Glu Val Ser          #           270                                                                - Tyr Arg Val Leu Arg His Leu Ala Gln Pro Th - #r Pro Leu Gly Pro Ala          #       285                                                                    - Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Se - #r Leu Glu Gln Val Arg          #   300                                                                        - Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Gl - #u Lys Leu Cys Ala Thr          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - (2) INFORMATION FOR SEQ ID NO:178:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 305 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:178:                                - Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro          #                15                                                            - Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser          #            30                                                                - Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val          #        45                                                                    - Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu          #    60                                                                        - Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg          #80                                                                            - His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys          #                95                                                            - Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr          #           110                                                                - Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gl - #y Ser Gly Gly Gly Ser          #       125                                                                    - Asn Met Ala Pro Glu Leu Gly Pro Thr Leu As - #p Thr Leu Gln Leu Asp          #   140                                                                        - Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gl - #n Met Glu Glu Leu Gly          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Al - #a Met Pro Ala Phe Ala          #               175                                                            - Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Le - #u Val Ala Ser His Leu          #           190                                                                - Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Le - #u Arg His Leu Ala Gln          #       205                                                                    - Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pr - #o Gln Ser Phe Leu Leu          #   220                                                                        - Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gl - #y Asp Gly Ala Ala Leu          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cy - #s His Pro Glu Glu Leu          #               255                                                            - Val Leu Leu Gly His Ser Leu Gly Ile Pro Tr - #p Ala Pro Leu Ser Ser          #           270                                                                - Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cy - #s Leu Ser Gln Leu His          #       285                                                                    - Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gl - #n Ala Leu Glu Gly Ile          #   300                                                                        - Ser                                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:179:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 320 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:179:                                - Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro          #                15                                                            - Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser          #            30                                                                - Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val          #        45                                                                    - Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu          #    60                                                                        - Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg          #80                                                                            - His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys          #                95                                                            - Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr          #           110                                                                - Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pr - #o Ser Gly Pro Ile Ser          #       125                                                                    - Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Se - #r His Lys Ser Pro Asn          #   140                                                                        - Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Th - #r Leu Gln Leu Asp Val          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Me - #t Glu Glu Leu Gly Met          #               175                                                            - Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Me - #t Pro Ala Phe Ala Ser          #           190                                                                - Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Va - #l Ala Ser His Leu Gln          #       205                                                                    - Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Ar - #g His Leu Ala Gln Pro          #   220                                                                        - Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gl - #n Ser Phe Leu Leu Lys          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Ser Leu Glu Gln Val Arg Lys Ile Gln Gly As - #p Gly Ala Ala Leu Gln          #               255                                                            - Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys Hi - #s Pro Glu Glu Leu Val          #           270                                                                - Leu Leu Gly His Ser Leu Gly Ile Pro Trp Al - #a Pro Leu Ser Ser Cys          #       285                                                                    - Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Le - #u Ser Gln Leu His Ser          #   300                                                                        - Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Al - #a Leu Glu Gly Ile Ser          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - (2) INFORMATION FOR SEQ ID NO:180:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 305 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:180:                                - Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro          #                15                                                            - Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser          #            30                                                                - Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val          #        45                                                                    - Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu          #    60                                                                        - Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg          #80                                                                            - His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys          #                95                                                            - Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr          #           110                                                                - Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gl - #y Ser Gly Gly Gly Ser          #       125                                                                    - Asn Met Ala Met Ala Pro Ala Leu Gln Pro Th - #r Gln Gly Ala Met Pro          #   140                                                                        - Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gl - #y Gly Val Leu Val Ala          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Ser His Leu Gln Ser Phe Leu Glu Val Ser Ty - #r Arg Val Leu Arg His          #               175                                                            - Leu Ala Gln Pro Thr Pro Leu Gly Pro Ala Se - #r Ser Leu Pro Gln Ser          #           190                                                                - Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Ly - #s Ile Gln Gly Asp Gly          #       205                                                                    - Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Ty - #r Lys Leu Cys His Pro          #   220                                                                        - Glu Glu Leu Val Leu Leu Gly His Ser Leu Gl - #y Ile Pro Trp Ala Pro          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Le - #u Ala Gly Cys Leu Ser          #               255                                                            - Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gl - #y Leu Leu Gln Ala Leu          #           270                                                                - Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Le - #u Asp Thr Leu Gln Leu          #       285                                                                    - Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gl - #n Gln Met Glu Glu Leu          #   300                                                                        - Gly                                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:181:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 320 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:181:                                - Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro          #                15                                                            - Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser          #            30                                                                - Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val          #        45                                                                    - Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu          #    60                                                                        - Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg          #80                                                                            - His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys          #                95                                                            - Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr          #           110                                                                - Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pr - #o Ser Gly Pro Ile Ser          #       125                                                                    - Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Se - #r His Lys Ser Pro Asn          #   140                                                                        - Met Ala Met Ala Pro Ala Leu Gln Pro Thr Gl - #n Gly Ala Met Pro Ala          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gl - #y Val Leu Val Ala Ser          #               175                                                            - His Leu Gln Ser Phe Leu Glu Val Ser Tyr Ar - #g Val Leu Arg His Leu          #           190                                                                - Ala Gln Pro Thr Pro Leu Gly Pro Ala Ser Se - #r Leu Pro Gln Ser Phe          #       205                                                                    - Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Il - #e Gln Gly Asp Gly Ala          #   220                                                                        - Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Ly - #s Leu Cys His Pro Glu          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Glu Leu Val Leu Leu Gly His Ser Leu Gly Il - #e Pro Trp Ala Pro Leu          #               255                                                            - Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Al - #a Gly Cys Leu Ser Gln          #           270                                                                - Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Le - #u Leu Gln Ala Leu Glu          #       285                                                                    - Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu As - #p Thr Leu Gln Leu Asp          #   300                                                                        - Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gl - #n Met Glu Glu Leu Gly          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - (2) INFORMATION FOR SEQ ID NO:182:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 305 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:182:                                - Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro          #                15                                                            - Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser          #            30                                                                - Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val          #        45                                                                    - Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu          #    60                                                                        - Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg          #80                                                                            - His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys          #                95                                                            - Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr          #           110                                                                - Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gl - #y Ser Gly Gly Gly Ser          #       125                                                                    - Asn Met Ala Thr Gln Gly Ala Met Pro Ala Ph - #e Ala Ser Ala Phe Gln          #   140                                                                        - Arg Arg Ala Gly Gly Val Leu Val Ala Ser Hi - #s Leu Gln Ser Phe Leu          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Glu Val Ser Tyr Arg Val Leu Arg His Leu Al - #a Gln Pro Thr Pro Leu          #               175                                                            - Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Le - #u Leu Lys Ser Leu Glu          #           190                                                                - Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Al - #a Leu Gln Glu Lys Leu          #       205                                                                    - Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Gl - #u Leu Val Leu Leu Gly          #   220                                                                        - His Ser Leu Gly Ile Pro Trp Ala Pro Leu Se - #r Ser Cys Pro Ser Gln          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Le - #u His Ser Gly Leu Phe          #               255                                                            - Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gl - #y Ile Ser Pro Glu Leu          #           270                                                                - Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Va - #l Ala Asp Phe Ala Thr          #       285                                                                    - Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Me - #t Ala Pro Ala Leu Gln          #   300                                                                        - Pro                                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:183:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 320 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:183:                                - Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro          #                15                                                            - Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser          #            30                                                                - Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val          #        45                                                                    - Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu          #    60                                                                        - Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg          #80                                                                            - His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys          #                95                                                            - Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr          #           110                                                                - Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pr - #o Ser Gly Pro Ile Ser          #       125                                                                    - Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Se - #r His Lys Ser Pro Asn          #   140                                                                        - Met Ala Thr Gln Gly Ala Met Pro Ala Phe Al - #a Ser Ala Phe Gln Arg          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Arg Ala Gly Gly Val Leu Val Ala Ser His Le - #u Gln Ser Phe Leu Glu          #               175                                                            - Val Ser Tyr Arg Val Leu Arg His Leu Ala Gl - #n Pro Thr Pro Leu Gly          #           190                                                                - Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Le - #u Lys Ser Leu Glu Gln          #       205                                                                    - Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Le - #u Gln Glu Lys Leu Cys          #   220                                                                        - Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Le - #u Val Leu Leu Gly His          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Se - #r Cys Pro Ser Gln Ala          #               255                                                            - Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu Hi - #s Ser Gly Leu Phe Leu          #           270                                                                - Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Il - #e Ser Pro Glu Leu Gly          #       285                                                                    - Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Al - #a Asp Phe Ala Thr Thr          #   300                                                                        - Ile Trp Gln Gln Met Glu Glu Leu Gly Met Al - #a Pro Ala Leu Gln Pro          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - (2) INFORMATION FOR SEQ ID NO:184:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 305 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:184:                                - Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro          #                15                                                            - Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser          #            30                                                                - Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val          #        45                                                                    - Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu          #    60                                                                        - Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg          #80                                                                            - His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys          #                95                                                            - Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr          #           110                                                                - Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gl - #y Ser Gly Gly Gly Ser          #       125                                                                    - Asn Met Ala Ser Ala Phe Gln Arg Arg Ala Gl - #y Gly Val Leu Val Ala          #   140                                                                        - Ser His Leu Gln Ser Phe Leu Glu Val Ser Ty - #r Arg Val Leu Arg His          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Leu Ala Gln Pro Thr Pro Leu Gly Pro Ala Se - #r Ser Leu Pro Gln Ser          #               175                                                            - Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Ly - #s Ile Gln Gly Asp Gly          #           190                                                                - Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Ty - #r Lys Leu Cys His Pro          #       205                                                                    - Glu Glu Leu Val Leu Leu Gly His Ser Leu Gl - #y Ile Pro Trp Ala Pro          #   220                                                                        - Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Le - #u Ala Gly Cys Leu Ser          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gl - #y Leu Leu Gln Ala Leu          #               255                                                            - Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Le - #u Asp Thr Leu Gln Leu          #           270                                                                - Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gl - #n Gln Met Glu Glu Leu          #       285                                                                    - Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gl - #y Ala Met Pro Ala Phe          #   300                                                                        - Ala                                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:185:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 320 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:185:                                - Asn Cys Ser Ile Met Ile Asp Glu Ile Ile Hi - #s His Leu Lys Arg Pro          #                15                                                            - Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu As - #n Asp Glu Asp Val Ser          #            30                                                                - Ile Leu Met Asp Arg Asn Leu Arg Leu Pro As - #n Leu Glu Ser Phe Val          #        45                                                                    - Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gl - #y Ile Glu Ala Ile Leu          #    60                                                                        - Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Th - #r Ala Ala Pro Ser Arg          #80                                                                            - His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gl - #n Glu Phe Arg Glu Lys          #                95                                                            - Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Al - #a Gln Glu Gln Gln Tyr          #           110                                                                - Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pr - #o Ser Gly Pro Ile Ser          #       125                                                                    - Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Se - #r His Lys Ser Pro Asn          #   140                                                                        - Met Ala Ser Ala Phe Gln Arg Arg Ala Gly Gl - #y Val Leu Val Ala Ser          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - His Leu Gln Ser Phe Leu Glu Val Ser Tyr Ar - #g Val Leu Arg His Leu          #               175                                                            - Ala Gln Pro Thr Pro Leu Gly Pro Ala Ser Se - #r Leu Pro Gln Ser Phe          #           190                                                                - Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Il - #e Gln Gly Asp Gly Ala          #       205                                                                    - Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Ly - #s Leu Cys His Pro Glu          #   220                                                                        - Glu Leu Val Leu Leu Gly His Ser Leu Gly Il - #e Pro Trp Ala Pro Leu          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Al - #a Gly Cys Leu Ser Gln          #               255                                                            - Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Le - #u Leu Gln Ala Leu Glu          #           270                                                                - Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu As - #p Thr Leu Gln Leu Asp          #       285                                                                    - Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gl - #n Met Glu Glu Leu Gly          #   300                                                                        - Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Al - #a Met Pro Ala Phe Ala          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - (2) INFORMATION FOR SEQ ID NO:186:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 321 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:186:                                - Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va - #l Ser Ile Leu Met Asp          #                15                                                            - Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph - #e Val Arg Ala Val Lys          #            30                                                                - Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Il - #e Leu Arg Asn Leu Gln          #        45                                                                    - Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Se - #r Arg His Pro Ile Ile          #    60                                                                        - Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Gl - #u Lys Leu Thr Phe Tyr          #80                                                                            - Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gl - #n Gly Gly Gly Ser Asn          #                95                                                            - Cys Ser Ile Met Ile Asp Glu Ile Ile His Hi - #s Leu Lys Arg Pro Pro          #           110                                                                - Ala Pro Leu Tyr Val Glu Gly Gly Gly Gly Se - #r Pro Gly Glu Pro Ser          #       125                                                                    - Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pr - #o Ser Lys Glu Ser His          #   140                                                                        - Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Me - #t Pro Ala Phe Ala Ser          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Va - #l Ala Ser His Leu Gln          #               175                                                            - Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Ar - #g His Leu Ala Gln Pro          #           190                                                                - Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Le - #u Leu Lys Ser Leu Glu          #       205                                                                    - Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Al - #a Leu Gln Glu Lys Leu          #   220                                                                        - Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Gl - #u Leu Val Leu Leu Gly          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - His Ser Leu Gly Ile Pro Trp Ala Pro Leu Se - #r Ser Cys Pro Ser Gln          #               255                                                            - Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Le - #u His Ser Gly Leu Phe          #           270                                                                - Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gl - #y Ile Ser Pro Glu Leu          #       285                                                                    - Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Va - #l Ala Asp Phe Ala Thr          #   300                                                                        - Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Me - #t Ala Pro Ala Leu Gln          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Pro                                                                          - (2) INFORMATION FOR SEQ ID NO:187:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 321 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:187:                                - Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg As - #n Leu Gln Pro Cys Leu          #                15                                                            - Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pr - #o Ile Ile Ile Lys Ala          #            30                                                                - Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Th - #r Phe Tyr Leu Val Thr          #        45                                                                    - Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gl - #y Ser Asn Cys Ser Ile          #    60                                                                        - Met Ile Asp Glu Ile Ile His His Leu Lys Ar - #g Pro Pro Ala Pro Leu          #80                                                                            - Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va - #l Ser Ile Leu Met Asp          #                95                                                            - Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph - #e Val Arg Ala Val Lys          #           110                                                                - Asn Leu Glu Tyr Val Glu Gly Gly Gly Gly Se - #r Pro Gly Glu Pro Ser          #       125                                                                    - Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pr - #o Ser Lys Glu Ser His          #   140                                                                        - Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Me - #t Pro Ala Phe Ala Ser          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Va - #l Ala Ser His Leu Gln          #               175                                                            - Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Ar - #g His Leu Ala Gln Pro          #           190                                                                - Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Le - #u Leu Lys Ser Leu Glu          #       205                                                                    - Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Al - #a Leu Gln Glu Lys Leu          #   220                                                                        - Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Gl - #u Leu Val Leu Leu Gly          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - His Ser Leu Gly Ile Pro Trp Ala Pro Leu Se - #r Ser Cys Pro Ser Gln          #               255                                                            - Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Le - #u His Ser Gly Leu Phe          #           270                                                                - Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gl - #y Ile Ser Pro Glu Leu          #       285                                                                    - Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Va - #l Ala Asp Phe Ala Thr          #   300                                                                        - Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Me - #t Ala Pro Ala Leu Gln          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Pro                                                                          - (2) INFORMATION FOR SEQ ID NO:188:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 321 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:188:                                - Ala Pro Ser Arg His Pro Ile Ile Ile Lys Al - #a Gly Asp Trp Gln Glu          #                15                                                            - Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Th - #r Leu Glu Gln Ala Gln          #            30                                                                - Glu Gln Gln Gly Gly Gly Ser Asn Cys Ser Il - #e Met Ile Asp Glu Ile          #        45                                                                    - Ile His His Leu Lys Arg Pro Pro Ala Pro Le - #u Leu Asp Pro Asn Asn          #    60                                                                        - Leu Asn Asp Glu Asp Val Ser Ile Leu Met As - #p Arg Asn Leu Arg Leu          #80                                                                            - Pro Asn Leu Glu Ser Phe Val Arg Ala Val Ly - #s Asn Leu Glu Asn Ala          #                95                                                            - Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gl - #n Pro Cys Leu Pro Ser          #           110                                                                - Ala Thr Ala Tyr Val Glu Gly Gly Gly Gly Se - #r Pro Gly Glu Pro Ser          #       125                                                                    - Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pr - #o Ser Lys Glu Ser His          #   140                                                                        - Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Me - #t Pro Ala Phe Ala Ser          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Va - #l Ala Ser His Leu Gln          #               175                                                            - Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Ar - #g His Leu Ala Gln Pro          #           190                                                                - Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Le - #u Leu Lys Ser Leu Glu          #       205                                                                    - Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Al - #a Leu Gln Glu Lys Leu          #   220                                                                        - Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Gl - #u Leu Val Leu Leu Gly          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - His Ser Leu Gly Ile Pro Trp Ala Pro Leu Se - #r Ser Cys Pro Ser Gln          #               255                                                            - Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Le - #u His Ser Gly Leu Phe          #           270                                                                - Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gl - #y Ile Ser Pro Glu Leu          #       285                                                                    - Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Va - #l Ala Asp Phe Ala Thr          #   300                                                                        - Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Me - #t Ala Pro Ala Leu Gln          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Pro                                                                          - (2) INFORMATION FOR SEQ ID NO:189:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 321 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:189:                                - Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Le - #u Thr Phe Tyr Leu Val          #                15                                                            - Thr Leu Glu Gln Ala Gln Glu Gln Gln Gly Gl - #y Gly Ser Asn Cys Ser          #            30                                                                - Ile Met Ile Asp Glu Ile Ile His His Leu Ly - #s Arg Pro Pro Ala Pro          #        45                                                                    - Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu As - #p Val Ser Ile Leu Met          #    60                                                                        - Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Se - #r Phe Val Arg Ala Val          #80                                                                            - Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Al - #a Ile Leu Arg Asn Leu          #                95                                                            - Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pr - #o Ser Arg His Pro Ile          #           110                                                                - Ile Ile Lys Tyr Val Glu Gly Gly Gly Gly Se - #r Pro Gly Glu Pro Ser          #       125                                                                    - Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pr - #o Ser Lys Glu Ser His          #   140                                                                        - Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Me - #t Pro Ala Phe Ala Ser          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Va - #l Ala Ser His Leu Gln          #               175                                                            - Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Ar - #g His Leu Ala Gln Pro          #           190                                                                - Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Le - #u Leu Lys Ser Leu Glu          #       205                                                                    - Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Al - #a Leu Gln Glu Lys Leu          #   220                                                                        - Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Gl - #u Leu Val Leu Leu Gly          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - His Ser Leu Gly Ile Pro Trp Ala Pro Leu Se - #r Ser Cys Pro Ser Gln          #               255                                                            - Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Le - #u His Ser Gly Leu Phe          #           270                                                                - Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gl - #y Ile Ser Pro Glu Leu          #       285                                                                    - Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Va - #l Ala Asp Phe Ala Thr          #   300                                                                        - Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Me - #t Ala Pro Ala Leu Gln          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Pro                                                                          - (2) INFORMATION FOR SEQ ID NO:190:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 329 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:190:                                - Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va - #l Ser Ile Leu Met Asp          #                15                                                            - Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph - #e Val Arg Ala Val Lys          #            30                                                                - Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Il - #e Leu Arg Asn Leu Gln          #        45                                                                    - Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Se - #r Arg His Pro Ile Ile          #    60                                                                        - Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Gl - #u Lys Leu Thr Phe Tyr          #80                                                                            - Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gl - #n Gly Gly Gly Ser Gly          #                95                                                            - Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser Il - #e Met Ile Asp Glu Ile          #           110                                                                - Ile His His Leu Lys Arg Pro Pro Ala Pro Le - #u Tyr Val Glu Gly Gly          #       125                                                                    - Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il - #e Ser Thr Ile Asn Pro          #   140                                                                        - Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr - #o Asn Met Ala Thr Gln          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gl - #n Arg Arg Ala Gly Gly          #               175                                                            - Val Leu Val Ala Ser His Leu Gln Ser Phe Le - #u Glu Val Ser Tyr Arg          #           190                                                                - Val Leu Arg His Leu Ala Gln Pro Ser Gly Gl - #y Ser Gly Gly Ser Gln          #       205                                                                    - Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Ar - #g Lys Ile Gln Gly Asp          #   220                                                                        - Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Th - #r Tyr Lys Leu Cys His          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Pro Glu Glu Leu Val Leu Leu Gly His Ser Le - #u Gly Ile Pro Trp Ala          #               255                                                            - Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gl - #n Leu Ala Gly Cys Leu          #           270                                                                - Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gl - #n Gly Leu Leu Gln Ala          #       285                                                                    - Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Th - #r Leu Asp Thr Leu Gln          #   300                                                                        - Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Tr - #p Gln Gln Met Glu Glu          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Leu Gly Met Ala Pro Ala Leu Gln Pro                                                          325                                                            - (2) INFORMATION FOR SEQ ID NO:191:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 329 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:191:                                - Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg As - #n Leu Gln Pro Cys Leu          #                15                                                            - Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pr - #o Ile Ile Ile Lys Ala          #            30                                                                - Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Th - #r Phe Tyr Leu Val Thr          #        45                                                                    - Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gl - #y Ser Gly Gly Gly Ser          #    60                                                                        - Gly Gly Gly Ser Asn Cys Ser Ile Met Ile As - #p Glu Ile Ile His His          #80                                                                            - Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pr - #o Asn Asn Leu Asn Asp          #                95                                                            - Glu Asp Val Ser Ile Leu Met Asp Arg Asn Le - #u Arg Leu Pro Asn Leu          #           110                                                                - Glu Ser Phe Val Arg Ala Val Lys Asn Leu Gl - #u Tyr Val Glu Gly Gly          #       125                                                                    - Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il - #e Ser Thr Ile Asn Pro          #   140                                                                        - Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr - #o Asn Met Ala Thr Gln          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gl - #n Arg Arg Ala Gly Gly          #               175                                                            - Val Leu Val Ala Ser His Leu Gln Ser Phe Le - #u Glu Val Ser Tyr Arg          #           190                                                                - Val Leu Arg His Leu Ala Gln Pro Ser Gly Gl - #y Ser Gly Gly Ser Gln          #       205                                                                    - Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Ar - #g Lys Ile Gln Gly Asp          #   220                                                                        - Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Th - #r Tyr Lys Leu Cys His          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Pro Glu Glu Leu Val Leu Leu Gly His Ser Le - #u Gly Ile Pro Trp Ala          #               255                                                            - Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gl - #n Leu Ala Gly Cys Leu          #           270                                                                - Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gl - #n Gly Leu Leu Gln Ala          #       285                                                                    - Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Th - #r Leu Asp Thr Leu Gln          #   300                                                                        - Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Tr - #p Gln Gln Met Glu Glu          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Leu Gly Met Ala Pro Ala Leu Gln Pro                                                          325                                                            - (2) INFORMATION FOR SEQ ID NO:192:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 329 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:192:                                - Ala Pro Ser Arg His Pro Ile Ile Ile Lys Al - #a Gly Asp Trp Gln Glu          #                15                                                            - Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Th - #r Leu Glu Gln Ala Gln          #            30                                                                - Glu Gln Gln Gly Gly Gly Ser Gly Gly Gly Se - #r Gly Gly Gly Ser Asn          #        45                                                                    - Cys Ser Ile Met Ile Asp Glu Ile Ile His Hi - #s Leu Lys Arg Pro Pro          #    60                                                                        - Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn As - #p Glu Asp Val Ser Ile          #80                                                                            - Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Le - #u Glu Ser Phe Val Arg          #                95                                                            - Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Il - #e Glu Ala Ile Leu Arg          #           110                                                                - Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Al - #a Tyr Val Glu Gly Gly          #       125                                                                    - Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il - #e Ser Thr Ile Asn Pro          #   140                                                                        - Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr - #o Asn Met Ala Thr Gln          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gl - #n Arg Arg Ala Gly Gly          #               175                                                            - Val Leu Val Ala Ser His Leu Gln Ser Phe Le - #u Glu Val Ser Tyr Arg          #           190                                                                - Val Leu Arg His Leu Ala Gln Pro Ser Gly Gl - #y Ser Gly Gly Ser Gln          #       205                                                                    - Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Ar - #g Lys Ile Gln Gly Asp          #   220                                                                        - Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Th - #r Tyr Lys Leu Cys His          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Pro Glu Glu Leu Val Leu Leu Gly His Ser Le - #u Gly Ile Pro Trp Ala          #               255                                                            - Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gl - #n Leu Ala Gly Cys Leu          #           270                                                                - Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gl - #n Gly Leu Leu Gln Ala          #       285                                                                    - Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Th - #r Leu Asp Thr Leu Gln          #   300                                                                        - Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Tr - #p Gln Gln Met Glu Glu          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Leu Gly Met Ala Pro Ala Leu Gln Pro                                                          325                                                            - (2) INFORMATION FOR SEQ ID NO:193:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 299 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:193:                                - Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser Il - #e Met Ile Asp Glu Ile          #                15                                                            - Ile His His Leu Lys Arg Pro Pro Ala Pro Le - #u Leu Asp Pro Asn Asn          #            30                                                                - Leu Asn Asp Glu Asp Val Ser Ile Leu Met As - #p Arg Asn Leu Arg Leu          #        45                                                                    - Pro Asn Leu Glu Ser Phe Val Arg Ala Val Ly - #s Asn Leu Glu Asn Ala          #    60                                                                        - Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gl - #n Pro Cys Leu Pro Ser          #80                                                                            - Ala Thr Ala Ala Pro Ser Arg His Pro Ile Il - #e Ile Lys Tyr Val Glu          #                95                                                            - Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gl - #y Pro Ile Ser Thr Ile          #           110                                                                - Asn Pro Ser Pro Pro Ser Lys Glu Ser His Ly - #s Ser Pro Asn Met Ala          #       125                                                                    - Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Al - #a Phe Gln Arg Arg Ala          #   140                                                                        - Gly Gly Val Leu Val Ala Ser His Leu Gln Se - #r Phe Leu Glu Val Ser          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Tyr Arg Val Leu Arg His Leu Ala Gln Pro Se - #r Gly Gly Ser Gly Gly          #               175                                                            - Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gl - #n Val Arg Lys Ile Gln          #           190                                                                - Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cy - #s Ala Thr Tyr Lys Leu          #       205                                                                    - Cys His Pro Glu Glu Leu Val Leu Leu Gly Hi - #s Ser Leu Gly Ile Pro          #   220                                                                        - Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Al - #a Leu Gln Leu Ala Gly          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Cys Leu Ser Gln Leu His Ser Gly Leu Phe Le - #u Tyr Gln Gly Leu Leu          #               255                                                            - Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gl - #y Pro Thr Leu Asp Thr          #           270                                                                - Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Th - #r Ile Trp Gln Gln Met          #       285                                                                    - Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pr - #o                              #   295                                                                        - (2) INFORMATION FOR SEQ ID NO:194:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 329 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:194:                                - Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys          #                15                                                            - Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp          #            30                                                                - Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser          #        45                                                                    - Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala          #    60                                                                        - Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro          #80                                                                            - Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg          #                95                                                            - Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln          #           110                                                                - Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro          #       125                                                                    - Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser          #   140                                                                        - Pro Asn Met Ala Tyr Lys Leu Cys His Pro Gl - #u Glu Leu Val Leu Leu          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Gly His Ser Leu Gly Ile Pro Trp Ala Pro Le - #u Ser Ser Cys Pro Ser          #               175                                                            - Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gl - #n Leu His Ser Gly Leu          #           190                                                                - Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Gl - #u Gly Ile Ser Pro Glu          #       205                                                                    - Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu As - #p Val Ala Asp Phe Ala          #   220                                                                        - Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gl - #y Met Ala Pro Ala Leu          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Al - #a Ser Ala Phe Gln Arg          #               255                                                            - Arg Ala Gly Gly Val Leu Val Ala Ser His Le - #u Gln Ser Phe Leu Glu          #           270                                                                - Val Ser Tyr Arg Val Leu Arg His Leu Ala Gl - #n Pro Gly Gly Gly Ser          #       285                                                                    - Asp Met Ala Thr Pro Leu Gly Pro Ala Ser Se - #r Leu Pro Gln Ser Phe          #   300                                                                        - Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Il - #e Gln Gly Asp Gly Ala          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Ala Leu Gln Glu Lys Leu Cys Ala Thr                                                          325                                                            - (2) INFORMATION FOR SEQ ID NO:195:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 329 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:195:                                - Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys          #                15                                                            - Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp          #            30                                                                - Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser          #        45                                                                    - Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala          #    60                                                                        - Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro          #80                                                                            - Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg          #                95                                                            - Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln          #           110                                                                - Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro          #       125                                                                    - Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser          #   140                                                                        - Pro Asn Met Ala Pro Glu Leu Gly Pro Thr Le - #u Asp Thr Leu Gln Leu          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gl - #n Gln Met Glu Glu Leu          #               175                                                            - Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gl - #y Ala Met Pro Ala Phe          #           190                                                                - Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Va - #l Leu Val Ala Ser His          #       205                                                                    - Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Va - #l Leu Arg His Leu Ala          #   220                                                                        - Gln Pro Gly Gly Gly Ser Asp Met Ala Thr Pr - #o Leu Gly Pro Ala Ser          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Le - #u Glu Gln Val Arg Lys          #               255                                                            - Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Ly - #s Leu Cys Ala Thr Tyr          #           270                                                                - Lys Leu Cys His Pro Glu Glu Leu Val Leu Le - #u Gly His Ser Leu Gly          #       285                                                                    - Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Se - #r Gln Ala Leu Gln Leu          #   300                                                                        - Ala Gly Cys Leu Ser Gln Leu His Ser Gly Le - #u Phe Leu Tyr Gln Gly          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Leu Leu Gln Ala Leu Glu Gly Ile Ser                                                          325                                                            - (2) INFORMATION FOR SEQ ID NO:196:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 329 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:196:                                - Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys          #                15                                                            - Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp          #            30                                                                - Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser          #        45                                                                    - Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala          #    60                                                                        - Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro          #80                                                                            - Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg          #                95                                                            - Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln          #           110                                                                - Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro          #       125                                                                    - Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser          #   140                                                                        - Pro Asn Met Ala Ser Ala Phe Gln Arg Arg Al - #a Gly Gly Val Leu Val          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Ala Ser His Leu Gln Ser Phe Leu Glu Val Se - #r Tyr Arg Val Leu Arg          #               175                                                            - His Leu Ala Gln Pro Gly Gly Gly Ser Asp Me - #t Ala Thr Pro Leu Gly          #           190                                                                - Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Le - #u Lys Ser Leu Glu Gln          #       205                                                                    - Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Le - #u Gln Glu Lys Leu Cys          #   220                                                                        - Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Le - #u Val Leu Leu Gly His          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Se - #r Cys Pro Ser Gln Ala          #               255                                                            - Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu Hi - #s Ser Gly Leu Phe Leu          #           270                                                                - Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Il - #e Ser Pro Glu Leu Gly          #       285                                                                    - Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Al - #a Asp Phe Ala Thr Thr          #   300                                                                        - Ile Trp Gln Gln Met Glu Glu Leu Gly Met Al - #a Pro Ala Leu Gln Pro          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Thr Gln Gly Ala Met Pro Ala Phe Ala                                                          325                                                            - (2) INFORMATION FOR SEQ ID NO:197:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 329 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:197:                                - Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys          #                15                                                            - Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp          #            30                                                                - Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser          #        45                                                                    - Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala          #    60                                                                        - Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro          #80                                                                            - Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg          #                95                                                            - Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln          #           110                                                                - Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro          #       125                                                                    - Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser          #   140                                                                        - Pro Asn Met Ala Met Ala Pro Ala Leu Gln Pr - #o Thr Gln Gly Ala Met          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Al - #a Gly Gly Val Leu Val          #               175                                                            - Ala Ser His Leu Gln Ser Phe Leu Glu Val Se - #r Tyr Arg Val Leu Arg          #           190                                                                - His Leu Ala Gln Pro Gly Gly Gly Ser Asp Me - #t Ala Thr Pro Leu Gly          #       205                                                                    - Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Le - #u Lys Ser Leu Glu Gln          #   220                                                                        - Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Le - #u Gln Glu Lys Leu Cys          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Le - #u Val Leu Leu Gly His          #               255                                                            - Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Se - #r Cys Pro Ser Gln Ala          #           270                                                                - Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu Hi - #s Ser Gly Leu Phe Leu          #       285                                                                    - Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Il - #e Ser Pro Glu Leu Gly          #   300                                                                        - Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Al - #a Asp Phe Ala Thr Thr          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Ile Trp Gln Gln Met Glu Glu Leu Gly                                                          325                                                            - (2) INFORMATION FOR SEQ ID NO:198:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 329 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:198:                                - Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys          #                15                                                            - Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp          #            30                                                                - Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser          #        45                                                                    - Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala          #    60                                                                        - Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro          #80                                                                            - Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg          #                95                                                            - Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln          #           110                                                                - Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro          #       125                                                                    - Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser          #   140                                                                        - Pro Asn Met Ala Thr Gln Gly Ala Met Pro Al - #a Phe Ala Ser Ala Phe          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Gln Arg Arg Ala Gly Gly Val Leu Val Ala Se - #r His Leu Gln Ser Phe          #               175                                                            - Leu Glu Val Ser Tyr Arg Val Leu Arg His Le - #u Ala Gln Pro Gly Gly          #           190                                                                - Gly Ser Asp Met Ala Thr Pro Leu Gly Pro Al - #a Ser Ser Leu Pro Gln          #       205                                                                    - Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Ar - #g Lys Ile Gln Gly Asp          #   220                                                                        - Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Th - #r Tyr Lys Leu Cys His          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Pro Glu Glu Leu Val Leu Leu Gly His Ser Le - #u Gly Ile Pro Trp Ala          #               255                                                            - Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gl - #n Leu Ala Gly Cys Leu          #           270                                                                - Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gl - #n Gly Leu Leu Gln Ala          #       285                                                                    - Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Th - #r Leu Asp Thr Leu Gln          #   300                                                                        - Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Tr - #p Gln Gln Met Glu Glu          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Leu Gly Met Ala Pro Ala Leu Gln Pro                                                          325                                                            - (2) INFORMATION FOR SEQ ID NO:199:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 319 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:199:                                - Met Ala Asn Cys Ser Asn Met Ile Asp Glu Il - #e Ile Thr His Leu Lys          #                15                                                            - Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn As - #n Leu Asn Gly Glu Asp          #            30                                                                - Gln Asp Ile Leu Met Asp Asn Asn Leu Arg Ar - #g Pro Asn Leu Glu Ala          #        45                                                                    - Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Al - #a Ser Ala Ile Glu Ser          #    60                                                                        - Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Le - #u Ala Thr Ala Ala Pro          #80                                                                            - Thr Arg His Pro Ile His Ile Lys Asp Gly As - #p Trp Asn Glu Phe Arg          #                95                                                            - Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Gl - #u Asn Ala Gln Ala Gln          #           110                                                                - Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro          #       125                                                                    - Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser          #   140                                                                        - Pro Asn Met Ala Thr Gln Gly Ala Met Pro Al - #a Phe Ala Ser Ala Phe          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Gln Arg Arg Ala Gly Gly Val Leu Val Ala Se - #r His Leu Gln Ser Phe          #               175                                                            - Leu Glu Val Ser Tyr Arg Val Leu Arg His Le - #u Ala Gln Pro Ser Gly          #           190                                                                - Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Ly - #s Ser Leu Glu Gln Val          #       205                                                                    - Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gl - #n Glu Lys Leu Cys Ala          #   220                                                                        - Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Va - #l Leu Leu Gly His Ser          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cy - #s Pro Ser Gln Ala Leu          #               255                                                            - Gln Leu Ala Gly Cys Leu Ser Gln Leu His Se - #r Gly Leu Phe Leu Tyr          #           270                                                                - Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Se - #r Pro Glu Leu Gly Pro          #       285                                                                    - Thr Leu Asp Thr Leu Gln Leu Asp Val Ala As - #p Phe Ala Thr Thr Ile          #   300                                                                        - Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pr - #o Ala Leu Gln Pro              305                 3 - #10                 3 - #15                            - (2) INFORMATION FOR SEQ ID NO:200:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 322 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:200:                                - Met Ala Asn Cys Ser Asn Met Ile Asp Glu Il - #e Ile Thr His Leu Lys          #                15                                                            - Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn As - #n Leu Asn Gly Glu Asp          #            30                                                                - Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Ar - #g Pro Asn Leu Glu Ala          #        45                                                                    - Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Al - #a Ser Ala Ile Glu Ser          #    60                                                                        - Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Le - #u Ala Thr Ala Ala Pro          #80                                                                            - Thr Arg His Pro Ile Ile Ile Arg Asp Gly As - #p Trp Asn Glu Phe Arg          #                95                                                            - Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Gl - #u Asn Ala Gln Ala Gln          #           110                                                                - Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro          #       125                                                                    - Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser          #   140                                                                        - Pro Asn Met Ala Thr Gln Gly Ala Met Pro Al - #a Phe Ala Ser Ala Phe          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Gln Arg Arg Ala Gly Gly Val Leu Val Ala Se - #r His Leu Gln Ser Phe          #               175                                                            - Leu Glu Val Ser Tyr Arg Val Leu Arg His Le - #u Ala Gln Pro Thr Pro          #           190                                                                - Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Ph - #e Leu Leu Lys Ser Leu          #       205                                                                    - Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Al - #a Ala Leu Gln Glu Lys          #   220                                                                        - Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Gl - #u Glu Leu Val Leu Leu          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Gly His Ser Leu Gly Ile Pro Trp Ala Pro Le - #u Ser Ser Cys Pro Ser          #               255                                                            - Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gl - #n Leu His Ser Gly Leu          #           270                                                                - Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Gl - #u Gly Ile Ser Pro Glu          #       285                                                                    - Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu As - #p Val Ala Asp Phe Ala          #   300                                                                        - Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gl - #y Met Ala Pro Ala Leu          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Gln Pro                                                                      - (2) INFORMATION FOR SEQ ID NO:201:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 319 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:201:                                - Met Ala Asn Cys Ser Asn Met Ile Asp Glu Il - #e Ile Thr His Leu Lys          #                15                                                            - Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn As - #n Leu Asn Gly Glu Asp          #            30                                                                - Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Ar - #g Pro Asn Leu Glu Ala          #        45                                                                    - Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Al - #a Ser Ala Ile Glu Ser          #    60                                                                        - Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Le - #u Ala Thr Ala Ala Pro          #80                                                                            - Thr Arg His Pro Ile Ile Ile Arg Asp Gly As - #p Trp Asn Glu Phe Arg          #                95                                                            - Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Gl - #u Asn Ala Gln Ala Gln          #           110                                                                - Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro          #       125                                                                    - Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser          #   140                                                                        - Pro Asn Met Ala Thr Gln Gly Ala Met Pro Al - #a Phe Ala Ser Ala Phe          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Gln Arg Arg Ala Gly Gly Val Leu Val Ala Se - #r His Leu Gln Ser Phe          #               175                                                            - Leu Glu Val Ser Tyr Arg Val Leu Arg His Le - #u Ala Gln Pro Ser Gly          #           190                                                                - Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Ly - #s Ser Leu Glu Gln Val          #       205                                                                    - Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gl - #n Glu Lys Leu Cys Ala          #   220                                                                        - Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Va - #l Leu Leu Gly His Ser          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cy - #s Pro Ser Gln Ala Leu          #               255                                                            - Gln Leu Ala Gly Cys Leu Ser Gln Leu His Se - #r Gly Leu Phe Leu Tyr          #           270                                                                - Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Se - #r Pro Glu Leu Gly Pro          #       285                                                                    - Thr Leu Asp Thr Leu Gln Leu Asp Val Ala As - #p Phe Ala Thr Thr Ile          #   300                                                                        - Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pr - #o Ala Leu Gln Pro              305                 3 - #10                 3 - #15                            - (2) INFORMATION FOR SEQ ID NO:202:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 322 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:202:                                - Met Ala Asn Cys Ser Asn Met Ile Asp Glu Il - #e Ile Thr His Leu Lys          #                15                                                            - Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn As - #n Leu Asn Gly Glu Asp          #            30                                                                - Gln Asp Ile Leu Met Asp Asn Asn Leu Arg Ar - #g Pro Asn Leu Glu Ala          #        45                                                                    - Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Al - #a Ser Ala Ile Glu Ser          #    60                                                                        - Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Le - #u Ala Thr Ala Ala Pro          #80                                                                            - Thr Arg His Pro Ile His Ile Lys Asp Gly As - #p Trp Asn Glu Phe Arg          #                95                                                            - Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Gl - #u Asn Ala Gln Ala Gln          #           110                                                                - Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro          #       125                                                                    - Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser          #   140                                                                        - Pro Asn Met Ala Thr Gln Gly Ala Met Pro Al - #a Phe Ala Ser Ala Phe          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Gln Arg Arg Ala Gly Gly Val Leu Val Ala Se - #r His Leu Gln Ser Phe          #               175                                                            - Leu Glu Val Ser Tyr Arg Val Leu Arg His Le - #u Ala Gln Pro Thr Pro          #           190                                                                - Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Ph - #e Leu Leu Lys Ser Leu          #       205                                                                    - Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Al - #a Ala Leu Gln Glu Lys          #   220                                                                        - Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Gl - #u Glu Leu Val Leu Leu          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Gly His Ser Leu Gly Ile Pro Trp Ala Pro Le - #u Ser Ser Cys Pro Ser          #               255                                                            - Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gl - #n Leu His Ser Gly Leu          #           270                                                                - Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Gl - #u Gly Ile Ser Pro Glu          #       285                                                                    - Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu As - #p Val Ala Asp Phe Ala          #   300                                                                        - Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gl - #y Met Ala Pro Ala Leu          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Gln Pro                                                                      - (2) INFORMATION FOR SEQ ID NO:203:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 306 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:203:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Glu Val His Pro Leu Pro Thr Pro Va - #l Leu Leu Pro Ala Val          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Me - #t Glu Glu Thr Lys Ala          #               175                                                            - Gln Asp Ile Leu Gly Ala Val Thr Leu Leu Le - #u Glu Gly Val Met Ala          #           190                                                                - Ala Arg Gly Gln Leu Gly Pro Thr Cys Leu Se - #r Ser Leu Leu Gly Gln          #       205                                                                    - Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Al - #a Leu Gln Ser Leu Leu          #   220                                                                        - Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Th - #r Ala His Lys Asp Pro          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Asn Ala Ile Phe Leu Ser Phe Gln His Leu Le - #u Arg Gly Lys Val Arg          #               255                                                            - Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cy - #s Val Arg Glu Phe Gly          #           270                                                                - Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cy - #s Asp Leu Arg Val Leu          #       285                                                                    - Ser Lys Leu Leu Arg Asp Ser His Val Leu Hi - #s Ser Arg Leu Ser Gln          #   300                                                                        - Cys Pro                                                                      305                                                                            - (2) INFORMATION FOR SEQ ID NO:204:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 306 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:204:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu          #               175                                                            - Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln          #           190                                                                - Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln          #       205                                                                    - Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Leu          #   220                                                                        - Pro Pro Gln Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu          #               255                                                            - Val Gly Gly Ser Thr Leu Cys Val Arg Glu Ph - #e Gly Gly Asn Met Ala          #           270                                                                - Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu          #       285                                                                    - Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val          #   300                                                                        - His Pro                                                                      305                                                                            - (2) INFORMATION FOR SEQ ID NO:205:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 306 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:205:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Val Leu Leu Pro Ala Val Asp Phe Se - #r Leu Gly Glu Trp Lys          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Thr Gln Met Glu Glu Thr Lys Ala Gln Asp Il - #e Leu Gly Ala Val Thr          #               175                                                            - Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gl - #y Gln Leu Gly Pro Thr          #           190                                                                - Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gl - #y Gln Val Arg Leu Leu          #       205                                                                    - Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gl - #n Leu Pro Pro Gln Gly          #   220                                                                        - Arg Thr Thr Ala His Lys Asp Pro Asn Ala Il - #e Phe Leu Ser Phe Gln          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - His Leu Leu Arg Gly Lys Val Arg Phe Leu Me - #t Leu Val Gly Gly Ser          #               255                                                            - Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Me - #t Ala Ser Pro Ala Pro          #           270                                                                - Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Le - #u Leu Arg Asp Ser His          #       285                                                                    - Val Leu His Ser Arg Leu Ser Gln Cys Pro Gl - #u Val His Pro Leu Pro          #   300                                                                        - Thr Pro                                                                      305                                                                            - (2) INFORMATION FOR SEQ ID NO:206:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 306 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:206:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Ala Val Asp Phe Ser Leu Gly Glu Tr - #p Lys Thr Gln Met Glu          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Glu Thr Lys Ala Gln Asp Ile Leu Gly Ala Va - #l Thr Leu Leu Leu Glu          #               175                                                            - Gly Val Met Ala Ala Arg Gly Gln Leu Gly Pr - #o Thr Cys Leu Ser Ser          #           190                                                                - Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Le - #u Leu Leu Gly Ala Leu          #       205                                                                    - Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro Gl - #n Gly Arg Thr Thr Ala          #   220                                                                        - His Lys Asp Pro Asn Ala Ile Phe Leu Ser Ph - #e Gln His Leu Leu Arg          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Gly Lys Val Arg Phe Leu Met Leu Val Gly Gl - #y Ser Thr Leu Cys Val          #               255                                                            - Arg Glu Phe Gly Gly Asn Met Ala Ser Pro Al - #a Pro Pro Ala Cys Asp          #           270                                                                - Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Se - #r His Val Leu His Ser          #       285                                                                    - Arg Leu Ser Gln Cys Pro Glu Val His Pro Le - #u Pro Thr Pro Val Leu          #   300                                                                        - Leu Pro                                                                      305                                                                            - (2) INFORMATION FOR SEQ ID NO:207:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 306 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:207:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Asp Phe Ser Leu Gly Glu Trp Lys Th - #r Gln Met Glu Glu Thr          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Lys Ala Gln Asp Ile Leu Gly Ala Val Thr Le - #u Leu Leu Glu Gly Val          #               175                                                            - Met Ala Ala Arg Gly Gln Leu Gly Pro Thr Cy - #s Leu Ser Ser Leu Leu          #           190                                                                - Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Le - #u Gly Ala Leu Gln Ser          #       205                                                                    - Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly Ar - #g Thr Thr Ala His Lys          #   220                                                                        - Asp Pro Asn Ala Ile Phe Leu Ser Phe Gln Hi - #s Leu Leu Arg Gly Lys          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Val Arg Phe Leu Met Leu Val Gly Gly Ser Th - #r Leu Cys Val Arg Glu          #               255                                                            - Phe Gly Gly Asn Met Ala Ser Pro Ala Pro Pr - #o Ala Cys Asp Leu Arg          #           270                                                                - Val Leu Ser Lys Leu Leu Arg Asp Ser His Va - #l Leu His Ser Arg Leu          #       285                                                                    - Ser Gln Cys Pro Glu Val His Pro Leu Pro Th - #r Pro Val Leu Leu Pro          #   300                                                                        - Ala Val                                                                      305                                                                            - (2) INFORMATION FOR SEQ ID NO:208:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 306 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:208:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Gly Glu Trp Lys Thr Gln Met Glu Gl - #u Thr Lys Ala Gln Asp          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gl - #y Val Met Ala Ala Arg          #               175                                                            - Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser Le - #u Leu Gly Gln Leu Ser          #           190                                                                - Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gl - #n Ser Leu Leu Gly Thr          #       205                                                                    - Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala Hi - #s Lys Asp Pro Asn Ala          #   220                                                                        - Ile Phe Leu Ser Phe Gln His Leu Leu Arg Gl - #y Lys Val Arg Phe Leu          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Met Leu Val Gly Gly Ser Thr Leu Cys Val Ar - #g Glu Phe Gly Gly Asn          #               255                                                            - Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Le - #u Arg Val Leu Ser Lys          #           270                                                                - Leu Leu Arg Asp Ser His Val Leu His Ser Ar - #g Leu Ser Gln Cys Pro          #       285                                                                    - Glu Val His Pro Leu Pro Thr Pro Val Leu Le - #u Pro Ala Val Asp Phe          #   300                                                                        - Ser Leu                                                                      305                                                                            - (2) INFORMATION FOR SEQ ID NO:209:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 306 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:209:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Gly Pro Thr Cys Leu Ser Ser Leu Le - #u Gly Gln Leu Ser Gly          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Se - #r Leu Leu Gly Thr Gln          #               175                                                            - Leu Pro Pro Gln Gly Arg Thr Thr Ala His Ly - #s Asp Pro Asn Ala Ile          #           190                                                                - Phe Leu Ser Phe Gln His Leu Leu Arg Gly Ly - #s Val Arg Phe Leu Met          #       205                                                                    - Leu Val Gly Gly Ser Thr Leu Cys Val Arg Gl - #u Phe Gly Gly Asn Met          #   220                                                                        - Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Ar - #g Val Leu Ser Lys Leu          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Leu Arg Asp Ser His Val Leu His Ser Arg Le - #u Ser Gln Cys Pro Glu          #               255                                                            - Val His Pro Leu Pro Thr Pro Val Leu Leu Pr - #o Ala Val Asp Phe Ser          #           270                                                                - Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Th - #r Lys Ala Gln Asp Ile          #       285                                                                    - Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Va - #l Met Ala Ala Arg Gly          #   300                                                                        - Gln Leu                                                                      305                                                                            - (2) INFORMATION FOR SEQ ID NO:210:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 306 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:210:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Gly Thr Gln Leu Pro Pro Gln Gly Ar - #g Thr Thr Ala His Lys          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Asp Pro Asn Ala Ile Phe Leu Ser Phe Gln Hi - #s Leu Leu Arg Gly Lys          #               175                                                            - Val Arg Phe Leu Met Leu Val Gly Gly Ser Th - #r Leu Cys Val Arg Glu          #           190                                                                - Phe Gly Gly Asn Met Ala Ser Pro Ala Pro Pr - #o Ala Cys Asp Leu Arg          #       205                                                                    - Val Leu Ser Lys Leu Leu Arg Asp Ser His Va - #l Leu His Ser Arg Leu          #   220                                                                        - Ser Gln Cys Pro Glu Val His Pro Leu Pro Th - #r Pro Val Leu Leu Pro          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Th - #r Gln Met Glu Glu Thr          #               255                                                            - Lys Ala Gln Asp Ile Leu Gly Ala Val Thr Le - #u Leu Leu Glu Gly Val          #           270                                                                - Met Ala Ala Arg Gly Gln Leu Gly Pro Thr Cy - #s Leu Ser Ser Leu Leu          #       285                                                                    - Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Le - #u Gly Ala Leu Gln Ser          #   300                                                                        - Leu Leu                                                                      305                                                                            - (2) INFORMATION FOR SEQ ID NO:211:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 306 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:211:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Gly Arg Thr Thr Ala His Lys Asp Pr - #o Asn Ala Ile Phe Leu          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Ser Phe Gln His Leu Leu Arg Gly Lys Val Ar - #g Phe Leu Met Leu Val          #               175                                                            - Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gl - #y Gly Asn Met Ala Ser          #           190                                                                - Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Le - #u Ser Lys Leu Leu Arg          #       205                                                                    - Asp Ser His Val Leu His Ser Arg Leu Ser Gl - #n Cys Pro Glu Val His          #   220                                                                        - Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Va - #l Asp Phe Ser Leu Gly          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Al - #a Gln Asp Ile Leu Gly          #               255                                                            - Ala Val Thr Leu Leu Leu Glu Gly Val Met Al - #a Ala Arg Gly Gln Leu          #           270                                                                - Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gl - #n Leu Ser Gly Gln Val          #       285                                                                    - Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Le - #u Gly Thr Gln Leu Pro          #   300                                                                        - Pro Gln                                                                      305                                                                            - (2) INFORMATION FOR SEQ ID NO:212:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 306 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:212:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Ala His Lys Asp Pro Asn Ala Ile Ph - #e Leu Ser Phe Gln His          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Leu Leu Arg Gly Lys Val Arg Phe Leu Met Le - #u Val Gly Gly Ser Thr          #               175                                                            - Leu Cys Val Arg Glu Phe Gly Gly Asn Met Al - #a Ser Pro Ala Pro Pro          #           190                                                                - Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Le - #u Arg Asp Ser His Val          #       205                                                                    - Leu His Ser Arg Leu Ser Gln Cys Pro Glu Va - #l His Pro Leu Pro Thr          #   220                                                                        - Pro Val Leu Leu Pro Ala Val Asp Phe Ser Le - #u Gly Glu Trp Lys Thr          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Gln Met Glu Glu Thr Lys Ala Gln Asp Ile Le - #u Gly Ala Val Thr Leu          #               255                                                            - Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gl - #n Leu Gly Pro Thr Cys          #           270                                                                - Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gl - #n Val Arg Leu Leu Leu          #       285                                                                    - Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Le - #u Pro Pro Gln Gly Arg          #   300                                                                        - Thr Thr                                                                      305                                                                            - (2) INFORMATION FOR SEQ ID NO:213:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 306 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:213:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Asp Pro Asn Ala Ile Phe Leu Ser Ph - #e Gln His Leu Leu Arg          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Gly Lys Val Arg Phe Leu Met Leu Val Gly Gl - #y Ser Thr Leu Cys Val          #               175                                                            - Arg Glu Phe Gly Gly Asn Met Ala Ser Pro Al - #a Pro Pro Ala Cys Asp          #           190                                                                - Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Se - #r His Val Leu His Ser          #       205                                                                    - Arg Leu Ser Gln Cys Pro Glu Val His Pro Le - #u Pro Thr Pro Val Leu          #   220                                                                        - Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Tr - #p Lys Thr Gln Met Glu          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Glu Thr Lys Ala Gln Asp Ile Leu Gly Ala Va - #l Thr Leu Leu Leu Glu          #               255                                                            - Gly Val Met Ala Ala Arg Gly Gln Leu Gly Pr - #o Thr Cys Leu Ser Ser          #           270                                                                - Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Le - #u Leu Leu Gly Ala Leu          #       285                                                                    - Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro Gl - #n Gly Arg Thr Thr Ala          #   300                                                                        - His Lys                                                                      305                                                                            - (2) INFORMATION FOR SEQ ID NO:214:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 306 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:214:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Ala Ile Phe Leu Ser Phe Gln His Le - #u Leu Arg Gly Lys Val          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Arg Phe Leu Met Leu Val Gly Gly Ser Thr Le - #u Cys Val Arg Glu Phe          #               175                                                            - Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Al - #a Cys Asp Leu Arg Val          #           190                                                                - Leu Ser Lys Leu Leu Arg Asp Ser His Val Le - #u His Ser Arg Leu Ser          #       205                                                                    - Gln Cys Pro Glu Val His Pro Leu Pro Thr Pr - #o Val Leu Leu Pro Ala          #   220                                                                        - Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gl - #n Met Glu Glu Thr Lys          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Ala Gln Asp Ile Leu Gly Ala Val Thr Leu Le - #u Leu Glu Gly Val Met          #               255                                                            - Ala Ala Arg Gly Gln Leu Gly Pro Thr Cys Le - #u Ser Ser Leu Leu Gly          #           270                                                                - Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gl - #y Ala Leu Gln Ser Leu          #       285                                                                    - Leu Gly Thr Gln Leu Pro Pro Gln Gly Arg Th - #r Thr Ala His Lys Asp          #   300                                                                        - Pro Asn                                                                      305                                                                            - (2) INFORMATION FOR SEQ ID NO:215:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 305 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:215:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Glu Val His Pro Leu Pro Thr Pro Va - #l Leu Leu Pro Ala Val          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Me - #t Glu Glu Thr Lys Ala          #               175                                                            - Gln Asp Ile Leu Gly Ala Val Thr Leu Leu Le - #u Glu Gly Val Met Ala          #           190                                                                - Ala Arg Gly Gln Leu Gly Pro Thr Cys Leu Se - #r Ser Leu Leu Gly Gln          #       205                                                                    - Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Al - #a Leu Gln Ser Leu Leu          #   220                                                                        - Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Th - #r Ala His Lys Asp Pro          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Asn Ala Ile Phe Leu Ser Phe Gln His Leu Le - #u Arg Gly Lys Val Arg          #               255                                                            - Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cy - #s Val Arg Glu Phe Gly          #           270                                                                - Asn Met Ala Ser Pro Ala Pro Pro Ala Cys As - #p Leu Arg Val Leu Ser          #       285                                                                    - Lys Leu Leu Arg Asp Ser His Val Leu His Se - #r Arg Leu Ser Gln Cys          #   300                                                                        - Pro                                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:216:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 305 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:216:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu          #               175                                                            - Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln          #           190                                                                - Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln          #       205                                                                    - Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Leu          #   220                                                                        - Pro Pro Gln Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu          #               255                                                            - Val Gly Gly Ser Thr Leu Cys Val Arg Glu Ph - #e Gly Asn Met Ala Ser          #           270                                                                - Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Le - #u Ser Lys Leu Leu Arg          #       285                                                                    - Asp Ser His Val Leu His Ser Arg Leu Ser Gl - #n Cys Pro Glu Val His          #   300                                                                        - Pro                                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:217:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 305 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:217:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Val Leu Leu Pro Ala Val Asp Phe Se - #r Leu Gly Glu Trp Lys          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Thr Gln Met Glu Glu Thr Lys Ala Gln Asp Il - #e Leu Gly Ala Val Thr          #               175                                                            - Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gl - #y Gln Leu Gly Pro Thr          #           190                                                                - Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gl - #y Gln Val Arg Leu Leu          #       205                                                                    - Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gl - #n Leu Pro Pro Gln Gly          #   220                                                                        - Arg Thr Thr Ala His Lys Asp Pro Asn Ala Il - #e Phe Leu Ser Phe Gln          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - His Leu Leu Arg Gly Lys Val Arg Phe Leu Me - #t Leu Val Gly Gly Ser          #               255                                                            - Thr Leu Cys Val Arg Glu Phe Gly Asn Met Al - #a Ser Pro Ala Pro Pro          #           270                                                                - Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Le - #u Arg Asp Ser His Val          #       285                                                                    - Leu His Ser Arg Leu Ser Gln Cys Pro Glu Va - #l His Pro Leu Pro Thr          #   300                                                                        - Pro                                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:218:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 305 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:218:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Ala Val Asp Phe Ser Leu Gly Glu Tr - #p Lys Thr Gln Met Glu          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Glu Thr Lys Ala Gln Asp Ile Leu Gly Ala Va - #l Thr Leu Leu Leu Glu          #               175                                                            - Gly Val Met Ala Ala Arg Gly Gln Leu Gly Pr - #o Thr Cys Leu Ser Ser          #           190                                                                - Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Le - #u Leu Leu Gly Ala Leu          #       205                                                                    - Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro Gl - #n Gly Arg Thr Thr Ala          #   220                                                                        - His Lys Asp Pro Asn Ala Ile Phe Leu Ser Ph - #e Gln His Leu Leu Arg          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Gly Lys Val Arg Phe Leu Met Leu Val Gly Gl - #y Ser Thr Leu Cys Val          #               255                                                            - Arg Glu Phe Gly Asn Met Ala Ser Pro Ala Pr - #o Pro Ala Cys Asp Leu          #           270                                                                - Arg Val Leu Ser Lys Leu Leu Arg Asp Ser Hi - #s Val Leu His Ser Arg          #       285                                                                    - Leu Ser Gln Cys Pro Glu Val His Pro Leu Pr - #o Thr Pro Val Leu Leu          #   300                                                                        - Pro                                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:219:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 305 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:219:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Asp Phe Ser Leu Gly Glu Trp Lys Th - #r Gln Met Glu Glu Thr          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Lys Ala Gln Asp Ile Leu Gly Ala Val Thr Le - #u Leu Leu Glu Gly Val          #               175                                                            - Met Ala Ala Arg Gly Gln Leu Gly Pro Thr Cy - #s Leu Ser Ser Leu Leu          #           190                                                                - Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Le - #u Gly Ala Leu Gln Ser          #       205                                                                    - Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly Ar - #g Thr Thr Ala His Lys          #   220                                                                        - Asp Pro Asn Ala Ile Phe Leu Ser Phe Gln Hi - #s Leu Leu Arg Gly Lys          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Val Arg Phe Leu Met Leu Val Gly Gly Ser Th - #r Leu Cys Val Arg Glu          #               255                                                            - Phe Gly Asn Met Ala Ser Pro Ala Pro Pro Al - #a Cys Asp Leu Arg Val          #           270                                                                - Leu Ser Lys Leu Leu Arg Asp Ser His Val Le - #u His Ser Arg Leu Ser          #       285                                                                    - Gln Cys Pro Glu Val His Pro Leu Pro Thr Pr - #o Val Leu Leu Pro Ala          #   300                                                                        - Val                                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:220:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 305 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:220:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Gly Glu Trp Lys Thr Gln Met Glu Gl - #u Thr Lys Ala Gln Asp          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gl - #y Val Met Ala Ala Arg          #               175                                                            - Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser Le - #u Leu Gly Gln Leu Ser          #           190                                                                - Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gl - #n Ser Leu Leu Gly Thr          #       205                                                                    - Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala Hi - #s Lys Asp Pro Asn Ala          #   220                                                                        - Ile Phe Leu Ser Phe Gln His Leu Leu Arg Gl - #y Lys Val Arg Phe Leu          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Met Leu Val Gly Gly Ser Thr Leu Cys Val Ar - #g Glu Phe Gly Asn Met          #               255                                                            - Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Ar - #g Val Leu Ser Lys Leu          #           270                                                                - Leu Arg Asp Ser His Val Leu His Ser Arg Le - #u Ser Gln Cys Pro Glu          #       285                                                                    - Val His Pro Leu Pro Thr Pro Val Leu Leu Pr - #o Ala Val Asp Phe Ser          #   300                                                                        - Leu                                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:221:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 305 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:221:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Gly Pro Thr Cys Leu Ser Ser Leu Le - #u Gly Gln Leu Ser Gly          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Se - #r Leu Leu Gly Thr Gln          #               175                                                            - Leu Pro Pro Gln Gly Arg Thr Thr Ala His Ly - #s Asp Pro Asn Ala Ile          #           190                                                                - Phe Leu Ser Phe Gln His Leu Leu Arg Gly Ly - #s Val Arg Phe Leu Met          #       205                                                                    - Leu Val Gly Gly Ser Thr Leu Cys Val Arg Gl - #u Phe Gly Asn Met Ala          #   220                                                                        - Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val          #               255                                                            - His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu          #           270                                                                - Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu          #       285                                                                    - Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln          #   300                                                                        - Leu                                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:222:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 305 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:222:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Gly Thr Gln Leu Pro Pro Gln Gly Ar - #g Thr Thr Ala His Lys          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Asp Pro Asn Ala Ile Phe Leu Ser Phe Gln Hi - #s Leu Leu Arg Gly Lys          #               175                                                            - Val Arg Phe Leu Met Leu Val Gly Gly Ser Th - #r Leu Cys Val Arg Glu          #           190                                                                - Phe Gly Asn Met Ala Ser Pro Ala Pro Pro Al - #a Cys Asp Leu Arg Val          #       205                                                                    - Leu Ser Lys Leu Leu Arg Asp Ser His Val Le - #u His Ser Arg Leu Ser          #   220                                                                        - Gln Cys Pro Glu Val His Pro Leu Pro Thr Pr - #o Val Leu Leu Pro Ala          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gl - #n Met Glu Glu Thr Lys          #               255                                                            - Ala Gln Asp Ile Leu Gly Ala Val Thr Leu Le - #u Leu Glu Gly Val Met          #           270                                                                - Ala Ala Arg Gly Gln Leu Gly Pro Thr Cys Le - #u Ser Ser Leu Leu Gly          #       285                                                                    - Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gl - #y Ala Leu Gln Ser Leu          #   300                                                                        - Leu                                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:223:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 305 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:223:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Gly Arg Thr Thr Ala His Lys Asp Pr - #o Asn Ala Ile Phe Leu          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Ser Phe Gln His Leu Leu Arg Gly Lys Val Ar - #g Phe Leu Met Leu Val          #               175                                                            - Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gl - #y Asn Met Ala Ser Pro          #           190                                                                - Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Se - #r Lys Leu Leu Arg Asp          #       205                                                                    - Ser His Val Leu His Ser Arg Leu Ser Gln Cy - #s Pro Glu Val His Pro          #   220                                                                        - Leu Pro Thr Pro Val Leu Leu Pro Ala Val As - #p Phe Ser Leu Gly Glu          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gl - #n Asp Ile Leu Gly Ala          #               255                                                            - Val Thr Leu Leu Leu Glu Gly Val Met Ala Al - #a Arg Gly Gln Leu Gly          #           270                                                                - Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Le - #u Ser Gly Gln Val Arg          #       285                                                                    - Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gl - #y Thr Gln Leu Pro Pro          #   300                                                                        - Gln                                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:224:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 305 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:224:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Gly Arg Thr Thr Ala His Lys Asp Pr - #o Asn Ala Ile Phe Leu          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Ser Phe Gln His Leu Leu Arg Gly Lys Val Ar - #g Phe Leu Met Leu Val          #               175                                                            - Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gl - #y Asn Met Ala Ser Pro          #           190                                                                - Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Se - #r Lys Leu Leu Arg Asp          #       205                                                                    - Ser His Val Leu His Ser Arg Leu Ser Gln Cy - #s Pro Glu Val His Pro          #   220                                                                        - Leu Pro Thr Pro Val Leu Leu Pro Ala Val As - #p Phe Ser Leu Gly Glu          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gl - #n Asp Ile Leu Gly Ala          #               255                                                            - Val Thr Leu Leu Leu Glu Gly Val Met Ala Al - #a Arg Gly Gln Leu Gly          #           270                                                                - Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Le - #u Ser Gly Gln Val Arg          #       285                                                                    - Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gl - #y Thr Gln Leu Pro Pro          #   300                                                                        - Gln                                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:225:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 305 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:225:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Asp Pro Asn Ala Ile Phe Leu Ser Ph - #e Gln His Leu Leu Arg          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Gly Lys Val Arg Phe Leu Met Leu Val Gly Gl - #y Ser Thr Leu Cys Val          #               175                                                            - Arg Glu Phe Gly Asn Met Ala Ser Pro Ala Pr - #o Pro Ala Cys Asp Leu          #           190                                                                - Arg Val Leu Ser Lys Leu Leu Arg Asp Ser Hi - #s Val Leu His Ser Arg          #       205                                                                    - Leu Ser Gln Cys Pro Glu Val His Pro Leu Pr - #o Thr Pro Val Leu Leu          #   220                                                                        - Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Ly - #s Thr Gln Met Glu Glu          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Thr Lys Ala Gln Asp Ile Leu Gly Ala Val Th - #r Leu Leu Leu Glu Gly          #               255                                                            - Val Met Ala Ala Arg Gly Gln Leu Gly Pro Th - #r Cys Leu Ser Ser Leu          #           270                                                                - Leu Gly Gln Leu Ser Gly Gln Val Arg Leu Le - #u Leu Gly Ala Leu Gln          #       285                                                                    - Ser Leu Leu Gly Thr Gln Leu Pro Pro Gln Gl - #y Arg Thr Thr Ala His          #   300                                                                        - Lys                                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:226:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 305 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:226:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Ala Ile Phe Leu Ser Phe Gln His Le - #u Leu Arg Gly Lys Val          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Arg Phe Leu Met Leu Val Gly Gly Ser Thr Le - #u Cys Val Arg Glu Phe          #               175                                                            - Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cy - #s Asp Leu Arg Val Leu          #           190                                                                - Ser Lys Leu Leu Arg Asp Ser His Val Leu Hi - #s Ser Arg Leu Ser Gln          #       205                                                                    - Cys Pro Glu Val His Pro Leu Pro Thr Pro Va - #l Leu Leu Pro Ala Val          #   220                                                                        - Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Me - #t Glu Glu Thr Lys Ala          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Gln Asp Ile Leu Gly Ala Val Thr Leu Leu Le - #u Glu Gly Val Met Ala          #               255                                                            - Ala Arg Gly Gln Leu Gly Pro Thr Cys Leu Se - #r Ser Leu Leu Gly Gln          #           270                                                                - Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Al - #a Leu Gln Ser Leu Leu          #       285                                                                    - Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Th - #r Ala His Lys Asp Pro          #   300                                                                        - Asn                                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:227:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 309 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:227:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu          #               175                                                            - Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln          #           190                                                                - Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln          #       205                                                                    - Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Leu          #   220                                                                        - Pro Pro Gln Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu          #               255                                                            - Val Gly Gly Ser Thr Leu Cys Val Arg Glu Ph - #e Gly Gly Asn Gly Gly          #           270                                                                - Asn Met Ala Ser Pro Ala Pro Pro Ala Cys As - #p Leu Arg Val Leu Ser          #       285                                                                    - Lys Leu Leu Arg Asp Ser His Val Leu His Se - #r Arg Leu Ser Gln Cys          #   300                                                                        - Pro Glu Val His Pro                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:228:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 309 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:228:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu          #               175                                                            - Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln          #           190                                                                - Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln          #       205                                                                    - Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Leu          #   220                                                                        - Pro Pro Gln Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu          #               255                                                            - Val Gly Gly Ser Thr Leu Cys Val Arg Glu Ph - #e Gly Gly Asn Gly Gly          #           270                                                                - Asn Met Ala Ser Pro Ala Pro Pro Ala Cys As - #p Leu Arg Val Leu Ser          #       285                                                                    - Lys Leu Leu Arg Asp Ser His Val Leu His Se - #r Arg Leu Ser Gln Cys          #   300                                                                        - Pro Glu Val His Pro                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:229:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 309 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:229:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Val Leu Leu Pro Ala Val Asp Phe Se - #r Leu Gly Glu Trp Lys          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Thr Gln Met Glu Glu Thr Lys Ala Gln Asp Il - #e Leu Gly Ala Val Thr          #               175                                                            - Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gl - #y Gln Leu Gly Pro Thr          #           190                                                                - Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gl - #y Gln Val Arg Leu Leu          #       205                                                                    - Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gl - #n Leu Pro Pro Gln Gly          #   220                                                                        - Arg Thr Thr Ala His Lys Asp Pro Asn Ala Il - #e Phe Leu Ser Phe Gln          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - His Leu Leu Arg Gly Lys Val Arg Phe Leu Me - #t Leu Val Gly Gly Ser          #               255                                                            - Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Gl - #y Gly Asn Met Ala Ser          #           270                                                                - Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Le - #u Ser Lys Leu Leu Arg          #       285                                                                    - Asp Ser His Val Leu His Ser Arg Leu Ser Gl - #n Cys Pro Glu Val His          #   300                                                                        - Pro Leu Pro Thr Pro                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:230:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 309 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:230:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Ala Val Asp Phe Ser Leu Gly Glu Tr - #p Lys Thr Gln Met Glu          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Glu Thr Lys Ala Gln Asp Ile Leu Gly Ala Va - #l Thr Leu Leu Leu Glu          #               175                                                            - Gly Val Met Ala Ala Arg Gly Gln Leu Gly Pr - #o Thr Cys Leu Ser Ser          #           190                                                                - Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Le - #u Leu Leu Gly Ala Leu          #       205                                                                    - Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro Gl - #n Gly Arg Thr Thr Ala          #   220                                                                        - His Lys Asp Pro Asn Ala Ile Phe Leu Ser Ph - #e Gln His Leu Leu Arg          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Gly Lys Val Arg Phe Leu Met Leu Val Gly Gl - #y Ser Thr Leu Cys Val          #               255                                                            - Arg Glu Phe Gly Gly Asn Gly Gly Asn Met Al - #a Ser Pro Ala Pro Pro          #           270                                                                - Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Le - #u Arg Asp Ser His Val          #       285                                                                    - Leu His Ser Arg Leu Ser Gln Cys Pro Glu Va - #l His Pro Leu Pro Thr          #   300                                                                        - Pro Val Leu Leu Pro                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:231:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 309 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:231:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Asp Phe Ser Leu Gly Glu Trp Lys Th - #r Gln Met Glu Glu Thr          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Lys Ala Gln Asp Ile Leu Gly Ala Val Thr Le - #u Leu Leu Glu Gly Val          #               175                                                            - Met Ala Ala Arg Gly Gln Leu Gly Pro Thr Cy - #s Leu Ser Ser Leu Leu          #           190                                                                - Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Le - #u Gly Ala Leu Gln Ser          #       205                                                                    - Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly Ar - #g Thr Thr Ala His Lys          #   220                                                                        - Asp Pro Asn Ala Ile Phe Leu Ser Phe Gln Hi - #s Leu Leu Arg Gly Lys          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Val Arg Phe Leu Met Leu Val Gly Gly Ser Th - #r Leu Cys Val Arg Glu          #               255                                                            - Phe Gly Gly Asn Gly Gly Asn Met Ala Ser Pr - #o Ala Pro Pro Ala Cys          #           270                                                                - Asp Leu Arg Val Leu Ser Lys Leu Leu Arg As - #p Ser His Val Leu His          #       285                                                                    - Ser Arg Leu Ser Gln Cys Pro Glu Val His Pr - #o Leu Pro Thr Pro Val          #   300                                                                        - Leu Leu Pro Ala Val                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:232:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 309 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:232:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Gly Glu Trp Lys Thr Gln Met Glu Gl - #u Thr Lys Ala Gln Asp          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gl - #y Val Met Ala Ala Arg          #               175                                                            - Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser Le - #u Leu Gly Gln Leu Ser          #           190                                                                - Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gl - #n Ser Leu Leu Gly Thr          #       205                                                                    - Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala Hi - #s Lys Asp Pro Asn Ala          #   220                                                                        - Ile Phe Leu Ser Phe Gln His Leu Leu Arg Gl - #y Lys Val Arg Phe Leu          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Met Leu Val Gly Gly Ser Thr Leu Cys Val Ar - #g Glu Phe Gly Gly Asn          #               255                                                            - Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Al - #a Cys Asp Leu Arg Val          #           270                                                                - Leu Ser Lys Leu Leu Arg Asp Ser His Val Le - #u His Ser Arg Leu Ser          #       285                                                                    - Gln Cys Pro Glu Val His Pro Leu Pro Thr Pr - #o Val Leu Leu Pro Ala          #   300                                                                        - Val Asp Phe Ser Leu                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:233:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 309 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:233:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Gly Pro Thr Cys Leu Ser Ser Leu Le - #u Gly Gln Leu Ser Gly          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Se - #r Leu Leu Gly Thr Gln          #               175                                                            - Leu Pro Pro Gln Gly Arg Thr Thr Ala His Ly - #s Asp Pro Asn Ala Ile          #           190                                                                - Phe Leu Ser Phe Gln His Leu Leu Arg Gly Ly - #s Val Arg Phe Leu Met          #       205                                                                    - Leu Val Gly Gly Ser Thr Leu Cys Val Arg Gl - #u Phe Gly Gly Asn Gly          #   220                                                                        - Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cy - #s Asp Leu Arg Val Leu          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Ser Lys Leu Leu Arg Asp Ser His Val Leu Hi - #s Ser Arg Leu Ser Gln          #               255                                                            - Cys Pro Glu Val His Pro Leu Pro Thr Pro Va - #l Leu Leu Pro Ala Val          #           270                                                                - Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Me - #t Glu Glu Thr Lys Ala          #       285                                                                    - Gln Asp Ile Leu Gly Ala Val Thr Leu Leu Le - #u Glu Gly Val Met Ala          #   300                                                                        - Ala Arg Gly Gln Leu                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:234:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 309 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:234:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Gly Thr Gln Leu Pro Pro Gln Gly Ar - #g Thr Thr Ala His Lys          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Asp Pro Asn Ala Ile Phe Leu Ser Phe Gln Hi - #s Leu Leu Arg Gly Lys          #               175                                                            - Val Arg Phe Leu Met Leu Val Gly Gly Ser Th - #r Leu Cys Val Arg Glu          #           190                                                                - Phe Gly Gly Asn Gly Gly Asn Met Ala Ser Pr - #o Ala Pro Pro Ala Cys          #       205                                                                    - Asp Leu Arg Val Leu Ser Lys Leu Leu Arg As - #p Ser His Val Leu His          #   220                                                                        - Ser Arg Leu Ser Gln Cys Pro Glu Val His Pr - #o Leu Pro Thr Pro Val          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Leu Leu Pro Ala Val Asp Phe Ser Leu Gly Gl - #u Trp Lys Thr Gln Met          #               255                                                            - Glu Glu Thr Lys Ala Gln Asp Ile Leu Gly Al - #a Val Thr Leu Leu Leu          #           270                                                                - Glu Gly Val Met Ala Ala Arg Gly Gln Leu Gl - #y Pro Thr Cys Leu Ser          #       285                                                                    - Ser Leu Leu Gly Gln Leu Ser Gly Gln Val Ar - #g Leu Leu Leu Gly Ala          #   300                                                                        - Leu Gln Ser Leu Leu                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:235:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 309 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:235:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Gly Arg Thr Thr Ala His Lys Asp Pr - #o Asn Ala Ile Phe Leu          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Ser Phe Gln His Leu Leu Arg Gly Lys Val Ar - #g Phe Leu Met Leu Val          #               175                                                            - Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gl - #y Gly Asn Gly Gly Asn          #           190                                                                - Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Le - #u Arg Val Leu Ser Lys          #       205                                                                    - Leu Leu Arg Asp Ser His Val Leu His Ser Ar - #g Leu Ser Gln Cys Pro          #   220                                                                        - Glu Val His Pro Leu Pro Thr Pro Val Leu Le - #u Pro Ala Val Asp Phe          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Ser Leu Gly Glu Trp Lys Thr Gln Met Glu Gl - #u Thr Lys Ala Gln Asp          #               255                                                            - Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gl - #y Val Met Ala Ala Arg          #           270                                                                - Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser Le - #u Leu Gly Gln Leu Ser          #       285                                                                    - Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gl - #n Ser Leu Leu Gly Thr          #   300                                                                        - Gln Leu Pro Pro Gln                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:236:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 309 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:236:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Ala His Lys Asp Pro Asn Ala Ile Ph - #e Leu Ser Phe Gln His          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Leu Leu Arg Gly Lys Val Arg Phe Leu Met Le - #u Val Gly Gly Ser Thr          #               175                                                            - Leu Cys Val Arg Glu Phe Gly Gly Asn Gly Gl - #y Asn Met Ala Ser Pro          #           190                                                                - Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Se - #r Lys Leu Leu Arg Asp          #       205                                                                    - Ser His Val Leu His Ser Arg Leu Ser Gln Cy - #s Pro Glu Val His Pro          #   220                                                                        - Leu Pro Thr Pro Val Leu Leu Pro Ala Val As - #p Phe Ser Leu Gly Glu          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gl - #n Asp Ile Leu Gly Ala          #               255                                                            - Val Thr Leu Leu Leu Glu Gly Val Met Ala Al - #a Arg Gly Gln Leu Gly          #           270                                                                - Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Le - #u Ser Gly Gln Val Arg          #       285                                                                    - Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gl - #y Thr Gln Leu Pro Pro          #   300                                                                        - Gln Gly Arg Thr Thr                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:237:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 309 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:237:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Asp Pro Asn Ala Ile Phe Leu Ser Ph - #e Gln His Leu Leu Arg          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Gly Lys Val Arg Phe Leu Met Leu Val Gly Gl - #y Ser Thr Leu Cys Val          #               175                                                            - Arg Glu Phe Gly Gly Asn Gly Gly Asn Met Al - #a Ser Pro Ala Pro Pro          #           190                                                                - Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Le - #u Arg Asp Ser His Val          #       205                                                                    - Leu His Ser Arg Leu Ser Gln Cys Pro Glu Va - #l His Pro Leu Pro Thr          #   220                                                                        - Pro Val Leu Leu Pro Ala Val Asp Phe Ser Le - #u Gly Glu Trp Lys Thr          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Gln Met Glu Glu Thr Lys Ala Gln Asp Ile Le - #u Gly Ala Val Thr Leu          #               255                                                            - Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gl - #n Leu Gly Pro Thr Cys          #           270                                                                - Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gl - #n Val Arg Leu Leu Leu          #       285                                                                    - Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Le - #u Pro Pro Gln Gly Arg          #   300                                                                        - Thr Thr Ala His Lys                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:238:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 309 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:238:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Ala Ile Phe Leu Ser Phe Gln His Le - #u Leu Arg Gly Lys Val          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Arg Phe Leu Met Leu Val Gly Gly Ser Thr Le - #u Cys Val Arg Glu Phe          #               175                                                            - Gly Gly Asn Gly Gly Asn Met Ala Ser Pro Al - #a Pro Pro Ala Cys Asp          #           190                                                                - Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Se - #r His Val Leu His Ser          #       205                                                                    - Arg Leu Ser Gln Cys Pro Glu Val His Pro Le - #u Pro Thr Pro Val Leu          #   220                                                                        - Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Tr - #p Lys Thr Gln Met Glu          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Glu Thr Lys Ala Gln Asp Ile Leu Gly Ala Va - #l Thr Leu Leu Leu Glu          #               255                                                            - Gly Val Met Ala Ala Arg Gly Gln Leu Gly Pr - #o Thr Cys Leu Ser Ser          #           270                                                                - Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Le - #u Leu Leu Gly Ala Leu          #       285                                                                    - Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro Gl - #n Gly Arg Thr Thr Ala          #   300                                                                        - His Lys Asp Pro Asn                                                          305                                                                            - (2) INFORMATION FOR SEQ ID NO:239:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 302 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:239:                                - Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Il - #e His His Leu Lys Arg          #                15                                                            - Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Le - #u Asn Asp Glu Asp Val          #            30                                                                - Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pr - #o Asn Leu Glu Ser Phe          #        45                                                                    - Val Arg Ala Val Lys Asn Leu Glu Asn Ala Se - #r Gly Ile Glu Ala Ile          #    60                                                                        - Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Al - #a Thr Ala Ala Pro Ser          #80                                                                            - Arg His Pro Ile Ile Ile Lys Ala Gly Asp Tr - #p Gln Glu Phe Arg Glu          #                95                                                            - Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gl - #n Ala Gln Glu Gln Gln          #           110                                                                - Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gl - #u Pro Ser Gly Pro Ile          #       125                                                                    - Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Gl - #u Ser His Lys Ser Pro          #   140                                                                        - Asn Met Asp Pro Asn Ala Ile Phe Leu Ser Ph - #e Gln His Leu Leu Arg          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Gly Lys Val Arg Phe Leu Met Leu Val Gly Gl - #y Ser Thr Leu Cys Val          #               175                                                            - Arg Glu Phe Gly Gly Asn Met Ala Ser Pro Al - #a Pro Pro Ala Cys Asp          #           190                                                                - Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Se - #r His Val Leu His Ser          #       205                                                                    - Arg Leu Ser Gln Cys Pro Glu Val His Pro Le - #u Pro Thr Pro Val Leu          #   220                                                                        - Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Tr - #p Lys Thr Gln Met Glu          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Glu Thr Lys Ala Gln Asp Ile Leu Gly Ala Va - #l Thr Leu Leu Leu Glu          #               255                                                            - Gly Val Met Ala Ala Arg Gly Gln Leu Gly Pr - #o Thr Cys Leu Ser Ser          #           270                                                                - Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Le - #u Leu Leu Gly Ala Leu          #       285                                                                    - Gln Ser Leu Leu Gly Thr Gln Gly Arg Thr Th - #r Ala His Lys                  #   300                                                                        - (2) INFORMATION FOR SEQ ID NO:240:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 83 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:240:                                - AATTCCGTCG TAAACTGACC TTCTATCTGA AAACCTTGGA GAACGCGCAG GC - #TCAACAGT          60                                                                           #                83AGGC TCC                                                    - (2) INFORMATION FOR SEQ ID NO:241:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 83 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:241:                                - CCGGGGAGCC TCCACCGCCC TCTACGTACT GTTGAGCCTG CGCGTTCTCC AA - #GGTTTTCA          60                                                                           #                83ACGA CGG                                                    - (2) INFORMATION FOR SEQ ID NO:242:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 8 amino                                                            (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:242:                                - Gly Gly Gly Ser Gly Gly Gly Ser                                              1               5                                                              - (2) INFORMATION FOR SEQ ID NO:243:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 12 amino                                                           (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:243:                                - Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gl - #y Ser                          #                10                                                            - (2) INFORMATION FOR SEQ ID NO:244:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 7 amino                                                            (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:244:                                - Ser Gly Gly Ser Gly Gly Ser                                                  1               5                                                              - (2) INFORMATION FOR SEQ ID NO:245:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 6 amino                                                            (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:245:                                - Glu Phe Gly Asn Met Ala                                                      1               5                                                              - (2) INFORMATION FOR SEQ ID NO:246:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 7 amino                                                            (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:246:                                - Glu Phe Gly Gly Asn Met Ala                                                  1               5                                                              - (2) INFORMATION FOR SEQ ID NO:247:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 10 amino                                                           (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:247:                                - Glu Phe Gly Gly Asn Gly Gly Asn Met Ala                                      #                10                                                            - (2) INFORMATION FOR SEQ ID NO:248:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 7 amino                                                            (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:248:                                - Gly Gly Ser Asp Met Ala Gly                                                  1               5                                                              - (2) INFORMATION FOR SEQ ID NO:249:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 459 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "SYNTHETIC"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:249:                                - TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TG - #ACTCCCAT          60                                                                           - GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC AC - #CTGTCCTG         120                                                                           - CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GA - #CCAAGGCA         180                                                                           - CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC AC - #GGGGACAA         240                                                                           - CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CC - #GTCTCCTC         300                                                                           - CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GA - #CCACAGCT         360                                                                           - CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AA - #AGGTGCGT         420                                                                           #   459            GAGG GTCCACCCTC TGCGTCAGG                                   - (2) INFORMATION FOR SEQ ID NO:250:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 447 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "SYNTHETIC"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:250:                                - TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TG - #ACTCCCAT          60                                                                           - GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC AC - #CTGTCCTG         120                                                                           - CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GA - #CCAAGGCA         180                                                                           - CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC AC - #GGGGACAA         240                                                                           - CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CC - #GTCTCCTC         300                                                                           - CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGGGCAGGA CCACAGCTCA CA - #AGGATCCC         360                                                                           - AATGCCATCT TCCTGAGCTT CCAACACCTG CTCCGAGGAA AGGTGCGTTT CC - #TGATGCTT         420                                                                           #            447   TCTG CGTCAGG                                                - (2) INFORMATION FOR SEQ ID NO:251:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 459 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "SYNTHETIC"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:251:                                - TCCCCAGCGC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TG - #ACTCCCAT          60                                                                           - GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC AC - #CTGTCCTG         120                                                                           - CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GA - #CCAAGGCA         180                                                                           - CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC AC - #GGGGACAA         240                                                                           - CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CC - #GTCTCCTC         300                                                                           - CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GA - #CCACAGCT         360                                                                           - CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AA - #AGGTGCGT         420                                                                           #   459            GAGG GTCCACCCTC TGCGTCAGG                                   - (2) INFORMATION FOR SEQ ID NO:252:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 153 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:252:                                - Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu          #                15                                                            - Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val          #            30                                                                - His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu          #        45                                                                    - Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu          #    60                                                                        - Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln          #80                                                                            - Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln          #                95                                                            - Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Leu          #           110                                                                - Pro Pro Gln Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe          #       125                                                                    - Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu          #   140                                                                        - Val Gly Gly Ser Thr Leu Cys Val Arg                                          145                 1 - #50                                                    - (2) INFORMATION FOR SEQ ID NO:253:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 149 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:253:                                - Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu          #                15                                                            - Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val          #            30                                                                - His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu          #        45                                                                    - Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu          #    60                                                                        - Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln          #80                                                                            - Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln          #                95                                                            - Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Gly          #           110                                                                - Arg Thr Thr Ala His Lys Asp Pro Asn Ala Il - #e Phe Leu Ser Phe Gln          #       125                                                                    - His Leu Leu Arg Gly Lys Val Arg Phe Leu Me - #t Leu Val Gly Gly Ser          #   140                                                                        - Thr Leu Cys Val Arg                                                          145                                                                            - (2) INFORMATION FOR SEQ ID NO:254:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 153 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:254:                                - Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu          #                15                                                            - Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val          #            30                                                                - His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu          #        45                                                                    - Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu          #    60                                                                        - Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln          #80                                                                            - Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln          #                95                                                            - Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Leu          #           110                                                                - Pro Pro Gln Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe          #       125                                                                    - Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu          #   140                                                                        - Val Gly Gly Ser Thr Leu Cys Val Arg                                          145                 1 - #50                                                    - (2) INFORMATION FOR SEQ ID NO:255:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 64 base                                                            (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "SYNTHETIC"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:255:                                - GGATCCACCA TGAGCCGCCT GCCCGTCCTG CTCCTGCTCC AACTCCTGGT CC - #GCCCCGCC          60                                                                           #             64                                                               - (2) INFORMATION FOR SEQ ID NO:256:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 153 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: protein                                              -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 112                                                    #/note= "position 112 is deleted or                                                           Leu, Ala, - #VAl, Ile, Pro, Phe, Trp or Met"                    -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 113                                                    #/note= "positoin 113 is deleted or                                                           Pro, Phe, - # Ala, Val, Leu, Ile, Trp or Met"                   -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 114                                                    #/note= "position 114 is deleted or                                                           Pro, Phe, - # Ala, Val, Leu, Ile, Trp or Met"                   -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 115                                                    #/note= "positon 115 is deleted or                                                            Gln, Gly, - # Ser, Thr, Tyr, or Asn"                            -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:256:                                - Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va - #l Leu Ser Lys Leu Leu          #                15                                                            - Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val          #            30                                                                - His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu          #        45                                                                    - Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu          #    60                                                                        - Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln          #80                                                                            - Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln          #                95                                                            - Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Xaa          #           110                                                                - Xaa Xaa Xaa Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe          #       125                                                                    - Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu          #   140                                                                        - Val Gly Gly Ser Thr Leu Cys Val Arg                                          145                 1 - #50                                                    - (2) INFORMATION FOR SEQ ID NO:257:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 464 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "SYNTHETIC"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:257:                                - CCATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG AG - #ACCACCTG          60                                                                           - CACCTTTGCT GGACCCGAAC AACCTCAATG ACGAAGACGT CTCTATCCTG AT - #GGATCGAA         120                                                                           - ACCTTCGACT TCCAAACCTG GAGAGCTTCG TAAGGGCTGT CAAGAACTTA GA - #AAATGCAT         180                                                                           - CAGGTATTGA GGCAATTCTT CGTAATCTCC AACCATGTCT GCCCTCTGCC AC - #GGCCGCAC         240                                                                           - CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GA - #AAAACTGA         300                                                                           - CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GTACGTAGAG GG - #CGGTGGAG         360                                                                           - GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CCCGTCTCCT CC - #GTCTAAAG         420                                                                           #464               AAAC ATGTAAGGTA CCGCATGCAA GCTT                             - (2) INFORMATION FOR SEQ ID NO:258:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 100 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "SYNTHETIC"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:258:                                - AAAACAAGAA GAAAGGCGAT AAAAAGGTTG TGGTAAGAGA AATGGATAAA AA - #GGGGTCGG          60                                                                           #   100            TTAA AAAAGAGGAA GTAGGTCAAG                                  - (2) INFORMATION FOR SEQ ID NO:259:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 11808 base                                                         (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:259:                                - ACGTACTCCA TGGCTAACTG CTCTATAATG ATCGATGAAA TTATACATCA CT - #TAAAGAGA          60                                                                           - CCACCTGCAC CTTTGCTGGA CCCGAACAAC CTCAATGACG AAGACGTCTC TA - #TCCTGATG         120                                                                           - GATCGAAACC TTCGACTTCC AAACCTGGAG AGCTTCGTAA GGGCTGTCAA GA - #ACTTAGAA         180                                                                           - AATGCATCAG GTATTGAGGC AATTCTTCGT AATCTCCAAC CATGTCTGCC CT - #CTGCCACG         240                                                                           - GCCGCACCCT CTCGACATCC AATCATCATC AAGGCAGGTG ACTGGCAAGA AT - #TCCGGGAA         300                                                                           - AAACTGACGT TCTATCTGGT TACCCTTGAG CAAGCGCAGG AACAACAGTA CG - #TAGAGGGC         360                                                                           - GGTGGAGGCT CCCCGGGTGA ACCGTCTGGT CCAATCTCTA CTATCAACCC GT - #CTCCTCCG         420                                                                           - TCTAAAGAAT CTCATAAATC TCCAAACATG GCTTTAGGCC CTGCCAGCTC CC - #TGCCCCAG         480                                                                           - AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGGAAGATCC AGGGCGATGG CG - #CAGCGCTC         540                                                                           - CAGGAGAAGC TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GC - #TGCTCGGA         600                                                                           - CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC CC - #TGCAGCTG         660                                                                           - GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT ACCAGGGGCT CC - #TGCAGGCC         720                                                                           - CTGGAAGGGA TATCCCCCGA GTTGGGTCCC ACCTTGGACA CACTGCAGCT GG - #ACGTCGCC         780                                                                           - GACTTTGCCA CCACCATCTG GCAGCAGATG GAAGAACTGG GAATGGCCCC TG - #CCCTGCAG         840                                                                           - CCCACCCAGG GTGCCATGCC GGCCTTCGCC TCTGCTTTCC AGCGCCGGGC AG - #GAGGGGTC         900                                                                           - CTGGTTGCTA GCCATCTGCA GAGCTTCCTG GAGGTGTCGT ACCGCGTTCT AC - #GCCACCTT         960                                                                           - GCGCAGCCCG ACATGGCTAC ACCAACGTAC TCCATGGCTA ACTGCTCTAT AA - #TGATCGAT        1020                                                                           - GAAATTATAC ATCACTTAAA GAGACCACCT GCACCTTTGC TGGACCCGAA CA - #ACCTCAAT        1080                                                                           - GACGAAGACG TCTCTATCCT GATGGATCGA AACCTTCGAC TTCCAAACCT GG - #AGAGCTTC        1140                                                                           - GTAAGGGCTG TCAAGAACTT AGAAAATGCA TCAGGTATTG AGGCAATTCT TC - #GTAATCTC        1200                                                                           - CAACCATGTC TGCCCTCTGC CACGGCCGCA CCCTCTCGAC ATCCAATCAT CA - #TCAAGGCA        1260                                                                           - GGTGACTGGC AAGAATTCCG GGAAAAACTG ACGTTCTATC TGGTTACCCT TG - #AGCAAGCG        1320                                                                           - CAGGAACAAC AGTACGTAGA GGGCGGTGGA GGCTCCCCGG GTGAACCGTC TG - #GTCCAATC        1380                                                                           - TCTACTATCA ACCCGTCTCC TCCGTCTAAA GAATCTCATA AATCTCCAAA CA - #TGGCTCAG        1440                                                                           - AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGGAAGATCC AGGGCGATGG CG - #CAGCGCTC        1500                                                                           - CAGGAGAAGC TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GC - #TGCTCGGA        1560                                                                           - CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC CC - #TGCAGCTG        1620                                                                           - GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT ACCAGGGGCT CC - #TGCAGGCC        1680                                                                           - CTGGAAGGGA TATCCCCCGA GTTGGGTCCC ACCTTGGACA CACTGCAGCT GG - #ACGTCGCC        1740                                                                           - GACTTTGCCA CCACCATCTG GCAGCAGATG GAAGAACTGG GAATGGCCCC TG - #CCCTGCAG        1800                                                                           - CCCACCCAGG GTGCCATGCC GGCCTTCGCC TCTGCTTTCC AGCGCCGGGC AG - #GAGGGGTC        1860                                                                           - CTGGTTGCTA GCCATCTGCA GAGCTTCCTG GAGGTGTCGT ACCGCGTTCT AC - #GCCACCTT        1920                                                                           - GCGCAGCCCG ACATGGCTAC ACCATTAGGC CCTGCCAGCT CCCTGCCCAC GT - #ACTCCATG        1980                                                                           - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT        2040                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA TC - #GAAACCTT        2100                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT        2160                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT        2220                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC        2280                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC        2340                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT        2400                                                                           - CATAAATCTC CAAACATGGC TTTCCTGCTC AAGTCTTTAG AGCAAGTGAG GA - #AGATCCAG        2460                                                                           - GGCGATGGCG CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG CC - #ACCCCGAG        2520                                                                           - GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CT - #CCTGCCCC        2580                                                                           - AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TT - #TCCTCTAC        2640                                                                           - CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CT - #TGGACACA        2700                                                                           - CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AG - #AACTGGGA        2760                                                                           - ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTC TG - #CTTTCCAG        2820                                                                           - CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGA GG - #TGTCGTAC        2880                                                                           - CGCGTTCTAC GCCACCTTGC GCAGCCCGAC ATGGCTACAC CATTAGGCCC TG - #CCAGCTCC        2940                                                                           - CTGCCCCAGA GCACGTACTC CATGGCTAAC TGCTCTATAA TGATCGATGA AA - #TTATACAT        3000                                                                           - CACTTAAAGA GACCACCTGC ACCTTTGCTG GACCCGAACA ACCTCAATGA CG - #AAGACGTC        3060                                                                           - TCTATCCTGA TGGATCGAAA CCTTCGACTT CCAAACCTGG AGAGCTTCGT AA - #GGGCTGTC        3120                                                                           - AAGAACTTAG AAAATGCATC AGGTATTGAG GCAATTCTTC GTAATCTCCA AC - #CATGTCTG        3180                                                                           - CCCTCTGCCA CGGCCGCACC CTCTCGACAT CCAATCATCA TCAAGGCAGG TG - #ACTGGCAA        3240                                                                           - GAATTCCGGG AAAAACTGAC GTTCTATCTG GTTACCCTTG AGCAAGCGCA GG - #AACAACAG        3300                                                                           - TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GAACCGTCTG GTCCAATCTC TA - #CTATCAAC        3360                                                                           - CCGTCTCCTC CGTCTAAAGA ATCTCATAAA TCTCCAAACA TGGCTGAGCA AG - #TGAGGAAG        3420                                                                           - ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAA GC - #TGTGCCAC        3480                                                                           - CCCGAGGAGC TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CC - #TGAGCTCC        3540                                                                           - TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG CG - #GCCTTTTC        3600                                                                           - CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG TC - #CCACCTTG        3660                                                                           - GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GA - #TGGAAGAA        3720                                                                           - CTGGGAATGG CCCCTGCCCT GCAGCCCACC CAGGGTGCCA TGCCGGCCTT CG - #CCTCTGCT        3780                                                                           - TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CC - #TGGAGGTG        3840                                                                           - TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCGACATGG CTACACCATT AG - #GCCCTGCC        3900                                                                           - AGCTCCCTGC CCCAGAGCTT CCTGCTCAAG TCTTTAACGT ACTCCATGGC TA - #ACTGCTCT        3960                                                                           - ATAATGATCG ATGAAATTAT ACATCACTTA AAGAGACCAC CTGCACCTTT GC - #TGGACCCG        4020                                                                           - AACAACCTCA ATGACGAAGA CGTCTCTATC CTGATGGATC GAAACCTTCG AC - #TTCCAAAC        4080                                                                           - CTGGAGAGCT TCGTAAGGGC TGTCAAGAAC TTAGAAAATG CATCAGGTAT TG - #AGGCAATT        4140                                                                           - CTTCGTAATC TCCAACCATG TCTGCCCTCT GCCACGGCCG CACCCTCTCG AC - #ATCCAATC        4200                                                                           - ATCATCAAGG CAGGTGACTG GCAAGAATTC CGGGAAAAAC TGACGTTCTA TC - #TGGTTACC        4260                                                                           - CTTGAGCAAG CGCAGGAACA ACAGTACGTA GAGGGCGGTG GAGGCTCCCC GG - #GTGAACCG        4320                                                                           - TCTGGTCCAA TCTCTACTAT CAACCCGTCT CCTCCGTCTA AAGAATCTCA TA - #AATCTCCA        4380                                                                           - AACATGGCTC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CT - #CCTGCCCC        4440                                                                           - AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TT - #TCCTCTAC        4500                                                                           - CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CT - #TGGACACA        4560                                                                           - CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AG - #AACTGGGA        4620                                                                           - ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTC TG - #CTTTCCAG        4680                                                                           - CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGA GG - #TGTCGTAC        4740                                                                           - CGCGTTCTAC GCCACCTTGC GCAGCCCGAC ATGGCTACAC CATTAGGCCC TG - #CCAGCTCC        4800                                                                           - CTGCCCCAGA GCTTCCTGCT CAAGTCTTTA GAGCAAGTGA GGAAGATCCA GG - #GCGATGGC        4860                                                                           - GCAGCGCTCC AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGA GG - #AGCTGGTG        4920                                                                           - ACGTACTCCA TGGCTAACTG CTCTATAATG ATCGATGAAA TTATACATCA CT - #TAAAGAGA        4980                                                                           - CCACCTGCAC CTTTGCTGGA CCCGAACAAC CTCAATGACG AAGACGTCTC TA - #TCCTGATG        5040                                                                           - GATCGAAACC TTCGACTTCC AAACCTGGAG AGCTTCGTAA GGGCTGTCAA GA - #ACTTAGAA        5100                                                                           - AATGCATCAG GTATTGAGGC AATTCTTCGT AATCTCCAAC CATGTCTGCC CT - #CTGCCACG        5160                                                                           - GCCGCACCCT CTCGACATCC AATCATCATC AAGGCAGGTG ACTGGCAAGA AT - #TCCGGGAA        5220                                                                           - AAACTGACGT TCTATCTGGT TACCCTTGAG CAAGCGCAGG AACAACAGTA CG - #TAGAGGGC        5280                                                                           - GGTGGAGGCT CCCCGGGTGA ACCGTCTGGT CCAATCTCTA CTATCAACCC GT - #CTCCTCCG        5340                                                                           - TCTAAAGAAT CTCATAAATC TCCAAACATG GCTCCCCTGA GCTCCTGCCC CA - #GCCAGGCC        5400                                                                           - CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTA CC - #AGGGGCTC        5460                                                                           - CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA CCTTGGACAC AC - #TGCAGCTG        5520                                                                           - GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AA - #TGGCCCCT        5580                                                                           - GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GC - #GCCGGGCA        5640                                                                           - GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CC - #GCGTTCTA        5700                                                                           - CGCCACCTTG CGCAGCCCGA CATGGCTACA CCATTAGGCC CTGCCAGCTC CC - #TGCCCCAG        5760                                                                           - AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGGAAGATCC AGGGCGATGG CG - #CAGCGCTC        5820                                                                           - CAGGAGAAGC TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GC - #TGCTCGGA        5880                                                                           - CACTCTCTGG GCATCCCCTG GGCTACGTAC TCCATGGCTA ACTGCTCTAT AA - #TGATCGAT        5940                                                                           - GAAATTATAC ATCACTTAAA GAGACCACCT GCACCTTTGC TGGACCCGAA CA - #ACCTCAAT        6000                                                                           - GACGAAGACG TCTCTATCCT GATGGATCGA AACCTTCGAC TTCCAAACCT GG - #AGAGCTTC        6060                                                                           - GTAAGGGCTG TCAAGAACTT AGAAAATGCA TCAGGTATTG AGGCAATTCT TC - #GTAATCTC        6120                                                                           - CAACCATGTC TGCCCTCTGC CACGGCCGCA CCCTCTCGAC ATCCAATCAT CA - #TCAAGGCA        6180                                                                           - GGTGACTGGC AAGAATTCCG GGAAAAACTG ACGTTCTATC TGGTTACCCT TG - #AGCAAGCG        6240                                                                           - CAGGAACAAC AGTACGTAGA GGGCGGTGGA GGCTCCCCGG GTGAACCGTC TG - #GTCCAATC        6300                                                                           - TCTACTATCA ACCCGTCTCC TCCGTCTAAA GAATCTCATA AATCTCCAAA CA - #TGGCTCAG        6360                                                                           - GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT CT - #ACCAGGGG        6420                                                                           - CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTC CCACCTTGGA CA - #CACTGCAG        6480                                                                           - CTGGACGTCG CCGACTTTGC CACCACCATC TGGCAGCAGA TGGAAGAACT GG - #GAATGGCC        6540                                                                           - CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCG CCTCTGCTTT CC - #AGCGCCGG        6600                                                                           - GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC TGGAGGTGTC GT - #ACCGCGTT        6660                                                                           - CTACGCCACC TTGCGCAGCC CGACATGGCT ACACCATTAG GCCCTGCCAG CT - #CCCTGCCC        6720                                                                           - CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGGAAGA TCCAGGGCGA TG - #GCGCAGCG        6780                                                                           - CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GG - #TGCTGCTC        6840                                                                           - GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCAC GT - #ACTCCATG        6900                                                                           - GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC AC - #CTGCACCT        6960                                                                           - TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA TC - #GAAACCTT        7020                                                                           - CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TG - #CATCAGGT        7080                                                                           - ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CG - #CACCCTCT        7140                                                                           - CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA AC - #TGACGTTC        7200                                                                           - TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TG - #GAGGCTCC        7260                                                                           - CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TA - #AAGAATCT        7320                                                                           - CATAAATCTC CAAACATGGC TCTGCAGCTG GCAGGCTGCT TGAGCCAACT CC - #ATAGCGGC        7380                                                                           - CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GT - #TGGGTCCC        7440                                                                           - ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GC - #AGCAGATG        7500                                                                           - GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCACCCAGG GTGCCATGCC GG - #CCTTCGCC        7560                                                                           - TCTGCTTTCC AGCGCCGGGC AGGAGGGGTC CTGGTTGCTA GCCATCTGCA GA - #GCTTCCTG        7620                                                                           - GAGGTGTCGT ACCGCGTTCT ACGCCACCTT GCGCAGCCCG ACATGGCTAC AC - #CATTAGGC        7680                                                                           - CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT TAGAGCAAGT GA - #GGAAGATC        7740                                                                           - CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GT - #GCCACCCC        7800                                                                           - GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GA - #GCTCCTGC        7860                                                                           - CCCAGCCAGG CCACGTACTC CATGGCTAAC TGCTCTATAA TGATCGATGA AA - #TTATACAT        7920                                                                           - CACTTAAAGA GACCACCTGC ACCTTTGCTG GACCCGAACA ACCTCAATGA CG - #AAGACGTC        7980                                                                           - TCTATCCTGA TGGATCGAAA CCTTCGACTT CCAAACCTGG AGAGCTTCGT AA - #GGGCTGTC        8040                                                                           - AAGAACTTAG AAAATGCATC AGGTATTGAG GCAATTCTTC GTAATCTCCA AC - #CATGTCTG        8100                                                                           - CCCTCTGCCA CGGCCGCACC CTCTCGACAT CCAATCATCA TCAAGGCAGG TG - #ACTGGCAA        8160                                                                           - GAATTCCGGG AAAAACTGAC GTTCTATCTG GTTACCCTTG AGCAAGCGCA GG - #AACAACAG        8220                                                                           - TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GAACCGTCTG GTCCAATCTC TA - #CTATCAAC        8280                                                                           - CCGTCTCCTC CGTCTAAAGA ATCTCATAAA TCTCCAAACA TGGCTCTGGC AG - #GCTGCTTG        8340                                                                           - AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC TGCAGGCCCT GG - #AAGGGATA        8400                                                                           - TCCCCCGAGT TGGGTCCCAC CTTGGACACA CTGCAGCTGG ACGTCGCCGA CT - #TTGCCACC        8460                                                                           - ACCATCTGGC AGCAGATGGA AGAACTGGGA ATGGCCCCTG CCCTGCAGCC CA - #CCCAGGGT        8520                                                                           - GCCATGCCGG CCTTCGCCTC TGCTTTCCAG CGCCGGGCAG GAGGGGTCCT GG - #TTGCTAGC        8580                                                                           - CATCTGCAGA GCTTCCTGGA GGTGTCGTAC CGCGTTCTAC GCCACCTTGC GC - #AGCCCGAC        8640                                                                           - ATGGCTACAC CATTAGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CA - #AGTCTTTA        8700                                                                           - GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GT - #GTGCCACC        8760                                                                           - TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CA - #TCCCCTGG        8820                                                                           - GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC CTGCAGACGT ACTCCATGGC TA - #ACTGCTCT        8880                                                                           - ATAATGATCG ATGAAATTAT ACATCACTTA AAGAGACCAC CTGCACCTTT GC - #TGGACCCG        8940                                                                           - AACAACCTCA ATGACGAAGA CGTCTCTATC CTGATGGATC GAAACCTTCG AC - #TTCCAAAC        9000                                                                           - CTGGAGAGCT TCGTAAGGGC TGTCAAGAAC TTAGAAAATG CATCAGGTAT TG - #AGGCAATT        9060                                                                           - CTTCGTAATC TCCAACCATG TCTGCCCTCT GCCACGGCCG CACCCTCTCG AC - #ATCCAATC        9120                                                                           - ATCATCAAGG CAGGTGACTG GCAAGAATTC CGGGAAAAAC TGACGTTCTA TC - #TGGTTACC        9180                                                                           - CTTGAGCAAG CGCAGGAACA ACAGTACGTA GAGGGCGGTG GAGGCTCCCC GG - #GTGAACCG        9240                                                                           - TCTGGTCCAA TCTCTACTAT CAACCCGTCT CCTCCGTCTA AAGAATCTCA TA - #AATCTCCA        9300                                                                           - AACATGGCTG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CA - #TGCCGGCC        9360                                                                           - TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TC - #TGCAGAGC        9420                                                                           - TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCGACAT GG - #CTACACCA        9480                                                                           - TTAGGCCCTG CCAGCTCCCT GCCCCAGAGC TTCCTGCTCA AGTCTTTAGA GC - #AAGTGAGG        9540                                                                           - AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CA - #AGCTGTGC        9600                                                                           - CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TC - #CCCTGAGC        9660                                                                           - TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA TA - #GCGGCCTT        9720                                                                           - TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GG - #GTCCCACC        9780                                                                           - TTGGACACAC TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA GC - #AGATGGAA        9840                                                                           - ACGTACTCCA TGGCTAACTG CTCTATAATG ATCGATGAAA TTATACATCA CT - #TAAAGAGA        9900                                                                           - CCACCTGCAC CTTTGCTGGA CCCGAACAAC CTCAATGACG AAGACGTCTC TA - #TCCTGATG        9960                                                                           - GATCGAAACC TTCGACTTCC AAACCTGGAG AGCTTCGTAA GGGCTGTCAA GA - #ACTTAGAA        10020                                                                          - AATGCATCAG GTATTGAGGC AATTCTTCGT AATCTCCAAC CATGTCTGCC CT - #CTGCCACG        10080                                                                          - GCCGCACCCT CTCGACATCC AATCATCATC AAGGCAGGTG ACTGGCAAGA AT - #TCCGGGAA        10140                                                                          - AAACTGACGT TCTATCTGGT TACCCTTGAG CAAGCGCAGG AACAACAGTA CG - #TAGAGGGC        10200                                                                          - GGTGGAGGCT CCCCGGGTGA ACCGTCTGGT CCAATCTCTA CTATCAACCC GT - #CTCCTCCG        10260                                                                          - TCTAAAGAAT CTCATAAATC TCCAAACATG GCTGGAATGG CCCCTGCCCT GC - #AGCCCACC        10320                                                                          - CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT TTCCAGCGCC GGGCAGGAGG GG - #TCCTGGTT        10380                                                                          - GCTAGCCATC TGCAGAGCTT CCTGGAGGTG TCGTACCGCG TTCTACGCCA CC - #TTGCGCAG        10440                                                                          - CCCGACATGG CTACACCATT AGGCCCTGCC AGCTCCCTGC CCCAGAGCTT CC - #TGCTCAAG        10500                                                                          - TCTTTAGAGC AAGTGAGGAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA GA - #AGCTGTGT        10560                                                                          - GCCACCTACA AGCTGTGCCA CCCCGAGGAG CTGGTGCTGC TCGGACACTC TC - #TGGGCATC        10620                                                                          - CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG CT - #GCTTGAGC        10680                                                                          - CAACTCCATA GCGGCCTTTT CCTCTACCAG GGGCTCCTGC AGGCCCTGGA AG - #GGATATCC        10740                                                                          - CCCGAGTTGG GTCCCACCTT GGACACACTG CAGCTGGACG TCGCCGACTT TG - #CCACCACC        10800                                                                          - ATCTGGCAGC AGATGGAAGA ACTGACGTAC TCCATGGCTA ACTGCTCTAT AA - #TGATCGAT        10860                                                                          - GAAATTATAC ATCACTTAAA GAGACCACCT GCACCTTTGC TGGACCCGAA CA - #ACCTCAAT        10920                                                                          - GACGAAGACG TCTCTATCCT GATGGATCGA AACCTTCGAC TTCCAAACCT GG - #AGAGCTTC        10980                                                                          - GTAAGGGCTG TCAAGAACTT AGAAAATGCA TCAGGTATTG AGGCAATTCT TC - #GTAATCTC        11040                                                                          - CAACCATGTC TGCCCTCTGC CACGGCCGCA CCCTCTCGAC ATCCAATCAT CA - #TCAAGGCA        11100                                                                          - GGTGACTGGC AAGAATTCCG GGAAAAACTG ACGTTCTATC TGGTTACCCT TG - #AGCAAGCG        11160                                                                          - CAGGAACAAC AGTACGTAGA GGGCGGTGGA GGCTCCCCGG GTGAACCGTC TG - #GTCCAATC        11220                                                                          - TCTACTATCA ACCCGTCTCC TCCGTCTAAA GAATCTCATA AATCTCCAAA CA - #TGGCTAGC        11280                                                                          - TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCGACAT GG - #CTACACCA        11340                                                                          - TTAGGCCCTG CCAGCTCCCT GCCCCAGAGC TTCCTGCTCA AGTCTTTAGA GC - #AAGTGAGG        11400                                                                          - AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CA - #AGCTGTGC        11460                                                                          - CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TC - #CCCTGAGC        11520                                                                          - TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA TA - #GCGGCCTT        11580                                                                          - TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GG - #GTCCCACC        11640                                                                          - TTGGACACAC TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA GC - #AGATGGAA        11700                                                                          - GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CT - #TCGCCTCT        11760                                                                          #             11808CAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAG                         - (2) INFORMATION FOR SEQ ID NO:260:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 975 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:260:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GGCTCAGAGC TTCCTGCTCA AGTCTTTAGA GC - #AAGTGAGG         480                                                                           - AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CA - #AGCTGTGC         540                                                                           - CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TC - #CCCTGAGC         600                                                                           - TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA TA - #GCGGCCTT         660                                                                           - TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GG - #GTCCCACC         720                                                                           - TTGGACACAC TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA GC - #AGATGGAA         780                                                                           - GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CT - #TCGCCTCT         840                                                                           - GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG CT - #TCCTGGAG         900                                                                           - GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCGACA TGGCTACACC AT - #TAGGCCCT         960                                                                           #   975                                                                        - (2) INFORMATION FOR SEQ ID NO:261:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 975 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:261:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GGCTCAGAGC TTCCTGCTCA AGTCTTTAGA GC - #AAGTGAGG         480                                                                           - AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CA - #AGCTGTGC         540                                                                           - CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TC - #CCCTGAGC         600                                                                           - TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA TA - #GCGGCCTT         660                                                                           - TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GG - #GTCCCACC         720                                                                           - TTGGACACAC TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA GC - #AGATGGAA         780                                                                           - GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CT - #TCGCCTCT         840                                                                           - GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG CT - #TCCTGGAG         900                                                                           - GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCGACA TGGCTACACC AT - #TAGGCCCT         960                                                                           #   975                                                                        - (2) INFORMATION FOR SEQ ID NO:262:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 975 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:262:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GGCTGAGCAA GTGAGGAAGA TCCAGGGCGA TG - #GCGCAGCG         480                                                                           - CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GG - #TGCTGCTC         540                                                                           - GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GG - #CCCTGCAG         600                                                                           - CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GC - #TCCTGCAG         660                                                                           - GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GC - #TGGACGTC         720                                                                           - GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CC - #CTGCCCTG         780                                                                           - CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GG - #CAGGAGGG         840                                                                           - GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TC - #TACGCCAC         900                                                                           - CTTGCGCAGC CCGACATGGC TACACCATTA GGCCCTGCCA GCTCCCTGCC CC - #AGAGCTTC         960                                                                           #   975                                                                        - (2) INFORMATION FOR SEQ ID NO:263:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 975 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:263:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GGCTCTGCTC GGACACTCTC TGGGCATCCC CT - #GGGCTCCC         480                                                                           - CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA AC - #TCCATAGC         540                                                                           - GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CG - #AGTTGGGT         600                                                                           - CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CT - #GGCAGCAG         660                                                                           - ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GC - #CGGCCTTC         720                                                                           - GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GC - #AGAGCTTC         780                                                                           - CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCGACATGGC TA - #CACCATTA         840                                                                           - GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA AG - #TGAGGAAG         900                                                                           - ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAA GC - #TGTGCCAC         960                                                                           #   975                                                                        - (2) INFORMATION FOR SEQ ID NO:264:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 975 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:264:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC CC - #TGCAGCTG         480                                                                           - GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT ACCAGGGGCT CC - #TGCAGGCC         540                                                                           - CTGGAAGGGA TATCCCCCGA GTTGGGTCCC ACCTTGGACA CACTGCAGCT GG - #ACGTCGCC         600                                                                           - GACTTTGCCA CCACCATCTG GCAGCAGATG GAAGAACTGG GAATGGCCCC TG - #CCCTGCAG         660                                                                           - CCCACCCAGG GTGCCATGCC GGCCTTCGCC TCTGCTTTCC AGCGCCGGGC AG - #GAGGGGTC         720                                                                           - CTGGTTGCTA GCCATCTGCA GAGCTTCCTG GAGGTGTCGT ACCGCGTTCT AC - #GCCACCTT         780                                                                           - GCGCAGCCCG ACATGGCTAC ACCATTAGGC CCTGCCAGCT CCCTGCCCCA GA - #GCTTCCTG         840                                                                           - CTCAAGTCTT TAGAGCAAGT GAGGAAGATC CAGGGCGATG GCGCAGCGCT CC - #AGGAGAAG         900                                                                           - CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG AC - #ACTCTCTG         960                                                                           #   975                                                                        - (2) INFORMATION FOR SEQ ID NO:265:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 975 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:265:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GGCTCAGGCC CTGCAGCTGG CAGGCTGCTT GA - #GCCAACTC         480                                                                           - CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT AT - #CCCCCGAG         540                                                                           - TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CA - #CCATCTGG         600                                                                           - CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC CCACCCAGGG TG - #CCATGCCG         660                                                                           - GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CC - #ATCTGCAG         720                                                                           - AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCGA CA - #TGGCTACA         780                                                                           - CCATTAGGCC CTGCCAGCTC CCTGCCCCAG AGCTTCCTGC TCAAGTCTTT AG - #AGCAAGTG         840                                                                           - AGGAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CT - #ACAAGCTG         900                                                                           - TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GG - #CTCCCCTG         960                                                                           #   975                                                                        - (2) INFORMATION FOR SEQ ID NO:266:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 975 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:266:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GGCTCTGCAG CTGGCAGGCT GCTTGAGCCA AC - #TCCATAGC         480                                                                           - GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CG - #AGTTGGGT         540                                                                           - CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CT - #GGCAGCAG         600                                                                           - ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GC - #CGGCCTTC         660                                                                           - GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GC - #AGAGCTTC         720                                                                           - CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCGACATGGC TA - #CACCATTA         780                                                                           - GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA AG - #TGAGGAAG         840                                                                           - ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAA GC - #TGTGCCAC         900                                                                           - CCCGAGGAGC TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CC - #TGAGCTCC         960                                                                           #   975                                                                        - (2) INFORMATION FOR SEQ ID NO:267:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 975 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:267:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GGCTCTGGCA GGCTGCTTGA GCCAACTCCA TA - #GCGGCCTT         480                                                                           - TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GG - #GTCCCACC         540                                                                           - TTGGACACAC TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA GC - #AGATGGAA         600                                                                           - GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CT - #TCGCCTCT         660                                                                           - GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG CT - #TCCTGGAG         720                                                                           - GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCGACA TGGCTACACC AT - #TAGGCCCT         780                                                                           - GCCAGCTCCC TGCCCCAGAG CTTCCTGCTC AAGTCTTTAG AGCAAGTGAG GA - #AGATCCAG         840                                                                           - GGCGATGGCG CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG CC - #ACCCCGAG         900                                                                           - GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CT - #CCTGCCCC         960                                                                           #   975                                                                        - (2) INFORMATION FOR SEQ ID NO:268:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 975 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                 -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:268:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GGCTGAACTG GGAATGGCCC CTGCCCTGCA GC - #CCACCCAG         480                                                                           - GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT CC - #TGGTTGCT         540                                                                           - AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC TACGCCACCT TG - #CGCAGCCC         600                                                                           - GACATGGCTA CACCATTAGG CCCTGCCAGC TCCCTGCCCC AGAGCTTCCT GC - #TCAAGTCT         660                                                                           - TTAGAGCAAG TGAGGAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GC - #TGTGTGCC         720                                                                           - ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCT GG - #GCATCCCC         780                                                                           - TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CT - #TGAGCCAA         840                                                                           - CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GA - #TATCCCCC         900                                                                           - GAGTTGGGTC CCACCTTGGA CACACTGCAG CTGGACGTCG CCGACTTTGC CA - #CCACCATC         960                                                                           #   975                                                                        - (2) INFORMATION FOR SEQ ID NO:269:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 975 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:269:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GGCTGGAATG GCCCCTGCCC TGCAGCCCAC CC - #AGGGTGCC         480                                                                           - ATGCCGGCCT TCGCCTCTGC TTTCCAGCGC CGGGCAGGAG GGGTCCTGGT TG - #CTAGCCAT         540                                                                           - CTGCAGAGCT TCCTGGAGGT GTCGTACCGC GTTCTACGCC ACCTTGCGCA GC - #CCGACATG         600                                                                           - GCTACACCAT TAGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GT - #CTTTAGAG         660                                                                           - CAAGTGAGGA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TG - #CCACCTAC         720                                                                           - AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CC - #CCTGGGCT         780                                                                           - CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CC - #AACTCCAT         840                                                                           - AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CC - #CCGAGTTG         900                                                                           - GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CA - #TCTGGCAG         960                                                                           #   975                                                                        - (2) INFORMATION FOR SEQ ID NO:270:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 975 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:270:                                - ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG AC - #CACCTGCA          60                                                                           - CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GG - #ATCGAAAC         120                                                                           - CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AA - #ATGCATCA         180                                                                           - GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GG - #CCGCACCC         240                                                                           - TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AA - #AACTGACG         300                                                                           - TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CG - #GTGGAGGC         360                                                                           - TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GT - #CTAAAGAA         420                                                                           - TCTCATAAAT CTCCAAACAT GGCTAGCTTC CTGGAGGTGT CGTACCGCGT TC - #TACGCCAC         480                                                                           - CTTGCGCAGC CCGACATGGC TACACCATTA GGCCCTGCCA GCTCCCTGCC CC - #AGAGCTTC         540                                                                           - CTGCTCAAGT CTTTAGAGCA AGTGAGGAAG ATCCAGGGCG ATGGCGCAGC GC - #TCCAGGAG         600                                                                           - AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CG - #GACACTCT         660                                                                           - CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA GC - #TGGCAGGC         720                                                                           - TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GG - #CCCTGGAA         780                                                                           - GGGATATCCC CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CG - #CCGACTTT         840                                                                           - GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GC - #AGCCCACC         900                                                                           - CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT TTCCAGCGCC GGGCAGGAGG GG - #TCCTGGTT         960                                                                           #   975                                                                        - (2) INFORMATION FOR SEQ ID NO:271:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 325 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:271:                                - Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys          #                15                                                            - Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp          #            30                                                                - Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser          #        45                                                                    - Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala          #    60                                                                        - Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro          #80                                                                            - Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg          #                95                                                            - Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln          #           110                                                                - Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro          #       125                                                                    - Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser          #   140                                                                        - Pro Asn Met Ala Leu Gly Pro Ala Ser Ser Le - #u Pro Gln Ser Phe Leu          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gl - #n Gly Asp Gly Ala Ala          #               175                                                            - Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Le - #u Cys His Pro Glu Glu          #           190                                                                - Leu Val Leu Leu Gly His Ser Leu Gly Ile Pr - #o Trp Ala Pro Leu Ser          #       205                                                                    - Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gl - #y Cys Leu Ser Gln Leu          #   220                                                                        - His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Le - #u Gln Ala Leu Glu Gly          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Th - #r Leu Gln Leu Asp Val          #               255                                                            - Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Me - #t Glu Glu Leu Gly Met          #           270                                                                - Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Me - #t Pro Ala Phe Ala Ser          #       285                                                                    - Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Va - #l Ala Ser His Leu Gln          #   300                                                                        - Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Ar - #g His Leu Ala Gln Pro          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Asp Met Ala Thr Pro                                                                          325                                                            - (2) INFORMATION FOR SEQ ID NO:272:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 325 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:272:                                - Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys          #                15                                                            - Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp          #            30                                                                - Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser          #        45                                                                    - Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala          #    60                                                                        - Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro          #80                                                                            - Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg          #                95                                                            - Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln          #           110                                                                - Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro          #       125                                                                    - Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser          #   140                                                                        - Pro Asn Met Ala Leu Gly Pro Ala Ser Ser Le - #u Pro Gln Ser Phe Leu          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gl - #n Gly Asp Gly Ala Ala          #               175                                                            - Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Le - #u Cys His Pro Glu Glu          #           190                                                                - Leu Val Leu Leu Gly His Ser Leu Gly Ile Pr - #o Trp Ala Pro Leu Ser          #       205                                                                    - Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gl - #y Cys Leu Ser Gln Leu          #   220                                                                        - His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Le - #u Gln Ala Leu Glu Gly          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Th - #r Leu Gln Leu Asp Val          #               255                                                            - Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Me - #t Glu Glu Leu Gly Met          #           270                                                                - Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Me - #t Pro Ala Phe Ala Ser          #       285                                                                    - Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Va - #l Ala Ser His Leu Gln          #   300                                                                        - Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Ar - #g His Leu Ala Gln Pro          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Asp Met Ala Thr Pro                                                                          325                                                            - (2) INFORMATION FOR SEQ ID NO:273:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 325 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:273:                                - Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys          #                15                                                            - Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp          #            30                                                                - Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser          #        45                                                                    - Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala          #    60                                                                        - Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro          #80                                                                            - Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg          #                95                                                            - Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln          #           110                                                                - Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro          #       125                                                                    - Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser          #   140                                                                        - Pro Asn Met Ala Phe Leu Leu Lys Ser Leu Gl - #u Gln Val Arg Lys Ile          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Le - #u Cys Ala Thr Tyr Lys          #               175                                                            - Leu Cys His Pro Glu Glu Leu Val Leu Leu Gl - #y His Ser Leu Gly Ile          #           190                                                                - Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gl - #n Ala Leu Gln Leu Ala          #       205                                                                    - Gly Cys Leu Ser Gln Leu His Ser Gly Leu Ph - #e Leu Tyr Gln Gly Leu          #   220                                                                        - Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Le - #u Gly Pro Thr Leu Asp          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Th - #r Thr Ile Trp Gln Gln          #               255                                                            - Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gl - #n Pro Thr Gln Gly Ala          #           270                                                                - Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Ar - #g Ala Gly Gly Val Leu          #       285                                                                    - Val Ala Ser His Leu Gln Ser Phe Leu Glu Va - #l Ser Tyr Arg Val Leu          #   300                                                                        - Arg His Leu Ala Gln Pro Asp Met Ala Thr Pr - #o Leu Gly Pro Ala Ser          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Ser Leu Pro Gln Ser                                                                          325                                                            - (2) INFORMATION FOR SEQ ID NO:274:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 325 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:274:                                - Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys          #                15                                                            - Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp          #            30                                                                - Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser          #        45                                                                    - Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala          #    60                                                                        - Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro          #80                                                                            - Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg          #                95                                                            - Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln          #           110                                                                - Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro          #       125                                                                    - Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser          #   140                                                                        - Pro Asn Met Ala Glu Gln Val Arg Lys Ile Gl - #n Gly Asp Gly Ala Ala          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Le - #u Cys His Pro Glu Glu          #               175                                                            - Leu Val Leu Leu Gly His Ser Leu Gly Ile Pr - #o Trp Ala Pro Leu Ser          #           190                                                                - Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gl - #y Cys Leu Ser Gln Leu          #       205                                                                    - His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Le - #u Gln Ala Leu Glu Gly          #   220                                                                        - Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Th - #r Leu Gln Leu Asp Val          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Me - #t Glu Glu Leu Gly Met          #               255                                                            - Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Me - #t Pro Ala Phe Ala Ser          #           270                                                                - Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Va - #l Ala Ser His Leu Gln          #       285                                                                    - Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Ar - #g His Leu Ala Gln Pro          #   300                                                                        - Asp Met Ala Thr Pro Leu Gly Pro Ala Ser Se - #r Leu Pro Gln Ser Phe          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Leu Leu Lys Ser Leu                                                                          325                                                            - (2) INFORMATION FOR SEQ ID NO:275:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 325 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:275:                                - Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys          #                15                                                            - Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp          #            30                                                                - Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser          #        45                                                                    - Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala          #    60                                                                        - Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro          #80                                                                            - Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg          #                95                                                            - Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln          #           110                                                                - Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro          #       125                                                                    - Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser          #   140                                                                        - Pro Asn Met Ala Leu Leu Gly His Ser Leu Gl - #y Ile Pro Trp Ala Pro          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Le - #u Ala Gly Cys Leu Ser          #               175                                                            - Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gl - #y Leu Leu Gln Ala Leu          #           190                                                                - Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Le - #u Asp Thr Leu Gln Leu          #       205                                                                    - Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gl - #n Gln Met Glu Glu Leu          #   220                                                                        - Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gl - #y Ala Met Pro Ala Phe          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Va - #l Leu Val Ala Ser His          #               255                                                            - Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Va - #l Leu Arg His Leu Ala          #           270                                                                - Gln Pro Asp Met Ala Thr Pro Leu Gly Pro Al - #a Ser Ser Leu Pro Gln          #       285                                                                    - Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Ar - #g Lys Ile Gln Gly Asp          #   300                                                                        - Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Th - #r Tyr Lys Leu Cys His          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Pro Glu Glu Leu Val                                                                          325                                                            - (2) INFORMATION FOR SEQ ID NO:276:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 325 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:276:                                - Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys          #                15                                                            - Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp          #            30                                                                - Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser          #        45                                                                    - Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala          #    60                                                                        - Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro          #80                                                                            - Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg          #                95                                                            - Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln          #           110                                                                - Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro          #       125                                                                    - Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser          #   140                                                                        - Pro Asn Met Ala Pro Leu Ser Ser Cys Pro Se - #r Gln Ala Leu Gln Leu          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Ala Gly Cys Leu Ser Gln Leu His Ser Gly Le - #u Phe Leu Tyr Gln Gly          #               175                                                            - Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Gl - #u Leu Gly Pro Thr Leu          #           190                                                                - Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Al - #a Thr Thr Ile Trp Gln          #       205                                                                    - Gln Met Glu Glu Leu Gly Met Ala Pro Ala Le - #u Gln Pro Thr Gln Gly          #   220                                                                        - Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Ar - #g Arg Ala Gly Gly Val          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Leu Val Ala Ser His Leu Gln Ser Phe Leu Gl - #u Val Ser Tyr Arg Val          #               255                                                            - Leu Arg His Leu Ala Gln Pro Asp Met Ala Th - #r Pro Leu Gly Pro Ala          #           270                                                                - Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Se - #r Leu Glu Gln Val Arg          #       285                                                                    - Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Gl - #u Lys Leu Cys Ala Thr          #   300                                                                        - Tyr Lys Leu Cys His Pro Glu Glu Leu Val Le - #u Leu Gly His Ser Leu          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Gly Ile Pro Trp Ala                                                                          325                                                            - (2) INFORMATION FOR SEQ ID NO:277:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 325 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:277:                                - Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys          #                15                                                            - Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp          #            30                                                                - Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser          #        45                                                                    - Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala          #    60                                                                        - Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro          #80                                                                            - Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg          #                95                                                            - Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln          #           110                                                                - Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro          #       125                                                                    - Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser          #   140                                                                        - Pro Asn Met Ala Gln Ala Leu Gln Leu Ala Gl - #y Cys Leu Ser Gln Leu          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Le - #u Gln Ala Leu Glu Gly          #               175                                                            - Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Th - #r Leu Gln Leu Asp Val          #           190                                                                - Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Me - #t Glu Glu Leu Gly Met          #       205                                                                    - Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Me - #t Pro Ala Phe Ala Ser          #   220                                                                        - Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Va - #l Ala Ser His Leu Gln          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Ar - #g His Leu Ala Gln Pro          #               255                                                            - Asp Met Ala Thr Pro Leu Gly Pro Ala Ser Se - #r Leu Pro Gln Ser Phe          #           270                                                                - Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Il - #e Gln Gly Asp Gly Ala          #       285                                                                    - Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Ly - #s Leu Cys His Pro Glu          #   300                                                                        - Glu Leu Val Leu Leu Gly His Ser Leu Gly Il - #e Pro Trp Ala Pro Leu          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Ser Ser Cys Pro Ser                                                                          325                                                            - (2) INFORMATION FOR SEQ ID NO:278:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 325 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:278:                                - Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys          #                15                                                            - Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp          #            30                                                                - Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser          #        45                                                                    - Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala          #    60                                                                        - Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro          #80                                                                            - Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg          #                95                                                            - Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln          #           110                                                                - Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro          #       125                                                                    - Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser          #   140                                                                        - Pro Asn Met Ala Leu Gln Leu Ala Gly Cys Le - #u Ser Gln Leu His Ser          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Al - #a Leu Glu Gly Ile Ser          #               175                                                            - Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gl - #n Leu Asp Val Ala Asp          #           190                                                                - Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Gl - #u Leu Gly Met Ala Pro          #       205                                                                    - Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Al - #a Phe Ala Ser Ala Phe          #   220                                                                        - Gln Arg Arg Ala Gly Gly Val Leu Val Ala Se - #r His Leu Gln Ser Phe          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Leu Glu Val Ser Tyr Arg Val Leu Arg His Le - #u Ala Gln Pro Asp Met          #               255                                                            - Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pr - #o Gln Ser Phe Leu Leu          #           270                                                                - Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gl - #y Asp Gly Ala Ala Leu          #       285                                                                    - Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cy - #s His Pro Glu Glu Leu          #   300                                                                        - Val Leu Leu Gly His Ser Leu Gly Ile Pro Tr - #p Ala Pro Leu Ser Ser          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Cys Pro Ser Gln Ala                                                                          325                                                            - (2) INFORMATION FOR SEQ ID NO:279:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 325 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:279:                                - Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys          #                15                                                            - Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp          #            30                                                                - Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser          #        45                                                                    - Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala          #    60                                                                        - Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro          #80                                                                            - Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg          #                95                                                            - Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln          #           110                                                                - Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro          #       125                                                                    - Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser          #   140                                                                        - Pro Asn Met Ala Leu Ala Gly Cys Leu Ser Gl - #n Leu His Ser Gly Leu          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Gl - #u Gly Ile Ser Pro Glu          #               175                                                            - Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu As - #p Val Ala Asp Phe Ala          #           190                                                                - Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gl - #y Met Ala Pro Ala Leu          #       205                                                                    - Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Al - #a Ser Ala Phe Gln Arg          #   220                                                                        - Arg Ala Gly Gly Val Leu Val Ala Ser His Le - #u Gln Ser Phe Leu Glu          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Val Ser Tyr Arg Val Leu Arg His Leu Ala Gl - #n Pro Asp Met Ala Thr          #               255                                                            - Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Se - #r Phe Leu Leu Lys Ser          #           270                                                                - Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gl - #y Ala Ala Leu Gln Glu          #       285                                                                    - Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pr - #o Glu Glu Leu Val Leu          #   300                                                                        - Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pr - #o Leu Ser Ser Cys Pro          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Ser Gln Ala Leu Gln                                                                          325                                                            - (2) INFORMATION FOR SEQ ID NO:280:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 325 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:280:                                - Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys          #                15                                                            - Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp          #            30                                                                - Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser          #        45                                                                    - Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala          #    60                                                                        - Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro          #80                                                                            - Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg          #                95                                                            - Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln          #           110                                                                - Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro          #       125                                                                    - Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser          #   140                                                                        - Pro Asn Met Ala Glu Leu Gly Met Ala Pro Al - #a Leu Gln Pro Thr Gln          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gl - #n Arg Arg Ala Gly Gly          #               175                                                            - Val Leu Val Ala Ser His Leu Gln Ser Phe Le - #u Glu Val Ser Tyr Arg          #           190                                                                - Val Leu Arg His Leu Ala Gln Pro Asp Met Al - #a Thr Pro Leu Gly Pro          #       205                                                                    - Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Ly - #s Ser Leu Glu Gln Val          #   220                                                                        - Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gl - #n Glu Lys Leu Cys Ala          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Va - #l Leu Leu Gly His Ser          #               255                                                            - Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cy - #s Pro Ser Gln Ala Leu          #           270                                                                - Gln Leu Ala Gly Cys Leu Ser Gln Leu His Se - #r Gly Leu Phe Leu Tyr          #       285                                                                    - Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Se - #r Pro Glu Leu Gly Pro          #   300                                                                        - Thr Leu Asp Thr Leu Gln Leu Asp Val Ala As - #p Phe Ala Thr Thr Ile          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Trp Gln Gln Met Glu                                                                          325                                                            - (2) INFORMATION FOR SEQ ID NO:281:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 325 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:281:                                - Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys          #                15                                                            - Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp          #            30                                                                - Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser          #        45                                                                    - Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala          #    60                                                                        - Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro          #80                                                                            - Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg          #                95                                                            - Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln          #           110                                                                - Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro          #       125                                                                    - Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser          #   140                                                                        - Pro Asn Met Ala Gly Met Ala Pro Ala Leu Gl - #n Pro Thr Gln Gly Ala          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Ar - #g Ala Gly Gly Val Leu          #               175                                                            - Val Ala Ser His Leu Gln Ser Phe Leu Glu Va - #l Ser Tyr Arg Val Leu          #           190                                                                - Arg His Leu Ala Gln Pro Asp Met Ala Thr Pr - #o Leu Gly Pro Ala Ser          #       205                                                                    - Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Le - #u Glu Gln Val Arg Lys          #   220                                                                        - Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Ly - #s Leu Cys Ala Thr Tyr          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Lys Leu Cys His Pro Glu Glu Leu Val Leu Le - #u Gly His Ser Leu Gly          #               255                                                            - Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Se - #r Gln Ala Leu Gln Leu          #           270                                                                - Ala Gly Cys Leu Ser Gln Leu His Ser Gly Le - #u Phe Leu Tyr Gln Gly          #       285                                                                    - Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Gl - #u Leu Gly Pro Thr Leu          #   300                                                                        - Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Al - #a Thr Thr Ile Trp Gln          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Gln Met Glu Glu Leu                                                                          325                                                            - (2) INFORMATION FOR SEQ ID NO:282:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 325 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:282:                                - Met Ala Asn Cys Ser Ile Met Ile Asp Glu Il - #e Ile His His Leu Lys          #                15                                                            - Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn As - #n Leu Asn Asp Glu Asp          #            30                                                                - Val Ser Ile Leu Met Asp Arg Asn Leu Arg Le - #u Pro Asn Leu Glu Ser          #        45                                                                    - Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al - #a Ser Gly Ile Glu Ala          #    60                                                                        - Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se - #r Ala Thr Ala Ala Pro          #80                                                                            - Ser Arg His Pro Ile Ile Ile Lys Ala Gly As - #p Trp Gln Glu Phe Arg          #                95                                                            - Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Gl - #u Gln Ala Gln Glu Gln          #           110                                                                - Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gl - #y Glu Pro Ser Gly Pro          #       125                                                                    - Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Ly - #s Glu Ser His Lys Ser          #   140                                                                        - Pro Asn Met Ala Ser Phe Leu Glu Val Ser Ty - #r Arg Val Leu Arg His          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Leu Ala Gln Pro Asp Met Ala Thr Pro Leu Gl - #y Pro Ala Ser Ser Leu          #               175                                                            - Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gl - #n Val Arg Lys Ile Gln          #           190                                                                - Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cy - #s Ala Thr Tyr Lys Leu          #       205                                                                    - Cys His Pro Glu Glu Leu Val Leu Leu Gly Hi - #s Ser Leu Gly Ile Pro          #   220                                                                        - Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Al - #a Leu Gln Leu Ala Gly          225                 2 - #30                 2 - #35                 2 -        #40                                                                            - Cys Leu Ser Gln Leu His Ser Gly Leu Phe Le - #u Tyr Gln Gly Leu Leu          #               255                                                            - Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gl - #y Pro Thr Leu Asp Thr          #           270                                                                - Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Th - #r Ile Trp Gln Gln Met          #       285                                                                    - Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pr - #o Thr Gln Gly Ala Met          #   300                                                                        - Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Al - #a Gly Gly Val Leu Val          305                 3 - #10                 3 - #15                 3 -        #20                                                                            - Ala Ser His Leu Gln                                                                          325                                                            - (2) INFORMATION FOR SEQ ID NO:283:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 153 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 7                                                      #/note= "Xaa at position 7 is Ser or                                                          Ala;"                                                           -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 112                                                    #/note= "Xaa at position 112 is:                                                              deleted o - #r Leu, Ala, Val, Ile, Pro, Phe, Trp, or Met;       - #"                                                                           -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 113                                                    #/note= "Xaa at position 113 is:                                                              deleted o - #r Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met;       - #"                                                                           -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 114                                                    #/note= "Xaa at position 114 is:                                                              deleted o - #r Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met;       - #"                                                                           -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 115                                                    #/note= "Xaa at position 115 is:                                                              deleted o - #r Gln, Gly, Ser, Thr, Tyr, or Asn;"                -     (ix) FEATURE:                                                                      (A) NAME/KEY: Modified-sit - #e                                                (B) LOCATION: 151                                                    #/note= "Xaa at position 151 is Ser                                                           or Ala;"                                                        -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:283:                                - Ser Pro Ala Pro Pro Ala Xaa Asp Leu Arg Va - #l Leu Ser Lys Leu Leu          #                15                                                            - Arg Asp Ser His Val Leu His Ser Arg Leu Se - #r Gln Cys Pro Glu Val          #            30                                                                - His Pro Leu Pro Thr Pro Val Leu Leu Pro Al - #a Val Asp Phe Ser Leu          #        45                                                                    - Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Ly - #s Ala Gln Asp Ile Leu          #    60                                                                        - Gly Ala Val Thr Leu Leu Leu Glu Gly Val Me - #t Ala Ala Arg Gly Gln          #80                                                                            - Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl - #y Gln Leu Ser Gly Gln          #                95                                                            - Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le - #u Leu Gly Thr Gln Xaa          #           110                                                                - Xaa Xaa Xaa Gly Arg Thr Thr Ala His Lys As - #p Pro Asn Ala Ile Phe          #       125                                                                    - Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va - #l Arg Phe Leu Met Leu          #   140                                                                        - Val Gly Gly Ser Thr Leu Xaa Val Arg                                          145                 1 - #50                                                    - (2) INFORMATION FOR SEQ ID NO:284:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 162 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:284:                                - Met Ala Gly Arg Thr Thr Ala His Lys Asp Pr - #o Asn Ala Ile Phe Leu          #                15                                                            - Ser Phe Gln His Leu Leu Arg Gly Lys Val Ar - #g Phe Leu Met Leu Val          #            30                                                                - Gly Gly Ser Thr Leu Ala Val Arg Glu Phe Gl - #y Gly Asn Met Ala Ser          #        45                                                                    - Pro Ala Pro Pro Ala Ala Asp Leu Arg Val Le - #u Ser Lys Leu Leu Arg          #    60                                                                        - Asp Ser His Val Leu His Ser Arg Leu Ser Gl - #n Cys Pro Glu Val His          #80                                                                            - Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Va - #l Asp Phe Ser Leu Gly          #                95                                                            - Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Al - #a Gln Asp Ile Leu Gly          #           110                                                                - Ala Val Thr Leu Leu Leu Glu Gly Val Met Al - #a Ala Arg Gly Gln Leu          #       125                                                                    - Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gl - #n Leu Ser Gly Gln Val          #   140                                                                        - Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Le - #u Gly Thr Gln Leu Pro          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Pro Gln                                                                      - (2) INFORMATION FOR SEQ ID NO:285:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 162 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:285:                                - Met Ala Gly Pro Thr Cys Leu Ser Ser Leu Le - #u Gly Gln Leu Ser Gly          #                15                                                            - Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Se - #r Leu Leu Gly Thr Gln          #            30                                                                - Leu Pro Pro Gln Gly Arg Thr Thr Ala His Ly - #s Asp Pro Asn Ala Ile          #        45                                                                    - Phe Leu Ser Phe Gln His Leu Leu Arg Gly Ly - #s Val Arg Phe Leu Met          #    60                                                                        - Leu Val Gly Gly Ser Thr Leu Ala Val Arg Gl - #u Phe Gly Gly Asn Met          #80                                                                            - Ala Ser Pro Ala Pro Pro Ala Ala Asp Leu Ar - #g Val Leu Ser Lys Leu          #                95                                                            - Leu Arg Asp Ser His Val Leu His Ser Arg Le - #u Ser Gln Cys Pro Glu          #           110                                                                - Val His Pro Leu Pro Thr Pro Val Leu Leu Pr - #o Ala Val Asp Phe Ser          #       125                                                                    - Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Th - #r Lys Ala Gln Asp Ile          #   140                                                                        - Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Va - #l Met Ala Ala Arg Gly          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Gln Leu                                                                      - (2) INFORMATION FOR SEQ ID NO:286:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 180 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                                             "                                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:286:                                - Ala Thr Gly Gly Cys Thr Gly Gly Ala Cys Cy - #s Cys Ala Cys Thr Thr          #                15                                                            - Gly Cys Cys Thr Cys Thr Cys Ala Thr Cys Cy - #s Cys Thr Cys Cys Thr          #            30                                                                - Gly Gly Gly Gly Cys Ala Gly Cys Thr Thr Th - #r Cys Thr Gly Gly Ala          #        45                                                                    - Cys Ala Gly Gly Thr Cys Cys Gly Thr Cys Th - #r Cys Cys Thr Cys Cys          #    60                                                                        - Thr Thr Gly Gly Gly Gly Cys Cys Cys Thr Gl - #y Cys Ala Gly Ala Gly          #80                                                                            - Cys Cys Thr Cys Cys Thr Thr Gly Gly Ala Al - #a Cys Cys Cys Ala Gly          #                95                                                            - Cys Thr Thr Cys Cys Thr Cys Cys Ala Cys Al - #a Gly Gly Gly Cys Ala          #           110                                                                - Gly Gly Ala Cys Cys Ala Cys Ala Gly Cys Th - #r Cys Ala Cys Ala Ala          #       125                                                                    - Gly Gly Ala Thr Cys Cys Cys Ala Ala Thr Gl - #y Cys Cys Ala Thr Cys          #   140                                                                        - Thr Thr Cys Cys Thr Gly Ala Gly Cys Thr Th - #r Cys Cys Ala Ala Cys          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Ala Cys Cys Thr Gly Cys Thr Cys Cys Gly Al - #a Gly Gly Ala Ala Ala          #               175                                                            - Gly Gly Thr Gly                                                                          180                                                                - (2) INFORMATION FOR SEQ ID NO:287:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 486 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:287:                                - ATGGCTGGCA GGACCACAGC TCACAAGGAT CCCAATGCCA TCTTCCTGAG CT - #TCCAACAC          60                                                                           - CTGCTCCGAG GAAAGGTGCG TTTCCTGATG CTTGTAGGAG GGTCCACCCT CG - #CCGTCAGG         120                                                                           - GAATTCGGCG GCAACATGGC GTCTCCGGCG CCGCCTGCTG CTGACCTCCG AG - #TCCTCAGT         180                                                                           - AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AG - #AGGTTCAC         240                                                                           - CCTTTGCCTA CACCTGTCCT GCTGCCTGCT GTGGACTTTA GCTTGGGAGA AT - #GGAAAACC         300                                                                           - CAGATGGAGG AGACCAAGGC ACAGGACATT CTGGGAGCAG TGACCCTTCT GC - #TGGAGGGA         360                                                                           - GTGATGGCAG CACGGGGACA ACTGGGACCC ACTTGCCTCT CATCCCTCCT GG - #GGCAGCTT         420                                                                           - TCTGGACAGG TCCGTCTCCT CCTTGGGGCC CTGCAGAGCC TCCTTGGAAC CC - #AGCTTCCT         480                                                                           #          486                                                                 - (2) INFORMATION FOR SEQ ID NO:288:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 531 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:288:                                - CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGGAAGA TCCAGGGCGA TG - #GCGCAGCG          60                                                                           - CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GG - #TGCTGCTC         120                                                                           - GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GG - #CCCTGCAG         180                                                                           - CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GC - #TCCTGCAG         240                                                                           - GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GC - #TGGACGTC         300                                                                           - GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CC - #CTGCCCTG         360                                                                           - CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GG - #CAGGAGGG         420                                                                           - GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TC - #TACGCCAC         480                                                                           #            531ACATGGC TACACCATTA GGCCCTGCCA GCTCCCTGCC C                     - (2) INFORMATION FOR SEQ ID NO:289:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 531 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:289:                                - GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CT - #TCGCCTCT          60                                                                           - GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG CT - #TCCTGGAG         120                                                                           - GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCGACA TGGCTACACC AT - #TAGGCCCT         180                                                                           - GCCAGCTCCC TGCCCCAGAG CTTCCTGCTC AAGTCTTTAG AGCAAGTGAG GA - #AGATCCAG         240                                                                           - GGCGATGGCG CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG CC - #ACCCCGAG         300                                                                           - GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CT - #CCTGCCCC         360                                                                           - AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TT - #TCCTCTAC         420                                                                           - CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CT - #TGGACACA         480                                                                           #            531TCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA A                     - (2) INFORMATION FOR SEQ ID NO:290:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 531 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:290:                                - GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CT - #CTGCTTTC          60                                                                           - CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GG - #AGGTGTCG         120                                                                           - TACCGCGTTC TACGCCACCT TGCGCAGCCC GACATGGCTA CACCATTAGG CC - #CTGCCAGC         180                                                                           - TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG TGAGGAAGAT CC - #AGGGCGAT         240                                                                           - GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC ACCTACAAGC TGTGCCACCC CG - #AGGAGCTG         300                                                                           - GTGCTGCTCG GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CC - #CCAGCCAG         360                                                                           - GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT CT - #ACCAGGGG         420                                                                           - CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTC CCACCTTGGA CA - #CACTGCAG         480                                                                           #            531ACTTTGC CACCACCATC TGGCAGCAGA TGGAAGAACT G                     - (2) INFORMATION FOR SEQ ID NO:291:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 531 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:291:                                - TTCCTGCTCA AGTCTTTAGA GCAAGTGAGG AAGATCCAGG GCGATGGCGC AG - #CGCTCCAG          60                                                                           - GAGAAGCTGT GTGCCACCTA CAAGCTGTGC CACCCCGAGG AGCTGGTGCT GC - #TCGGACAC         120                                                                           - TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GC - #AGCTGGCA         180                                                                           - GGCTGCTTGA GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GC - #AGGCCCTG         240                                                                           - GAAGGGATAT CCCCCGAGTT GGGTCCCACC TTGGACACAC TGCAGCTGGA CG - #TCGCCGAC         300                                                                           - TTTGCCACCA CCATCTGGCA GCAGATGGAA GAACTGGGAA TGGCCCCTGC CC - #TGCAGCCC         360                                                                           - ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AG - #GGGTCCTG         420                                                                           - GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CC - #ACCTTGCG         480                                                                           #            531CTACACC ATTAGGCCCT GCCAGCTCCC TGCCCCAGAG C                     - (2) INFORMATION FOR SEQ ID NO:292:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 531 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:292:                                - AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCGA CA - #TGGCTACA          60                                                                           - CCATTAGGCC CTGCCAGCTC CCTGCCCCAG AGCTTCCTGC TCAAGTCTTT AG - #AGCAAGTG         120                                                                           - AGGAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CT - #ACAAGCTG         180                                                                           - TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GG - #CTCCCCTG         240                                                                           - AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CC - #ATAGCGGC         300                                                                           - CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GT - #TGGGTCCC         360                                                                           - ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GC - #AGCAGATG         420                                                                           - GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCACCCAGG GTGCCATGCC GG - #CCTTCGCC         480                                                                           #            531GCCGGGC AGGAGGGGTC CTGGTTGCTA GCCATCTGCA G                     - (2) INFORMATION FOR SEQ ID NO:293:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 531 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:293:                                - AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCGA CA - #TGGCTACA          60                                                                           - CCATTAGGCC CTGCCAGCTC CCTGCCCCAG AGCTTCCTGC TCAAGTCTTT AG - #AGCAAGTG         120                                                                           - AGGAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CT - #ACAAGCTG         180                                                                           - TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GG - #CTCCCCTG         240                                                                           - AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CC - #ATAGCGGC         300                                                                           - CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GT - #TGGGTCCC         360                                                                           - ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GC - #AGCAGATG         420                                                                           - GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCACCCAGG GTGCCATGCC GG - #CCTTCGCC         480                                                                           #            531GCCGGGC AGGAGGGGTC CTGGTTGCTA GCCATCTGCA G                     - (2) INFORMATION FOR SEQ ID NO:294:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 531 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:294:                                - TTAGGCCCTG CCAGCTCCCT GCCCCAGAGC TTCCTGCTCA AGTCTTTAGA GC - #AAGTGAGG          60                                                                           - AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CA - #AGCTGTGC         120                                                                           - CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TC - #CCCTGAGC         180                                                                           - TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA TA - #GCGGCCTT         240                                                                           - TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GG - #GTCCCACC         300                                                                           - TTGGACACAC TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA GC - #AGATGGAA         360                                                                           - GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CT - #TCGCCTCT         420                                                                           - GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG CT - #TCCTGGAG         480                                                                           #            531TTCTACG CCACCTTGCG CAGCCCGACA TGGCTACACC A                     - (2) INFORMATION FOR SEQ ID NO:295:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 531 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:295:                                - CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC CA - #GCCAGGCC          60                                                                           - CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTA CC - #AGGGGCTC         120                                                                           - CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA CCTTGGACAC AC - #TGCAGCTG         180                                                                           - GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AA - #TGGCCCCT         240                                                                           - GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GC - #GCCGGGCA         300                                                                           - GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CC - #GCGTTCTA         360                                                                           - CGCCACCTTG CGCAGCCCGA CATGGCTACA CCATTAGGCC CTGCCAGCTC CC - #TGCCCCAG         420                                                                           - AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGGAAGATCC AGGGCGATGG CG - #CAGCGCTC         480                                                                           #            531GTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT G                     - (2) INFORMATION FOR SEQ ID NO:296:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 531 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:296:                                - CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CC - #AACTCCAT          60                                                                           - AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CC - #CCGAGTTG         120                                                                           - GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CA - #TCTGGCAG         180                                                                           - CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CA - #TGCCGGCC         240                                                                           - TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TC - #TGCAGAGC         300                                                                           - TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCGACAT GG - #CTACACCA         360                                                                           - TTAGGCCCTG CCAGCTCCCT GCCCCAGAGC TTCCTGCTCA AGTCTTTAGA GC - #AAGTGAGG         420                                                                           - AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CA - #AGCTGTGC         480                                                                           #            531TGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC T                     - (2) INFORMATION FOR SEQ ID NO:297:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 531 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:297:                                - CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC CAACTCCATA GCGGCCTTTT CC - #TCTACCAG          60                                                                           - GGGCTCCTGC AGGCCCTGGA AGGGATATCC CCCGAGTTGG GTCCCACCTT GG - #ACACACTG         120                                                                           - CAGCTGGACG TCGCCGACTT TGCCACCACC ATCTGGCAGC AGATGGAAGA AC - #TGGGAATG         180                                                                           - GCCCCTGCCC TGCAGCCCAC CCAGGGTGCC ATGCCGGCCT TCGCCTCTGC TT - #TCCAGCGC         240                                                                           - CGGGCAGGAG GGGTCCTGGT TGCTAGCCAT CTGCAGAGCT TCCTGGAGGT GT - #CGTACCGC         300                                                                           - GTTCTACGCC ACCTTGCGCA GCCCGACATG GCTACACCAT TAGGCCCTGC CA - #GCTCCCTG         360                                                                           - CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGGA AGATCCAGGG CG - #ATGGCGCA         420                                                                           - GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GC - #TGGTGCTG         480                                                                           #            531TGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG C                     - (2) INFORMATION FOR SEQ ID NO:298:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 531 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:298:                                - CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTA CC - #AGGGGCTC          60                                                                           - CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA CCTTGGACAC AC - #TGCAGCTG         120                                                                           - GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AA - #TGGCCCCT         180                                                                           - GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GC - #GCCGGGCA         240                                                                           - GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CC - #GCGTTCTA         300                                                                           - CGCCACCTTG CGCAGCCCGA CATGGCTACA CCATTAGGCC CTGCCAGCTC CC - #TGCCCCAG         360                                                                           - AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGGAAGATCC AGGGCGATGG CG - #CAGCGCTC         420                                                                           - CAGGAGAAGC TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GC - #TGCTCGGA         480                                                                           #            531TCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC C                     - (2) INFORMATION FOR SEQ ID NO:299:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 531 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:299:                                - CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GC - #TCCTGCAG          60                                                                           - GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GC - #TGGACGTC         120                                                                           - GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CC - #CTGCCCTG         180                                                                           - CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GG - #CAGGAGGG         240                                                                           - GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TC - #TACGCCAC         300                                                                           - CTTGCGCAGC CCGACATGGC TACACCATTA GGCCCTGCCA GCTCCCTGCC CC - #AGAGCTTC         360                                                                           - CTGCTCAAGT CTTTAGAGCA AGTGAGGAAG ATCCAGGGCG ATGGCGCAGC GC - #TCCAGGAG         420                                                                           - AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CG - #GACACTCT         480                                                                           #            531GGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA G                     - (2) INFORMATION FOR SEQ ID NO:300:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 177 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:300:                                - Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Va - #l Arg Lys Ile Gln Gly          #                15                                                            - Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Al - #a Thr Tyr Lys Leu Cys          #            30                                                                - His Pro Glu Glu Leu Val Leu Leu Gly His Se - #r Leu Gly Ile Pro Trp          #        45                                                                    - Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Le - #u Gln Leu Ala Gly Cys          #    60                                                                        - Leu Ser Gln Leu His Ser Gly Leu Phe Leu Ty - #r Gln Gly Leu Leu Gln          #80                                                                            - Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pr - #o Thr Leu Asp Thr Leu          #                95                                                            - Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Il - #e Trp Gln Gln Met Glu          #           110                                                                - Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Th - #r Gln Gly Ala Met Pro          #       125                                                                    - Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gl - #y Gly Val Leu Val Ala          #   140                                                                        - Ser His Leu Gln Ser Phe Leu Glu Val Ser Ty - #r Arg Val Leu Arg His          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Leu Ala Gln Pro Asp Met Ala Thr Pro Leu Gl - #y Pro Ala Ser Ser Leu          #               175                                                            - Pro                                                                          - (2) INFORMATION FOR SEQ ID NO:301:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 177 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:301:                                - Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Th - #r Gln Gly Ala Met Pro          #                15                                                            - Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gl - #y Gly Val Leu Val Ala          #            30                                                                - Ser His Leu Gln Ser Phe Leu Glu Val Ser Ty - #r Arg Val Leu Arg His          #        45                                                                    - Leu Ala Gln Pro Asp Met Ala Thr Pro Leu Gl - #y Pro Ala Ser Ser Leu          #    60                                                                        - Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gl - #n Val Arg Lys Ile Gln          #80                                                                            - Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cy - #s Ala Thr Tyr Lys Leu          #                95                                                            - Cys His Pro Glu Glu Leu Val Leu Leu Gly Hi - #s Ser Leu Gly Ile Pro          #           110                                                                - Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Al - #a Leu Gln Leu Ala Gly          #       125                                                                    - Cys Leu Ser Gln Leu His Ser Gly Leu Phe Le - #u Tyr Gln Gly Leu Leu          #   140                                                                        - Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gl - #y Pro Thr Leu Asp Thr          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Th - #r Ile Trp Gln Gln Met          #               175                                                            - Glu                                                                          - (2) INFORMATION FOR SEQ ID NO:302:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 177 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:302:                                - Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gl - #y Ala Met Pro Ala Phe          #                15                                                            - Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Va - #l Leu Val Ala Ser His          #            30                                                                - Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Va - #l Leu Arg His Leu Ala          #        45                                                                    - Gln Pro Asp Met Ala Thr Pro Leu Gly Pro Al - #a Ser Ser Leu Pro Gln          #    60                                                                        - Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Ar - #g Lys Ile Gln Gly Asp          #80                                                                            - Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Th - #r Tyr Lys Leu Cys His          #                95                                                            - Pro Glu Glu Leu Val Leu Leu Gly His Ser Le - #u Gly Ile Pro Trp Ala          #           110                                                                - Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gl - #n Leu Ala Gly Cys Leu          #       125                                                                    - Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gl - #n Gly Leu Leu Gln Ala          #   140                                                                        - Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Th - #r Leu Asp Thr Leu Gln          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Tr - #p Gln Gln Met Glu Glu          #               175                                                            - Leu                                                                          - (2) INFORMATION FOR SEQ ID NO:303:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 177 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:303:                                - Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Ly - #s Ile Gln Gly Asp Gly          #                15                                                            - Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Ty - #r Lys Leu Cys His Pro          #            30                                                                - Glu Glu Leu Val Leu Leu Gly His Ser Leu Gl - #y Ile Pro Trp Ala Pro          #        45                                                                    - Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Le - #u Ala Gly Cys Leu Ser          #    60                                                                        - Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gl - #y Leu Leu Gln Ala Leu          #80                                                                            - Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Le - #u Asp Thr Leu Gln Leu          #                95                                                            - Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gl - #n Gln Met Glu Glu Leu          #           110                                                                - Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gl - #y Ala Met Pro Ala Phe          #       125                                                                    - Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Va - #l Leu Val Ala Ser His          #   140                                                                        - Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Va - #l Leu Arg His Leu Ala          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Gln Pro Asp Met Ala Thr Pro Leu Gly Pro Al - #a Ser Ser Leu Pro Gln          #               175                                                            - Ser                                                                          - (2) INFORMATION FOR SEQ ID NO:304:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 177 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:304:                                - Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Ar - #g His Leu Ala Gln Pro          #                15                                                            - Asp Met Ala Thr Pro Leu Gly Pro Ala Ser Se - #r Leu Pro Gln Ser Phe          #            30                                                                - Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Il - #e Gln Gly Asp Gly Ala          #        45                                                                    - Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Ly - #s Leu Cys His Pro Glu          #    60                                                                        - Glu Leu Val Leu Leu Gly His Ser Leu Gly Il - #e Pro Trp Ala Pro Leu          #80                                                                            - Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Al - #a Gly Cys Leu Ser Gln          #                95                                                            - Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Le - #u Leu Gln Ala Leu Glu          #           110                                                                - Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu As - #p Thr Leu Gln Leu Asp          #       125                                                                    - Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gl - #n Met Glu Glu Leu Gly          #   140                                                                        - Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Al - #a Met Pro Ala Phe Ala          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Le - #u Val Ala Ser His Leu          #               175                                                            - Gln                                                                          - (2) INFORMATION FOR SEQ ID NO:305:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 177 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:305:                                - Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Al - #a Ala Leu Gln Glu Lys          #                15                                                            - Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Gl - #u Glu Leu Val Leu Leu          #            30                                                                - Gly His Ser Leu Gly Ile Pro Trp Ala Pro Le - #u Ser Ser Cys Pro Ser          #        45                                                                    - Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gl - #n Leu His Ser Gly Leu          #    60                                                                        - Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Gl - #u Gly Ile Ser Pro Glu          #80                                                                            - Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu As - #p Val Ala Asp Phe Ala          #                95                                                            - Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gl - #y Met Ala Pro Ala Leu          #           110                                                                - Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Al - #a Ser Ala Phe Gln Arg          #       125                                                                    - Arg Ala Gly Gly Val Leu Val Ala Ser His Le - #u Gln Ser Phe Leu Glu          #   140                                                                        - Val Ser Tyr Arg Val Leu Arg His Leu Ala Gl - #n Pro Asp Met Ala Thr          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Se - #r Phe Leu Leu Lys Ser          #               175                                                            - Leu                                                                          - (2) INFORMATION FOR SEQ ID NO:306:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 177 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:306:                                - Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Ph - #e Leu Leu Lys Ser Leu          #                15                                                            - Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Al - #a Ala Leu Gln Glu Lys          #            30                                                                - Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Gl - #u Glu Leu Val Leu Leu          #        45                                                                    - Gly His Ser Leu Gly Ile Pro Trp Ala Pro Le - #u Ser Ser Cys Pro Ser          #    60                                                                        - Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gl - #n Leu His Ser Gly Leu          #80                                                                            - Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Gl - #u Gly Ile Ser Pro Glu          #                95                                                            - Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu As - #p Val Ala Asp Phe Ala          #           110                                                                - Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gl - #y Met Ala Pro Ala Leu          #       125                                                                    - Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Al - #a Ser Ala Phe Gln Arg          #   140                                                                        - Arg Ala Gly Gly Val Leu Val Ala Ser His Le - #u Gln Ser Phe Leu Glu          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Val Ser Tyr Arg Val Leu Arg His Leu Ala Gl - #n Pro Asp Met Ala Thr          #               175                                                            - Pro                                                                          - (2) INFORMATION FOR SEQ ID NO:307:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 177 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:307:                                - Leu Leu Gly His Ser Leu Gly Ile Pro Trp Al - #a Pro Leu Ser Ser Cys          #                15                                                            - Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Le - #u Ser Gln Leu His Ser          #            30                                                                - Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Al - #a Leu Glu Gly Ile Ser          #        45                                                                    - Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gl - #n Leu Asp Val Ala Asp          #    60                                                                        - Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Gl - #u Leu Gly Met Ala Pro          #80                                                                            - Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Al - #a Phe Ala Ser Ala Phe          #                95                                                            - Gln Arg Arg Ala Gly Gly Val Leu Val Ala Se - #r His Leu Gln Ser Phe          #           110                                                                - Leu Glu Val Ser Tyr Arg Val Leu Arg His Le - #u Ala Gln Pro Asp Met          #       125                                                                    - Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pr - #o Gln Ser Phe Leu Leu          #   140                                                                        - Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gl - #y Asp Gly Ala Ala Leu          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cy - #s His Pro Glu Glu Leu          #               175                                                            - Val                                                                          - (2) INFORMATION FOR SEQ ID NO:308:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 177 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:308:                                - Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gl - #n Leu Ala Gly Cys Leu          #                15                                                            - Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gl - #n Gly Leu Leu Gln Ala          #            30                                                                - Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Th - #r Leu Asp Thr Leu Gln          #        45                                                                    - Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Tr - #p Gln Gln Met Glu Glu          #    60                                                                        - Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gl - #n Gly Ala Met Pro Ala          #80                                                                            - Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gl - #y Val Leu Val Ala Ser          #                95                                                            - His Leu Gln Ser Phe Leu Glu Val Ser Tyr Ar - #g Val Leu Arg His Leu          #           110                                                                - Ala Gln Pro Asp Met Ala Thr Pro Leu Gly Pr - #o Ala Ser Ser Leu Pro          #       125                                                                    - Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Va - #l Arg Lys Ile Gln Gly          #   140                                                                        - Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Al - #a Thr Tyr Lys Leu Cys          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - His Pro Glu Glu Leu Val Leu Leu Gly His Se - #r Leu Gly Ile Pro Trp          #               175                                                            - Ala                                                                          - (2) INFORMATION FOR SEQ ID NO:309:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 177 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:309:                                - Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gl - #n Leu His Ser Gly Leu          #                15                                                            - Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Gl - #u Gly Ile Ser Pro Glu          #            30                                                                - Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu As - #p Val Ala Asp Phe Ala          #        45                                                                    - Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gl - #y Met Ala Pro Ala Leu          #    60                                                                        - Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Al - #a Ser Ala Phe Gln Arg          #80                                                                            - Arg Ala Gly Gly Val Leu Val Ala Ser His Le - #u Gln Ser Phe Leu Glu          #                95                                                            - Val Ser Tyr Arg Val Leu Arg His Leu Ala Gl - #n Pro Asp Met Ala Thr          #           110                                                                - Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Se - #r Phe Leu Leu Lys Ser          #       125                                                                    - Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gl - #y Ala Ala Leu Gln Glu          #   140                                                                        - Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pr - #o Glu Glu Leu Val Leu          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pr - #o Leu Ser Ser Cys Pro          #               175                                                            - Ser                                                                          - (2) INFORMATION FOR SEQ ID NO:310:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 177 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:310:                                - Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu Hi - #s Ser Gly Leu Phe Leu          #                15                                                            - Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Il - #e Ser Pro Glu Leu Gly          #            30                                                                - Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Al - #a Asp Phe Ala Thr Thr          #        45                                                                    - Ile Trp Gln Gln Met Glu Glu Leu Gly Met Al - #a Pro Ala Leu Gln Pro          #    60                                                                        - Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Al - #a Phe Gln Arg Arg Ala          #80                                                                            - Gly Gly Val Leu Val Ala Ser His Leu Gln Se - #r Phe Leu Glu Val Ser          #                95                                                            - Tyr Arg Val Leu Arg His Leu Ala Gln Pro As - #p Met Ala Thr Pro Leu          #           110                                                                - Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Le - #u Leu Lys Ser Leu Glu          #       125                                                                    - Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Al - #a Leu Gln Glu Lys Leu          #   140                                                                        - Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Gl - #u Leu Val Leu Leu Gly          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - His Ser Leu Gly Ile Pro Trp Ala Pro Leu Se - #r Ser Cys Pro Ser Gln          #               175                                                            - Ala                                                                          - (2) INFORMATION FOR SEQ ID NO:311:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 177 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:311:                                - Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gl - #y Leu Phe Leu Tyr Gln          #                15                                                            - Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pr - #o Glu Leu Gly Pro Thr          #            30                                                                - Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Ph - #e Ala Thr Thr Ile Trp          #        45                                                                    - Gln Gln Met Glu Glu Leu Gly Met Ala Pro Al - #a Leu Gln Pro Thr Gln          #    60                                                                        - Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gl - #n Arg Arg Ala Gly Gly          #80                                                                            - Val Leu Val Ala Ser His Leu Gln Ser Phe Le - #u Glu Val Ser Tyr Arg          #                95                                                            - Val Leu Arg His Leu Ala Gln Pro Asp Met Al - #a Thr Pro Leu Gly Pro          #           110                                                                - Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Ly - #s Ser Leu Glu Gln Val          #       125                                                                    - Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gl - #n Glu Lys Leu Cys Ala          #   140                                                                        - Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Va - #l Leu Leu Gly His Ser          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cy - #s Pro Ser Gln Ala Leu          #               175                                                            - Gln                                                                          - (2) INFORMATION FOR SEQ ID NO:312:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #acids    (A) LENGTH: 177 amino                                                          (B) TYPE: amino acid                                                           (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: peptide                                              -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:312:                                - His Leu Ala Gln Pro Asp Met Ala Thr Pro Le - #u Gly Pro Ala Ser Ser          #                15                                                            - Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Gl - #u Gln Val Arg Lys Ile          #            30                                                                - Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Le - #u Cys Ala Thr Tyr Lys          #        45                                                                    - Leu Cys His Pro Glu Glu Leu Val Leu Leu Gl - #y His Ser Leu Gly Ile          #    60                                                                        - Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gl - #n Ala Leu Gln Leu Ala          #80                                                                            - Gly Cys Leu Ser Gln Leu His Ser Gly Leu Ph - #e Leu Tyr Gln Gly Leu          #                95                                                            - Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Le - #u Gly Pro Thr Leu Asp          #           110                                                                - Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Th - #r Thr Ile Trp Gln Gln          #       125                                                                    - Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gl - #n Pro Thr Gln Gly Ala          #   140                                                                        - Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Ar - #g Ala Gly Gly Val Leu          145                 1 - #50                 1 - #55                 1 -        #60                                                                            - Val Ala Ser His Leu Gln Ser Phe Leu Glu Va - #l Ser Tyr Arg Val Leu          #               175                                                            - Arg                                                                          - (2) INFORMATION FOR SEQ ID NO:313:                                           -      (i) SEQUENCE CHARACTERISTICS:                                           #pairs    (A) LENGTH: 531 base                                                           (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: unknown                                                      (D) TOPOLOGY: unknown                                                -     (ii) MOLECULE TYPE: other nucleic acid                                   #= "synthetic"DESCRIPTION: /desc                                               -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:313:                                - CACCTTGCGC AGCCCGACAT GGCTACACCA TTAGGCCCTG CCAGCTCCCT GC - #CCCAGAGC          60                                                                           - TTCCTGCTCA AGTCTTTAGA GCAAGTGAGG AAGATCCAGG GCGATGGCGC AG - #CGCTCCAG         120                                                                           - GAGAAGCTGT GTGCCACCTA CAAGCTGTGC CACCCCGAGG AGCTGGTGCT GC - #TCGGACAC         180                                                                           - TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GC - #AGCTGGCA         240                                                                           - GGCTGCTTGA GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GC - #AGGCCCTG         300                                                                           - GAAGGGATAT CCCCCGAGTT GGGTCCCACC TTGGACACAC TGCAGCTGGA CG - #TCGCCGAC         360                                                                           - TTTGCCACCA CCATCTGGCA GCAGATGGAA GAACTGGGAA TGGCCCCTGC CC - #TGCAGCCC         420                                                                           - ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AG - #GGGTCCTG         480                                                                           #            531TGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG C                     __________________________________________________________________________ 

What is claimed is:
 1. A hematopoietic protein comprising; an amino acid sequence of the formula:

    R1-L1-R2, R2-L1-R1, R1-R2, or R2-R1

wherein R1 is a biologically active human c-mpl ligand comprising a modified amino acid sequence selected from the group consisting of: (a) an amino acid sequence of SEQ ID NO:256 wherein; Xaa at position 112 is deleted or Leu, Ala, Val, Ile, Pro, Phe, Trp, or Met; Xaa at position 113 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met; Xaa at position 114 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met; Xaa at position 115 is deleted or Gln, Gly, Ser, Thr, Tyr, or Asn; and wherein the N-terminus is joined to the C-terminus directly or through a linker (L2) capable of joining the N-terminus to the C-terminus wherein new C-termini and N-termini are created between the amino acid reside pairs of SEQ ID NO:256 selected from the group consisting of:26-27, 27-28, 28-29, 29-30, 30-31, 32-33, 33-34, 34-35, 36-37, 37-38, 38-39, 40-41, 41-42, 42-43, 43-44, 44-45, 46-47, 47-48, 48-49, 50-51, 51-52, 52-53, 53-54, 54-55, 55-56, 56-57, 57-58, 58-59, 59-60, 78-79, 79-80, 80-81, 81-82, 82-83, 83-84, 84-85, 85-86, 86-87, 87-88, 88-89, 108-109, 109-110, 110-111, 111-112, 112-113, 113-114, 114-115, 115-116, 116-117, 117-118, 118-119, 119-120, 120-121, 121-122, 122-123, 123-124, 124-125, 125-126, 126-127 or 127-128; and (b) an amino acid sequence of SEQ ID NO:283 wherein;Xaa at position 7 is Ser or Ala; Xaa at position 112 is deleted or Leu, Ala, Val, Ile, Pro, Phe, Trp, or Met; Xaa at position 113 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met; Xaa at position 114 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met; Xaa at position 115 is deleted or Gln, Gly, Ser, Thr, Tyr, or Asn; Xaa at position 151 is Ser or Ala; wherein the N-terminus is joined to the C-terminus directly or through a linker (L2) capable of joining the N-terminus to the C-terminus wherein new C-termini and N-termini are created between the amino acid reside pairs of SEQ ID NO:283 selected from the group consisting of: 2-
 27. 27-28, 28-29, 29-30, 30-31, 32-33, 33-34, 34-35, 36-37, 37-38, 38-39, 40-41, 41-42, 42-43, 43-44, 44-45, 46-47, 47-48, 48-49, 50-51, 51-52, 52-53, 53-54, 54-55, 55-56, 56-57, 57-58, 58-59, 59-60, 78-79, 79-80, 80-81, 81-82, 82-83, 83-84, 84-85, 85-86, 86-87, 87-88, 88-89, 108-109, 109-110, 110-111, 111-112, 112-113, 113-114, 114-115, 115-116, 116-117, 117-118, 118-119, 119-120, 120-121, 121-122, 122-123, 123-124, 124-125, 125-126, 126-127 or 127-128;R2 is selected from the group consisting of: a biologically active human IL-3 variant comprising a modified amino acid sequence of (SEQ ID NO:2) wherein Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln, or Arg;Xaa at position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln; Xaa at position 19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys; Xaa at position 20 is Ile, Cys, Gln, Glu, Arg, Pro, or Ala; Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val; Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly; Xaa at position 23 is Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, or Arg; Xaa at position 24 is Ile, Gly, Val, Arg, Ser, Phe, or Leu; Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro, or Ala; Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala, or Trp; Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala; Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp; Xaa at position 29 is Gln, Asn, Leu, Pro, Arg, or Val; Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys; Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln; Xaa at position 32 is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu; Xaa at position 33 is Pro, Leu, Gln, Ala, Thr, or Glu; Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met; Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gln, or Val; Xaa at position 36 is Asp, Leu, or Val; Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile; Xaa at position 38 is Asn, or Ala; Xaa at position 40 is Leu, Trp, or Arg; Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, or Pro; Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Met or Ala; Xaa at position 43 is Glu, Asn,. Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly or Ser; Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro; Xaa at position 45 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, Ile, Glu or His; Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly; Xaa at position 47 is Ile, Gly, Val, Ser, Arg, Pro, or His; Xaa at position 48 is Leu, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn; Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp; Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His, Phe, Met or Gln; Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His; Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr; Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met; Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His, Ala or Leu; Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly; Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys; Xaa at position 57 is Asn or Gly; Xaa at position 58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys; Xaa at position 59 is Glu Tyr, His, Leu, Pro, or Arg; Xaa at position 60 is Ala, Ser, Pro, Tyr, Asn, or Thr; Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser; Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile; Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val; Xaa at position 64 is Ala, Asn, Pro, Ser, or Lys; Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser; Xaa at position 66 is Lys, Ile, Arg, Val, Asn, Glu, or Ser; Xaa at position 67 is Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro, or His; Xaa at position 68 is Leu, Val, Trp, Ser, Ile, Phe, Thr, or His; Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Leu; Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala; Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, or Asn; Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp; Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg; Xaa at position 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala; Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu; Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp; Xaa at position 77 is Ile, Ser, Arg, Thr, or Leu; Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg; Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile, Gly, or Asp; Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg; Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys; Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, Ile, Met or Val; Xaa at position 83 is Pro, Ala, Thr, Trp, Arg, or Met; Xaa at position 84 is Cys, Glu, Gly, Arg, Met, or Val; Xaa at position 85 is Leu, Asn, Val, or Gln; Xaa at position 86 is Pro, Cys, Arg, Ala, or Lys; Xaa at position 87 is Leu, Ser, Trp, or Gly; Xaa at position 88 is Ala, Lys, Arg, Val, or Trp; Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser; Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, Ile, or Met; Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His; Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile or Leu; Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg; Xaa at position 94 is Arg, Ile, Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro; Xaa at position 95 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr Asn, Lys, Ser, Ala, Trp, Phe, Ile, or Tyr; Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr; Xaa at position 97 is Ile, Val, Lys, Ala, or Asn; Xaa at position 98 is His, Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro; Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, Phe, or His; Xaa at position 100 is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gln, or Pro; Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu, or Gln; Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro; Xaa at position 103 is Asp, or Ser; Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe, or Gly; Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His; Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro; Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala or Pro; Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly; Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser, or Trp; Xaa at position 111 is Leu, Ile, Arg, Asp, or Met; Xaa at position 112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe; Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val or Asn; Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu; Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met; Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gln, or Ile; Xaa at position 117 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro; Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg; Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gln; Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly; Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys; Xaa at position 123 is Ala, Met, Glu, His, Ser., Pro, Tyr, or Leu; wherein from 1 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3; and wherein from 1 to 14 amino acids are optionally deleted from the N-terminus and/or from 1 to 15 amino acids are optionally deleted from the C-terminus of said modified human IL-3 amino acid sequence; a colony stimulating factor, a cytokine, a lymphokine, an interleukin, and a hematopoietic growth factor; L1 is a linker capable of linking R1 to R2; and said hematopoietic protein is optionally immediately preceded by (methionine-1), (alanine-1) or (methionine-2, alanine-1).
 2. The hematopoietic protein as recited in claim 1 wherein said protein is selected from the group consisting of;SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, and SEQ ID NO:239.
 3. A nucleic acid molecule encoding said hematopoietic protein of claim
 2. 4. The nucleic acid molecule according to claim 3 selected from group consisting of:SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, and SEQ ID NO:154.
 5. The hematopoietic protein as recited in claim 1 wherein said c-mpl receptor agonist is selected from the group consisting of:

    MetAlaGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHis                   LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuAlaValArg                   GluPheGlyGlyAsnMetAlaSerProAlaProProAlaAlaAspLeuArgValLeuSer                   LysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHis                   ProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThr                   GlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGly                   ValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeu                   SerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuPro                   ProGln (SEQ ID NO:284); and                                                    MetAlaGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeu                   LeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThr                   AlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysVal                   ArgPheLeuMetLeuValGlyGlySerThrLeuAlaValArgGluPheGlyGlyAsnMet                   AlaSerProAlaProProAlaAlaAspLeuArgValLeuSerLysLeuLeuArgAspSer                   HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProVal                   LeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLys                   AlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGly                   GlnLeu (SEQ ID NO:285)                                                    


6. A nucleic acid molecule encoding said hematopoietic protein of claim
 5. 7. A nucleic acid molecule encoding said hematopoietic protein of claim
 1. 8. A method for selective ex vivo expansion of hematopoietic stem cells, comprising the steps of;(a) separating hematopoietic stem cells from other cells; (b) culturing the separated hematopoietic stem cells from step (a) with a selected culture medium comprising; an amount of the hematopoietic protein of claim 1, effective to expand said hematopoietic stem cells; and (c) harvesting the cultured hematopoietic cells of step (b).
 9. A method for treatment of a patient having a hematopoietic disorder, comprising the steps of;(a) removing hematopoietic cells from said patient; (b) separating hematopoietic stem cells from other cells removed from said patient; (c) culturing said separated hematopoietic stem cells from step (b) with a selected culture medium comprising; an amount of the hematopoietic protein of claim 1 effective to expand and/or differentiate the hematopoietic stem cells; (d) harvesting the cultured hematopoietic cells from step (c); and (e) introducing the cultured hematopoietic cells from step (d) into said patient to increase the number of hematopoietic cells.
 10. A method of expanding the transducing hematopoietic cells for use in gene therapy, comprising the steps of;(a) removing hematopoietic cells from a patient; (b) separating hematopoietic stem cells from other cells removed from the patient in step (a); (c) culturing said separated hematopoietic stem cells from step (b) with a selected culture medium comprising; an amount of the hematopoietic protein of claim 1 effective to expand the hematopoietic stem cells; (d) transducing the cultured hematopoietic cells from step (c) by introducing DNA into said cultured hematopoietic cells; and (e) harvesting said transduced hematopoietic cells.
 11. A pharmaceutical composition comprising; the hematopoietic protein according to claim 1; at least one colony stimulating factor, cytokine, lymphokine, interleukin, or hematopoietic growth factor selected from the group consisting of: GM-CSF, G-CSF, c-mpl ligand (TPO), MGDF, M-CSF, erythropoietin (EPO), IL-1, IL-4, IL-2, IL-3, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-16, LIF, flt3 ligand, and stem cell factor (SCF); and a pharmaceutically acceptable carrier.
 12. A method of stimulating the production of hematopoietic cells in a patient comprising the step of; administering to said patient an amount of the composition as recited in claim 11, effective to stimulate the production of hematopoietic cells.
 13. A method for selective ex vivo expansion of hematopoietic cells, comprising the steps of;(a) culturing hematopoietic cells with a culture medium comprising; an amount of the composition of claim 11, effective to expand said hematopoietic cells; and (b) harvesting the cultured hematopoietic cells of step (a).
 14. A method for selective ex vivo expansion of hematopoietic stem cells, comprising the steps of;(a) separating hematopoietic stem cells from other cells; (b) culturing the separated hematopoietic stem cells from step (a) with a selected culture medium comprising; an amount of the composition of claim 11, effective to expand said hematopoietic stem cells; and (c) harvesting the cultured hematopoietic cells of step (b).
 15. A method for treatment of a patient having a hematopoietic disorder, comprising the steps of;(a) removing hematopoietic cells from said patient; (b) separating hematopoietic stem cells from other cells removed from said patient; (c) culturing said separated hematopoietic stem cells from step (b) with a selected culture medium comprising; an amount of the composition of claim 11, effective to expand and/or differentiate the hematopoietic stem cells; (d) harvesting the cultured hematopoietic cells from step (c); and (e) introducing the cultured hematopoietic cells from step (d) into said patient to increase the number of hematopoietic cells.
 16. A method of expanding and transducing hematopoietic cells for use in gene therapy, comprising the steps of;(a) removing hematopoietic cells from a patient; (b) separating hematopoietic stem cells from other cells removed from the patient in step (a); (c) culturing said separated hematopoietic stem cells from step (b) with a selected culture medium comprising; an amount of the hematopoietic protein of claim 11 effective to expand the hematopoietic stem cells; (d) transducing the cultured hematopoietic cells from step (c) by introducing DNA into said cultured hematopoietic cells; and (e) harvesting said transduced hematopoietic cells.
 17. A hematopoietic protein comprising; an amino acid sequence of the formula:

    R1-L1-R2, R2-L1-R1, R1-R2, or R2-R1

wherein R1 is a biologically active human c-mpl ligand comprising a modified amino acid sequence of SEQ ID NO:256 wherein;Xaa at position 112 is deleted or Leu, Ala, Val, Ile, Pro, Phe, Trp, or Met; Xaa at position 113 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met; Xaa at position 114 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met; Xaa at position 115 is deleted or Gln, Gly, Ser, Thr, Tyr, or Asn; and wherein the N-terminus is joined to the C-terminus directly or through a linker (L2) capable of joining the N-terminus to the C-terminus wherein new C-termini and N-termini are created between the amino acid reside pairs of SEQ ID NO:256 selected from the group consisting of:26-27, 27-28, 28-29, 29-30, 30-31, 32-33, 33-34, 34-35, 36-37, 37-38, 38-39, 40-41, 41-42, 42-43, 43-44, 44-45, 46-47, 47-48, 48-49, 50-51, 51-52, 52-53, 53-54, 54-55, 55-56, 56-57, 57-58, 58-59, 59-60, 78-79, 79-80, 80-81, 81-82, 82-83, 83-84, 84-85, 85-86, 86-87, 87-88, 88-89, 108-109, 109-110, 110-111, 111-112, 112-113, 113-114, 114-115, 115-116, 116-117, 117-118, 118-119, 119-120, 120-121, 121-122, 122-123, 123-124, 124-125, 125-126, 126-127 or 127-128; R2 is selected from the group consisting of: a biologically active human IL-3 variant comprising a modified amino acid sequence of SEQ ID NO:2 wherein Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln, or Arg;Xaa at position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln; Xaa at position 19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys; Xaa at position 20 is Ile, Cys, Gln, Glu, Arg, Pro, or Ala; Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val; Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly; Xaa at position 23 is Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, or Arg; Xaa at position 24 is Ile, Gly, Val, Arg, Ser, Phe, or Leu; Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro, or Ala; Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala, or Trp; Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala; Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp; Xaa at position 29 is Gln, Asn, Leu, Pro, Arg, or Val; Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys; Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln; Xaa at position 32 is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu; Xaa at position 33 is Pro, Leu, Gln, Ala, Thr, or Glu; Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met; Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gln, or Val; Xaa at position 36 is Asp, Leu, or Val; Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile; Xaa at position 38 is Asn, or Ala; Xaa at position 40 is Leu, Trp, or Arg; Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, or Pro; Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Met or Ala; Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly or Ser; Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro; Xaa at position 45 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, Ile, Glu or His; Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly; Xaa at position 47 is Ile, Gly, Val, Ser, Arg, Pro, or His; Xaa at position 48 is Leu, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn; Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp; Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His, Phe, Met or Gln; Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His; Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr; Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met; Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His, Ala or Leu; Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly; Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys; Xaa at position 57 is Asn or. Gly; Xaa at position 58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys; Xaa at position 59 is Glu Tyr, His, Leu, Pro, or Arg; Xaa at position 60 is Ala, Ser, Pro, Tyr, Asn, or Thr; Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser; Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile; Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val; Xaa at position 64 is Ala, Asn, Pro, Ser, or Lys; Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser; Xaa at position 66 is Lys, Ile, Arg, Val, Asn, Glu, or Ser; Xaa at position 67 is Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro, or His; Xaa at position 68 is Leu, Val, Trp, Ser, Ile, Phe, Thr, or His; Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Leu; Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala; Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, or Asn; Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp; Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg; Xaa at position 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala; Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu; Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp; Xaa at position 77 is Ile, Ser, Arg, Thr, or Leu; Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg; Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile, Gly, or Asp; Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg; Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys; Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, Ile, Met or Val; Xaa at position 83 is Pro, Ala, Thr, Trp, Arg, or Met; Xaa at position 84 is Cys, Glu, Gly, Arg, Met, or Val; Xaa at position 85 is Leu, Asn, Val, or Gln; Xaa at position 86 is Pro, Cys, Arg, Ala, or Lys; Xaa at position 87 is Leu, Ser, Trp, or Gly; Xaa at position 88 is Ala, Lys, Arg, Val, or Trp; Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser; Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, Ile, or Met; Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His; Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile or Leu; Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg; Xaa at position 94 is Arg, Ile, Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro; Xaa at position 95 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, Ile, or Tyr; Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr; Xaa at position 97 is Ile, Val, Lys, Ala, or Asn; Xaa at position 98 is His, Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro; Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, Phe, or His; Xaa at position 100 is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gln, or Pro; Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu, or Gln; Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro; Xaa at position 103 is Asp, or Ser; Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe, or Gly; Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His; Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro; Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala or Pro; Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly; Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser, or Trp; Xaa at position Ill is Leu, Ile, Arg, Asp, or Met; Xaa at position 112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe; Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val or Asn; Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu; Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met; Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser,.Asn, His, Ala, Tyr, Phe, Gln, or Ile; Xaa at position 117 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro; Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg; Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gln; Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly; Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys; Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu; wherein from 1 to 14 amino acids are optionally deleted from the N-terminus and/or from 1 to 15 amino acids are optionally deleted from the C-terminus of said modified human IL-3 amino acid sequence; and wherein from 1 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3; a colony stimulating factor, a cytokine, a lymphokine, an interleukin, and a hematopoietic growth factor; L1 is a linker capable of linking R1 to R2; and said hematopoietic protein is optionally immediately preceded by (methionine-1), (alanine-1) or (methionine-2, alanine-1).
 18. A nucleic acid molecule encoding said hematopoietic protein of claim
 17. 19. The hematopoietic protein of claim 1 or 17 wherein said colony stimulating factor, cytokine, interleukin, or hematopoietic growth factor, is selected from the group consisting of GM-CSF, G-CSF, G-CSF Ser17, c-mpl ligand (TPO), MGDF, M-CSF, erythropoietin (EPO), IL-1, IL-4, IL-2, IL-3, IL-5, IL 6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, LIF, flt3 ligand, human growth hormone, and stem cell factor (SCF).
 20. The hematopoietic protein as recited in claim 19 wherein said linker (L2) is selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247 and SEQ ID NO:
 248. 21. A method for treatment of a patient having a hematopoietic disorder, comprising the steps of;(a) removing hematopoietic cells from said patient; (b) separating hematopoietic stem cells from other cells removed from said patient; (c) culturing said separated hematopoietic stem cells from step (b) with a selected culture medium comprising; an amount of the hematopoietic protein of claim 20 effective to expand and/or differentiate the hematopoietic stem cells; (d) harvesting the cultured hematopoietic cells from step (c); and (e) introducing the cultured hematopoietic cells from step (d) into said patient to increase the number of hematopoietic cells.
 22. A nucleic acid molecule encoding said hematopoietic protein of claim
 20. 23. A method of producing a hematopoietic protein comprising: growing under suitable nutrient conditions, a host cell transformed or transfected with a replicable vector comprising a nucleic acid molecule of claim 22 under conditions which result in the expression of said hematopoietic protein and recovering said hematopoietic protein.
 24. A pharmaceutical composition comprising; the hematopoietic protein according to claim 20 and a pharmaceutically acceptable carrier.
 25. A method of stimulating the production of hematopoietic cells in a patient comprising the step of; administering to said patient an amount of the hematopoietic protein as recited in claim 20, effective to stimulate the production of hematopoietic cells.
 26. A method for selective ex vivo expansion of hematopoietic stem cells, comprising the steps of;(a) separating hematopoietic stem cells from other cells; (b) culturing the separated hematopoietic stem cells from step (a) with a selected culture medium comprising; an amount of the hematopoietic protein of claim 20, effective to expand said hematopoietic stem cells; and (c) harvesting the cultured hematopoietic cells of step (b).
 27. A method of expanding and transducing hematopoietic cells for use in gene therapy, comprising the steps of;(a) removing hematopoietic cells from a patient; (b) separating hematopoietic stem cells from other cells removed from the patient in step (a); (c) culturing said separated hematopoietic stem cells from step (b) with a selected culture medium comprising; an amount of the hematopoietic protein of claim 20 effective to expand the hematopoietic stem cells; (d) transducing the cultured hematopoietic cells from step (c) by introducing DNA into said cultured hematopoietic cells; and (e) harvesting said transduced hematopoietic cells.
 28. A nucleic acid molecule encoding said hematopoietic protein of claim
 19. 29. A method of producing a hematopoietic protein comprising: growing under suitable nutrient conditions, a host cell transformed or transfected with a replicable vector comprising a nucleic acid molecule of claim 28 under conditions which result in the expression of said hematopoietic protein and recovering said hematopoietic protein.
 30. A pharmaceutical composition comprising; the hematopoietic protein according to claim 19 and a pharmaceutically acceptable carrier.
 31. A method of stimulating the production of hematopoietic cells in a patient comprising the step of; administering to said patient an amount of the hematopoietic protein as recited in claim 19, effective to stimulate the production of hematopoietic cells.
 32. A method for selective ex vivo expansion of hematopoietic cells, comprising the steps of;(a) culturing hematopoietic cells with a culture medium comprising; an amount of the hematopoietic protein of claim 19, effective to expand said hematopoietic cells; and (b) harvesting the cultured hematopoietic cells of step (a).
 33. A method for selective ex vivo expansion of hematopoietic stem cells, comprising the steps of;(a) separating hematopoietic stem cells from other cells; (b) culturing the separated hematopoietic stem cells from step (a) with a selected culture medium comprising; an amount of the hematopoietic protein of claim 19, effective to expand said hematopoietic stem cells; and (c) harvesting the cultured hematopoietic cells of step (b).
 34. A method for treatment of a patient having a hematopoietic disorder, comprising the steps of;(a) removing hematopoietic cells from said patient; (b) separating hematopoietic stem cells from other cells removed from said patient; (c) culturing said separated hematopoietic stem cells from step (b) with a selected culture medium comprising; an amount of the hematopoietic protein of claim 19 effective to expand and/or differentiate the hematopoietic stem cells; (d) harvesting the cultured hematopoietic cells from step (c); and (e) introducing the cultured hematopoietic cells from step (d) into said patient to increase the number of hematopoietic cells.
 35. A method of expanding and transducing hematopoietic cells for use in gene therapy, comprising the steps of;(a) removing hematopoietic cells from a patient; (b) separating hematopoietic stem cells from other cells removed from the patient in step (a); (c) culturing said separated hematopoietic stem cells from step (b) with a selected culture medium comprising; an amount of the hematopoietic protein of claim 19 effective to expand the hematopoietic stem cells; (d) transducing the cultured hematopoietic cells from step (c) by introducing DNA into said cultured hematopoietic cells; and (e) harvesting said transduced hematopoietic cells.
 36. A hematopoietic protein comprising; an amino acid sequence of the formula:

    R1-L1-R2, R2-L1-R1, R1-R2, or R2-R1

wherein R1 is a biologically active human c-mpl ligand comprising a modified amino acid sequence of SEQ ID NO:256 wherein;Xaa at position 112 is deleted or Leu, Ala, Val, Ile, Pro, Phe, Trp, or Met; Xaa at position 113 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met; Xaa at position 114 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met; Xaa at position 115 is deleted or Gln, Gly, Ser, Thr, Tyr, or Asn; and wherein the N-terminus is joined to the C-terminus directly or through a linker (L2) capable of joining the N-terminus to the C-terminus wherein new C-termini and N-termini are created between the amino acid reside pairs of SEQ ID NO:256 selected from the group consisting of: 2-
 27. 27-28, 28-29, 29-30, 30-31, 32-33, 33-34, 34-35, 36-37, 37-38, 38-39, 40-41, 41-42, 42-43, 43-44, 44-45, 46-47, 47-48, 48-49, 50-51, 51-52, 52-53, 53-54, 54-55, 55-56, 56-57, 57-58, 58-59, 59-60, 78-79, 79-80, 80-81, 81-82, 82-83, 83-84, 84-85, 85-86, 86-87, 87-88, 88-89, 108-109, 109-110, 110-111, 111-112, 112-113, 113-114, 114-115, 115-116, 116-117, 117-118, 118-119, 119-120, 120-121, 121-122, 122-123, 123-124, 124-125, 125-126, 126-127 or 127-128;R2 is a biologically active human IL-3 variant comprising a modified amino acid sequence of SEQ ID NO:2 wherein Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln, or Arg;Xaa at position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln; Xaa at position 19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys; Xaa at position 20 is Ile, Cys, Gln, Glu, Arg, Pro, or Ala; Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val; Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly; Xaa at position 23 is Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, or Arg; Xaa at position 24 is Ile, Gly, Val, Arg, Ser, Phe, or Leu; Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro, or Ala; Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala, or Trp; Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala; Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp; Xaa at position 29 is Gln, Asn, Leu, Pro, Arg, or Val; Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys; Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln; Xaa at position 32 is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu; Xaa at position 33 is Pro, Leu, Gln, Ala, Thr, or Glu; Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met; Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gln, or Val; Xaa at position 36 is Asp, Leu, or Val; Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile; Xaa at position 38 is Asn, or Ala; Xaa at position 40 is Leu, Trp, or Arg; Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, or Pro; Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Met or Ala; Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly or Ser; Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro; Xaa at position 45 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, Ile, Glu or His; Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly; Xaa at position 47 is Ile, Gly, Val, Ser, Arg, Pro, or His; Xaa at position 48 is Leu, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn; Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp; Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His, Phe, Met or Gln; Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His; Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr; Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met; Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His, Ala or Leu; Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly; Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys; Xaa at position 57 is Asn or Gly; Xaa at position 58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys; Xaa at position 59 is Glu Tyr, His, Leu, Pro, or Arg; Xaa at position 60 is Ala, Ser, Pro, Tyr, Asn, or Thr; Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser; Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile; Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val; Xaa at position 64 is Ala, Asn, Pro, Ser, or Lys; Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser; Xaa at position 66 is Lys, Ile, Arg, Val, Asn, Glu, or Ser; Xaa at position 67 is Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro, or His; Xaa at position 68 is Leu, Val, Trp, Ser, Ile, Phe, Thr, or His; Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Leu; Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala; Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, or Asn; Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp; Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg; Xaa at position 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala; Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu; Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp; Xaa at position 77 is Ile, Ser, Arg, Thr, or Leu; Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg; Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile, Gly, or Asp; Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg; Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys; Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, Ile, Met or Val; Xaa at position 83 is Pro, Ala, Thr, Trp, Arg, or Met; Xaa at position 84 is Cys, Glu, Gly, Arg, Met, or Val; Xaa at position 85 is Leu, Asn, Val, or Gln; Xaa at position 86 is Pro, Cys, Arg, Ala, or Lys; Xaa at position 87 is Leu, Ser, Trp, or Gly; Xaa at position 88 is Ala, Lys, Arg, Val, or Trp; Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser; Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, Ile, or Met; Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His; Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile or Leu; Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg; Xaa at position 94 is Arg, Ile, Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro; Xaa at position 95 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, Ile, or Tyr; Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr; Xaa at position 97 is Ile, Val, Lys, Ala, or Asn; Xaa at position 98 is His, Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro; Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, Phe, or His; Xaa at position 100 is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gln, or Pro; Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu, or Gln; Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro; Xaa at position 103 is Asp, or Ser; Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe, or Gly; Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His; Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro; Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala or Pro; Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly; Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser, or Trp; Xaa at position 111 is Leu, Ile, Arg, Asp, or Met; Xaa at position 112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe; Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val or Asn; Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu; Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met; Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gln, or Ile; Xaa at position 117 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro; Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg; Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gln; Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly; Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys; Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu; wherein from 1 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3; and wherein from 1 to 14 amino acids are optionally deleted from the N-terminus and/or from 1 to 15 amino acids are optionally deleted from the C-terminus of said modified human IL-3 amino acid sequence; L1 is a linker capable of linking R1 to R2; and said hematopoietic protein is optionally immediately preceded by (methionine-1), (alanine-1) or (methionine-2, alanine-1).
 37. The hematopoietic protein as recited in claim 36 wherein in said modified human IL-3 sequence the amino acids which differ from the corresponding residue in native human interleukin-3 are selected from the group consisting of:position 42 wherein Xaa is Gly, Asp, Ser, Ile, Leu, Met, Tyr, or Ala; position 45 wherein Xaa is Gln, Val, Met or Asn; position 46 wherein Xaa is Asp, Ser, Gln, His or Val; position 50 wherein Xaa is Glu or Asp; position 51 wherein Xaa is Asn, Pro or Thr; position 62 wherein Xaa is Asn or Pro; position 76 wherein Xaa is Ser, or Pro; position 82 wherein Xaa is Leu, Trp, Asp, Asn Glu, His, Phe, Ser or Tyr; position 95 wherein Xaa is His, Arg, Thr, Asn or Ser; position 98 wherein Xaa is His, Ile, Leu, Ala, Gln, Lys, Met, Ser, Tyr or Val; position 100 wherein Xaa is Lys or Arg; position 101 wherein Xaa is Asp; position 105 wherein Xaa is Asn, or Pro; position 108 wherein Xaa is Arg, Ala, or Ser; position 116 wherein Xaa is Lys; position 121 wherein Xaa is Ala, or Ile; position 122 wherein Xaa is Gln, or Ile; position 123 wherein Xaa is Ala, Met or Glu.
 38. A nucleic acid molecule encoding said hematopoietic protein of claim
 37. 39. The hematopoietic protein as recited in claim 36 wherein said modified human IL-3 sequence is selected from the group consisting of SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, and SEQ ID NO:
 228. 40. A nucleic acid molecule encoding said hematopoietic protein of claim
 39. 41. The hematopoietic protein as recited in claim 36 wherein said modified human IL-3 sequence differs from native human IL-3 by substitution of Asp for Glu at position
 50. 42. A nucleic acid molecule encoding said hematopoietic protein of claim
 41. 43. A nucleic acid molecule encoding said hematopoietic protein of claim
 36. 44. A hematopoietic protein comprising an amino acid sequence of the formula:

    R1-L1-R2, R2-L1-R1, R1-R2, or R2-R1

wherein R1 is a biologically active human c-mpl ligand comprising a modified amino acid sequence of SEQ ID NO:256 wherein;Xaa at position 112 is deleted or Leu, Ala, Val, Ile, Pro, Phe, Trp, or Met; Xaa at position 113 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met; Xaa at position 114 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met; Xaa at position 115 is deleted or Gln, Gly, Ser, Thr, Tyr, or Asn; and wherein the N-terminus is joined to the C-terminus directly or through a linker (L2) capable of joining the N-terminus to the C-terminus wherein new C-termini and N-termini are created between the amino acid reside pairs of SEQ ID NO:256 selected from the group consisting of: 2-
 27. 27-28, 28-29, 29-30, 30-31, 32-33, 33-34, 34-35, 36-37, 37-38, 38-39, 40-41, 41-42, 42-43, 43-44, 44-45, 46-47, 47-48, 48-49, 50-51, 51-52, 52-53, 53-54, 54-55, 55-56, 56-57, 57-58, 58-59, 59-60, 78-79, 79-80, 80-81, 81-82, 82-83, 83-84, 84-85, 85-86, 86-87, 87-88, 88-89, 108-109, 109-110, 110-111, 111-112, 112-113, 113-114, 114-115, 115-116, 116-117, 117-118, 118-119, 119-120, 120-121, 121-122, 122-123, 123-124, 124-125, 125-126, 126-127 or 127-128;wherein R2 is G-CSF or G-CSF Ser17; L1 is a linker capable of linking R1 to R2; and said hematopoietic protein is optionally immediately preceded by (methionine-1), (alanine-1) or (methionine-2, alanine-1).
 45. A nucleic acid molecule encoding said hematopoietic protein of claim
 44. 46. The hematopoietic protein as recited in claim 1, 17, 36, 37, 39, 41, or 44 wherein said linker (L2) is selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247 and SEQ ID NO:
 248. 47. A nucleic acid molecule encoding said hematopoietic protein of claim
 46. 48. A method of producing a hematopoietic protein comprising: growing under suitable nutrient conditions, a host cell transformed or transfected with a replicable vector comprising a nucleic acid molecule of claim 47 under conditions which result in the expression of said hematopoietic protein and recovering said hematopoietic protein.
 49. A pharmaceutical composition comprising; the hematopoietic protein according to claim 46 and a pharmaceutically acceptable carrier.
 50. A method of stimulating the production of hematopoietic cells in a patient comprising the step of; administering to said patient an amount of the hematopoietic protein as recited in claim 46, effective to stimulate the production of hematopoietic cells.
 51. A method for selective ex vivo expansion of hematopoietic cells, comprising the steps of;(a) culturing hematopoietic cells with a culture medium comprising; an amount of the hematopoietic protein of claim 46, effective to expand said hematopoietic cells; and (b) harvesting the cultured hematopoietic cells of step (a).
 52. A method for selective ex vivo expansion of hematopoietic stem cells, comprising the steps of;(a) separating hematopoietic stem cells from other cells; (b) culturing the separated hematopoietic stem cells from step (a) with a selected culture, medium comprising; an amount of the hematopoietic protein of claim 46, effective to expand said hematopoietic stem cells; and (c) harvesting the cultured hematopoietic cells of step (b).
 53. A method for treatment of a patient having a hematopoietic disorder, comprising the steps of;(a) removing hematopoietic cells from said patient; (b) separating hematopoietic stem cells from other cells removed from said patient; (c) culturing said separated hematopoietic stem cells from step (b) with a selected culture medium comprising; an amount of the hematopoietic protein of claim 46 effective to expand and/or differentiate the hematopoietic stem cells; (d) harvesting the cultured hematopoietic cells from step (c); and (e) introducing the cultured hematopoietic cells from step (d) into said patient to increase the number of hematopoietic cells.
 54. A method of expanding and transducing hematopoietic cells for use in gene therapy, comprising the steps of;(a) removing hematopoietic cells from a patient; (b) separating hematopoietic stem cells from other cells removed from the patient in step (a); (c) culturing said separated hematopoietic stem cells from step (b) with a selected culture medium comprising; an amount of the hematopoietic protein of claim 46 effective to expand the hematopoietic stem cells; (d) transducing the cultured hematopoietic cells from step (c) by introducing DNA into said cultured hematopoietic cells; and (e) harvesting said transduced hematopoietic cells.
 55. A method of producing a hematopoietic protein comprising: growing under suitable nutrient conditions, a host cell transformed or transfected with a replicable vector comprising a nucleic acid molecule of claim 7, 18, 43, 38, 40, 42, 45, 3, 4, or 6 under conditions which result in the expression of said hematopoietic protein and recovering said hematopoietic protein.
 56. A pharmaceutical composition comprising; the hematopoietic protein according to claim 1, 17, 36, 37, 39, 41, 44, 2, or 5 and a pharmaceutically acceptable carrier.
 57. A method of stimulating the production of hematopoietic cells in a patient comprising the step of; administering to said patient an amount of the hematopoietic protein as recited in claim 1, 17, 36, 37, 39, 41, 44, 2, or 5, effective to stimulate the production of hematopoietic cells.
 58. A method for selective ex vivo expansion of hematopoietic cells, comprising the steps of;(a) culturing hematopoietic cells with a culture medium comprising; an amount of the hematopoietic protein of claim 1, 17, 36, 37, 39, 41, 44, 2, or 5, effective to expand said hematopoietic cells; and (b) harvesting the cultured hematopoietic cells of step (a). 